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Stable isotope studies into the kinetics and bioavaiiability of vitamin Ki in 
humans
In Britain, vitamin Ki (phylloquinone) is the primary form of vitamin K in the human 
diet and blood. Evidence is accumulating for roles of vitamin K-i beyond established 
functions in blood coagulation, particularly in bone metabolism. To aid the determination 
of recommended intakes vitamin Ki kinetics and bioavailability were investigated in adult 
volunteers using stable isotopes.
Methods to measure reliably and accurately the isotopic enrichment of plasma 
vitamin K-i using gas chromatography mass spectrometry (GCMS) were developed. Two 
stable isotope labelled forms of vitamin Ki (13C and ring-D4) measured simultaneously 
disposal kinetics of intravenous doses and absolute absorption of 4 pg oral doses in ten 
lean, healthy volunteers (1 male and 9 female), aged 22 -  31 y. Isotopic data were fitted 
to a 2-compartment model with input and output from the sampled (blood plasma) pool, 
and exchange between it and a remote compartment. Mean half-times for vitamin Ki 
disappearance were 0.2 and 2.7 h and mean absolute absorption of oral doses was 13%.
A three-way crossover measured vitamin K-i bioavailability in twelve lean, healthy 
volunteers (7 male and 5 female) aged 22 -  49 y. Each volunteer consumed 20 pg of 
capsulated 13C-labelled vitamin Ki with one of three test-meals representing convenience, 
cosmopolitan or animal-oriented diets and balanced for fat, protein and carbohydrate but 
containing vitamin Ki in different components. Blood was sampled over 8 h. Relative 
bioavailability was greater from the convenience meal (relative bioavaiiability = 1.00), in 
which most vitamin Ki was in oils and fats not intact vegetables, compared to either the 
cosmopolitan (0.46) or animal-oriented (0.29) meals.
These studies demonstrate that stable isotope-based methods successfully 
measure vitamin Ki bioavaiiability and metabolism and their potential for use in 
establishing recommended dietary intakes.
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S ta b le  is to p e  s tu d ie s  in to  th e  k in e t ic s
AND BIOAVAILABILITY OF VITAMIN K-i IN
HUMANS
1 Introduction
1.1 Vitamin K
Vitamin K is a generic term that refers to a number of related molecules each 
sharing a similar chemical structure based on a 2-methyl-1,4-napthoquinone ring and 
possessing an alkyl side chain in position 3 (Figure 1-1). Vitamin K is related to other 
biologically active compounds, e.g. vitamin E and coenzyme Q families since all contain a 
quinone-derived ring structure.
Figure 1-1. Molecular structure of the 2-methyl-1,4-napthoquinone ring common to 
all forms of vitamin K. Forms differ in the length and degree of saturation of the 
alkyl side chain, R at position 3
The two natural forms of vitamin K are vitamin K1( also known as phylloquinone, 
which is synthesised in plants, and vitamin K2, or the menaquinones that are produced by 
bacteria. An additional synthetic form of vitamin K, designated K3 and known as 
menadione, comprises only the 2-methyl-1,4-napthoquinone ring. In western populations, 
the primary dietary form of vitamin K is vitamin Ki (Schurgers et al., 1999).
1.1.1 Vitamin Ki -  Phylloquinone
Vitamin Ki is only synthesised in plants where it is closely bound to the thylakoid 
membranes of chloroplasts. In the chloroplast, vitamin Ki plays a role in the production of 
chemical energy, in the form of NADPH, using solar energy. In photosynthesis, a number 
of cofactors act to transfer electrons along a transfer pathway. One such cofactor, A1, 
has been identified as two vitamin Ki molecules (Rustandi et al., 1990; Snyder et al., 
1991). It has also been proposed that vitamin Ki may play the role of a lipid-soluble 
electron carrier in plant organelle cell membranes, similar to that of coenzyme Q in
O
O
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animals (Lochner et a l, 2003). The vitamin Ki molecule comprises the 2-methyl-1,4- 
napthoquinone ring and a partially saturated phytyl side chain at position 3 (Figure 1-2).
Figure 1-2. Molecular structure of vitamin Ki
1.1.2 Vitamin K2 -  Menaquinones
The term menaquinone describes a number of molecules each comprising the 2- 
methyl-1,4-napthoquinone ring but differing in the length of the side chain at position 3 
(Figure 1-3). The side chain is made up of unsaturated isoprenyl units (marked [...] in 
Figure 1-3) with the menaquinone being designated by the number of isoprenoids in the 
form MK-n, where n equals the number of isoprenoid units, e.g. MK-4 contains 4 
isoprenoid units. As with vitamin Ki in plants, the menaquinones in bacteria act as 
electron carriers in the production of energy from a variety of substrates (Haddock & 
Jones, 1977).
Figure 1-3. Molecular structure of vitamin K2
1.2 Biochemistry of vitamin K
Crucial to identifying suitable markers of vitamin K status, and to investigating 
relationships between intake, status and health is an understanding of the biochemistry of 
vitamin K, and its unique biological functions.
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1.2.1 Discovery of vitamin K
Vitamin K was discovered during the 1930s, following observations on chicks with 
hemorrhagic disease. In an early study by Almquist & Stokstad (1935), it was shown that 
chicks fed meals that had been extracted with ether developed a hemorrhagic disease 
that could be reversed by adding the extracts back to the diets. Similarly, Dam (1935) 
demonstrated that symptoms could be suppressed by feeding chicks ‘hog liver fat, hemp 
seed and certain vegetables such as tomatoes and kale, and many cereals’. It was found 
the vitamin occurs in the ‘easily soluble non-sterol fraction of the non-saponifiable matter’. 
Identified as being similar to vitamin E, Henrik Dam suggested the term Vitamin K after 
the German word, Koagulation (Dam 1935). He later won the Nobel Prize for his 
discovery.
1.2.2 Biochemical role of vitamin K
The only known role for vitamin K is to act as a cofactor for the endoplasmic 
enzyme y-glutamyl carboxylase that catalyses the post-translational conversion of 
glutamic acid (Glu) to y-carboxyglutamic acid (Gla) in vitamin K-dependent (VKD) proteins 
(Berkner 2000). The amino acid y-carboxyglutamic acid was first discovered in 
prothrombin and subsequently in other VKD proteins necessary for hemostasis, including 
Factor VII, IX and X, protein C, protein S and protein Z (Suttie 1985). Other VKD proteins 
discovered since include those involved in bone metabolism, osteocalcin and matrix Gla 
protein (MGP). More recently, a new family of VKD proteins has been identified that have 
a broad distribution in foetal and adult tissues (Kulman et a!., 1997; 2001). This family is 
divided into two classes; proline-rich y-carboxyglutamic acid proteins (PRGP), and trans­
membrane Gla proteins (TMG). Table 1-1 summarises the currently known VKD proteins 
and their functions.
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Table 1-1. Known vitamin K-dependent proteins and their functions
Protein Function Reference
Factor II Blood clotting Berkner & Runge,
(prothrombin) 2004; Oldenburg
Factor VII 
Factor IX 
Factor X
& Schwabb, 2001
Protein C 
Protein S* 
Protein Z
Regulation of blood clotting
Growth-arrest Signal transduction; Kulman et al.,
specific 6 Cell survival factor; 2001
(Gas6) Cofactor in uptake of
apoptotic cells by 
macrophages
Osteocalcin Bone growth and Vermeer 1998
Matrix Gla protein extraosseous calcification
PRGP1 Unknown Kulman et al.,
PRGP2 1997
TMG3 Unknown Kulman et al.,
TMG4 2001
*Protein S is also found in bone
1.2.3 The mechanism of conversion of glutamic to y-carboxy glutamic acid
The activation of VKD proteins by conversion of Glu residues to Gla residues 
requires the reduced form of vitamin K, vitamin K hydroquinone, and the enzyme y- 
glutamyl carboxylase. However, the exact enzymatic mechanism of VKD protein 
carboxylation is not fully understood (Berkner & Runge, 2004). The proposed mechanism 
is based on base-strength amplification sequence (Figure 1-4). In this mechanism, the y- 
carboxylase enzyme provides a weak base (a proton acceptor) for the deprotonation of 
vitamin K hydroquinone. Oxygenation of vitamin K hydroquinone results in the generation 
of a strong base, possibly the dialkoxide intermediate (shown in Figure 1-4). The resulting 
strong base extracts a hydrogen atom from the glutamyl residue (Glu) that generates a 
electron-donating carbanion intermediate (not shown). This reaction is followed by a 
further reaction with C 02 and carboxylation (introduction of a carboxylic acid group, 
COOH) to form the y-carboxyglutamate product (Dowd et al., 1995; Rishavy et a!., 2004).
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Figure 1-4. The base amplification model for the carboxylation of glutamic acid, y- 
glutamyl carboxylase catalyses the conversion of vitamin K hydroquinone to 
vitamin K epoxide that extracts a hydrogen atom from glutamic acid. Addition of 
C 02 results in the conversion of glutamic acid to y-carboxyglutamic acid. (B: weak 
base) (adapted from Rishavy ef al., 2004 and Dowd ef al., 1995)
carboxylase enzyme carboxylase enzyme
OH
>
O
vitamin K epoxide
OH
vitamin K hydroquinone dialkoxide intermediate
COO-COO-
COO-
H protein proteinprotein
b o 2
protein
gamma-carboxyglutamate glutamate
There is some debate with regards to the precise mechanism of the base strength 
amplification model. It was initially proposed that one cysteine residue of the carboxylase 
enzyme acted as the weak base, and another served to incorporate C 02. Subsequent 
work demonstrated that in fact each of the cysteine residues is required for both 
epoxidation and carboxylation (Pudota et al., 2000). However, recent evidence has 
shown that the active residue is not cysteine, but rather histidine acting as a catalytic base 
(Rishavy et al., 2004). It is suggested that although the cysteine residues are not directly 
involved in the carboxylation reaction, they may still be important since their modification 
to serine or alanine causes inactivation of the protein (Tie et al., 2004).
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1.2.4 The vitamin K cycle
For every molecule of Glu converted to Gla a molecule of vitamin K 2, 3 epoxide is 
also produced. The epoxide is converted back to the quinone form of vitamin K via 
vitamin K epoxide reductase (Furie et al., 1999). Together with the conversion of vitamin 
K to vitamin K hydroquinone, these steps make up the vitamin K cycle (Figure 1-5). The 
vitamin K cycle is crucial for the continual carboxylation of VKD proteins since each 
conversion from Glu to Gla involves one molecule of vitamin K hydroquinone and VKD 
proteins contain up to 13 Glu residues. Thus, the availability of vitamin K hydroquinone is 
the limiting factor and crucial for full carboxylation of VKD proteins (Berkner 2005). 
Additionally, the cycle is important for the maintenance of vitamin K status within tissues, 
since concentrations are low and vitamin K turnover is relatively fast (Shearer et al., 
1974). Vitamin K must be continually recycled to prevent the accumulation of 
undercarboxylated intracellular VKD proteins and the subsequent secretion of non­
functioning, undercarboxylated VKD proteins into the circulation. From studies in rats, it 
has been estimated that a vitamin Ki molecule may be recycled between 1000 and 10000 
times per day (Uchida & Komeno, 1988).
Figure 1-5. The vitamin K cycle. The cycle is crucial for the maintenance of vitamin 
K stores to ensure carboxylation of VKD proteins. The product of the carboxylase 
reaction, vitamin K epoxide, is converted back to vitamin K, and subsequently to 
the active form, vitamin K hydroquinone. Dietary vitamin K can also enter the cycle
o
H
H O ' ' O  
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1.2.4.1 Vitamin K-dependent y-glutamyl carboxylase
The VKD y-glutamyl carboxylase enzyme catalyses the conversion of glutamic 
acid to y-carboxyglutamic acid. The gene coding for VKD y-carboxylase is found on 
chromosome 2 and encodes for a protein with a molecular weight of around 94,000 Da 
(Furie et al., 1999). It has been shown that the carboxylase sequence is found throughout 
the animal kingdom, including a highly conserved 38-amino acid motif, which suggests 
this domain is critical for enzyme function (Begley et al., 2000). The high degree of 
sequence homology throughout the animal kingdom highlights the functional importance 
of the VKD carboxylase.
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1.2.4.2 Vitamin K epoxide reductase
Vitamin K epoxide reductase (VKOR) has two functions. Firstly, it reduces vitamin 
K to vitamin K hydroquinone, the active cofactor for VKD carboxylase. Secondly, the 
enzyme reduces vitamin K epoxide, formed during carboxylation of glutamic acid, back to 
vitamin K (Suttie 1985). VKOR is likely the physiologically important enzyme for recycling 
vitamin K (Furie et a!., 1999) and for the maintenance of vitamin K status. The gene 
encoding for VKOR has only recently been discovered (Li et al., 2004; Rost et al., 2004a) 
and the protein purified (Chu et al., 2006). Warfarin works as an anticoagulant by 
blocking the action of vitamin K epoxide reductase.
A second enzyme, NADPH-dependent quinine reductase is also able to convert 
vitamin K to vitamin K hydroquinone. This enzyme requires a high concentration of 
vitamin K and is thus unlikely to be important at physiological concentrations. However, 
this pathway for the formation of vitamin K hydroquinone is important in the therapeutic 
use of vitamin K against over anticoagulation, since it is not blocked by warfarin (Berkner 
& Runge, 2004; Bovill et al., 2004).
1.2.5 Molecular interaction between VKD proteins and the y-glutamyl carboxylase
VKD proteins are selected for carboxylation via a highly conserved 18 amino acid 
propeptide incorporating the y-carboxylation recognition site (CRS). Carboxylation occurs 
in the endoplasmic reticulum. The conserved region occurs upstream of the Gla domain 
and, in blood proteins, is proteolytically removed in the Golgi apparatus to form the mature 
protein (Stanley et al., 1999). Matrix Gla protein is exceptional because it retains the CRS 
within the mature protein (Berkner & Runge, 2004). It may be expected that, because of 
the similarities of the propeptides between different VKD proteins, all would have similar 
affinities for y-glutamyl carboxylase. However, it has been demonstrated that there is 
considerable variation in the affinities of the propeptides for y-glutamyl carboxylase. This 
wide range could have physiological consequences when vitamin K levels are sub-optimal 
because it could lead to the preferential carboxylation of some VKD proteins (Stanley et 
al., 1999).
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Following removal of the propeptide region and conformational changes afforded 
by conversion of Glu to Gla in the Golgi apparatus, the resulting proteins undergo 
subsequent post-translational modifications including N- and O-linked glycosylation, 
sulfation, phosphorylation, p-aspartyl hydroxylation and proteolytic cleavage. Mature VKD 
proteins are either secreted extracellularly (e.g. blood clotting proteins) or secreted to the 
cell membrane (e.g. PRPG and TMG) (Berkner & Runge, 2004).
The number of Glu residues converted into Gla residues in the Gla domain of VKD 
proteins can vary between three (in osteocalcin), five (matrix Gla protein) and 13 in blood 
coagulation proteins (Berkner & Runge, 2004). In the presence of sufficient vitamin K 
hydroquinone, and assisted by the vitamin K cycle, secreted VKD proteins are usually fully 
carboxylated, suggesting that a mechanism exists to ensure complete carboxylation 
(Berkner & Runge, 2004). It is possible that there is cellular recognition of 
undercarboxylated forms, at least for some VKD proteins (Hallgren et al., 2002). An 
alternative mechanism is via ‘tethered processivity’ whereby all Glu are converted from a 
single binding between VKD protein and y-glutamyl carboxylase. In this model, the 
propeptide remains bound throughout the reaction, while the Gla domain undergoes 
intramolecular movement to reposition the Glu for carboxylation to Gla (Stenina et al., 
2001). The presence of ‘chaperones’ has also been suggested that may mediate the VKD 
protein-carboxylase interaction, and which may help override the different affinities of VKD 
proteins for the carboxylase (Berkner 2005).
1.2.6 The function of y-carboxy glutamic acid residues
Conversion of Glu to Gla in VKD proteins confers the ability to bind calcium ions 
(Ca2+). The consequences of Ca2+ binding on tertiary structure and properties of the 
protein depend on the number of Gla residues. In blood coagulation proteins that contain 
more than 9 Gla residues, the binding of multiple Ca2+ ions leads to a structural change in 
the protein that results in the exposure of a site that binds to phospholipids (Furie et al., 
1999). VKD proteins are then able to bind to cell membranes expressing 
phosphatidylserine via a serine head group of the membrane phospholipid binding to the
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Gla domain-bound Ca2+ ions (Figure 1-6). This binding is mediated by a number of 
interactions including calcium coordination, ionic, van der Waals and hydrophobic forces 
(Huang et al., 2003). Phosphatidylserine exposure on cell surfaces also occurs during cell 
injury or cell activation (in response to inflammatory signals) and is characteristic of 
apoptosis. Thus, it is possible that VKD proteins play an important role in other 
physiological processes (Berkner & Runge, 2004).
Figure 1-6. Gla residue of VKD protein binding to cell surface through the 
interaction of Ca2+ ions with membrane phospholipids (adapted from Dowd ef al., 
1995)
In addition, in the blood coagulation proteins, interaction between the Gla residues 
of VKD proteins and Ca2+ ions are believed to provide molecular linkages (Figure 1-7) 
(Dowd etal., 1995).
In osteocalcin and matrix Gla protein that contain fewer Gla residues, the effect of 
calcium binding is less well defined. There is evidence that osteocalcin binds to 
hydroxyapatite (the mineral component of bone) by ionic bonds between the negatively 
charged protein surface provided by the Gla residues and Ca2+ ions interacting with 
hydroxyapatite (Hoang et al., 2003).
O
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Figure 1-7. Gla residue-Ca2+ ion molecular linkage in blood coagulation proteins 
(adapted from Dowd e ta l., 1995)
protein
protein
protein
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2 +
protein
1.2.7 The consequences for health of undercarboxylated VKD proteins
To help understand the potential consequences of vitamin K deficiency and 
undercarboxylation of VKD proteins it is useful to highlight some molecular and genetic 
work. A study that selectively mutated Glu residues in VKD proteins yielded prothrombin 
and protein C that were unable to bind Ca2+ ions (Furie et al., 1999) and shows that 
undercarboxylation results in reduced Ca2+ ion binding and low biological activity of the 
VKD protein (Vermeer et al., 1998).
The release of undercarboxylated proteins into circulation can occur by various 
means and are summarised in Figure 1-8. A mutation in a single VKD protein can lead to 
specific disorders affecting, for example blood coagulation. There are a number of 
specific mutations in genes associated with the VKD coagulation proteins. For example, a 
mutation in the propeptide y-glutamyl carboxylase binding site of Factor IX causes 
haemophilia B. Clinical signs of this condition are haemorrhages, mainly in the muscles 
and joints (Oldenburg & Schwabb, 2001). The prevalence of mutations in the gene 
encoding protein C is around 1.5 per 1000 individuals, with mutations found throughout 
the gene (Oldenburg & Schwabb, 2001). Mutations in other VKD proteins (prothrombin, 
factors VII and X) are rare.
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Figure 1-8. Potential causes of undercarboxylated VKD proteins
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Undercarboxylation may also occur through a reduction in the availability of the 
cofactor vitamin K. The vitamin K cycle can be disrupted by genetic mutation, drug 
treatment or dietary deficiency. Disruption of vitamin K recycling may exert a universal 
effect on all VKD proteins resulting in possible bleeding, bone malformation and increased 
risk of arterial calcification.
Mutations that impact all VKD proteins are rare. A few have been linked to a 
specific mutation in the gene for y-glutamyl carboxylase (Brenner et al., 1998; Spronk et 
al., 2000; Rost et al., 2004b). In a single case, it was reported that hemostatic proteins 
and osteocalcin were both affected suggesting only one gene encodes for y-glutamyl 
carboxylase in all tissues (Spronk et al., 2000). There are also reports of mutations in the 
vitamin K epoxide reductase enzyme resulting in vitamin K epoxide accumulation 
(Oldenburg & Schwabb, 2000).
Whilst adults are generally safe from the acute effects of vitamin K deficiency, 
neonates are at risk of haemorrhagic disease of the newborn (HDNB) partly because of 
the low concentration of vitamin K in breast milk. As a result, newborns receive a dose of 
vitamin K shortly after delivery. Where vitamin K deficiency does occur in adults, it is 
usually the consequence of disease or medical treatment for other conditions. Diseases 
that interfere with the absorption of vitamin K include forms of biliary obstruction (e.g. 
gallstones), malabsorption syndromes (e.g. cystic fibrosis, celiac disease, ulcerative colitis 
and short-bowel syndrome) and liver disease. Lack of dietary vitamin K leading to 
haemorrhage is also a risk in hospitalised patients receiving total parenteral nutrition 
(Olson 1985).
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Drug therapies that interfere with vitamin K metabolism include the coumarin 
family of anticoagulants (e.g warfarin) and large doses of salicylates (Olson 1985). The 
potential effects of vitamin K antagonists was highlighted in infants from mothers on 
warfarin treatment, who were at risk of a bone defect, chondrodysplasia punctata, also 
known as fetal warfarin syndrome (Vermeer et al., 1998). The use anti-obesity drugs that 
inhibit fat absorption may also cause vitamin K deficiency even if it is plentiful in the diet, 
although any effects are likely to be mild and difficult to detect (see section 1.13.5.1). 
Some types of antibiotic can also inhibit vitamin K epoxide reductase (Suttie 1995).
There is evidence that warfarin treatment can lead to a competitive state among 
VKD proteins, resulting in the premature dissociation of undercarboxylated, inactive 
protein. A similar state could be reached by dietary deficiency. The effects of acute 
vitamin K deficiency are well known for blood coagulation. However, it is only relatively 
recently, and with the advent of sensitive techniques, that the relationships between 
vitamin K intake and markers of status could be investigated.
1.3 Vitamin K deficiency and human health
1.3.1 Blood coagulation
With respect to blood coagulation, vitamin K deficiency is rare in human adults on 
self-selected diets. The reasons are three-fold; firstly, the wide distribution of vitamin K in 
different foods (albeit in low amounts); secondly, recycling of the vitamin; and thirdly the 
potential production of vitamin K by gut bacteria, although the microbial contribution is 
controversial (see section 1.13.3). Of key relevance for the current investigation is that 
present dietary recommendations for vitamin K are based solely on the amount of dietary 
vitamin K necessary to maintain normal plasma concentrations of the VKD blood 
coagulation proteins (Department of Health 1991).
The first study to investigate the nutritional requirement for vitamin K was 
performed by Frick et al. (1967) with a depletion-repletion study in seven patients all 
receiving parental nutrition. It was concluded that, for the maintenance of blood 
coagulation, the minimum daily requirement was 0.03 to 1.5 pg/kg body wt (Frick et al.,
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1967). However, this range assumes 100% absorption and thus does not account for 
variable bioavailability. Since the work of Frick et al. there has until recently been little 
challenge to the 1 pg/kg body wt/d value. While blood coagulation was the only known 
role for vitamin K, other work provided evidence to support the requirement (Suttie et al., 
1988b), while another even suggested it was too high (Allison et al., 1987). The discovery 
of a requirement for the carboxylation of extrahepatic VKD proteins renewed interest in 
vitamin K nutrient requirements.
Dietary restriction can reduce circulating vitamin K levels and undercarboxylated 
coagulation proteins (Suttie et al., 1988b; Ferland et al., 1993; Booth et al., 2003b)), 
although no clinical manifestations of deficiency have been reported. In some instances, 
and with perhaps less sensitive assays, little or no vitamin K-related deficiencies were 
observed in blood coagulation markers (Allison et al., 1987; Ferland et al., 1993) and in 
particular prothrombin time (Suttie et al., 1988b). Some workers have found prothrombin 
time sensitive to vitamin K-i supplementation (Sokoll et al., 1997) while others have not 
(Binkley eta!., 2000) (see section 1.6.2 and 1.6.3).
1.3.2 Bone health
There is now a substantial body of evidence linking vitamin K intake and status to 
markers of bone health (Figure 1-9). In adults, bone turnover, or remodelling, is a balance 
between the resorption of old bone and the formation of new bone (Vermeer et at., 2004). 
The VKD protein, osteocalcin is a frequently used marker of bone turnover, and although 
its precise role is unclear, it likely acts as a regulator of bone formation. In addition, the 
VKD proteins, MGP (Price & Williamson, 1985) and protein S (Maillard et al., 1992) have 
also been implicated in bone metabolism. Described below are a number of studies that 
provide evidence for the importance of vitamin K in bone health.
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Figure 1-9. Summary of evidence for links between vitamin K and bone health
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1.3.2.1 Undercarboxylated osteocalcin and bone health
The central link between vitamin K and bone health is the carboxylation of 
osteocalcin. A number of prospective studies have shown that fracture risk was greater in 
women with a higher level of ucOC (Szulc et al., 1993; 1996; Vergnaud et al., 1997). 
Lower bone mineral density (BMD) has been reported in one study in women who had 
lower carboxylated osteocalcin (Schaafsma et al., 2000), and in another study with higher 
ucOC, although only in individuals with atherosclerosis (Jie et al., 1996).
1.3.2.2 Vitamin K-, intake and bone health
A number of epidemiological studies have identified relationships between vitamin 
K intake and markers of bone health. The largest involved 72,327 women and found that 
low vitamin K intake increased the risk of hip fracture (Feskanich et al., 1999). A similar 
conclusion was made in a separate study of 888 US men and women where low vitamin 
K intake was associated with an increased risk of hip fractures but not low BMD (Booth et 
al., 2000b). In a subsequent study on the same but enlarged (n = 1,591) US cohort, 
Booth et al., (2003a) found low vitamin K intake was associated with lower BMD in 
women, but not in men. However, a more recent study in Denmark in 2016 peri- 
menopausal women found no relationship between vitamin K intake and either BMD or 
fracture risk (Rejnmark et al., 2006). Undercarboxylated osteocalcin has also been 
associated with vitamin Ki intake in Irish post-menopausal women (Collins et al., 2006) 
and in a US population (McKeown et al., 2002).
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1.3.2.3 Vitamin K * status and bone health
A lower vitamin K status in patients with fractures compared to controls has been 
reported in a number of studies. However, many have reported retrospectively (i.e. status 
was measured after the fracture) and furthermore, and as will be discussed later, a single 
measure of vitamin K status may not be a reliable measure (see section 1.6). Lower 
vitamin K plasma status was observed in two studies that compared individuals with hip 
fracture and spinal crush fractures with controls (Hart et al., 1985; Hodges et al., 1991). 
One report recognised that lower vitamin K status in the fracture group could be due to a 
decline in status following the fracture, but concluded this explanation unlikely since the 
spinal crush fractures represent long-standing, chronic fractures (Hart et al., 1985). In 
other words, the authors concluded that low plasma vitamin Ki status contributed to, but 
was not the effect of the fracture. However, in another study that reported lower vitamin K 
status in individuals after a fracture compared to controls, it was also found that the time 
for vitamin K status to return to normal varied depending on the severity of the fracture 
(Bitensky et al., 1988) suggesting that low vitamin K status was an effect of the fracture. 
The measurement of vitamin K status after a fracture may not be a good indicator of the 
relationship between status and fracture risk, whereas prospective studies can provide 
this information. In a study in 68 haemodialysis patients, lower plasma vitamin Ki was 
associated with a greater risk of fracture (Kohlmeier et al., 1995a). A significant positive 
correlation between vitamin Ki status and BMD has also been observed (Tamatani et al., 
1998). Another recent study in 672 participants has shown an association between low 
plasma vitamin K and osteoarthitis in hand and knee joints (Neogi et al., 2006). An 
inverse relationship between undercarboxylated osteocalcin and vitamin K1 status has 
been observed in post-menopausal British women, but not in post-menopausal Gambian 
or Chinese women (Beavan et al., 2005).
1.3.2.4 Intervention studies
Intervention studies with vitamin K have investigated both the effect of vitamin K 
on bone health (fracture risk or BMD) and circulating undercarboxylated osteocalcin
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(Weber 2001). The major form of vitamin K in human bone is vitamin Ki (Hodges et al., 
1993; Shearer 1997) but the majority of studies have used vitamin K2 (typically MK-4), 
often at pharmacological levels unobtainable from a normal diet (Shiraki et al., 2000; 
Knapen et al., 2007). However, it is suggested that the effects of MK-4 may be mediated 
through an alternative mechanism to y-carboxylation (Shearer 1997).
Two studies have shown an effect of vitamin Ki supplementation on bone mineral 
density (Braam et al., 2003; Bolton-Smith et al., 2007) one of which used levels of vitamin 
Ki obtainable from the diet (Bolton-Smith et al., 2007). The latter study assigned 
individuals to one of four groups to receive either 200 pg/d of vitamin Ki, or 10 pg/d 
vitamin D3 plus 1000 mg of calcium, or vitamin Ki, vitamin D3 and calcium together, or a 
placebo. Bone quality was measured at four sites but only one showed a significant 
increase in BMD and bone mineral content (BMC), and only in the vitamin Ki+vitamin 
D3+calcium treatment group (Bolton-Smith et al., 2007).
The ability of vitamin Ki supplementation to lower undercarboxylated osteocalcin 
has been demonstrated in a number of intervention studies, over a range of doses and in 
men and women of varying ages (Sokoll et al., 1997; Binkley et al., 2000; Booth et al., 
2000a; Schaafsma et al., 2000; Binkley et al., 2002; Booth et al., 2003b; Bugel et al., 
2007). Sokoll et al. (1997) performed a controlled experiment in a metabolic ward in 9 
healthy volunteers to assess the effect of a diet containing 100 pg of vitamin Ki, and for 5 
d, the effect of increasing intake to 420 pg/d. With supplementation, plasma vitamin Ki 
significantly increased and %ucOC significantly decreased. Binkley et al., (2000) studied 
the effect of 1000 pg vitamin K-i or placebo for 2 wk in 219 healthy men and women. After 
1 wk of supplementation (and sustained through to the 2nd wk) plasma vitamin Ki 
increased 10-fold and %ucOC had significantly decreased to around 3% (P<0.001). A 
subsequent study by the same group measured the effect of a range of vitamin Ki 
supplementation on %ucOC over 2 wk. It was found that supplementation decreased 
%ucOC in all supplemented groups (250, 375, 500 and 1000 pg) compared to the 
placebo. It was concluded that around 1000 pg of vitamin K-i is required daily to achieve 
maximal carboxylation of osteocalcin (Binkley et al., 2002). Another study reported a
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significant decrease (P<0.001) from 44 to 20% ucOC with intake of 200 jjg/d after 10 d 
(Booth et al., 2000a). In a depletion-repletion study by Booth et al., %ucOC was shown to 
decrease in response to a vitamin K intake of 90 pg/d during the initial stages of the study, 
however no change was recorded during the depletion (18 pg/d) or repletion (up to 450 
pg/d) phases (Booth et al., 2003b). The authors attribute this outcome to the preferential 
use of vitamin K by hepatic VKD proteins. In a recent study, a 2 y supplementation with 
either 200 pg/d of vitamin Ki or vitamin Ki+vitamin D3+calcium significantly decreased 
undercarboxylated osteocalcin within 6 month (Bolton-Smith et al., 2007). A crossover 
study performed by Biigel et al. (2007) supplemented 31 post-menopausal women with a 
placebo, 200 pg/d or 500 pg/d of vitamin Ki for 6 wk. The volunteers also received 10 
pg/d vitamin D3. Supplementation with 200 pg/d and 500 pg/d did significantly increase 
total, and decrease undercarboxylated osteocalcin. However, only supplementation with 
500 pg/d significantly increased vitamin Ki plasma concentration (Bugel et al., 2007).
Interestingly, in a study of nutritional interventions to counteract bone loss during 
space flight, it was reported that vitamin Ki had a beneficial effect on bone formation 
markers (serum bone alkaline phosphatase), whereas vitamin D and calcium did not 
stabilise bone turnover (Heer 2002).
1.3.3 Atherosclerosis
It is now recognized that the processes involved in mineralisation of bone and 
vascular calcification are similar (Vermeer et al., 2004). There is increasing evidence from 
human studies linking low vitamin K intake to the development of atherosclerosis (Jie et 
al., 1995). High intakes of vitamin Ki have been associated with protection against 
vascular hardening and loss of arterial elasticity, however these associations were 
attenuated after adjustment for dietary and lifestyle patterns (Erkkila et al., 2005a). A 
subsequent prospective study in 40,087 men concluded that high vitamin Ki itself is not 
protective against cardiovascular disease but may be a marker for a ‘healthy’ diet and 
lifestyle (Erkkila et al., 2007). A study examining vitamin Ki intake and premature 
coronary artery calcification in a 39 -  45 y old population (n = 807) showed no significant
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correlation (Villines et al., 2005). However, it is possible the effect is subtler in this young 
population and may only become apparent in later life. The relative importance of vitamin 
Ki and K2 is unknown. A population-based study showed no protective effect of vitamin 
Ki against cardiac events or aortic atherosclerosis, but an association was observed with 
vitamin K2 (Geleijnse et al., 2004). Similar results have been found with rats where 
warfarin-induced arterial calcification could be blocked by vitamin K2, but not vitamin Ki 
(Vermeer et al., 2004). These observations may be associated with different transport 
pathways of these two forms of the vitamin (see section 1.13.3).
The mechanism behind the potential relationship between vitamin Ki and 
atherosclerosis may involve many of the VKD proteins including the coagulation proteins 
(during plaque rupture), growth-arrest specific protein (Gas6) (expressed in smooth 
muscle cells and mediates a number of activities in platelets and the endothelium), 
osteocalcin (which is up-regulated during calcification) and MGP (Berkner & Runge, 
2004). MGP is also up-regulated in smooth muscle cells adjacent to sites of calcification 
and is known to be an inhibitor of calcification as seen in studies with rats (Berkner & 
Runge, 2004). Additionally, Keutel syndrome in humans, an autosomal disorder affecting 
MGP, is characterized by calcification of cartilage (Berkner & Runge, 2004).
1.3.4 Anti-cancer effects
A small number of papers have reported that vitamin K is able to inhibit both the in 
vivo and in vitro growth of cancerous cells, however most observations have been made 
with vitamin K2 and vitamin K3 (Lamson & Plaza, 2003). The in vitro studies assessing 
anti-tumour effects of vitamin Ki on a number of cell lines used unphysiological 
concentrations. Similarly, in human trials, the amount of vitamin K administered was 
unphysiological at between 20 and 40 mg/d. In the context of vitamin K intake from the 
diet, these levels are nearly impossible to achieve and hence the relevance of these 
studies should be interpreted with caution.
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1.3.5 Vitamin K and the nervous system
The vitamin K-dependent growth factor, Gas6 is widely distributed throughout the 
nervous system. This wide distribution, along with other research demonstrating an in­
direct but important role for vitamin K in the synthesis of brain sphingolipids, has led to the 
suggestion that vitamin K is important to the nervous system, particularly during 
development (Tsaioun 1999). However, further research is required in this area.
1.4 Dietary recommendations for population health
The purpose of dietary recommendations is to ensure that, on a population level, 
average intakes are adequate for normal health and the maintenance of metabolic 
function. The estimated average requirement (EAR) is the mean requirement for a 
chosen level of adequacy. The reference nutrient intake (RNI) or recommended daily 
allowance (RDA) is ± 2 standard deviations around the mean, and results in a intake value 
that meets the needs of 97.5% of the population.
1.4.1 Defining adequacy
The requirement for a micronutrient can be defined as an intake level that meets a 
criterion for adequacy. The extreme criterion of micronutrient deficiency is death, however 
death resulting from a single micronutrient deficiency is rare. Preventing clinical 
deficiency, such as impaired blood coagulation, can be regarded as the minimum goal in 
defining requirements. However, clinical signs of deficiency can be considered an 
extreme endpoint and thus measures of adequacy with greater sensitivity are required. 
Such measures should be based on a thorough understanding of the metabolic function of 
the micronutrient, and have the goal of preserving all micronutrient-related functions. In 
the case of vitamin K, requirements are typically based on a level of adequacy to prevent 
disorders of blood coagulation, and were historically assessed by the relatively insensitive 
prothrombin time test. More sensitive, subclinical conditions can be identified by specific 
biochemical or functional measures; for example, high levels of undercarboxylated 
coagulation or bone proteins may be indicative of a subclinical vitamin K deficiency.
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These markers of vitamin status, such as plasma concentration or the level of functional 
proteins (e.g. undercarboxylated osteocalcin), may also provide an indication of tissue 
stores and hence adequacy. Finally, low urinary excretion of a nutrient or functional 
marker may reflect low intake and/or a deficiency; urinary y-carboxyglutamic acid residue 
is such a marker for vitamin K status.
1.4.2 Establishing requirements
A decision on the criterion or criteria of adequacy is one step on the path to 
establishing a nutritional requirement. The second stage is to obtain data on what levels 
of intake affect health and disease through the chosen marker of adequacy.
Since clinical signs of overt vitamin K deficiency are rare, they are in this instance, 
of little use for setting recommended intakes. For many nutrients, original nutritional 
requirements were often based on the estimation of mean intakes in an apparently healthy 
population. Indeed, this method was the basis for the recent increase in the vitamin Ki 
RDA for the American population. However, the use of mean intakes in a healthy 
population is limited by its insensitivity to reflect subclinical deficiency. To be useful, 
functional markers of subclinical deficiency need to be sensitive to changes in the intake 
of a specific nutrient. Also required is a solid understanding of biological effects of the 
nutrient along with sensitive instrumentation to measure these effects. There needs to be 
a clear link between the nutrient, the marker, and health outcomes.
Undercarboxylated osteocalcin appears to provide a suitable functional marker for 
the assessment of vitamin K status and possible subclinical deficiency. Osteocalcin is an 
established marker of bone turnover, and low %ucOC is related in some studies to 
improved bone health, including clinical outcomes such as fracture rate and BMD. 
Furthermore, the carboxylation of osteocalcin has been shown to be sensitive to changes 
in vitamin K-i intake (see sections 1.3.2. and 1.6.4). However, the biological action of 
osteocalcin remains uncertain and there are questions over the relevance of 
undercarboxylated osteocalcin measurements in plasma. Furthermore, recent evidence 
from work in Rhesus monkeys showed that warfarin-induced vitamin K deficiency had no
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effect on BMD or markers of bone turnover (Binkley et al., 2007) casting doubt on the 
importance of vitamin K in osteoporosis. These concerns notwithstanding, the evidence 
suggests that osteocalcin carboxylation could be used as an additional functional marker 
of vitamin K status for the setting of dietary recommendations.
Recommended intakes for vitamin K in the UK and elsewhere are largely based on 
the requirements to maintain blood coagulation often and were set prior to recognition of 
the importance of extrahepatic VKD proteins, their functions and their wide distribution in 
body tissues. In the UK the guideline intake is 1 pg/kg body wt/d (Department of Health 
1991). Similarly, the joint German, Austrian and Swiss body, Die Deutsche Gesellschaft 
fur Ernahrung e.V., has set recommended intakes for vitamin K as 60 pg/d and 70 pg/d, 
respectively for women and men aged between 15 y and 51 y, and 65 pg/d and 80 pg/d 
for women and men aged over 51 y 1. The physiological functions of vitamin K are now 
recognised as going beyond its importance in blood coagulation. The nutritional 
requirements of vitamin K for blood clotting are well-established and are met without 
difficultly in a normal population, but evidence suggests that requirements may be greater 
to maintain full carboxylation of extrahepatic VKD proteins, notably osteocalcin. Partly in 
recognition of the additional requirement of vitamin K for extrahepatic VKD proteins, 
recommended intakes in the US have been increased to 90 pg/d and 120 pg/d for women 
and men, respectively (Institute of Medicine 2001). Furthermore, a European Commission 
report on vitamin K stated that although vitamin Ki intake of around 1 pg/kg body wt/d is 
sufficient to meet hepatic requirements it is probably insufficient to fully carboxylate 
extrahepatic proteins (European Union Scientific Committee on Food 2003). At the same 
time, recent dietary surveys have shown that more than 50% of people do not meet 
current recommendations and have revealed temporal declines in vitamin Ki intake (see 
section 1.5).
1 http://www.dge.de/modules.php?name=Content&pa=showpage&pid=4&page=14 (accessed 21st February 
2007)
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The setting of recommended intakes requires evidence from a wide-range of 
sources and studies including data from both metabolic studies (including depletion- 
repletion experiments and supplementation interventions) and small population-based and 
large epidemiological studies. Data are required on food sources of a nutrient and on 
typical intakes within a population, specifically, how differences in bioavailability from 
different foods and genetic polymorphisms affect absorption and ultimately status. An 
understanding of nutrient utilisation to include kinetics of uptake, turnover and storage are 
also essential.
The focus of the present work was to develop novel, stable isotope-based 
methods to probe the kinetics of vitamin Ki absorption, uptake and turnover in humans, 
and to investigate the bioavailability of vitamin Ki from different foods to try and improve 
our understanding of the relationship between vitamin K-i intake and plasma status.
1.5 Sources and dietary intakes of vitamin K-i
1.5.1 Vitamin Ki content of foods
Vitamin Ki is widely distributed throughout the human diet although most foods are 
poor sources. A summary of the wide-range of foods and their vitamin Ki content is 
shown in Table 1-2. The richest sources of vitamin Ki are green leafy vegetables (e.g. 
broccoli, kale, spinach) with considerable amounts in other vegetables (e.g. beans, 
cucumber, cauliflower), which is not surprising since vitamin Ki is associated with 
photosynthesis. Indeed it has been shown that the greener outside leaves of a cabbage 
contain 3 to 6 times more vitamin Ki than the inner leaves (Ferland & Sadowski, 1992b). 
The second major source of vitamin Ki is vegetable oils and margarines, although as with 
vegetables, there is a broad range of values; rapeseed and soybean oils contain high 
levels of vitamin Ki, others are intermediate sources (olive, corn oil) whereas some have 
low amounts (groundnut). Generally, dairy, meat, cereal and fruit sources provide lower 
amounts of vitamin K-i.
The vitamin Ki content of the same food can also vary considerably due to 
geographical location, seasonal variation, and processing and storage factors. For
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example, the vitamin K-i concentration of six individual rapeseed oil bottles varied between 
140 and 187 pg per 100 g (CV of 11%) and average pooled values between two sampling 
time points varied by 13% for oils, and up to 36% in margarines of the same brand 
(Piironen & Koivu, 2000). In one study, the vitamin Ki content of 12, 70% fat vegetable oil 
margarines varied between 0.1 to 61 pg per 100 g (Peterson et al., 2002) and in another 
study the vitamin K-i content in six brands varied between 12 and 78 pg per 100 g (Bolton- 
Smith et al., 2000). These large variations in the vitamin Ki content of margarine can be 
attributed to seasonal and market-led variations in the oils used in the formulation of 
margarine.
Regarding storage, samples of margarine from a single manufacturer taken 
immediately after production contained 13% more vitamin Ki then samples tested from 
shop-bought packs (Piironen & Koivu, 2000). The processing of vegetable oils has been 
shown not to influence vitamin Ki concentration, whereas heating caused a small 
decrease. Daylight and fluorescent light were reported to decrease vitamin Ki content. 
After 2 d, fluorescent light decreased vitamin Ki content by around 50% and daylight by 
about 90%. Amber glass bottles were shown to offer some protective effect (Ferland & 
Sadowski, 1992a). The preparation of food will also affect vitamin Ki intake. For 
example, peeling of apples and cucumbers decreased the vitamin Ki content by up to 
60% (Koivu-Tikkanen 2001). In addition to the actual variation in vitamin Ki content 
between samples and foods, there is analytical variation due to different methods and 
laboratories.
The assessment of vitamin K in foods is necessary for estimates of dietary intake 
(Shearer & Bolton-Smith, 2000). The accuracy of food databases is crucial and depends 
on obtaining precise measurements on truly representative samples, as well as obtaining 
data on a broad range of foods. A study of the accuracy of two nutrient databases in the 
United States by direct analysis of the diets revealed that although one showed 
reasonably close agreement (+/- 22%) another overestimated the amount of vitamin Ki in 
the diet by up to 62% (McKeown et al., 2000).
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Table 1-2. Vitamin K-i content of foods (adapted from Shearer etal., 1996)
Concentration range (pg per 100 g fresh weight)
0.1 -1 .0 1-10 10-100 100-1000
Avocado Apples Beans, runner Broccoli tops
Bananas Aubergine Beans, French Brussel sprouts
Beef, steak Baked beans Beans, broad Green cabbage
Bread, white Barley Cabbage, red Kale
Chicken Beef, minced Cauliflower Lettuce
Cod Butter Cress Parsley
Cornflakes Carrots Chick peas Rapeseed oil
Flour, white Cheese Cucumber Soybean oil
Grapefruit Chocolate, plain Greengages Spinach
Maize Courgettes Olive oil, extra virgin Water cress
Mangoes Cream Peas
Melon Dates
Milk Egg
Mushrooms Figs
Oranges Grapes
Parsnips Leeks
Peanuts Liver
Pineapple Nectarines
Pork chops Oats
Potatoes Palm oil
Rice Peaches
Salmon, tinned Peppers
Sausages Plums
Spaghetti Rhubarb
Tuna, tin Strawberries
Turnips Sunflower oil
Yoghurt Tomatoes 
Swede 
Wheat bran 
Wholemeal bread
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1.5.2 Dietary intakes of vitamin Ki
Adult intakes in the UK are reported to be between 60 and 80 pg/d (Fenton et al., 
1997; Bolton-Smith et al., 1998; Fenton et al., 2000; Thane & Bolton-Smith, 2002; Thane 
et al., 2006a). It is generally considered that intakes at this level are sufficient to maintain 
VKD coagulation proteins in a fully y-carboxylated state (Booth & Suttie, 1998).
Data from the National Diet and Nutrition Survey (NDNS) of 1986-7 in 1,936 
individuals, reported that around 48% of British men and women had intakes below the 
UK guideline intake (Thane & Bolton-Smith, 2002). More recently, data from the NDNS 
2000 -  1 survey of adults, showed 66% of men and 52% of women had intakes below the 
recommended values (Thane & Coward, 2004). Mean intake between the two surveys 
significantly decreased from 72 to 67 pg/d (Thane et al., 2006a). A similar result was 
found in Irish adults where 52% had intakes below 1 pg/kg body wt/d (Duggan et al., 
2004).
The NDNS and Irish surveys all used intake data collected over 7 d. This protocol 
is important because of the large variation in foods, and the often-irregular consumption of 
foods that are very high in vitamin Ki (e.g. broccoli). Thus when estimating intake, it is 
recommended that measurements should be taken over at least 5 d (Institute of Medicine 
2001). In 1996, data from the US Food and Drug Administration Total Diet Survey were 
published that are similar to the British and Irish data. Three day dietary records (24 h 
recall and 2 d food diary) were collected from 2,706 adults (Booth et al., 1996b). The data 
are presented for four age groups (25 -  30, 40 -  45, 60 -  65 and 70 y +) and intakes 
ranged from 59 to 86 pg/d for all individuals. Based on the then-current dietary 
recommendations only individuals in the 25 -  30 y age range were below the 
recommended values. However, in the US intakes have recently been raised to 120 and 
90 pg/d for men and women, respectively (Institute of Medicine 2001). On this basis, all 
groups were below the adequate intake. A later study that used 14-d food diaries in 4,741 
people aged 13 y and above, showed mean intakes of 81 and 73 pg/d for males and 
females, respectively (Booth et al., 1999b). If the US guideline intake is applied to British
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NDNS data then 75% of participants in the 1986 -  7 survey, and 78% from the 2000 -  1 
survey had intakes below the cut off values (Thane et al., 2006a).
1.5.2.1 The relative importance o f different vitamin K-j sources
As might be predicted from the relative amounts of vitamin Ki in foods, the 
greatest contributor to intake is vegetables. Vegetables contribute between 50% and 70% 
of dietary vitamin ^  (Booth et al., 1996b; Thane & Bolton-Smith, 2002; Duggan et al., 
2004; Thane & Coward, 2004; Thane et al., 2006a), around half from green leafy 
vegetables, commonly cabbage, broccoli and spinach. Indeed, in one study spinach, 
collards (kale), lettuce and broccoli accounted for 34% to 42% of total vitamin Ki intake in 
men and women (Booth et al., 1996b). In the NDNS surveys, 19 -  23% of vitamin Ki was 
from green leafy vegetables, and 14 -  18% from raw vegetables (mainly lettuce). 
Interestingly, comparison of the 1986 -  7 and 2000 -  1 survey revealed a decline of the 
importance of traditional British vegetables (cabbage and Brussel sprouts) as sources of 
vitamin Ki (Thane et al., 2006a) that mirrors the overall decrease in vitamin Ki intake. 
Other food groups, meat, dairy, fats and oils, and cereals typically contribute around 5% to 
10% to total dietary intake of vitamin (Duggan et al., 2004; Thane et al., 2006a).
These values suggest that vegetables are the major dietary source of vitamin Ki. 
However, this conclusion assumes that the vitamin K1 is equally available for absorption 
between different foods and sources which is unlikely considering the location of vitamin 
Ki within plant cell membranes and evidence that suggests greater absorption from oil 
than from vegetable sources ( Booth et al., 2002).
The relative contribution of foods that contain lower amounts of vitamin Ki but that 
are eaten in higher quantities should also be considered. For example, a study from 
Brazil in 115 adults, showed that green leafy vegetables contribute around 30% of total 
dietary vitamin Ki, as assessed by a food frequency questionnaire. However, based on 
24-h recall of diet, kidney beans and soybean oil emerged as important sources of vitamin 
Ki contributing around 10% and 30%, respectively (Custodio das Dores et al., 2007).
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1.5.2.2 Non-dietary factors affecting intake o f vitamin K1
An understanding of non-dietary factors that may affect vitamin Ki intake is useful 
in identifying groups of a population that may be at risk of dietary deficiency and include 
age, gender, and geography.
In the US (Booth et al., 1999b), Irish (Duggan et al., 2004) and British surveys 
(Thane et al., 2006a) vitamin K-i intake significantly increased with age mainly due to the 
consumption of green leafy vegetables (Thane eta!., 2006a).
In the British NDNS data and a US survey there were significant gender 
differences when intake was expressed as pg/d however, these differences disappeared 
when intake was expressed as pg/kg body wt/d (Booth et al., 1999b; Thane et al., 2006a). 
In a study of 34 adults, the use of 4-d weighed records revealed no relationship between 
age or gender and vitamin Ki intake (Booth et al., 1997). In a cohort of 837 men and 
women that used a food frequency questionnaire (FFQ), daily intake was shown to be 
higher in women than men (151 pg/d and 115 pg/d, respectively) (McKeown et al., 2002), 
but again this difference would likely be reduced if expressed per kg of body weight.
There appears to be considerable geographical variation in dietary intakes of 
vitamin Ki. A study from The Netherlands has estimated intakes in an elderly (55 y and 
over) population to be 250 pg/d (Schurgers et al., 1999). Although, this value seems very 
high in comparison to data from other studies, it may be accurate since another study 
found similar levels in a population of Dutch post-menopausal women (Jie et al., 1996). 
Higher intakes in the Dutch population have been attributed to their high intake of spinach 
and broccoli (Thane et al., 2002b). The comparison of two populations of older people 
showed that people living in Shenyang, China had a vitamin K-i intake four-times that of 
people living in Cambridge, UK (285 and 59 pg/d) (Yan et al., 2002). Values from a 
population in New England, US (McKeown et al., 2002) were considerably higher than 
those reported in previous US studies. Regional differences have also been observed in 
the UK with decreasing intakes heading from London and the South-East towards 
Scotland (Thane & Bolton-Smith, 2002; Thane et al., 2006a).
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1.5.2.3 Potential toxicity of high vitamin Kt intakes
There is no evidence to suggest that high intakes of vitamin K pose any risk. 
Newborn babies commonly receive milligram doses of vitamin K-t either orally or 
intramuscularly against HDNB (Hey 2003). Large doses of vitamin Ki are also 
administered in cases of anticogualant poisoning, again with no systematic reports of 
adverse effects. A number of studies have been performed in human volunteers with 
milligram oral doses of vitamin Ki (Lamon-Fava et al., 1998; Binkley et al., 2002). One 
study reported the supplementation of female athletes with 10 mg/d vitamin Ki for one 
month to improve markers of bone status and documented no side effects (Craciun et al., 
1998). Vitamin K2 has also been given in large doses (up to 90 mg) in intervention trials 
with no reported adverse health effects (Weber 2001). One unpublished report cited in 
Vermeer et al. suggests that vitamin K-i supplementation (more than 1 mg/d) can 
contribute to periodontitis (Vermeer et al., 2004). Vitamin Ki is an essential growth factor 
for micro-organisms implicated in the progression of periodontal disease (Rawlinson et al., 
1998). However, it appears that, unlike vitamin A, there is little risk of vitamin K toxicity, 
possibly because vitamin Ki is rapidly excreted and does not accumulate in tissues to the 
same extent as other fat-soluble vitamins.
1.6 Vitamin Ki status and its measurement
A number of markers of vitamin Ki status are available. Some may provide an 
indication of whole body stores (plasma concentration, urinary Gla excretion), while others 
may provide information on the vitamin K status of specific tissues, e.g. PIVKA-II for liver 
and ucOC for bone. However, the relevance of most of the markers of vitamin K status 
has been questioned due to the lack of evidence for their physiological significance 
(Institute of Medicine 2001) and whether circulating levels of the markers reflect status at 
the tissue level. Some of the potential markers are discussed below.
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1.6.1 Plasma concentration
Plasma samples are relatively simple to obtain and vitamin Ki plasma 
concentration is the most common way to assess vitamin K status. However, this method 
can be considered a rather indirect and relatively insensitive marker because the 
biochemical function of vitamin K occurs within tissues and cells (Fell & Talwar, 1998). 
Furthermore, and as will be discussed in more detail, plasma concentration is highly 
dependent on recent intake (<12 h) rather than tissue stores (Sokoll et al., 1997).
Due to the low levels of vitamin K found in human plasma, it is only relatively 
recently that accurate determinations of vitamin Ki in plasma have been possible. 
Quantitative analysis of vitamin Ki in biological tissues is routinely performed using high 
performance liquid chromatography, usually after post-column reduction and fluorescence 
detection. Sadowski et al. published one of the first studies to measure plasma vitamin Ki 
concentration in a reasonable size population with a wide age range (Sadowski et al., 
1989). This study measured fasting plasma vitamin Ki in 396 adults. A normal range was 
established ranging from 0.29 to 2.64 nmol/L and the geometric mean was 0.87 nmol/L. 
Plasma concentrations within a population are not normally distributed, but are heavily 
skewed towards lower values. As a result, geometric means and median values are both 
used to report plasma vitamin Ki levels. In a study of 1,154 British adults, the geometric 
mean was reported as 0.94 nmol/L with 95% of values between 0.1 and 8.72 nmol/L. The 
higher upper range of values is due the inclusion of non-fasting plasma samples in the 
analysis (Thane et al., 2006b), although more typical post-prandial values are reported to 
be in the range 1 - 3  nmol/L (Suttie 1992). The geometric means of plasma vitamin Ki 
concentration in 1,042 US adults was 0.57 and 0.92 nmol/L in women and men, 
respectively (Rock et al., 1999).
The use of plasma vitamin Ki concentration as a sensitive marker of status has 
been questioned, since in a number of studies, supplementation with lower levels of 
vitamin Ki (25, 50 and 200 pg/d) after depletion had no effect on plasma vitamin Ki levels 
(Suttie et al., 1988b; Ferland et al., 1993; Booth et al., 2003b). However, Ferland et al. 
(1993) did observe a 30% increase in plasma vitamin Ki with 45 pg/d of vitamin Ki and
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Booth et al. reported an increase from 0.21 to 0.87 nmol/L after repletion with 200 pg/d for 
10 d (Booth et al., 2000a). Plasma vitamin K  ^ does respond to recent vitamin Ki intake 
(Gijsbers et al., 1996; Garber et al., 1999; Booth et al., 2002) thus is useful for 
measurements of absorption. Schurgers et al. (2004) performed a step-wise 
supplementation study where volunteers received an increasing supplement on a weekly 
basis. Plasma concentration was measured at 4 h post-dose at the beginning of each 
week and a linear relationship between dose (50, 100, 150, 200 or 250 pg) and plasma 
concentration (2.7 -  8.9 nmol/L) was observed. The response of plasma concentration to 
intake is short-lived and may explain the contrasting results obtained above. As a result, 
plasma status may not be suitable as a marker for whole body or tissue status. However, 
Olson et al., (2002) suggested that plasma levels do relate to body status since they 
observed a linear relationship between the two (r=0.6, p<0.05) when body pool sizes were 
calculated using radiolabelled vitamin K-i. In the study of Schurgers et al., (2004) fasting 
samples were also collected at the end of each week of supplementation. A linear 
relationship was still observed although the slope was very shallow with values ranging 
from 1.1 -  2.9 nmol/L.
There is also some evidence that plasma status may change throughout the day. 
In six volunteers, plasma vitamin Ki peaked at 2200 h and decreased to 32% of the 
maximum by 1000 h, and mirrored TAG concentration (Kamali et al., 2001). Depending 
on the research question, a potential advantage of using plasma status compared to the 
other methods listed below is the ability to distinguish between vitamin Ki and vitamin K2.
1.6.2 Prothrombin time
Before the advent of methods to measure plasma vitamin Ki and sensitive 
methods to measure uncarboxylated proteins, the use prothrombin time (PT) as a marker 
of vitamin K status was common. Simply, prothrombin time is the time required for a 
sample of blood to clot. However, it is not a sensitive assay for measuring vitamin K 
status because normal prothrombin times are still observed even when plasma contains 
only 50% of the normal amount of prothrombin (Suttie 1992). Early studies with diets
31
containing <25 pg/d for upward of 20 d have shown conflicting results with some reporting 
an increase in PT, while others have shown no change (Suttie et al., 1988b), even on a 
vitamin K-free diet (Allison et al., 1987). Since the advent of sensitive methods to 
measure vitamin Ki plasma status, studies have generally shown no significant change in 
prothrombin time with alterations in vitamin Ki intake (Suttie 1992; Ferland et al., 1993; 
Booth et al., 1999a), although one study reported a significant decrease of 1.5% in PT 
when subjects when repleted with 420 pg/d (Sokoll eta!., 1997).
1.6.3 Coagulation proteins
A more sensitive measure of hepatic vitamin K status is undercarboxylated 
prothrombin (factor II) known as ‘protein induced by vitamin K absence’ (PIVKA-II). Since 
prothrombin, along with the other coagulation proteins, are synthesised in the liver, this 
measure can provide information on liver stores. PIVKA-II has been show to be 
responsive to reduced vitamin K-i intake (Suttie et al., 1988b; Ferland etal., 1993; Booth et 
al., 2003b) and repletion with 200 pg/d (Booth et al., 2000a), 86 pg/d (Booth et al., 2003b) 
and 50 pg/d (Suttie et al., 1988a), although repletion with intake up to 45 pg/d had no 
effect (Ferland et al., 1993). In another study, undercarboxylated factor II decreased 
within 1 wk with supplementation of 100 pg/d and continued to show a linear decrease 
with supplementation up to 500 pg/d (Schurgers et al., 2004).
Factor VII and protein C activity have also been investigated as potential markers 
of vitamin K status. Although Factor VII and protein C circulate at much lower 
concentrations than prothrombin, the half-life is only 6 h (compared to 60 h for 
prothrombin) (Ferland et al., 1993) thus they were considered potentially useful indicators 
of current vitamin K status (Institute of Medicine 2001). However, Ferland et al., (1993) 
reported no change during depletion or repletion in the status of these coagulation 
proteins.
1.6.4 Undercarboxylated osteocalcin
The level of undercarboxylated osteocalcin (ucOC) is relatively sensitive to 
changes in vitamin K intake as demonstrated in controlled metabolic trials (Sokoll et al.,
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1997; Booth et al., 1999a; Binkley et al., 2000) and intervention studies (Bolton-Smith et 
al., 2007; Bugel et al., 2007). As with undercarboxylated prothrombin as a marker of 
vitamin K liver status, ucOC primarily provides a measure of vitamin K status of bone. 
Supplementation with 420 pg/d decreased %ucOC by around 40% within 5 d (from 22% to 
13%) (Sokoll et al., 1997), whereas another study observed an approximate 50% 
decrease with supplementation of 250, 375 and 500 pg/d, and a 75% decrease with 1000 
pg/d (with starting values of %ucOC of 6 -  8%) over 1 wk (Binkley et al., 2002). A step­
wise supplementation study where volunteers received an increasing supplement on a 
weekly basis showed no effect of daily intakes of 50, 100, 150, 200 or 250 pg/d 
incremental, but a significant decrease in %ucOC was observed with 300 pg/d (Schurgers 
et al., 2004). However, these observations may partly be explained by the gradual 
increase of vitamin K-i stores. A depletion-repletion study observed a significant increase 
in %ucOC (from 35% to 60%) after 90 pg/d for 14 d, but in contrast to Sokoll et al., (1997) 
failed to observe any significant decrease during step-wise repletion to 450 pg/d, 
explained by the preferential use of vitamin K-i by the liver (Booth et al., 2003b). Another 
study observed a decrease in %ucOC from 44 to 20% after depletion and subsequent 
repletion with 200 pg/d for 10 d (Booth et al., 2000a).
The usefulness of ucOC as a marker of vitamin K status is supported by evidence 
linking high %ucOC to physiological outcomes such as low bone mineral density and 
increased fracture rates. Furthermore, the apparent slower turnover of vitamin K in bone 
provides a marker of longer-term status (Schurgers et al., 2004). However, concern has 
been raised as to the usefulness of ucOC as a marker since results from monoclonal 
antibody kits for measuring ucOC from different manufacturers are reported to provide 
quite different results (Institute of Medicine 2001). Additionally, the relevance of 
measuring a non-functional protein has been questioned, since if ucOC makes around 5- 
10% of total osteocalcin then 90-95% is still fully functional, thus no ‘normal’ value has 
been established (Institute of Medicine 2001). In one study, McKeown et al. defined high 
%ucOC as >20% and suggested this value as a marker of low vitamin K status. On this
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basis, approximately half of 917 men and women had low vitamin K status (McKeown et 
al., 2002).
1.6.5 Urinary Gla excretion
An indirect method to measure vitamin K status is via the excretion of Gla residues 
in urine that derive from the metabolism of VKD proteins. Significant reductions (10 -  
20% from baseline) in urinary Gla excretion have been induced with intakes between 10 
and 100 pg/d (Suttie et al., 1988b; Ferland et al., 1993; Sokoll et al., 1997; Booth et al., 
2003b). However, repletion with between 45 to 500 pg/d was not sufficient to raise Gla 
excretion to baseline levels (Suttie et al., 1988b; Ferland etal., 1993; Booth et al., 2003b). 
Similarly, supplementation of 420 pg/d and 500 pg/d made no difference to Gla excretion 
(Booth et al., 1999a; Bugel et al., 2007). Although urinary Gla could provide an indicator 
of whole body status there are no reference values. Response to variation in vitamin K 
intake is not consistent, and there is no indication of the relative status of different tissues, 
although these data may be inferred from the estimated turnover values of vitamin K- 
dependent proteins. It is estimated that 60% of excreted Gla residues derive from 
coagulation proteins (Ferland et al., 1993). It has been suggested that urinary Gla is less 
responsive to short-term changes to vitamin Ki intake than other markers such as ucOC 
(Booth et al., 2001).
1.6.6 Urinary vitamin K metabolites
Recently a method for the measurement of the two major urinary metabolites has 
been published (Harrington et al., 2005; 2007). The methodology was proposed as a non- 
invasive marker of vitamin K metabolism and its use was demonstrated in subjects before 
and after supplementation with different levels of vitamin K1f K3 (menadione) and MK-4. 
Values of the aglycone metabolites with side chain lengths of 5 and 7 carbon atoms 
(Figure 1-12) were expressed relative to creatinine. Whether the method is suitable for 
detecting small changes in vitamin K status is unknown since supplementation levels were 
between 1 mg and 50 mg. Additionally, a proportion of vitamin K metabolites are excreted 
via the bile (Harrington et al., 2005).
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1.6.7 Relationships between markers of vitamin Ki status
No single marker provides a ‘gold standard’ for the assessment of vitamin K 
status. It is useful for the interpretation of data on individual markers to understand to 
what extent they are correlated. However, few studies have provided this comparison. In 
263 healthy individuals, %ucOC was inversely correlated with plasma vitamin K-i (r=-0.35, 
P<0.001) and PIVKA-II (r=-0.15, P<0.05). There was a positive correlation with %ucOC 
and PIVKA-II (r=0.27, P<0.001) (Sokoll & Sadowski, 1996). Another study in 219 
individuals reported a significant inverse correlation between %ucOC and plasma vitamin 
Ki (r=-0.245, P 0 .00 1 ) (Binkley et al., 2000) as did Beaven et al., (2005) (r=-0.57, 
P<0.001). Tsugawa et al., (2006) reported a significant correlation between plasma 
vitamin Ki and ucOC (r=0.22, P=0.001) in 396 women aged 30 -  79 y. McKeown et al., 
(2002) also reported an inverse association between %ucOC and plasma vitamin K1f with 
the odds of a high %ucOC in those in the lowest plasma vitamin K-i quintile, 2 and 3 times 
greater than those in the highest quintile, for women and men, respectively. More 
recently, a study in 142 haemodialysis patients reported no correlation between plasma 
vitamin Ki and %ucOC (Pilkey et al., 2007).
1.6.8 Non-dietary factors affecting vitamin Ki status
A number of non-dietary factors may affect one or more of the vitamin K status 
markers. It is necessary to understand which factors may play a role in determining 
status, so they can be considered in study design and interpretation.
1.6.8.1 Gender
A number of studies have shown that gender has no effect on vitamin K plasma 
status (Sadowski et al., 1989; Booth et al., 1997; McKeown et al., 2002; Thane et al., 
2002a), whereas others have identified a significant gender difference (Rock et al., 1999; 
Thane et al., 2006b). Thane et al., (2006b) report geometric means of 1.13 and 0.81 
nmol/L (P<0.001), in 530 and 624, men and women, respectively. Rock et al. (1999) 
report geometric means 0.92 and 0.57 nmol/L in 411 and 631 men and women and that
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gender is a significant (P<0.05) predictor of plasma status. It has also been shown that 
the menopause does not affect vitamin K status (Sokoll & Sadowski, 1996).
1.6.8.2 Age
Age has been shown by a number of studies to be related to vitamin K status 
(Sadowski et al., 1989; Booth et al., 1997; Tsugawa et al., 2006), but not all (McKeown et 
al., 2002). In 263 adults aged 18 -  85 y, Sokoll & Sadowski (1996) report that plasma 
levels in males and females were generally constant with the exception of lower levels in 
the 3rd decade. In the 2000 -  1 NDNS there were no significant differences in vitamin Ki 
plasma concentration between individuals in four age groups, with the exception of lower 
levels in young ( 1 9 - 3 4  y) women (Thane et al., 2006b). Rock et al. (1999) reported a 
4% change in vitamin Ki concentration with every decade of life.
The relationship between osteocalcin and age is complicated with numerous 
conflicting reports. Although total osteocalcin may vary with age, one study showed that 
when ucOC was expressed as a % of total osteocalcin, many of the age and sex 
differences were removed (Sokoll & Sadowski, 1996). One study in 219 subjects, 
reported that %ucOC was higher in young men than older men but there was no 
difference in women (Binkley et al., 2000). Another study in 396 women (aged 30 -  79 y) 
showed that ucOC was significantly correlated with age (Tsugawa et al., 2006).
Age was not related to PIVKA-II but differences were observed between young 
males and young females; urinary Gla excretion was also reported to increase with age 
(Sokoll & Sadowski, 1996).
1.6.8.3 Plasma lipids
A strong correlation between plasma vitamin Ki and TAG concentration has been 
described in a number of population studies (Sadowski et al., 1989; Kohlmeier et al., 
1995b; McKeown et al., 2002) and metabolic studies (Dolnikowski et al., 2002; Erkkila et 
al., 2004). In a study in 15 individuals, from whom blood samples were taken weekly for 
22 wk, vitamin Ki was positively and significantly correlated with TAG (r=0.51, P<0.001) 
(Talwar et al., 2005). This correlation may also explain observations in some studies of
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higher plasma vitamin Ki in the elderly since vitamin K-i is primarily associated with 
chylomicrons (Booth & Suttie, 1998). Indeed, in one study in 131 young and 195 elderly 
individuals, the higher plasma status of vitamin Ki in the elderly was reversed on 
correction for TAG, after which the young had proportionally higher levels (Sadowski et 
al., 1989). This relationship may be expected since, like vitamin E, which is also 
correlated with TAG (Sadowski et al., 1989), vitamin K is transported by lipoproteins.
In many studies plasma vitamin Ki has been adjusted for TAG levels in blood on 
the basis that this may provide a more appropriate marker for vitamin Ki status by 
removing inter-individual variation in TAG levels. One study that measured absorption of 
vitamin Ki adjusted plasma vitamin Ki by TAG concentration and found that after 
adjustment, area under the curve coefficient of variation (CV) was reduced from 43 to 
27% (Booth et al., 2002). A further study, noted that normalisation of plasma vitamin Ki 
for TAG concentration decreased inter-individual variation in post-prandial concentrations, 
as indicated by smaller standard deviations (Erkkila et al., 2004). However, in the study of 
Talwar et al. (2005) where individuals provided fasted samples regularly over 22 wk, 
correction of plasma vitamin Ki for TAG, decreased intra-individual variation from 38% to 
30% but inter-individual variation increased from 44% to 46%.
If there was a strong relationship between TAG and vitamin K1 then stronger 
gender and age differences in vitamin Ki plasma concentration might also be expected, 
since TAG are generally higher in males compared to females, and in the elderly (Shearer 
et al., 1988). This inconsistency suggests that dietary intake is probably a more important 
factor.
A correlation of plasma vitamin Ki with cholesterol has also been reported (Cham 
et al., 1999; Pilkey et al., 2007), although other studies have found no relationship (Erkkila 
et al., 2005b).
1.6.8.4 Seasonal variation
Season may affect plasma vitamin Ki concentration. In the US, higher values 
have been reported from spring to a maximum in late autumn and a reduction again in
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winter (Sadowski et al., 1989). Higher plasma Ki values have also been found in US 
populations measured in spring/autumn compared to those sampled during the winter 
(McKeown et al., 2002). However, another study in Scotland showed no seasonal
variation in plasma vitamin Ki levels (Fenton et al., 2000). The lack of agreement in
seasonal effects is probably in large part due to regional and temporal differences in
vitamin Ki content of foods (McKeown et al., 2002).
1.7 The relationship between vitamin Ki intake and vitamin Ki plasma status
The measurement of nutrient status is crucial to understanding its function and 
determining sufficiency and the development of recommended intakes. Since it is not 
always feasible to directly measure status, nutritional intake data provide indirect 
measurements of status. Estimates of nutrient intake in a population are assessed using 
epidemiological data. It is therefore important to understand the relationship between 
dietary intake and the biochemical marker, commonly plasma vitamin Ki. There are 
broadly two types of study that can be used to measure the relationship between intake 
and status, experimental or observational studies.
1.7.1.1 Experimental studies
Experimental studies generally require a period of stay in a metabolic unit where 
the participants undergo a period of depletion (reduced dietary vitamin K compared to 
habitual diet) followed by repletion at different levels of intake. Depletion significantly 
decreases plasma vitamin Ki concentrations (Suttie et al., 1988b; Ferland et al., 1993; 
Booth et al., 2003b) although the extent and rate of the decrease has been shown to vary 
between age groups. Ferland et al. (1993) reported that the plasma vitamin Ki 
concentration of older individuals decreased more slowly and maintained a higher level 
than concentrations of the younger age group. Intakes of 10 pg/d decreased levels to 
13% of the original values (p<0.001) whereas another study showed significant decreases 
at a relatively high intake of 90 pg/d (Booth et al., 2003b). However, plasma levels 
decreased no further with an intake of only 18 pg/d possibly suggesting the existence of a 
deeper pool with slow turnover (Booth et al., 2003b). In a further study in nine individuals,
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plasma vitamin Ki halved between recorded levels at the start of the study and 6 d after 
consuming 100 pg/d (Sokoll eta!., 1997).
Repletion has been investigated over a range of intakes from 15 pg/d to 1000 
pg/d. A single study showed no increase in plasma vitamin Ki at daily doses of 15, 25 
and 35 pg/d whereas 50 pg/d produced a small rise but only to 35% of the baseline value 
(Ferland etal., 1993). A further study showed a small increase in plasma vitamin (0.43 
to 0.57 nmol/L) after increasing intake from 30 to 55 pg/d but a significant increase (0.49 
to 1.66 nmol/L) was only recorded when intake rose to 500 pg/d (p<0.01) (Suttie et al., 
1988b). These data possibly suggest that there is limited capacity for the absorption of 
single doses of vitamin K, as might be expected if uptake was a saturable, energy- 
dependent process (Hollander 1973). Binkley et al. (2002) reported no difference in 
concentrations after supplementation with 250, 375 and 500 pg/d for 1 wk. A study in 21 
elderly people over 84 d using stepped-repletion found that 86 pg/d and 200 pg/d had no 
effect on plasma vitamin K-i concentration. Even on repletion of 450 pg/d plasma vitamin 
Ki did not reach pre-study values (Booth et al., 2003b). This observation could be 
explained by study design since vitamin K was given each morning only, with fasting 
blood samples taken the following morning (Booth et al., 2003b). However, a similar 
protocol was used in the study of Ferland et al. (1993) where 45 pg/d increased plasma 
vitamin Ki by 30%. Suttie et al. (1998b) divided the repletion dose between the morning 
and evening meals but did not observe any change in plasma vitamin Ki with 50 pg/d. As 
for the depletion described above, in the study of Ferland et al. (1993) older people were 
observed to increase plasma levels more rapidly during repletion than the young and it 
was suggested that higher hepatic body stores in the elderly results in a greater 
resistance to depletion and a greater response to repletion.
1.7.1.2 Observational studies
These involve either large epidemiological studies or smaller studies where intake 
and status have been measured on a number of occasions. Significant positive 
relationships have been observed between dietary intake and plasma concentration
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(Table 1-3). As may be predicted, the correlations are generally stronger if more 
measurements of intake and status have been taken (Booth et al., 1997; Bolton-Smith et 
al., 1998). One study showed no relationship between dietary intake and status 
(Schurgers et al., 1999) and was possibly a consequence of high intakes in this population 
since another study showed a plateau effect at higher intakes such that the association 
between plasma vitamin K-i and intake was only significant up to 200 pg/d (McKeown et 
al., 2002). Furthermore, if intakes between two populations with low and high intakes are 
compared, the correlation is less strong in the population with higher intakes (Yan et al., 
2004).
Table 1-3. Observational studies comparing vitamin Ki intake and vitamin Ki 
plasma status
Reference Population n Samples R value P value
Booth et 
al., 1997 Adults 34
3 x 4-d weighed 
record 0.51 =0.004
3 x fasted plasma
Booth et 
al., 1997 Adults 34
1 x 4-d weighed 
record 0.13 0.30
1 x fasted plasma
Bolton- 
Smith et 
al., 1998
Adults 65
3 x 7-d weighed 
record
3 x fasted plasma
Men: 0.28 
Women: 0.28
Men: 0.45a
Women:
0.41a
<0.05
<0.001
Schurgers 
etal., 1999 310
FFQ
Fasted plasma
No
relationship
McKeown 
et al., 2002 Adults 837 FFQ <0.0001
Thane et 
al., 2002b Elderly 1076
4-d weighed record 
Fasted plasma
Men: 0.18 
Women: 0.30
<0.001
Yan et al., UK 134 7-d food diary 0.29b =0.005
2004 Chinese 178 FFQ 0.17b =0.03
Thane et 
al., 2006b Adults 1,154
7-d weighed record 
1 x plasma
Men: 0.26 
Women: 0.32
<0.001
a After adjustment for TAG
b There was no change in the relationship after adjustment for TAG  
Abbreviations: FFQ, food frequency questionnaire; TAG, triacylglycerol
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Using regression analysis, the variance in plasma vitamin Ki explained by intake 
alone is reported as between 6% (Thane et al., 2002a) and 8% (Thane et al., 2006b). 
Multiple regression analysis showed that intake, season and TAG could explain 11% of 
plasma vitamin Ki variation in free-living elderly Britons (Thane et al., 2002a) whilst 
another study found 44% of the variation was due to vitamin Ki intake, energy intake and 
TAG (Bolton-Smith et al., 1998). Booth et al. (1997) state that the correlation between 
intake and status is partly determined by the reproducibility of the measures and as shown 
above, multiple measurements improved the correlation. Thane et al. (2006b) reported 
that around 20% of plasma vitamin Ki variation was explained by various biochemical 
indices (in addition to vitamin K  ^ intake) including cholesterol and plasma retinyl palmitate. 
However, the relevance of including some biochemical indices (e.g. plasma total Fe- 
binding capacity) is not clear. With the inclusion of other non-dietary factors around 40% 
of the vitamin Ki plasma concentration was explained by demographic, lifestyle factors 
and dietary factors in 1,042 adults in the US (Rock et al., 1999). These studies show that 
despite the inclusion of numerous factors in the regression models, still less than 50% of 
the variation in plasma vitamin Ki can be explained. Kohlmeier et al. (1995b) estimated 
that less than a third of the variation between plasma vitamin Ki of individuals is due to 
diet, whereas most of the variation is determined by apoE genotype and TAG metabolism.
1.7.1.3 Summary o f intake and status data
As discussed above, plasma status of vitamin K1 is not well correlated with vitamin 
Ki intake, but of interest it is reported to be the strongest of the fat-soluble vitamins (Booth 
et al., 1997). The strength of the relationship depends on the timing of collection of 
dietary and biochemical data, since plasma levels are largely determined by recent intake. 
Thus, the consumption of foods high in vitamin K-i has a large short-term effect on plasma 
levels. Based on three, 4-d dietary records, the within-subject variance ratio for intake has 
been shown to be greater than between-subject variance for all fat-soluble vitamins, but in 
particular vitamin Ki. For plasma status, only vitamin Ki of the fat-soluble vitamins had 
greater within-subject variance than between-subject variance (Booth et al., 1997) and
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suggests recent intake is the major factor in plasma concentration. Inter-subject variability 
is likely a consequence of differences in the uptake and metabolism of vitamin K-i between 
individuals, and will be determined by for example, apoE phenotype. Evidence from 
multiple regression analysis puts the contribution of intake at around 10%, which is 
probably an underestimate since no correction is made for bioavailability. Probably a 
major determinant of the intake-plasma relationship within an individual, particularly for 
vitamin K1f is bioavailability.
One of the methods for the determination of nutritional requirements is to use the 
mean intake of an apparently healthy population. Indeed, this method was adopted by the 
Institute of Medicine for setting of new Adequate Intake levels in the US (Institute of 
Medicine (IOM) Food and Nutrition Board (FNB) 2001). As a non-invasive method this 
approach is adequate but more information is required, and in particular a better 
understanding of the relationship between intake and status.
1.8 Bioavailability
The bioavailability of a nutrient depends on the efficiency of digestion, absorption 
and utilization, although only digestion and absorption combined can be quantified using 
plasma response (Schneeman 2004). Bioavailability has recently been defined as ‘the 
fraction of an ingested nutrient that is available for utilization in normal physiologic 
functions and for storage’ (Jackson 1997).
An understanding of nutrient bioavailability is important for setting dietary 
recommendations and to interpret the relationship between intake and status. Often, 
bioavailability data is limited and only available for a small number of individual foods. In 
the case of inorganic nutrients, the development of bioavailability algorithms has been 
explored, whereby available data are used to develop mathematical models to estimate 
nutrient bioavailability from different diets (Hunt 1996). Consideration of bioavailability is 
especially pertinent for vitamin K, where evidence from national surveys suggests intakes 
are marginal, and evidence is accumulating for a greater nutritional requirement for 
extrahepatic vitamin K-dependent proteins.
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The importance of bioavailability in our understanding of nutrient requirements has 
been recognised by a number of national bodies. The UK Food Standards Agency lists 
the development of methods to measure bioavailability as one its key aims under its 
optimal nutrition research programme (N05)1, with the objective of providing a scientific 
basis for population-level recommendations as to the optimal intake for micronutrients. In 
the US, the need for further studies on the bioavailability of vitamin K has also been 
recommended by the Institute of Medicine (Institute of Medicine 2001).
1.8.1 Definitions
For pharmacological studies of drugs, bioavailability is determined by the 
difference between an oral and an intravenous (/V) dose, compared by measuring the area 
under the curve fitted to changes in plasma concentration versus time.
Bioavailability = ^ Cjora/ * dose'v.
[AUC\IV x doseora,
Where:
AUC = area under the curve 
oral = oral dose 
IV  = intravenous dose
For nutrition research, the term is slightly less rigid and refers more generally to 
the amount available to the tissues after an oral dose, often measured by plasma 
concentration. Often in nutrition, relative bioavailability and not absolute bioavailability is 
calculated.
Relative bioavailability = * dose--
[AUC]b x doseA
1 http://www.foodstandards.gov.uk/science/research/researchinfo/nutritionresearch/ (accessed 13th March 
2007)
43
1.9 Vitamin K digestion and absorption
Before considering factors that may affect absorption, it is necessary to consider 
the mechanism of absorption of vitamin Ki. Following ingestion, vitamin K is digested with 
other fat-soluble vitamins and other lipid components. The gastric emptying of vitamins A 
and E have been shown to closely follow that of lipids in a study of that measured the 
vitamins in stomach and duodenum by direct sampling in healthy volunteers (Borel et al., 
2001). The primary dietary form of vitamin K, vitamin K1f is absorbed, as with other non­
polar lipids, chemically unaltered, in mixed micelles in the small intestine. Mixed micelles 
are mainly composed of bile salts, free fatty acids, monoglycerides and phospholipids. 
Evidence for the importance of bile comes from the comparison of radiolabelled vitamin K 
absorption between normal, healthy subjects and patients with fat malabsorption disorders 
(Blomstrand & Forsgren, 1968; Shearer et al., 1974). Once solubized, the components of 
the mixed micelles are absorbed into the enterocytes via diffusion down a concentration 
gradient towards the mucosal cell surface. Absorption appears to be similar in both 
between the proximal and distal small intestine (Hollander et al., 1977). In contrast to the 
passive absorption mechanism, work by Hollander (1973) using sacs everted from rat gut 
has suggested that vitamin K is absorbed by an energy-mediated saturable transport 
mechanism. Later experiments, this time using an in vivo technique in rats and a range of 
vitamin K concentrations, demonstrated saturable kinetics in the micromolar range, further 
supporting the earlier conclusion (Hollander et al., 1977). However, since these 
experiments, no laboratory has followed up these observations and no specific 
mechanism has been published. One explanation may be that there are specific 
receptors acting as part of a high-affinity, readily-saturated active transport mechanism for 
vitamin K, which can scavenge low concentrations of the vitamin, coupled with another 
passive transport route, which predominates at higher concentrations.
Once in the enterocytes, the components of the mixed micelle (including vitamin Ki 
and other fat-soluble vitamins) are repackaged into chylomicrons. Chylomicrons are the 
largest of the lipoproteins and consist of a non-polar, hydrophobic core of cholesterol 
esters, TAG and other non-polar fat-soluble components. The polar outer layer contains
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free cholesterol, phospholipids and apolipoproteins. The main role of chylomicrons is the 
transport of dietary lipids from the gut in lymph and blood. In the enterocytes, 
apolipoproteins are synthesised and incorporated into the chylomicrons. From the 
enterocytes, chylomicrons are secreted into the lymph and subsequently into the venous 
circulation. In humans, Blomstrand & Forsgren (1968) measured newly absorbed vitamin 
K-i in lymph by collection of lymph from the thoracic duct at the neck. Chylomicrons as the 
major carriers of newly absorbed vitamin K  ^ was demonstrated in experiments using 
tritiated vitamin Ki that showed around 70% of radioactivity in lymph was associated with 
the chylomicrons (Blomstrand & Forsgren, 1968; Shearer et al., 1970b). A similar 
proportion of radioactivity was also reported in chylomicron and lipoprotein fraction of 
serum at the peak time after administration of 3H-labelled vitamin K-i in humans (Shearer 
et al., 1970a). These early studies were performed using radiolabelled vitamin K since no 
method was available for the measurement of vitamin K-i. More recent studies have 
confirmed that chylomicrons are the major carrier of newly absorbed vitamin K-i (Lamon- 
Fava etal., 1998; Schurgers & Vermeer, 2002; Erkkila et al., 2004).
1.10 Vitamin K metabolism
Prior to describing the post-prandial transport of vitamin Ki, an overview of general 
lipoprotein metabolism is required. An understanding of the physiology of vitamin Ki 
uptake is necessary to interpret kinetic data and studies.
1.10.1 Lipoprotein metabolism
Figure 1-10 shows the major pathways of lipoprotein metabolism. Once in the 
blood, chylomicrons pick up the apolipoproteins, apoE and apoC from the high-density 
lipoproteins (HDL). A major role of HDL is the transfer of apoE and apoC between 
chylomicrons, very low-density lipoproteins (VLDL) and HDL. TAG are removed from 
chylomicrons through the action of lipoprotein lipase that is present on the luminal cell 
surface of adipose and muscle tissue. ApoC is required for the activation of lipoprotein 
lipase and subsequent hydrolysis of TAG. The remaining particles, known as chylomicron 
remnants (CR), are transported to the liver. One major pathway for uptake of CR is via
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the low-density lipoprotein (LDL) receptor on the surface of hepatocytes via interaction 
with apoE. Additional pathways include uptake via LDL-receptor related protein (LRP) or 
sequesterisation by binding to heparan sulfate proteoglycans (Cooper 1997). It is also 
believed that cholesterol is an essential component of CR uptake, since without 
cholesterol, CR remain in the plasma (Redgrave 2004). In the liver, CR are further 
metabolised with removal of cholesteryl esters and remaining TAG. A proportion of these 
molecules are subsequently packaged into VLDL (Redgrave 2004). VLDL particles 
synthesised in the liver are the major carrier of plasma TAG to other parts of the body. As 
in chylomicrons, and after interaction with HDL, the TAG in VLDL are hydrolysed by 
lipoprotein lipase and the fatty acids absorbed by adipose and muscle tissue. 
Intermediate-density lipoproteins (IDL), also referred to as [3-VLDL, are formed as VLDL 
remnants and are either taken up by the liver via apoE, or undergo further processing to 
low-density lipoproteins (LDL). LDL particles are the major carriers of both free and 
esterified cholesterol. The characteristics of lipoprotein particles are summarised in Table 
1-4.
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Figure 1-10. Major pathways of lipoprotein metabolism in humans. Newly 
absorbed lipids leave the intestine and enter circulation via the lymph. Hydrolysis 
of TAG from chylomicrons occurs in the tissues and the resulting chylomicron 
remnants are taken up by the liver. VLDL supply lipids to extrahepatic tissues from 
the liver. IDL are intermediates in the formation of LDL from VLDL and after 
hydrolysis of TAG. The purpose of HDL is primarily the transport of lipids from the 
tissues back to the liver
LiverIntestine HDL
Lymph LDL
VLDI
Chylomicron
remnants
Chylomicrons Peripheral
tissues
Hydrolysis 
of TAGCapillary Capillary
Table 1-4. Classes of lipoproteins, their source, density and function (adapted from 
Mann & Truswell, 1998)
Class Source Density (g/mL) Function
Chylomicron Intestine < 0.950 Transport of exogenous lipids from intestine
h d l 2 Intestine 1.063- 1.125 Removal and transfer of
h d l 3 Liver and VLDL 1.125-1.210 cholesterol from tissues
LDL VLDL 1.019-1.063 Transport of cholesterol to peripheral tissues and liver
IDL VLDL 1.006- 1.019 LDL precursor
VLDL Liver 0.950- 1.006 Transport of lipids from liver to peripheral tissues
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1.10.2 Post-prandial vitamin K-i transport
The major carriers of vitamin Ki in the plasma are chylomicrons, chylomicron 
remnants (CR) and VLDL. Evidence for the association of vitamin Ki with chylomicrons 
and CR comes from work by Lamon-Fava and colleagues (Lamon-Fava et al., 1998). In 
their first study, 15 volunteers were given 1.43 pg/kg body wt (around 100 pg) of vitamin 
Ki in a fat-rich milkshake. Samples were taken at 0, 3, 6, 9 and 12 h after ingestion and 
peak plasma vitamin Ki was observed at 6 h with 73% found in the TAG-rich lipoprotein 
(TRL) fraction that includes chylomicrons and VLDL. In the second study, volunteers 
ingested a higher dose of 50 pg/kg body wt of vitamin Ki, again in a milkshake, and the 
time course of vitamin Ki concentration in different lipoprotein fractions in blood plasma 
was measured. The size of the dose was around 4000 pg for men and 3000 pg for 
women. The results are summarised in Table 1-5 and show that the majority of vitamin 
Ki was carried in TRL. However, the distribution between chylomicrons and VLDL cannot 
be calculated. The authors postulate that as more chylomicron remnants are taken up by 
the liver vitamin Ki is gradually secreted in VLDL (Lamon-Fava et al., 1998). The ratio of 
IDL to LDL reflects CR clearance and it was reported by Saupe et al. that this ratio was a 
good predictor of vitamin Ki concentration (Saupe etal., 1993).
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Table 1-5. Vitamin K-i concentrations in plasma and lipoprotein fractions after 
ingestion of 50 pg/kg body weight of vitamin K, (adapted from Lamon-Fava et al., 
1998)
Time after ingestion (h)
0 3 6 9 12
Plasma vitamin K 
(nmol/L)
0.75 1.8a 274.6 212.7 146.8
TRL
189.8 237.6 151.3 83.3
(90.7%)b (85.8%) (76.0%) (69.9%)
LPFFC
HDL
LDL
IDL
2.5 5.2 8.0 3.8
(1.2%) (1.9%) (4.0%) (3.1%)
6.5 16.7 19.8 16.8
(3.1%) (6.0%) (9.9%) (14.1%)
9.0 15.0 17.7 13.1
(4.3%) (5.4%) (8.9%) (11.0%)
1.5 2.4 2.4 2.1
(0.7%) (0.2%) (1.2%) (1.8%)
a Value as reported in the publication. However, this is likely a typographical error because 1) it is unrelated to 
amounts in lipoprotein fractions and 2) sem is ± 26 nmol/L
b Percentage total vitamin Ki in lipoprotein fractions
0 Lipoprotein-free fraction
Smaller amounts of vitamin K-i were also found in IDL, LDL and HDL and might 
deliver vitamin K-i to parts of the body other than the liver (Lamon-Fava et al., 1998). It 
should be noted that in this study, volunteers were given very high doses of vitamin Ki 
that resulted in plasma concentrations of around 100 times the normal fasting level of 
vitamin Ki in plasma. The authors however dismiss this criticism since, in their first study 
(with a typical dose of 100 pg) a similar percentage of vitamin Ki was recovered in the 
TRL fraction.
Further evidence for TRL transport of dietary vitamin K comes from Schurgers & 
Vermeer (2002) who measured vitamin K1f MK-4 and MK-9 in volunteers for 48 h after 
consumption of a meal containing 2 pmol (900 pg) of vitamin K-|. In agreement with 
Lamon-Fava et al., they found the majority of vitamin K  ^ was carried in the TRL fraction 
(chylomicrons and VLDL) with lower amounts in both LDL and HDL. As a percentage, 
LDL contained no-more than 17% of the total plasma Ki and HDL no-more than 18% of
49
the total, which are slightly higher than maximum amounts at any time point found in LDL 
and HDL in the study of Lamon-Fava et al. (1998) (14 and 11% respectively at 12 h). In 
the two studies, the amount of vitamin Ki in LDL and HDL peaked at 6 h (Schurgers & 
Vermeer, 2002), and 12 h (Lamon-Fava et al., 1998) after ingestion. Appearance in LDL 
occurs through VLDL metabolism while appearance in HDL could be due to exchange 
along side lipids and apolipoproteins during chylomicron lipolysis (Lamon-Fava et al., 
1998).
The studies of Lamon-Fava et al. (1998) and Schurgers & Vermeer (2002) both 
utilised high levels of vitamin Ki that might have disrupted normal vitamin Ki metabolism. 
Stable isotopes provide a tool to investigate metabolism at physiological levels. In the 
study of Errikila et al. (2004) and to investigate post-prandial vitamin K1 metabolism, five 
volunteers were fed intrinsically labelled collard greens containing approximately 400 pg 
deuterium-labelled vitamin K-i. Blood sampling was performed for up to 216 h after 
consumption of the labelled vitamin Ki meal. However, due to reported analytical 
problems, the lipoprotein distribution profile is reported for total vitamin Ki only and not 
labelled vitamin Ki. The results of total vitamin Ki are in agreement with Lamon-Fava et 
al. (1998); the main carrier of vitamin Ki was the TRL fraction, with much lower amounts in 
IDL, LDL and HDL. No vitamin Ki was detected in lipoprotein-free fraction (LPFF) 
suggesting the appearance of vitamin Ki in LPFF in earlier studies was due to the high 
doses given. Deuterated vitamin Ki was measured in only the TRL fraction in three 
subjects. Uptake and disappearance of deuterated vitamin Ki in the plasma and TRL 
fraction was reported to be very similar in all three subjects with around 90% of plasma 
pool being enriched after 6 h suggesting a small pool size. Deuterated vitamin Ki was no 
longer detected after 72 h, which points to relatively fast turnover. The report of Errikila et 
al. (2004) supports earlier work that shows the TRL fraction, consisting primarily of 
chylomicrons, is the main carrier for vitamin Ki. Consequently, the liver must be the 
primary destination of vitamin Ki. The presence of vitamin K1t albeit in smaller amounts, 
in other lipoproteins suggests they may transport vitamin Ki to the tissues.
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1.10.3 Role of Apolipoproteins
Apolipoprotein E directs the fate and uptake of chylomicron remnants (CR). A 
number of codominant alleles have been found that result in one of six genotypes for 
apoE, namely E2/E2, E3/E3, E4/E4, E2/E3, E3/E4, E2/E4. The most common genotype 
is E3/E3, making up around two-thirds of most populations. Approximately one in three 
people carry the E2/E3 and E3/E4 genotypes, whilst the remaining combinations are very 
rare (Saupe et al., 1993). Saupe et al. found that vitamin K-i concentration in plasma of 
haemodialysis patients was related to apoE genotype in the order E2 > E3 > E4, such that 
individuals with the E2/E2 genotype had the highest vitamin K-i plasma levels. Similar 
associations have been found with a-tocopherol and y-tocopherol (Ortega et al., 2005). 
Kohlmeier et al. reported that apoE genotype is a strong determinant of vitamin Ki plasma 
status (Kohlmeier et al., 1995b). Since chylomicron clearance is also slower in individuals 
with the E2/E2 genotype (Saupe et al., 1993) this finding provides further evidence that 
chylomicrons are the major vitamin Ki transporting particles. In contrast, a superior 
vitamin Ki plasma status (and lower %ucOC) was reported in healthy older people with 
the apoE4 genotype in both Britain and China (Yan et al., 2005). More recently, a study in 
142 haemodialysis patients reported the opposite result; carriers of the apoE4 gene had 
the highest %ucOC (Pilkey et al., 2007). These conflicting results are likely due to the 
relatively small sample sizes, at least for genetic work.
It has also been suggested that apolipoproteins A1 and B can be used to predict 
plasma concentrations of vitamin Ki (and vitamin E) and might be important determinants 
of vitamin K-i metabolism (Cham et al., 1999). ApoA1 is associated with HDL and is 
involved in the transfer of cholesterol from tissues. ApoB is involved in chylomicron, VLDL 
and LDL metabolism and is present in two forms. ApoB100 is produced in the liver, and 
contains the LDL receptor-binding domain, and thus contributes to the hepatic and 
peripheral tissue uptake of LDL. ApoB48 is produced in intestinal mucosal cells, is 
incorporated into chylomicrons, and is involved in hepatic uptake of chylomicron 
remnants. ApoB48 lacks the part of the apoB100 molecule that is recognised by LDL
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receptors so whereas LDL provides cholesterol to peripheral tissues, chylomicron 
remnants are largely cleared via apoE receptors in the liver (Welty et al., 2004). As a 
result, the presence and distribution of apoB48 and apoB100 in lipoprotein particles may 
influence distribution of vitamin Ki between the liver and extrahepatic tissues.
1.10.4 Vitamin K-taurine conjugate
Petrosian and Haroutounian (2000) have proposed an alterative hypothesis in 
which taurine forms a water-soluble conjugate with vitamin K (Figure 1-11) that permits a 
secondary mechanism for the transport of vitamin K and other fat-soluble vitamins. Their 
hypothesis is based largely on circumstantial evidence, at least for vitamin K, since high 
concentrations of taurine, with an unknown role, are found in blood platelets and may act 
as a transporter for vitamin K-i (Petrosian & Haroutounian, 2000). Alternatively, the water- 
soluble conjugate may provide a mechanism for the uptake of menaquinones from the 
colon.
Figure 1-11. Postulated structure of vitamin K-taurine conjugate, 2-methyl-3-phityl- 
1,4,naphtochinolidine taurine. From Petrosian and Haroutounian, 2000
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1.10.5 Vitamin Ki transport and delivery
In contrast to the fat-soluble vitamins A and D, there appears to be no specific 
mechanism for the transport of vitamin Ki to other tissues. It seems likely that vitamin Ki 
transport is largely determined by the fate of lipoproteins, mainly chylomicrons and CR, 
and may be partly controlled by the distribution of apoE receptors on the surface of cell 
membranes (Kohlmeier et al., 1996). The importance of other lipoproteins in the transport 
of vitamin Ki is uncertain, although it has been suggested that in a state where vitamin Ki
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intake is very low, LDL is the main carrier for vitamin Ki, implying that any vitamin Ki 
stores in the liver could be mobilised and transported to other tissues via LDL (Olson et 
al., 2002). Uptake of vitamin Ki to the liver is probably highly effective, since functioning 
hepatic VKD proteins can be maintained even at low vitamin Ki intakes and plasma 
status. This effective uptake is consistent with primary GR clearance by the liver (Hussain 
et al., 1989). Booth et al. (2003b) have suggested that plasma vitamin Ki is preferentially 
used for hepatic VKD proteins, and only for extrahepatic VKD proteins once liver stores 
are adequate.
In addition to the liver, bone is also believed to have a high requirement for vitamin 
K since it is necessary for the VKD proteins, osteocalcin and MGP. In contrast to those of 
most tissues, cells in bone (in addition to liver and spleen) are in direct contact with the 
blood and therefore bind lipoproteins in preference to other tissues that are separated 
from the blood via layers of endothelial cells (Kohlmeier et al., 1996). It is postulated that 
vitamin K is transferred from circulating lipoproteins to the stromal and mesenchymal stem 
cells of bone marrow. From the marrow, these bone precursor cells migrate to sites of 
bone resorption where they form bone tissue. The migration times of these cells 
determine the rate at which the carboxylation of bone proteins can be influenced by 
vitamin K supplementation (Kohlmeier et al., 1996). Animal experiments show that a 
significant proportion of chylomicron uptake is by bone (Hussain et al., 1989). More 
recently, vitamin Kr enriched CR (produced in vivo) have been used to demonstrate the 
uptake of CR by osteoblasts in vitro, primarily through interaction with LRP receptor and 
apoE. Furthermore, this study showed that once internalised, vitamin Ki caused an 
increase in y-carboxylation of osteocalcin (Niemeier et al., 2005). Schurgers et al. (2002) 
have suggested, from data showing an inter-subject variability in the relationship between 
undercarboxylated Factor II and undercarboxylated osteocalcin, that there may be 
competition between liver and bone for vitamin K1. Niemeier et al. (2005) also 
commented that LRP uptake of CR might be greater for osteoblasts than for hepatic cells.
53
1.10.6 Summary of vitamin Ki absorption and transport
Vitamin Ki is absorbed from the small intestine in mixed micelles and is 
repackaged into chylomicrons before entering the circulation. The TAG-rich lipoprotein 
fraction is the main carrier of vitamin K-i. The TAG-rich lipoprotein fraction includes 
chylomicrons and chylomicron remnants that are the main carriers of vitamin Ki in the 
post-absorptive state. This fraction also includes VLDL that may be important in the 
transport of vitamin Ki to other tissues. Transport of vitamin Ki to tissues appears to be at 
the fate of factors affecting the metabolism of chylomicrons and CR, including apoE 
genotype. Other meal constituents that affect lipoprotein metabolism may also influence 
the absorption and transport of vitamin Ki, and have consequences for the distribution of 
vitamin Ki between hepatic and extrahepatic tissues. For example, a diet rich in PUFA 
stimulates higher lipoprotein lipase activity resulting in less hepatic uptake and potentially 
greater delivery to extrahepatic tissues. The importance of other lipoproteins in the 
transport of vitamin Ki is unclear.
1.10.7 Catabolism and excretion
Work with radioisotopes (Shearer et al., 1974; Olson et al., 2002) showed that 
vitamin Ki was rapidly catabolised to polar metabolites and excreted from the liver in both 
urine and faeces (from bile). The evidence suggests a greater proportion is excreted in 
bile than urine (Shearer et al., 1974). Urinary metabolites have been identified as 
aglycons (Shearer & Barkhan, 1973; Shearer et al., 1974; Harrington et al., 2005) and 
recently, with the development of a method for their routine analysis, have been 
suggested as a non-invasive marker of vitamin K status (Harrington et al., 2005) (Figure 
1- 12).
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Figure 1-12. Structures of vitamin K urinary metabolites a) 2-methyl-3-(5’carboxy- 
3’-methyl-2’pentenyl)-1,4-napthoquinone (7C-aglycone) and b) 2-methyl-3-(3’-3’- 
carboxymethylpropyl)-1,4-naphthoquinone (5C-aglycone) (adapted from Harrington 
etal., 2005)
O
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An alternative pathway of vitamin Ki metabolism has recently been suggested. 
Vitamin K-i (and menaquinone-4 and -7 ) may be converted to menadione during uptake 
from the gut. It is postulated that menadione is a precursor to menaquinone-4 and is 
delivered to tissues that do not have a ready supply of vitamin Ki (Thijssen et al., 2006).
1.11 Vitamin Ki kinetics and turnover
The study of nutrient kinetics provides information that, together with an 
understanding of the physiology, leads to a better understanding of metabolism and can 
contribute to the evidence-base for setting recommended intakes. Kinetic studies provide 
data on uptake, turnover, the number of kinetically distinct body pools, their masses, and 
their relative rates of turnover. Additionally, kinetic studies may provide data for more 
specific studies of nutrient absorption or metabolism; for example, duration and number of 
samples and dose levels (Gregory III & Quinlivan, 2002). Kinetics can be studied with 
unlabelled, radiolabelled or stable isotope labelled compounds. The relevance of 
unlabelled compounds is limited because it is impossible to distinguish between the 
endogenous nutrient and the dose, and their use is really only applicable to short-term 
studies using large doses. With a labelled compound, it is possible to measure 
unambiguously the tracer dose or its metabolites.
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1.11.1 Uptake kinetics
Early tracer studies of vitamin Ki kinetics were hampered by the lack of a suitable 
methodology to measure plasma levels of vitamin Ki. To overcome this problem, early 
studies used radiolabelled forms of vitamin Ki, often at pharmacological levels (Shearer et 
al., 1972; Shepherd et al., 1977; Bjornsson et al., 1979). However, other studies have 
used more physiologically relevant doses (Shearer et al., 1974; Olson et al., 2002).
Each of the above studies used iv doses and describe the kinetics of vitamin Ki 
uptake as a model with two compartment characteristics, comprising two exponential 
functions (relating to two T%). Most describe an initial clearance with Ty. of around 0.5 h 
followed by second exponential with T% of around 3 h. In contrast, Olson et al. (2002) 
describe a much slower second exponential of 28 h that the authors ascribe to the 
different time-scales of the experiments (up to 10 h compared to 72 h). However, the 
differences are more likely a reflection of measurement specificity, since radioactivity in 
the study of Olson et al. (2002) was not categorically associated with vitamin Ki. A recent 
study using an unlabelled pharmaceutical preparation of vitamin Ki (Konakion®) also 
describes two exponentials, one of “initial rapid decrease” followed by Ty2 of 3 h. 
However, this study, which was investigating pharmacokinetics of Konakion®, used very 
large doses of vitamin K-i (22 pM) (Soedirman et al., 1996).
In the study of Olson et al. (2002), vitamin Ki kinetics were measured in five 
individuals after either a control diet (75 pg vitamin Ki per d for 1 -  2 wk) or a low vitamin 
Ki diet (8 pg per d for 3 -  8 wk). Around 30% to 40% of the total dose was found in urine 
over 6 d and 30% or 13% in the stools of subjects consuming normal vitamin Ki or a low 
vitamin Ki diet, respectively. These data may suggest a possible mechanism for the 
retention of vitamin when status is low. Of the total dose, 30% remained unaccounted for 
after 6 d, suggesting storage in deeper stores such as bone or adipose tissue that are 
slow to turnover (Olson et al., 2002).
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1.11.2 Turnover
The often-quoted ‘rapid turnover’ of vitamin Ki largely derives from work by Usui et 
al. (1990) who measured changes in plasma and hepatic vitamin K-i in 22 patients after 
either 3 d of vitamin K-i restriction (5 pg) or a normal hospital diet. Assuming the adult 
liver weighs 1.2 kg, then the liver pool size of vitamin Ki decreased from 33.6 nmol (15 
pg) to 8.2 nmol (4 pg) within 3 d (Usui eta l ,  1990). Olson (1999) calculates this decrease 
to be equivalent to a 7% of 1.5 d, which is a turnover time of 2.2 d. The interpretation of 
turnover values is often complicated by the different expressions. Thus,
Fractional turnover constant (rate of exit of material from the pool)
= k = 0.693/7%
Absolute turnover rate (amount of material moving in or out of the pool per unit time)
= a = pool size x k
Turnover time (time required for a quantity of material equal to the pool size to move in 
and out of the pool)
=  Tt = V k =  TyJO.693
Calculation of the turnover time (from the reported 7% of the second, slower 
exponential) from a number of tracer studies provides values that fall into two groups. 
Firstly, values in the region of 2.6 to 4.9 h (Shearer et al., 1972; Shearer et al., 1974; 
Shepherd et al., 1977; Bjornsson et al., 1979), and secondly, a value of 39.7 h (Olson et 
al., 2002) that is consistent with that calculated from Usui et al. (1990). Two studies of the 
clearance of pharmacological doses (22 pM) of vitamin Ki, also reported values that fall 
into these two groups; 4.3 h (Soedirman et al., 1996) and 36.5 h (Pereira et al., 2005), 
although the latter study was performed in patients with acute liver dysfunction. Shorter 
sampling times and high doses have been shown to generate shorter turnover times 
(Olson et al., 2002). In the study of Olson et al. (2002), the slopes of the 2nd exponential 
of plasma disappearance matched those of the lines for decay of urinary metabolites,
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suggesting that both represent the true turnover rate. Furthermore, these are similar to 
the rates of excretion of urinary metabolites observed by Shearer et al. (1972; 1974). 
However, since Olson et al. (2002) did not measure radioactivity unequivocally associated 
with vitamin Ki, it is likely that the turnover time reflects that of excretory metabolites, as 
measured in the studies of Shearer et al., as well as menadione (Thijssen et al., 2006). 
However, the ability to calculate turnover rates from earlier studies was questioned 
because of the absence of a method for vitamin Ki quantitation and flooding of the body 
pool with high doses (Shearer & Barkhan, 1979).
1.11.3 Body pools
Direct tissue analysis can provide some information on vitamin K body stores but 
analysis in tissues other than plasma is difficult in humans. Liver is a major body store of 
vitamin K, although only 10% is vitamin Ki, the remainder consisting of menaquinones of 
various chain lengths (Shearer et al., 1988). Adult values for vitamin K-i liver stores have 
been estimated as between 10 and 30 nmol/kg (wet weight) (Shearer et al., 1988; Usui et 
al., 1990; Thijssen & Drittij-Reijnders, 1996). Bone also has been identified as a major 
body pool of vitamin Ki with values in region of 10 nmol/kg (dry weight) (Hodges et al., 
1993) and other organs (e.g. heart and pancreas) may make a significant contribution to 
total vitamin Ki body stores (Thijssen & Drittij-Reijnders, 1996).
It was not possible to calculate pool sizes from early tracer studies because 
accurate and sensitive methods did not exist for the quantitative measurements of vitamin 
Ki. In the study by Olson et al., total body pool size was estimated to be between 17 and 
195 pg (38 - 433 nmol (0.3 -  2.2 pg/kg; 0.7 - 4.9 nmol/kg) prior to vitamin Ki restriction. 
The pool sizes of vitamin Ki are believed to be relatively small, especially when compared 
to the other fat-soluble vitamins (vitamin D, 5 pg/kg; vitamin A, 5000 pg/kg and vitamin E, 
40000 pg/kg) (Olson et al., 2002).
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1.11.4 Summary of kinetic work
A number of conclusions can be drawn from the above work. Firstly, the evidence 
suggests the existence of at least two body pools, an initial pool (that can be identified 
physiologically as plasma) and a second pool (perhaps represented by the liver and other 
body stores). However, the observation that a significant amount of radioisotope 
remained in the body after 6 d (Olson et al., 2002), and evidence from tissue 
measurements, may suggest the existence of a third body pool with slow turnover that has 
not been identified in studies to date. The apparent absence of active transport of vitamin 
^  to extrahepatic tissues may result in slow kinetics that are difficult to detect given the 
low plasma concentration and body stores of vitamin Ki. The available evidence from 
kinetic work and earlier studies on the effect of vitamin K depletion, suggests a relatively 
fast turnover and limited body stores of vitamin K1t in contrast to other fat-soluble vitamins.
1.12 The measurement of bioavailability
Bioavailability is commonly assessed through comparison of circulating levels of the 
compound of interest hours after an oral and an iv dose. This approach is often not 
possible in nutrition research because the nutrient already exists within the measured 
pool; the use of isotopically labelled compounds however does allow such comparisons. 
The assessment of relative bioavailability is the common approach, as illustrated in 
studies that have measured vitamin K bioavailability from foods (Gijsbers et al., 1996; 
Booth et al., 1999a; Garber et al., 1999; Schurgers & Vermeer, 2000; Booth et al., 2002). 
Unfortunately, this approach does not readily permit comparisons between different 
studies because it is not known how much of the nutrient has been absorbed.
1.12.1 Marker selection
When quantifying the bioavailability of vitamin K, a number of markers of status 
could be measured e.g. plasma vitamin Ki, %ucOC etc. In the studies presented in this 
thesis, the primary outcome is how much of the vitamin is absorbed from a food or meal 
and thus the measurement of plasma vitamin Ki is the most suitable direct measure. The
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other markers may be more suitable for longer-term studies where the chronic intake is 
more related to whole-body status.
1.12.2 Plasma response
Assuming a linear relationship, the amount of vitamin absorbed is reflected in the 
rise in plasma concentration. This method is applicable to relative bioavailability 
measurements provided the study is performed over a sufficient period of time to ensure a 
new steady-state between test doses (Parker et al., 1999). However, this proviso is more 
relevant to other fat-soluble vitamins than for vitamin Ki due to their slower turnover.
Plasma responses can be measured after single or multiple doses. Relative 
absorption of a supplement source of vitamin K and of vitamin K from meals has been 
measured in a number of single dose experiments (Gijsbers et al., 1996; Booth et al., 
1999a; Garber et al., 1999; Schurgers & Vermeer, 2000; Booth et al., 2002). Plasma 
levels over a 5-d period using a multiple-dosing method has also been applied in the 
comparison of oil and broccoli diets (Booth et al., 1999a). Although relatively simple, the 
methodology is limited because plasma response is a function of not only absorption, but 
also breakdown, tissue uptake and release from body stores. Additionally, it is likely that 
the large doses used in some of these studies may not behave kinetically in the same way 
as physiological doses (Yeum & Russell, 2002).
When assessing the absorption of a nutrient, it is common to measure the area 
under the curve (AUC) as a measure of plasma concentration plotted against time. The 
mass of the nutrient absorbed is proportional to the area under the curve. Other 
parameters derived from the curve are the maximum plasma vitamin Ki concentration 
(Cmax) and the time of peak concentration (Tmax). In studies of nutrients, it is usually 
necessary to correct the area for the baseline values, although not if a labelled tracer is 
used. The methodology is best suited to measuring the effects of single doses and has 
been applied in a number of studies of vitamin K-i bioavailability (Gijsbers et al., 1996; 
Booth etal., 1999a; Garber et al., 1999; Schurgers & Vermeer, 2000; Booth et al., 2002).
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1.12.3 Post-prandial chylomicron response
In the field of vitamin A research, a method whereby only carotenoids in 
chylomicrons (or rather the TAG-rich lipoprotein fraction (density <1.006 kg/L) are 
measured, has been developed (PPC -  post-prandial chylomicron response). The 
rationale behind the method is that, while LDL and HDL transport endogenous 
carotenoids, newly absorbed carotenoids (as with vitamin Ki) enter the circulation and are 
transported to the liver in chylomicrons and chylomicrons remnants. Thus, carotenoids in 
these fractions are primarily exogenous in origin. Although the method could be applied 
to vitamin K research, it does have a number of short-comings, as outlined by Parker et al. 
(1999). Firstly, since chylomicrons are rapidly metabolised by the action of lipoprotein 
lipase, CR of a range of sizes are present. As a result, recovery of TAG-rich lipoprotein 
fraction may vary through differences resulting from centrifugation. The second problem 
is that during absorption, chylomicron production and clearance are highly variable 
between individuals (partly due to apoE genotypes). This inter-individual variation makes 
it difficult to discern differences in absorption (Parker et al., 1999). However, the same 
would be true for any method that measures fat-soluble vitamin absorption.
1.12.4 Faecal balance studies
In oral-faecal balance studies, the amount absorbed is calculated by the amount 
ingested minus the amount recovered in the faeces. This method suffers from a number 
of potential inaccuracies. Firstly, no account is made for losses due to bacterial 
degradation in the gut. Secondly, there is a lack of discrimination between the amount 
from normal diet and from the test meal. Thirdly, the results could be largely influenced by 
inter-individual variation in transit time through the gut. This method has only been 
applied to vitamin K research with the use of a radiolabelled dose (see section 1.12.6) 
therefore reducing errors from endogenous contribution.
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1.12.5 Depletion / repletion methods
The use of depletion/repletion methods was discussed earlier (section 1.6) in 
relation to intake and status. The major disadvantage of these studies is the required long 
stay in a metabolic unit that is both costly in terms of time and money. As discussed 
previously (section 1.7.1.1), the results from these studies have provided conflicting 
results as to the dose-response relationship. As with the other methods, only data on 
relative bioavailability is obtained.
1.12.6 Radioisotopes
Shearer et al. (1970a) used [T ,2 ’-3H2] vitamin Ki and faecal balance 
measurements to measure the absorption of vitamin Ki with a meal and concluded that 40 
-  50% of the oral dose of vitamin Ki was absorbed. Later, on the basis that much of the 
observed faecal radioactivity was associated with metabolites, the estimate of absorption 
was increased to 80% (Shearer et al., 1974). This study remains the only assessment of 
absolute vitamin K-i absorption. Radiolabelled compounds can act as tracers and allow 
the detection of low amounts of vitamin, however due to perceived health risks, as well as 
ethical, regulatory and disposal challenges, their use is no longer favoured.
1.12.7 Stable Isotopes
The use of stable isotopes for the measurement of nutrient absorption and 
metabolism has grown rapidly as the equipment to separate and quantify stable isotopes 
has become more economical and the availability of labelled compounds has improved. 
In the fields of vitamin A and E research, the use of stable isotope methodologies is 
relatively well established but only recently have they been applied to questions of vitamin 
K metabolism. Stable isotopes have a number of advantages over other methods. Firstly, 
stable isotopes are safe for use in all population groups. Secondly, it is possible to 
distinguish between the labelled dose and endogenous molecules and thirdly, it is 
possible to use low physiological doses that are typical of amounts in food and that do not 
perturb normal kinetics. Finally, with stable isotopes, it is possible to administer two
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labelled forms simultaneously that permits measurement of, for example, absorption and 
kinetics. In general, there are two approaches for labelling of compounds; intrinsic 
labelling describes the method of labelling a molecule in situ, whereas an extrinsic 
labelled molecule is synthesised chemically.
1.12.7.1 Intrinsic labelling
Three published studies have used stable isotope methodologies in order to 
measure vitamin Ki absorption from food. All have chosen to use intrinsically labelled 
vegetables. Intrinsic labelling involves growing a plant in isotopically-enriched 
environment so it takes up labelled precursors. The technique can be applied to both 
inorganic, e.g. Fox et al., (1991), Harvey et al., (2005) and organic molecules, e.g. 
Dolnikowski et al., (2002). For organic analysis, deuterated water and 13C labelled C 02 
have been used to label molecules of interest. The use of labelled C 0 2 may be preferable 
since deuterium enrichment over 50 atom percent excess can be deleterious to plant 
growth and thus only partial labelling can be achieved (Kurilich et al., 2003). The major 
advantage of intrinsic labelling is that the molecule of interest is labelled and contained 
within a matrix as it is usually eaten. The converse of course is that the number of foods 
that can be labelled in this way is limited. A further complication to intrinsic labelling is 
since there is no control over the extent or position of labelling, multiple isotopomers are 
formed. The location of the heavier atoms is apparently random, the heavier atoms may 
be more readily exchanged in chemical reactions or lost during GCMS analysis by 
fragmentation of the molecule. These problems can, to some extent, be overcome by the 
use of gas chromatography-combustion-isotope ratio mass spectrometry which 
quantitatively combusts the molecule after chromatographic separation and prior to 
analysis by isotope ratio mass spectrometry. This method has better sensitivity and 
precision for the measurement of isotope ratios but sensitivity in terms of sample 
concentrations is at least 1000 times lower than that afforded by the use of GCMS (Bier
1997). For vitamin Ki this consideration is important since concentrations in plasma are 
low.
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1.12.7.2 Application o f intrinsic labelling in human feeding studies
The first report of the use of intrinsic labelling applied to vitamin Ki research was 
from Dolnikowski and colleagues (Dolnikowski et al., 2002). In this study, broccoli plants 
were grown hydroponically with the addition of deuterated water during growth of broccoli 
heads. A single, 23 y old male volunteer took part in the study and was given a breakfast 
of 115 g of labelled broccoli (containing 168 pg of vitamin K-i after steaming) together with 
further food consisting of 850 kilocalories and 31% energy from fat. Blood samples were 
taken hourly to 5 h, then every 30 min until 8 h and finally at 10, 12, 16, 20 and 24 h. 
Measurement of labelled vitamin Ki from broccoli by GCMS gave an isotopomer profile 
from m/z 452 to m/z 467. The most abundant isotopomer was m/z 458 which 
corresponded to 14.1% of total labelled vitamin K-|. The pattern of isotopomer proportions 
was an approximate normal distribution. After 5 h, the isotopomer profile was a mixture of 
both unlabelled endogenous vitamin Ki and vitamin Ki from the labelled broccoli. 
Because of the limitations of GCMS, not all the heavier ions could be measured except in 
those samples with the greatest concentration of vitamin Ki. Thus, at the later time points 
the abundance of the isotopomers that could not be measured were fixed at their ratio to 
the larger isotopomers in the samples where they could be measured. The authors of this 
study reported that the labelled vitamin Ki appeared at 2 h in plasma and that peak 
enrichment was around 80% between 4 and 6 h. The high levels of enrichment are likely 
due to the low plasma concentration in the single subject. Interestingly, after a low- 
vitamin Ki meal at 5.5 h, total plasma Ki peaked again at 8 h post-dose although there 
was no rise in labelled vitamin K-i. These data suggest a) a rise in the label was 
undetected by GCMS, b) labelled vitamin had not mixed with endogenous vitamin Ki 
and was not released during the post-prandial rise in TAG, or c) that vitamin Ki in the 5.5 
h meal was highly bioavailable and caused a spike in the unlabelled vitamin Ki plasma 
concentration.
Later the same group applied this methodology to the study of vitamin Ki transport 
in five volunteers after a dose of intrinsically labelled collard greens (Erkkila et al., 2004).
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This study was described in section 1.10.2 in more detail. Vitamin K-i concentrations in 
plasma were measured by HPLC and isotope ratios by GCMS.
More recently liquid chromatography mass spectrometry (LCMS) has been applied 
to the measurement of carotenoids and vitamin Ki (Kurilich et al., 2003). In this study, 
kale was labelled with 13C 0 2 by growing the plant in a sealed acrylic box. A single 
volunteer consumed 400 g of kale (containing 156 nmol (*  70 pg) of vitamin with 30 g 
of peanut oil. Blood samples were collected hourly during the first day, daily during the 
first week and then biweekly for the next 5 wk. The analysis of isotope ratios was 
performed by LCMS with atmospheric pressure chemical ionisation. In this technique, the 
eluent from the LC is sprayed through a heated vaporiser at atmospheric pressure. The 
solvent ions are then ionised and transfer the charge to the analyte molecules in a similar 
way as methane molecules are used in GCMS with chemical ionisation. The base peaks 
for unlabelled and labelled vitamin Ki were m/z 451 (due to the additional proton) and m/z 
482, respectively, m/z 482 corresponding to the fully labelled vitamin Ki molecule. In 
other words, all of the carbon atoms in vitamin K-i were 13C atoms (13C3i). The isotopomer 
proportions were 13C3i 55%, 13C30 27%, 13C2g 9%, 13C28 4% and 0.6% unlabelled.
The bioavailability of vitamin K-i was estimated at 7%, calculated by multiplying 
labelled plasma vitamin Ki concentration by estimated plasma volume (assuming 45 mL 
plasma per kg body wt) and then dividing this value by total deuterated dose. Using this 
method, the bioavailability results for three of the subjects from the study by Errikila et al. 
(2004) are 4.7, 6.1 and 4.6% and from Dolnikowski et al. (2002) 1.7% (assuming 70 kg 
body weight since no details are provided).
1.13 Determinants of vitamin K bioavailability
This final section of the introduction considers the determinants of vitamin K 
bioavailability. A particular emphasis is on dietary factors; including matrix effects, the 
modulating effects of fat, and inhibitors of bioavailability. Also discussed is the potential 
contribution to vitamin K sufficiency of both dietary, and endogenous menaquinone 
production.
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1.13.1 Vitamin K-i isomers
Due to rotation around the double bond of the phytyl chain side-chain, vitamin Ki 
exists in two configurations, the c/s- and the trans-lsomers. Naturally-occurring vitamin Ki 
is found exclusively as the frans-isomer but synthetic forms may contain a certain 
proportion of the c/'s-isomer. The c/s-isomer may be found in certain foods and 
supplements due to the addition of the synthetic form. Additionally, the trans-isomer can 
undergo photo-isomerization on exposure to light (Woollard et al., 2002).
Work in rats has shown that although the cis-isomer was absorbed it did not have 
any biological activity as measured by levels of prothrombin. Rats receiving the c/'s- 
isomer only showed the same prothrombin as vitamin K-deficient control rats, whereas 
those supplemented with trans-vitamin Ki had normal prothrombin concentrations (Knauer 
et al., 1975). The authors also demonstrated with 3H-labelled compounds, hepatic 
retention of the c/'s-isomer, indicating it may not be metabolically active. It is suggested 
that the c/'s-isomer is unable to act as a substrate to vitamin K epoxidase (Knauer et al., 
1975). Other work in rats has shown that the c/'s-isomer had only 1% of the activity of the 
trans-isomer for Factor VII. In vitro work has demonstrated that the carboxylase enzyme 
has no activity with the c/'s-isomer (Suttie 1985).
Since the c/'s-isomer is effectively an inactive form of vitamin K, it is important to 
consider its contribution to vitamin K intake and adjust recommended values as 
necessary. A number of foods have been shown to contain appreciable amounts of the 
c/'s-isomer including oils (10 -  20%), vegetables (<1%) and processed foods (1 -  12%) 
(Woollard et al., 2002). A recent vitamin Ki supplementation study reported that the c/'s- 
isomer accounted for around 12% of vitamin Ki in tablets (Schurgers et al., 2004).
1.13.2 2’,3’-dihydro-vitamin Ki
To improve their shelf-life and other characteristics for food manufacture, 
vegetable oils are commonly hydrogenated. Hydrogenation of vitamin Ki results in the 
saturation of a single 2’,3’ double bond in the side chain and conversion to 2 ’,3’-dihydro-
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vitamin K (Davidson et al., 1996). Two of commonly hydrogenated oils are soybean and 
rapeseed oil, both good sources of vitamin K (Erkkila et al., 2005b).
Evidence from work in rats suggests that dihydro-vitamin Ki is well absorbed and 
is biologically active, for example reversing warfarin-induced hypoprothrombinaemia (Sato 
et al., 2003). Dihydro-vitamin Ki is absorbed by humans and does not appear to affect 
absorption of vitamin K (Booth et al., 1996a). In humans, a study of the bioavailability of 
hydrogenated vitamin K1t as measured by changes in PIVKA-II and ucOC after feeding 
with either vitamin Ki or dihydro-vitamin Ki following vitamin K depletion, showed that 
dihydro-vitamin K-i had less biological activity to PIVKA-II and no biological activity to the 
extrahepatic VKD, osteocalcin (Booth et al., 2000a). These differences are likely due to 
differences in absorption since plasma concentrations of both forms of the vitamin 
increased in response to 200 pg/d repletion but the increase in vitamin Ki was significantly 
greater than that of dihydro-vitamin K-i (Booth etal., 2000a).
Dihydro-vitamin Ki is present in a large range of processed foods (Dumont et al.,
2003) and thus it is important to consider its contribution to vitamin K intake and status. 
This form of vitamin K is thought to make up about 20% of vitamin Ki intake in the US, 
with mean intakes for men and women estimated at 19 and 15 pg/d, respectively (Booth 
et al., 1999b). Dihydro-vitamin Ki has also been related to elevated ucOC (Erkkila et al., 
2005b). Plasma dihydro-vitamin K-i has been shown to correlate with both the intake of 
dihydro-vitamin Ki and trans-laiiy acids (mainly from hydrogenated oils) (Erkkila et al., 
2005b). The limited evidence suggests that dihydro-vitamin Ki may have biological 
activity but absorption is reduced compared to vitamin Ki. The potential impact of 
hydrogenated vitamin Ki is largely unknown but could result in a decrease in vitamin K 
status. However, recent campaigns for the reduction in the consumption and use of 
hydrogenated oil in foods may reduce any longer-term concerns.
1.13.3 Menaquinones
Menaquinones (MK-n), collectively also known as vitamin K2, contain a 
polyisoprenoid side chain of varying length (section 1.1.2). Menaquinones do have
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biological activity and can act as co-factors for the y-glutamyl carboxylation of glutamic 
acid (Suttie 1995). There are two potential sources of menaquinones, the diet and 
intestinal bacteria. One exception is MK-4 that can be synthesised from vitamin Ki and 
may exert its effect by a pathway additional to carboxylation. The relative importance of 
menaquinones to vitamin K status remains a relatively unresolved issue and in particular, 
the relative importance of gut bacteria-derived menaquinones.
1.13.3.1 Dietary menaquinones
Dietary sources of menaquinones are typically fermented food or foods of animal 
origin. The menaquinone content of fermented foods is thought to derive from the 
bacterial starter cultures (Shearer 1997) and includes cheese and natto (fermented 
soybean product). Animal products are another source of menaquinones, especially liver 
(MK-7 -  MK-13). The presence of the short chain menaquinone MK-4 in animal products 
(cheese, meat, eggs etc.) may be partly due to conversion from the animal food 
supplement, menadione (Schurgers & Vermeer, 2000). In the typical Western diet, the 
menaquinones contribute a small proportion of total vitamin K intake (Booth & Suttie,
1998). In a Dutch population, based on a food frequency questionnaire, it was concluded 
that around 90% of total dietary intake derives from vitamin Ki (Schurgers et al., 1999).
The potential to absorb menaquinones of dietary origin has been demonstrated in 
animal models and in human studies. In rats, the injection of 14C-labelled vitamin K into 
the jejunal loop resulted in absorption values of MK-4, 17%; MK-9, 15% and vitamin Ki, 
13% (Uchida & Komeno, 1988). Experiments in humans studying absorption efficiency 
from different foods of menaquinones MK-7, MK-8 and MK-9, have shown that 
menaquinones reached a maximum plasma level 10-fold greater than vitamin Ki 
(Schurgers & Vermeer, 2000). Subsequent work measuring the absorption of pure 
vitamin K^ MK-4 and MK-9 dissolved in oil however, found greater serum levels of vitamin 
Ki compared to the menaquinones (Table 1-6). The distribution between lipoprotein 
fractions and clearance were also very different between vitamin K vitamers. Vitamin Ki 
was primarily associated with TRL fraction, whereas MK-4 was equally distributed
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between TRL, LDL and HDL. No MK-9 was found in HDL (Schurgers & Vermeer, 2002). 
The authors conclude that these differences may be due to the different lipophilicity of the 
vitamin K forms that in turn affect both plasma transport and delivery to target tissues. 
This work suggests that the dietary menaquinones may in fact contribute to vitamin K 
status in certain tissues (Schurgers & Vermeer, 2002).
Table 1-6. Comparisons of the appearance of vitamin Ki, MK-4 and MK-9 in plasma 
following consumption of a vitamin K^ and menaquinone-enriched meals. Data 
from Schurgers & Vermeer (2002)
Cmax
(nmol/L)
Tmax
(h)
Estimated Ty2
(h)
Vitamin K-i 40 4 12
MK-4 17 2.5 12
MK-9 9 5 60
1.13.3.2 Absorption o f menaquinones from gut bacteria
Relatively few of the normal intestinal bacteria are major producers of 
menaquinones (Suttie 1995). The major menaquinone produced in E. coli was reported 
as MK-8 while other bacteria produced mainly MK-10 and MK-11 and less MK-6 -7, -8 and 
-9 (Conly et al., 1994). It has been estimated that gut flora could provide a potential 
reservoir of up to 4.5 mg of menaquinones (Conly et al., 1994). Absorption of 
menaquinones from the gut has been inferred from their presence in liver and other 
tissues. Liver stores are thought to contain around 90% menaquinones and 10% vitamin 
K-i (Shearer et al., 1988; Usui et al., 1990). Bone tissue has been shown to contain, in 
addition to vitamin K1( MK-6 to MK-8 (Hodges et al., 1993). As discussed in section 1.6.2 
some early vitamin Ki depletion studies showed little or no effect on prothrombin time and 
were taken as evidence for the importance of menaquinones. However, and as discussed 
previously, prothrombin time is a relatively insensitive marker of vitamin K status. Other 
studies, that used more sensitive makers of vitamin K status have created a sub-clinical 
deficiency with low levels of dietary vitamin Ki. Clinical reports of antibiotic-induced 
vitamin K deficiency were also taken as evidence for the importance of bacterially-derived
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menaquinones. However, it has been demonstrated that certain antibiotics can disrupt 
the vitamin K cycle by inhibition of vitamin K epoxide reductase. Furthermore, in many 
cases vitamin K deficiency can be attributed to poor dietary intakes in seriously ill patients 
(Suttie 1995). The potential importance of menaquinones, rather than being based on 
the assumptions above, should be assessed on their function and metabolism, and is 
largely determined by their bioavailability. The bioavailability of menaquinones is 
dependent on a number of factors including release from bacteria, uptake from the gut 
and into the circulation, and utilisation in tissues.
In bacteria, menaquinones are tightly bound to the cytoplasmic membrane (Conly 
et al., 1994). There is some evidence that both water-soluble and lipid-soluble forms of 
menaquinones can be released from the bacteria although the majority of this research 
has been performed with in vitro cultures of menaquinone-producing and menaquinone- 
requiring bacteria (Conly etal., 1994).
In humans, the highest concentration of menaquinones is found in the colon with 
lower amounts in the terminal ileum. Bile-mediated absorption of colonic menaquinones 
is unlikely due to the lack of bile in this region of the gut (Shearer 1997). It has been 
demonstrated in humans that after oral administration, bacterially extracted 
menaquinones can be absorbed and impact vitamin K status (decreased prothrombin 
time) (Conly & Stein, 1992). However, the relevance of this experiment must be 
questioned since oral intake of gut bacteria is not representative of the physiology. Later, 
the same group used a similar protocol but delivered menaquinones directly to the ileum 
using a naso-ileal tube. Similarly, they observed an increase in Factor VII and a decrease 
in prothrombin time and suggested that absorption of menaquinones was possible from 
the distal small bowel (Conly et al., 1994). It can be summarised that absorption may be 
possible in the terminal ileum where there are reasonable concentrations of bile salts to 
mediate absorption (Shearer 1997).
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1.13.3.3 Utilisation
In humans, menaquinones constitute the majority of liver vitamin K stores, 
although vitamin Ki is the major circulating form. Although MK-6 -  12 are present in liver 
(Shearer et al., 1988; Thijssen & Drittij-Reijnders, 1996), only MK-4, MK-7 (Tsugawa et 
al., 2006) and MK-8 have been positively reported in the circulation of normal individuals 
(Suttie 1995; Shearer et al., 1988). Interestingly, the abundance of MK-4, -5, -6 and -7  in 
bone lipid was found to correlate with decreasing side-chain length (Shearer 1997), further 
supporting the importance of lipophilicty in distribution of menaquinones. Although certain 
tissues contain high levels of menaquinones, some evidence suggests that they may not 
be available for y-glutamyl carboxylation (Vermeer et al., 1995). In studies in rats, both 
conventional and germ-free animals showed signs of vitamin K deficiency after 3 d 
restriction, and liver stores of menaquinones were not decreased (Uchida & Komeno, 
1988). In human studies also, the presence of significant liver and bone stores of 
menaquinones have proved insufficient to prevent signs of vitamin K deficiency (Suttie et 
al., 1988b).
1.13.3.4 Menaquinone summary
Considerable debate surrounds the question of the relative importance of 
menaquionones in maintaining vitamin K status. Dietary menaquinones make up only a 
small percentage of total dietary vitamin K but absorption does appear greater than 
vitamin Ki and thus they may provide an additional source of vitamin K. However, the 
contribution of menaquinones from gut bacteria is probably very small since bioavailability 
from the gut is low. In addition, the absorption and tissue distribution of menaquinones 
appears to be related to the length of the isoprenoid side chain and long chain 
menaquinones appear to accumulate in the liver where they may not be accessible for 
carboxylation. The situation is different for MK-4 for which there is evidence for tissue 
specific accumulation (Thijssen et al., 2002), predominantly from the conversion of dietary 
vitamin K-i (Thijssen et al., 2006), although the biological activity of MK-4 may be related 
to a mechanism other than y-glutamyl carboxylation (Shearer 1997).
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1.13.4 Matrix effects
Only a small number of studies using a range of techniques have explored the 
bioavailabilty of vitamin Ki from different food sources. These studies have only 
compared the relative absorption of vitamin Ki and not absolute absorption.
Three studies have compared absorption parameters after consumption of 
different test meals or foods. Gjisbers and colleagues (Gijsbers et al., 1996) measured 
AUC over 24 h (sampling every hour to 10 h and then at 24 h) of 1 mg (2.2 pM) vitamin Ki 
as either detergent-solubised concentrate (Konakion®), 227 g boiled spinach with 25 g 
butter or 227 g boiled spinach only. The crossover study was performed in three men and 
two women, aged 25 -  45 y. AUC was calculated after subtraction of baseline plasma 
vitamin Ki values. Time to peak absorption (Tmax) was faster for Konakion® compared to 
either of the meals (4.5 h compared to 6 h), presumably due to extraction efficiency of 
vitamin Ki from spinach but possibly influenced by other components present in spinach. 
The addition of butter with the spinach meal increased both the maximum plasma vitamin 
K-i concentration (Cmax) and AUC compared to spinach alone. In the five subjects, vitamin 
K-i from spinach with butter was 26% as available as Konakion® whereas, vitamin K-i from 
spinach only was 4% as available. These results suggest a substantial improvement in 
absorption when fat is consumed with a meal as might be expected considering the 
uptake mechanism of vitamin K-i. It needs to be noted that the amounts of vitamin K given 
were high compared to normal intakes. Based on the assumption that the standard 
Konakion® used in this study had the same absorption as that recorded by Shearer et al. 
(1974) then the authors estimate that 10% of vitamin Ki from the spinach was absorbed 
(Gijsbers et al., 1996).
A later study by Garber et al. (1999) compared AUC, Cmax, and Tmax of vitamin Ki 
absorption from a range of sources. The results from this study are summarised in Table 
1-7. Values were measured over 9 h in subjects aged 22 to 30 y. Each source of vitamin 
K-i (either spinach, broccoli or lettuce) was consumed with a test meal (one Egg 
McMuffin® and 240 mL of orange juice) containing 1682 kJ and 27% fat. As in the 
previous study, AUC were calculated after subtraction of the baseline plasma vitamin K-i
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values. In agreement with Gjisbers et al., (1996) absorption from pure vitamin K1 was 
greater and faster than from the test meals, the equivalent amount of vitamin Ki from 
spinach was only 17% as available as that from a tablet. Using AUC values there was no 
significant difference between fresh and cooked broccoli and no difference in absorption 
from lettuce with either 30% or 45% fat (adjusted with corn oil). However, mean 
absorption from a high-fat lettuce meal reached a higher concentration (2.2 nmol/L 
compared to 3.7 nmol/L) and was more slowly absorbed than vitamin Ki from a low-fat 
lettuce meal. Together with the study by Gijsbers et al. (1996) these data suggest that fat 
is important for the maximal absorption of vitamin Ki, yet the amount of fat may be less 
important. There was no significant difference found in absorption between the three 
vegetable sources. These results should be observed with caution since the numbers in 
each group were very small, mostly comprising only two or three individuals. Additionally 
it is difficult to compare with other studies since no description of the vitamin K-i tablet is 
provided.
Table 1-7. Mean (± SD) absorption parameters of vitamin Ki from different sources 
in humans. From Garber eta l., (1999)
Source of vitamin K-i
Energy 
from fat
(%)
VitaminKi
dose
(M9) n
Plasma vitamin Ki
Cmax Tmax AUC
(nmol/L) (h) (nmol/L.h)
Tablet 27 500 8 9.4 ±4.7 2.4 ±0 .5 27.6 ± 10.1
Fresh spinach, 150 g 25 495 3 2.9 ±0.5 4.0 ±0 .0 4.8 ± 1.1
Fresh spinach, 50 g 26 165 4 2.1 ±0.6 3.5 ± 1.0 2.5 ± 1.1
Fresh broccoli, 150 g 30 214 2 2.1 ±0.8 5.5 ±2.1 4.0 ±0 .7
Cooked broccoli, 150 g 30 184 3 2.6 ± 1.6 2.7 ±0 .6 6.3 ±4 .4
Fresh romaine, 200 g 30 179 3 2.2 ±0.6 5.7 ± 1.2 3.2 ± 1.0
Fresh romaine, 200 g 45 179 3 3.7 ± 1.1 7.7 ± 1.2 4.3 ±2 .0
Schurgers & Vermeer (2000) have compared vitamin K-i absorption from spinach 
(400 g) with and without fat (corn oil, 30 g) to absorption from a supplement. Plasma 
values were measured hourly up to 12 h and then at 24, 48 and 72 h. To correct for 
baseline values, each volunteer was provided with a vitamin Kr poor breakfast and these
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baseline values were subtracted from the post-test meal values. Each meal contained 3.5 
pM (1.6 mg) of vitamin Ki. Unfortunately, few quantitative data are provided but it was 
shown that Tmax was faster for the Konakion® meal (4 h) compared to the vegetable meals 
(6 h). Absorption of vitamin Ki from vegetables without fat was 5 -  10% compared to 
absorption from Konakion®, whereas consumption with fat, increased absorption to 10 -  
15%. However, this study used very high doses of vitamin Ki of over 1 mg.
Booth et al. (1999a) applied a multiple dosing methodology in a crossover study. 
During three, 15-d residency periods, 36 subjects consumed a mixed baseline diet 
containing around 100 pg/d of vitamin Ki. On days 6 to 10 of two of the residency 
periods, and in addition to the baseline diet, the subjects received two servings per day of 
either broccoli or vitamin K-i-enriched corn oil. The diets contained around 417 and 377 
pg/d, respectively. Plasma vitamin Ki was measured on days 1, 2, 4, 6, 7, 9, 11, 12, 14, 
and 16. Using single plasma values, there were significant increases in plasma vitamin Ki 
from baseline to both test diets in younger and older subjects. However, on day 11 (final 
day of test diet), there were no differences between the broccoli and oil diets. AUC data 
over 5 d also showed a significant increase in both the broccoli and oil diets compared to 
baseline diet in both younger and older groups. However, only in the older group was 
there a significant difference between the oil and broccoli diets. This study also measured 
osteocalcin, %ucOC and urinary Gla. Both diets reduced %ucOC by around 10% 
(between day 6 and day 11) compared to the baseline diet, but there was no difference 
between the two diets. There were no significant differences between the three 
treatments in urinary Gla excretion.
As part of this study, the authors also measured plasma vitamin K-i concentrations 
over a 24 h period on day 6 (Booth et al., 1999a) corresponding to the first day of the test 
diets as mentioned above (baseline, broccoli or oil) (Booth et al., 2002). Table 1-8 
summarises the different methods used to assess bioavailability and the observed 
differences. AUC values over 24 h were significantly greater (P<0.001) after the oil diet 
compared to the broccoli diet, both adjusted and unadjusted for TAG concentration, and in 
both younger and older adults. However, the measurement of fasting plasma vitamin K-i
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after 24 h showed no significant difference between the two treatments in either younger 
or older groups. The absence of a significant difference between treatments at 24 h post 
dose is not surprising given the rapid clearance of vitamin Ki from the circulation and high 
turnover of the vitamin.
Table 1-8. Summary of methods that assessed absorption of vitamin K-i from 
fortified-oil and broccoli in younger and older subjects, and the respective 
outcomes (Booth e ta l., 1999a; 2002)
Method Observed differences in absorption
24 h AUC Greater from oil than broccoli diet
24 h fasting plasma No difference between oil and broccoli diets
5 d  AUC Greater from oil diet in older subjects only
Post intervention fasting plasma (d 11) No difference between oil and broccoli diets
A study by Schurgers et al. (2004) although not primarily designed to measure the 
absorption of vitamin Ki, estimated that vitamin Ki from broccoli and spinach were only 13 
and 29% as available as that from tablet form, based on a single 4 h post dose blood 
sample. However, given the variation in Tmax between different sources of vitamin Ki, 
measurement at a single time point may provide misleading data.
Three studies (see section 1.12.7.2 for detail) have measured absorption of 
vitamin Ki from intrinsically labelled vegetables, and although no comparisons were made 
between matrices they do provide some data on absorption from these sources 
(Dolnikowski et al., 2002; Kurilich et al., 2003; Erkkila et al., 2004). In general, values for 
Tmax and relationship between dose and Cmax are in concordance with previous studies. 
Key information from comparable studies described above is shown in Table 1-9.
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Table 1-9. Results summary of single-dose vitamin K1 bioavailability studies
Reference 7~max Vitamin K-i source Dose amount Cmax
Vegetables (nmol) (nmol/L)
Gijsbers etai., 1996 6.1 Spinach & butter 2200 7.50
6.1 Spinach only 2200 2.50
Garber et al., 1999 4.0 Spinach (150 g) 1100 2.02
3.5 Spinach (50 g) 367 1.19
5.5 Broccoli (150 g) 476 1.17
2.7 Cooked broccoli (150 g) 409 1.81
5.7 Lettuce (with 35% fat) 398 4.81
7.7 Lettuce (with 45% fat) 398 6.81
Schurgers & Vermeer, 
2000 6.0 Spinach (400 g) meal 3500 9.00
6.0 Spinach & natto meal 3500 9.00
Dolnikowski et al., 2002 5.0 Broccoli 373 2.25
Kurilich et al., 2003 7.0 Kale 156 3.00
Errikila et al., 2004 6.0 Greens 880 11.00
Supplements (nmol) (nmol/L)
Gijsbers eta i ,  1996 4.0 Konakion® 2200 47.50
Garber et al., 1999 2.4 Tablet 1111 8.50
Schurgers & Vermeer, 
2000 4.0 Konakion® 3500 43.00
From these data a number of conclusions can be drawn. Firstly, it can be seen 
how different types of study can produce different results. For example, from what is 
know about vitamin K-i turnover it is perhaps not surprising that no difference was found 
between two test meals in a 24 h post-dose sample. Secondly, absorption is both faster 
and greater from artificial forms of vitamin Ki compared to absorption from meals. Thirdly, 
absorption from different vegetables is similar and the addition of fat is likely to increase 
absorption (Gijsbers et al., 1996; Booth et al., 2002) but the amount of fat may be less 
important (Garber et al., 1999). However, as highlighted by Booth et al. (2002) 
differences in AUC may not be so important if there are no longer term benefits for other 
markers of vitamin K status (Booth et al., 1999a). A weakness of most of the 
bioavailability studies described is the sample size and the large inter-individual variation.
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1.13.5 Potential inhibitors of vitamin K-i absorption
The bioavailability of vitamin Ki may be inhibited by both naturally-occurring and 
man-made compounds. Inhibition can occur either through an effect on absorption or 
metabolism.
1.13.5.1 Fat absorption inhibitors
Statins are drugs used to lower cholesterol levels by inhibiting an enzyme 
necessary for the synthesis of cholesterol. Inhibition leads to the up-regulation of LDL 
receptors in the liver and increased clearance of LDL from circulation that could affect 
vitamin Ki uptake and metabolism. However, there is very little mention in the literature 
with regard to the potential to decrease plasma vitamin Ki, presumably because any small 
effect on vitamin K status is outweighed by the benefits of the treatment.
Orlistat (marketed as Xenical by Roche) is a obesity-treatment and works by the 
inhibition of gastric and pancreatic lipases (Melia et a l, 1996), thereby reducing fat 
absorption. Few studies have been published on the effects of Orlistat on vitamin K 
bioavailability. A small study in obese adolescents reported a non-significant decrease in 
plasma vitamin Ki (McDuffie et al., 2002). A systematic review of Orlistat reported that 
use of the drug was associated with lower serum fat-soluble vitamin status (O'Meara et 
al., 2001). However, none of the studies considered vitamin K. One study reported that 
Orlistat reduced absorption of vitamin E by around 50% but not vitamin A. In this study, 
each vitamin was given as the acetate ester that must be hydrolysed before absorption, 
however this enzyme is also inhibited by Orlistat (Melia et al., 1996). It is likely that the 
use of Orlistat could decrease vitamin K bioavailability but further research is required.
Phytosterols on the other hand, are natural plant-derived inhibitors of cholesterol 
absorption and are viewed as a relatively simple dietary modification to reduce population 
cholesterol levels, and ultimately heart disease (Ostlund 2002). Phytosterols are now 
included in a wide range of foods marketed as beneficial for health, examples include 
Flora pro-activ® and the Benecol® range of products.
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Some studies have shown reductions in a- and p-carotene (after adjustment for 
cholesterol) of up to 22%, although no decrease in vitamin Ki plasma levels has been 
observed (Ostlund 2002). A study comparing two types of phytosterol-enriched margarine 
to a normal margarine in 15 hypercholesterolemic subjects reported no difference in 
plasma vitamin Ki between the three diets after 21 d (Raeini-Sarjaz et al., 2002). A 
randomised, double-blind, controlled trial was performed in 85 healthy adults who were 
assigned to one of four groups, three who received phytosterols at three dosage levels 
from a fat spread and salad dressing and a control group who received no phytosterols. 
Over an 8-wk period, there was no reduction in plasma vitamin Ki (Davidson et al., 2001). 
A year-long study comparing the effects of a plant-sterol enriched spread to a normal 
spread in 185 volunteers also reported no decrease in vitamin Ki concentration or 
osteocalcin carboxylation (Hendriks et al., 2003). The evidence suggests that phytosterol 
consumption does not interfere with vitamin Ki absorption, although most studies have 
relied on fasting plasma status as a marker, which is known to be highly dependent on 
recent intake. More recently, a study using stable isotope labelled a- tocopherol and p- 
carotene, showed a 20 and 50% reduction in bioavailability with phytosterol consumption 
(Richelle et al., 2004). The potential effect of phytosterols on vitamin K bioavailability 
requires further investigation.
Olestra is an indigestible sucrose polyester that is used as a fat substitute in 
processed foods. Because it is lipophilic, olestra can interfere with fat-soluble vitamin 
absorption because of partitioning of vitamins into the olestra rather than mixed micelles 
(Schlagheck et al., 1997). Evidence for an effect of olestra on fat-soluble vitamin status, 
and in particular, vitamin Ki is mixed. A dose response study in 90 individuals reported 
that olestra did decrease plasma vitamin K1( however it did not affect other markers of 
vitamin K status, Gla concentration or undercarboxylated prothrombin (Schlagheck et al., 
1997). The authors do comment that the intake of olestra in this study is likely at the 
higher end of typical intake. A double-blind placebo-controlled trial of olestra that 
measured undercarboxylated prothrombin, but not plasma vitamin Ki showed no effect 
(Koonsvitsky et al., 1997). Data from 403 adults showed that olestra consumption does
78
not predict circulating vitamin Ki levels, indeed higher intakes of olestra were associated 
with higher vitamin Ki status (Thornquist et al., 2000). Finally, data from over 2000 adults 
revealed no trend for an effect of olestra consumption on vitamin Ki status, but those 
individuals in the highest tertile of olestra consumption had a lower (9%) plasma vitamin 
Ki concentration than individuals who consumed no olestra (Neuhouser et al., 2006). 
Taken together, this evidence suggests that although there is the potential for olestra to 
decrease vitamin Ki in plasma status, it is unlikely at typical intakes of olestra.
1.13.5.2 Menaquinones/ dihydro-vitamin Ki
Potential inhibitors of vitamin absorption include menaquinones and dihydro- 
vitamin Ki. The potential effect of menaquinones was tested in a human feeding study by 
giving a Ki meal with and without food containing menaquinones. The results were 
reported to be similar in each case suggesting no inhibition (Schurgers & Vermeer, 2000). 
The potential effect of dihydro-vitamin Ki on vitamin K1 absorption is largely unknown 
(Booth & Suttie, 1998) although one study has shown that compared to vitamin Ki, 
dihydro-vitamin Ki was less well absorbed and had no effect on bone markers (Booth et 
al., 2001).
1.13.5.3 Vitamin A and E
Large doses of both vitamins A and E are reported to affect vitamin K status 
(Olson 1985). Vitamin A may affect absorption of vitamin K (Olson 1985) but there is no 
evidence for an interaction at physiological levels. Other quinone-derived molecules 
(such as vitamin E and ubiquinone) have been shown to act as potential competitive 
inhibitors for vitamin K-dependent carboxylase (Schurgers & Vermeer, 2001) and there 
are limited reports of vitamin E affecting plasma vitamin K status (Alexander & Suttie, 
1999; Mitchell et al., 2001). The evidence comes primarily from animal studies and often 
with large doses of vitamin E and suggests the effect may be via a metabolic or transport 
route rather than an effect on absorption (Schurgers et al., 2002).
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1.13.6 Fatty acids
The potential of fatty acids to modify vitamin K absorption and metabolism has 
been demonstrated in a number of studies. In vitro studies have demonstrated that 
polyunsaturated and monounsaturated fatty acids can reduce absorption of vitamin Ki 
(Hollander & Rim, 1976). However, in rats only polyunsaturated fatty acids were shown to 
reduce vitamin Ki absorption (Hollander et al., 1977). Of three saturated fatty acids 
tested, only one (short chain butyric acid of 4 carbon atroms) reduced vitamin Ki 
absorption (Hollander et al., 1977). It may be possible to influence the primary tissue 
destination of vitamin Ki by altering the types of fat consumed. Schurgers & Vermeer 
(2001) demonstrated in rats that a diet high in saturated fatty acids (SFA) from hardened 
coconut oil (HCO) led to plasma levels of vitamin Ki twice as high as from diets lower in 
SFA and higher in polyunsaturated (PUFA) and monounsaturated fatty acids (MUFA). 
This rise can largely be attributed to the doubling of plasma TAG since vitamin Ki plasma 
status has been shown to correlate with plasma TAG (Sadowski et al., 1989). Rats on a 
corn oil-enriched diet (CO) showed a significant decrease in vitamin Ki and TAG 
concentration, whilst rats on a sunflower oil-enriched diet (SO), showed a slight decrease 
in TAG but no difference in vitamin Ki concentration, compared to rats on a low fat diet. 
To explain the differences between the HCO and CO diets, the authors focus on the 
potential modulating affect of PUFA on lipoprotein and consequently vitamin Ki 
metabolism, primarily the greater activity of lipoprotein lipase on PUFA-rich chylomicrons. 
However, this explanation doesn’t tally with observed differences in the CO and SO-diets 
that contain similar proportions of fatty acid classes. The SFA content in the SO-enriched 
diet was 12% compared to 13% in the CO diet. PUFA accounted for 63% of fatty acids in 
SO-enriched diet and 54% in the corn oil-enriched diet. Therefore, if the hypothesis of the 
effect of PUFA is correct, it is unclear why the CO diet, but not the SO diet decreased 
vitamin Ki concentration. All vitamin K-i-deficient diets were supplemented with around 40 
pg of vitamin Ki per day, whereas the contribution of vitamin Ki from the oils was 0.14 pg 
from corn oil and 0.8 pg from sunflower oil. The authors consider this difference negligible
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in comparison to the supplemental vitamin Ki added to the meals, however no 
consideration is given to possible differences in bioavailability of vitamin Ki between the 
various forms. Another study in rats has demonstrated that both a diet rich in n-3 and n-6 
PUFA reduced TAG, however only the fish oil (n-3) diet reduced the level of vitamin K- 
dependent coagulation proteins (Nieuwenhuys et al., 1998).
In humans, evidence for altered vitamin Ki absorption or metabolism is provided 
from a crossover feeding study. Twenty-six men spent 2 wk on an adjustment diet and 
then either a corn oil (CO) or olive/sunflower oil (OSO) diet. The CO diet was considered 
PUFA-rich since the percent energy of the diet from PUFA was 11 -  13% compared to 7 -  
8% in the OSO diet. TAG and vitamin Ki were lower in the group on the CO diet 
compared to the adjustment group and the OSO diet. Measurements of blood coagulation 
showed conflicting results, since prothrombin time showed no difference in any of the 
diets. Undercarboxylated Factor II was increased in both diets compared to the 
adjustment diet. %ucOC was increased in both the CO and OSO diets compared to the 
adjustment diet. Matrix Gla protein was also significantly lower in the CO diet compared 
to OSO and adjustment diets (Schurgers et al., 2002). The observations are primarily 
attributed to the elevated PUFA content of the corn oil meal. An alternative explanation 
may be the vitamin Ki content of the CO compared to the OSO. Total vitamin Ki intake 
for the CO and OSO diets was 291 pg, and contribution of vitamin Ki intrinsic to the oils 
was 15.4 pg and 2.8 pg, respectively. The CO and OSO contributed 73% of total fat 
intake, thus in terms of vitamin Ki from fats, and with consideration for potential variation 
in bioavailability, the difference between CO and OSO may be significant and could partly 
explain the observations. Together, these studies provide some evidence that PUFA-rich 
diets may reduce plasma vitamin K-i, potentially by affecting absorption and/or transport of 
vitamin K.
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1.13.7 Non-dietary factors
A number of non-dietary, host-related factors may also influence the absorption, 
uptake and utilisation of vitamin Ki, including genetic factors, gender and age.
1.13.7.1 Nutrient status
Bioavailability of vitamin A is known to be affected by body stores since 
homeostatic controls can up-regulate absorption and release vitamin A from the liver. 
There is no evidence for this type of mechanism for vitamin K, although in times of low 
body stores vitamin K may be preferentially used for carboxylation of the important hepatic 
blood coagulation proteins (Booth et al., 2003b). Additionally, after a low vitamin Ki diet 
Olson et al. (2002) reported both a more rapid entry of vitamin Ki into cells (determined by 
a decrease in the half-time of the first exponential of the plasma radioactivity decay curve) 
and a reduction in biliary secretion identified using radiolabelled vitamin K.
1.13.7.2 Genetic factors
The uptake of vitamin K is probably by incorporation into mixed micelles and 
transfer across enterocytes, as has been discussed in section 1.9, although it has been 
suggested that absorption may occur through an energy dependent process (Hollander 
1973), but little evidence is available to support this theory. If transporters exist then 
absorption could be affected by genotypic differences in their manifestation. The apoE 
genotype is known to be important in the clearance of chylomicrons remnants (and hence 
vitamin K uptake) with the different phenotypes resulting in altered clearance and plasma 
concentrations of vitamin Ki (Saupe et al., 1993; Yan et al., 2005).
1.13.7.3 Gender
Epidemiological evidence generally suggests vitamin K status is not related to 
gender (Sadowski et al., 1989; Booth et al., 1997; McKeown et al., 2002; Thane et al., 
2002a). Evidence from metabolic studies also suggests that gender has little impact on 
the bioavailability of vitamin K-i (Ferland et al., 1993; Binkley et al., 2000; Booth et al., 
2002). Any observed differences in bioavailability may be related to differences in
82
lipoprotein metabolism and chylomicron clearance, rather than vitamin Ki absorption. 
However, a difference in AUC was seen during a 5 d feeding study, where older men had 
a significantly higher AUC than older women (P=0.008) but there was no difference 
between younger men and women (Booth et al., 1999a).
1.13.7.4 Age
For age, the observational evidence is mixed with some reporting effect of age on 
plasma concentration (Sadowski et al., 1989; Booth et al., 1997) while others have 
recorded no relationship with age (McKeown et al., 2002). Controlled feeding studies 
have shown that older adults had higher plasma vitamin Ki levels assessed by single time 
points and by AUC, compared to the young. This difference was maintained after 
correction for TAG at single time points but not for AUC (Booth et al., 2002). Ferland et al. 
(1993) reported a 40% higher plasma vitamin Ki concentration in elderly subjects 
compared to younger subjects that was maintained during depletion. In addition, urinary 
Gla did not decrease in the elderly during depletion. However, these differences are likely 
due to metabolism, rather than absorption. Binkley et al. (2000) reported that at baseline 
and after 1 wk supplementation with 1000 pg of vitamin Ki, serum vitamin Ki was 
significantly lower in young ( 1 8 - 3 5  y) compared to old (>65 y) subjects, presumably due 
to greater TAG concentration with age, although the difference was not reflected in 
%ucOC.
1.13.8 Summary of factors affecting bioavailability of vitamin Ki
A wide range of factors influence the bioavailability of vitamin K-i. Some are 
dietary dependent factors that may affect digestion, absorption and/or utilisation, for 
example dietary fat. Other non-dietary factors such as apoE genotype may also affect 
observed inter-individual variation. Probably the major intra-individual determinant of the 
relationship between vitamin Ki intake and status is the bioavailability of vitamin Ki from 
different food sources. However, only a small number of studies have compared vitamin 
Ki bioavailability from different foods. These studies have been typically performed in a 
small number of subjects, using unusual combinations of food, and different methods that
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have produced some conflicting results. Thus, further work is necessary to probe factors 
that may influence vitamin Ki bioavailability.
1.14 Conclusions
The most important form of vitamin K for meeting the body’s vitamin K 
requirements is vitamin Ki (phylloquinone). Recent work has demonstrated a role for 
vitamin K in health beyond its well-established function in blood coagulation, specifically in 
bone health and cardiovascular disease. A number of studies have found positive 
associations between both vitamin K intake and status and markers of bone health. 
Additionally, evidence is emerging for a benefit of increased vitamin K intake for 
prevention of vascular calcification. Cardiovascular disease is a major consequence of 
atherosclerosis and is estimated to cost the UK economy around £26 billion per year, 
around 57% of which is accounted for by direct health care costs 1. Osteoporosis also has 
major economic consequences and is reported to cost the NHS and UK government 
around £1.7 billion per yea r2. Since osteoporosis is primarily a disease of older people, it 
is particularly pertinent considering the ageing UK population. The number of people 
aged 50+ y is expected to increase by around 7 million between 2002 and 2031 while the 
number of people aged over 85 y is expected to double over the same period (Office for 
National Statistics 2004).
Through an understanding of the biochemistry of vitamin K, it is clear that the 
benefits of higher vitamin Ki status result from an increase in the level of fully 
carboxylated VKD proteins. A number of studies have demonstrated that by increasing 
vitamin K intake, both plasma levels of vitamin Ki and levels of undercarboxylated 
proteins can be improved.
The data suggest that current vitamin Ki dietary recommendations may not be 
sufficient for the full y-carboxylation of some vitamin K-dependent proteins. Furthermore, 
around half of the UK population does meet the current recommendation. Research is
1 Data from British Heart Foundation: www.heartstats.org (accessed 11th March, 2007)
2 Data from National Osteoporotic Society: www.nos.org.uk (accessed 11th March, 2007)
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required on the relationship between vitamin Ki plasma status and vitamin Ki dietary 
intake, and in particular, how the relationship is determined by bioavailability.
The starting point for studies of absorption should be through a thorough 
understanding of the kinetics of vitamin K absorption and body pool sizes. At the current 
time, no studies have applied a stable isotope methodology to the assessment of vitamin 
K metabolism and previous work using alternative methods has primarily utilised only 
pharmacological doses.
The focus of this thesis was to develop stable isotope based methods to improve 
our understanding of vitamin K-i kinetics and bioavailability. The work had three specific 
aims:
1) Development of a method to measure isotope ratios of vitamin Ki in plasma
2) Measurement of vitamin Ki kinetics and body pool sizes in humans
3) Development and application of methods to measure the bioavailability of 
vitamin Ki from food
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2 A n a ly s is  o f  is o to p e  r a t io s  o f  v ita m in  K 1 f r o m  p la s m a
This section addresses the issues relevant to the analysis of vitamin K1t and 
focuses primarily on the analysis of isotope ratios that is the major challenge of this work. 
Stable isotopes and mass spectrometry are described, including a review of work by 
previous authors. Strategies for the extraction of vitamin K1 are reported along with the 
final methodology chosen for use in subsequent studies of vitamin K1 kinetics (section 3) 
and bioavailability (section 4) in human volunteers.
2.1 Challenges
Specific challenges for vitamin Ki analysis from plasma result from its low 
concentration, interfering plasma lipid components, and the sensitivity of the molecule to 
degradation. Sample preparation, clean-up and separation of compounds by 
chromatography are all essential for the analysis of vitamin (Fauler et al., 2000).
In comparison with other fat-soluble vitamins (Figure 2-1) and co-extracted non­
polar constituents of blood plasma, fasting concentrations of vitamin Ki are low, with 
typical values between 0.29 and 2.64 nmol/L (Institute of Medicine 2001). The use of 
large volumes of plasma to achieve the required sensitivity is often not compatible with 
sensitive separation and detection methods because of high amounts of co-extracted 
interfering compounds (Fauler et al., 2000).
Figure 2-1. Comparison o f mean fasting plasma concentrations o f a-tocopherol, 
retinol, 25-hydroxy vitam in D and vitam in K  ^ (adapted from Sadowski et al., 1989)
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The major challenge to the extraction and analysis of vitamin K-i is the presence of 
lipid components of plasma that are of a similar low polarity and present in much greater 
concentrations. Many extraction procedures that remove vitamin Ki also extract other 
non-polar constituents of plasma. These compounds may mask vitamin Ki in the 
chromatogram, interfere with chromatography, or result in rapid loss of chromatographic 
resolution. Typical concentrations of lipids (and vitamin Ki) are listed in Table 2-1.
Table 2-1. Concentrations of lipids in blood plasma (adapted from Harper, 1963 
except for * from Sadowski et al., 1989)
Lipid fraction
Concentration in plasma 
(mg/mL)
Mean Range
Total lipids 5.8 3.6-8 .2
Triacylglcyerols 1.4
001COo
Total cholesterol 2.0 1.1 -3.2
as cholesterol esters 1.4 1.3-1.5
Total Phospholipids 2.2 1.2-2.9
Vitamin Ki* 0.4 ng/mL 0.1 -1.2 ng/mL
Vitamin K is sensitive to light, especially blues and ultra-violet, thus procedures 
need to be performed either with subdued or yellow lighting to minimise degradation. It is 
reported that, in samples of bone, vitamin Ki became undetectable after exposure to 
sunlight for 1 h (Hodges et al., 1993). Degradation is also caused by strong alkalis that 
can originate from detergents used for glass washing. Thorough rinsing of glassware or 
heating to > 500 °C is necessary to ensure removal of alkaline agents.
2.2 Measurement of vitamin K by mass spectrometry
Quantitative analysis of vitamin K is routinely performed using high performance 
liquid chromatography (HPLC) (Fauler et al., 2000). Prior to 1993, no method had been 
reported to measure vitamin Ki at physiological levels using gas chromatography mass 
spectrometry (GCMS). Since then, a small number of reports have described the use of 
mass spectrometry, with gas chromatography or liquid chromatography, either for the
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quantitation of vitamin K-i or for the measurement of isotope ratios of vitamin K-i from 
plasma. The strategies for extraction of vitamin K-i from plasma prior to mass 
spectrometric analysis are summarised in Table 2-2. The various GGMS approaches and 
configurations are detailed in Table 2-3.
Table 2-2. Methods for extraction of vitamin Ki from plasma prior to analysis with 
mass spectrometry. All methods used GCMS except for Kurilich et al., (2003) who 
analysed vitamin Ki by LCMS
Reference
Plasma
volume
(ML) Extraction
Final
volume
(ML)
Injection
volume
(ML)
LOD
(pg)
Fauler et al., 
1996
1000 Add 1 ml_ water, mix, and 
stand for 10 min. Add 2 mL 
hexane, stand for 10 min. Add 
4 mL hexane. Centrifuge.
40 10 1
Raith et al., 
2000
200 Add 0.2 mL water, 0.6 mL 
ethanol and 5 mL of hexane. 
Extract for 15 min. Centrifuge
50 10 1
Dolnikowski 
et al.,
2002
500 Deproteination with ethanol. 
Extraction with hexane. SPE 
with silica column. Purification 
by HPLC.
50 1-2 5
Erkkila et 
al.,
2004
500 Deproteination with ethanol. 
Extraction with hexane. SPE 
with silica column. Purification 
by HPLC.
50 5 5
Kurilich et 
al., 2003
500 Deproteination with 500 pL 
ethanol. Extracted twice with 
1.5 mL hexane. Dried under 
N2 reconstituted in 200 pL.
200 50
Abbreviations: HPLC, high performance liquid chromatography; LOD, limit of detection; SPE, solid phase 
extraction
2.2.1 Gas chromatography mass spectrometry
Gleispach et al. (1993) used GCMS to investigate a number of techniques for the 
chemical derivatisation of vitamin K-i, including silyation (substitution of an active hydrogen 
with a silicon-containing group) and acylation (substitution of an active hydrogen atom 
with an acyl group) after reduction with zinc or hydrogen. However, the authors
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concluded that they were unable to find any derivative that was more sensitive than 
underivatised vitamin Ki, using splitless injection with either electron ionisation (El) or 
negative ion chemical ionisation (NCI). The limit of detection (LOD) was reported as 100 
pg per injection, although injection volume is not reported. It is important to note that this 
work was apparently performed with vitamin Ki standards and not with vitamin K-i from 
plasma. Except for the LOD, no information is provided on the working concentrations.
Later, the same group compared three different acyl-derivatives, trifluoroacetyl-, 
pentafluoropropionyl- and heptafluorobutyryl (HFB)-vitamin Kv Derivatisation with the N- 
perfluoroacyl anhydride and /V-perfluoroacid was performed after reduction with zinc. The 
chosen derivative was heptafluorobutyryl ester since, although all three derivatives 
provided similar analytical sensitivity, the HFB-derivative was the least impaired by 
extraneous lipids in the plasma matrix. Vitamin Ki was purified from plasma only with 
solvent extraction. Large volumes (10 pL) were injected and the limit of detection was 
recorded as 1 pg and limit of quantitation as 2 pg (Fauler et al., 1996).
The heptafluorobutyryl derivative-method was then successfully applied to the 
measurement of vitamin Ki concentrations in neonates (Raith et al., 2000). However, 
following a dose of vitamin Ki to protect against haemorrhagic disease of the newborn 
(HDNB), neonates have relatively high plasma concentrations of vitamin K<\ and also lower 
levels of potentially interfering lipid-soluble compounds, particularly when compared with 
adults (Gleispach et al., 1993). Therefore, it is questionable if this method could be 
applied to vitamin Ki in adult plasma.
At the present time, only one methodology has been published that describes the 
extraction and measurement of isotope ratios of vitamin Ki from plasma in adults by 
GCMS (Dolnikowski et al., 2002). The methodology was subsequently applied to the 
measurement of lipoprotein transport of vitamin Ki after consumption of labelled vitamin 
K-i by human volunteers (Erkkila et al., 2004). The procedure involves solvent extraction, 
solid phase extraction, and semi-preparative HPLC prior to isotope ratio analysis by 
GCMS. Since the method involves two analytical techniques HPLC and GCMS the 
analysis time per sample is considerable (HPLC run time 24 min, GCMS runtime at least
89
16 min). Despite the extensive sample preparation, problems with analysis were reported, 
such that isotopic data from only 60% of subjects were useful for analysis (Erkkila et al.,
2004).
2.2.2 Liquid chromatography mass spectrometry
The use of liquid chromatography mass spectrometry (LCMS) has also been 
described for the analysis of vitamin K-i (Kurilich et al., 2003). The use of LCMS is less 
well established than GCMS for the precise measurement of isotope ratios. The 
combination of liquid chromatography and mass spectrometry is complicated by the large 
amount of mobile phase (liquid solvent) entering the vacuum enclosure of the mass 
spectrometer. However, in theory at least, this method has a number of advantages over 
GCMS in terms of requirements for sample preparation, particularly in samples with 
complicated matrices. In this report, plasma samples undergo only solvent extraction 
prior to analysis by LCMS. The limit of detection is reported as 3 fmol (1.5 pg) (Kurilich et 
al., 2003).
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2.2.3 Conclusions
The sum of previous work on vitamin Ki and gas chromatography mass 
spectrometry (GCMS) suggested that prior to analysis, extraction of vitamin K-i from 
plasma could be achieved with solvent extraction alone, followed by derivatisation. The 
subsequent pages provide a general introduction to stable isotopes and GCMS and 
precede a description of the development of a method for the measurement of isotope 
ratios of vitamin Ki from human plasma.
2.3 Stable Isotopes
2.3.1 Definition
Stable isotopes are atoms that have a different number of neutrons but the same 
number of protons and electrons. An additional neutron will increase the atomic mass, 
whilst one fewer will decrease the atomic mass. It is these differences in atomic mass 
that can be measured using mass spectrometry and allow the exploitation of stable 
isotopes to identify particular molecules.
Unlike radioactive isotopes, stable isotopes do not decay. In terrestrial 
ecosystems, the proportion of stable isotopes is comparatively constant. However, 
chemical and biological mechanisms can discriminate between stable isotopes. For 
example, the different photosynthetic pathways between C3 and C4 plants can result in 
different carbon isotope ratios between these two categories of plants. In addition, 
discrimination between the isotopes can occur in chemical processes, particularly with 
hydrogen, since this element has the greatest difference between the two stable isotope 
forms (protium and deuterium). Reaction rates are frequently slower in samples enriched 
with deuterium. The properties of the two stable isotopes used in this work are shown in 
Table 2-4.
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Table 2-4. Atomic mass and percent abundance of carbon and hydrogen isotopes1
% abundance in 
terrestrial
Element Atomic mass ecosystems
Carbon 12C 12.000 98.930
13c 13.003 1.070
Hydrogen H 1.008 99.9885
2H or D 2.014 0.0115
Abbreviations: D, deuterium (2H)
2.3.2 Isotopomers
Molecules of the same chemical composition but with a different abundance of the 
heavier isotope are known as isotopomers. Because of the natural occurrence of heavier 
atoms, isotopomers exist naturally, for example, carbon dioxide has six common 
isotopomers (Table 2-5). Artificially increasing the proportion of one of the rarer 
isotopomers is the basis for stable isotope tracer studies.
Table 2-5. Major isotopomers of carbon dioxide and their molecular weights1
Molecular % relative
weight * Isotopomers abundance
44 12c 16o 2 100
45 13C160 2; 12C160 170 1.2
46 13C160 170; 12C170 2; 12C160 180 0.4
* molecular weights are rounded to whole numbers
In mass spectrometric terminology, the ion of the intact molecule is referred to as 
the molecular ion (M). Isotopomers of the same molecule are referred to as M+1, M+2, 
M+3 etc, with the number referring to the incremental increase in molecular weight. The 
chemical composition of a material determines the number and proportion of each 
isotopomer.
1 http://www.webelements.com/ (accessed 9th February 2007)
93
2.4 Mass spectrometry
2.4.1 Introduction
The measurement of isotope ratios is dependent on the separation and detection 
of molecules using mass spectrometry. This powerful technique is used widely in 
analytical science and has numerous applications, for example in the detection of very low 
levels of compounds, identification of unknown compounds, quantifying the level of known 
compounds and determining chemical structures. Measurements of natural isotopic 
composition are also widely used in tests for food authenticity, in forensic science, the use 
of performance-enhancing drugs and also in geochemistry. The artificial enrichment of 
compounds with stable isotopes for use as tracers, and analysis by mass spectrometry, 
are frequently used in many fields of chemistry and biology.
2.4.1.1 Ionisation
In order for molecules to be measured by mass spectrometry, the molecule must 
first be ionised before separation by the mass spectrometer. Ionisation can be achieved 
in many ways, such as electron ionisation (El) or chemical ionisation (Cl). As a result, it is 
the mass to charge ratio (m/z) of ions that is measured.
2.4.1.2 Electron ionisation
In electron ionisation (El), a current passing through a filament produces free 
electrons. These are accelerated (typically 70 eV) and then used to bombard the analyte 
molecules, removing an electron and giving the molecule a positive charge. Since the 
energy of chemical bonds (typically a few eV) is much smaller than the energy of the 
electrons, bond cleavage in the target molecule is a frequent occurrence, which leads to 
considerable fragmentation of the parent molecule. This fragmentation produces 
characteristic patterns in the mass spectra that can act as a fingerprint and aid in positive 
identification of the molecule. Important terms in the description of mass spectra are the 
‘molecular ion’ that describes the ion corresponding to the molecular weight of the intact
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molecule and the ‘base peak’ that describes the peak with the greatest abundance in the 
mass spectrum.
2.4.1.3 Chemical ionisation
Chemical ionisation (Cl) is considered a ‘softer’ form of ionisation and usually 
results in less fragmentation of the molecular ion. In Cl, a reagent gas (often methane) is 
introduced into the ionisation chamber along with the sample and carrier gas. Most of the 
electrons emitted from the filament collide with reagent gas molecules forming reagent 
ions. These ions then react in various ways with sample molecules. There are two 
important factors to consider with Cl. One is the need for an excellent vacuum in the MS 
chamber since water contamination of reagent gases dramatically decreases sensitivity. 
Secondly, one must consider the type of ionisation. There are two forms of Cl, negative 
chemical ionisation (NCI) and positive chemical ionisation (PCI). With PCI, the ionised 
reagent gas ions react chemically with the sample molecules. There are four forms of 
ionisation in PCI, proton transfer, hydride abstraction, addition and charge exchange. The 
effect of proton transfer is to produce M+1 ions that may not be compatible with stable 
isotope work. PCI is not especially sensitive because of the high background due to 
reagent gas ions, however it is a very soft ionisation method that results in less 
fragmentation and a greater abundance of the molecular ion. With NCI, the voltage 
polarities of the analyser are reversed to select negative ions. Ionisation mechanisms can 
include electron capture, dissociative electron capture, ion pair formation and ion- 
molecule reactions. NCI can provide excellent sensitivity, however for isotope ratio work 
there is a greater risk of non-linearity through isotope effects.
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2.4.2 Ion focusing
After ionisation, ions are focussed with electrostatic lenses (Figure 2-2). 
Figure 2-2. Focussing parts of the Agilent 5973N electron ionisation source
Entrance lens
Ion focus lens
Drawout cylinder
Drawout plate
Lens insulator
2.4.3 Mass separation
Benchtop GCMS instruments are commonly fitted with quadrupole mass filters. 
Following beam focussing, the ionised molecules pass to the mass filter and are 
separated on the basis of their mass to charge ratio (m/z). The quadrupole mass filter 
consists of four rods. A combination of direct current (dc) and radio frequency (RF) 
signals are applied to the rods. It is the magnitude of the RF signal that determines which 
ions can pass through the mass filter. The ratio of dc to RF voltage determines the 
resolution (widths of the mass peaks). The signals applied to the rods are set to allow 
ions of only a certain m/z to pass through; the other ions collide with the rods. In a 
quadrupole instrument, ions with different m/z are not measured simultaneously but 
rather, via alternation of the signals applied to the rods, pass through the mass filter 
sequentially. Compared to alternative methods of measuring isotope ratios (e.g. multiple- 
collector magnetic sector instruments that measure specific ions continuously) the use of 
quadrupole filter provides lower precision since only a single ion can be measured at any 
time point.
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A quadrupole mass filter can be operated in two modes: full scan or selected ion 
monitoring (SIM). In full scan a wide range of ions are analysed generating a full 
fragmentation pattern that is essential for positive identification of the molecule of interest. 
In SIM, a small number of chosen ions are analysed repeatedly. In this way, greater 
sensitivity is achieved and better precision is obtained in the measurement of isotope 
ratios.
2.4.4 Detector
A single detector known as an electron multiplier is used with a quadrupole 
instrument. Separated ions hit a high-energy diode that releases electrons. The signal is 
amplified as the electrons cascade through the electron multiplier horn. The limitation is 
that multiple ions cannot be measured simultaneously, thus the detector must have a fast 
response and high gain, that rules out the use of a Faraday detector. The integral 
amplifier of the electron multiplier provides the fast response but lower stability than can 
be obtained with Faraday cups.
2.5 Sample introduction - gas chromatography
Analysis by mass spectrometry requires that a pure specimen as possible be 
presented to the ion source. The most common method is by gas chromatography (GC). 
Together gas chromatography and mass spectrometry (GCMS) provide a flexible and 
affordable method with excellent selectivity and sensitivity. Gas chromatography 
describes the separation of volatile molecules on the basis of their affinity for the 
stationary phase of the capillary column while in a stream of carrier gas, commonly helium 
or nitrogen. The two most important components of the GC are the injector and the 
chromatography column.
2.5.1 Injector
There are a number of injector systems available for GC, two of the most common 
and those considered here are the split/splitless injector and cool on-column injector. 
They have in common a continual flow of carrier gas through the injector that moves
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constituents through the capillary column. The sample to be analysed is dissolved in a 
solvent and is transferred to the injector via a syringe.
2.5.1.1 Split/Splitless injector
In a split/splitless injector, the sample is injected into a glass liner contained within 
the heated injector. The sample is vaporised on entry to the liner and transferred to the 
column by the flow of carrier gas. The shape and size of the liner can be altered 
depending on the application. Often a small amount of deactivated glass wool is inserted 
into the liner to improve mixing of the sample and act as a filter to remove non-volatile 
contaminants that can degrade chromatography. On vaporisation, the volume of the liquid 
solvent increases thus injection volume is partly limited by the capacity of the liner. 
Vaporisation volume is dependent on the temperature and pressure of the injector. The 
crucial step here is efficient transfer of the sample to the column in order to minimise peak 
broadening and to ensure maximum resolution. During split injection, a set amount of 
carrier gas is continually purged from the injector, thus only a set portion of the vapour 
enters the capillary column, but flow through the liner is relatively fast. In splitless 
injection mode, the purge line is shut for a specified time to allow sample to condense at 
the top of the column. The purge line is opened at a set time after injection to remove 
excess solvent before raising the temperature of the column. Split injection has the 
advantage of reduced peak broadening and increased resolution. The splitless injection 
method can increase sensitivity but often with peak broadening due the relatively slow 
flow through the liner and transfer to the column that results in a loss of resolving power.
2.5.1.2 Pulsed split/splitless method
A variation on the split/splitless technique is the pulsed split/splitless method. This 
option is available on GCs equipped with electronic pressure control (EPC) (or similar 
systems) to accurately control gas flow rates. During injection, the pressure within the 
injector is increased to improve transfer to the column. Additionally, because of the higher 
pressure, larger sample volumes can be injected since the vaporisation volume is 
reduced.
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2.5.1.3 Cool-on column
With a cool on-column injector, the entire sample is injected and directly 
transferred onto the capillary column. This method can provide high sensitivity and 
reduce adsorption of analytes on active surfaces present in split/splitless injectors. During 
injection, the injector and oven are kept below the boiling point of the solvent. If low- 
boiling point solvents are used, the injector can be further cooled by the use of liquid 
nitrogen piped around the injector. The major disadvantage of this method is that 
contaminating non-volatile components are also transferred to the column along with the 
sample. To partly overcome this problem, and to reduce contamination to the capillary 
column, a retention gap or guard column can be used that consists of a length of 
deactivated uncoated capillary that connects the inlet to the capillary column.
2.5.2 Capillary columns
Capillary columns consist of a fused silica tube with a polyamide coating for 
strength. The inside of the column is coated with a stationary phase. The characteristics 
of the phase determine the selectivity of the column. The simplest phases are non-polar 
and primarily separate compounds on the basis of boiling point. With the addition of 
phenyl or cyanopropyl units, separation is also determined by polarity. The capillary 
column is housed within a temperature-controlled oven. By raising the temperature of the 
oven during analysis, compounds are released from the stationary phase to pass through 
the column to the detector. The flow of gas through a capillary column can be crucial to 
the efficient separation of compounds. Helium permits near optimum separation at even 
relatively high velocities (up to around 50 cm s'1).
2.6 Analysis of standards
Pure unlabelled vitamin Ki was obtained from Supelco (Dorset, UK). Two stable 
isotope labelled forms (Figure 2-3) of the vitamin (methyl-13C and ring-D4) were custom 
synthesised by ARC Laboratories (Apeldoorn, The Netherlands).
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Figure 2-3. Structures of labelled versions of vitamin Ki a) methyl-13C b) ring-D4
2.6.1 Preparation of vitamin standards
Samples of vitamin Ki were prepared in hexane. Since pure vitamin Ki is a 
viscous material, solutions were prepared by the following general method. A volumetric 
flask was covered in foil and weighed containing a stainless steel spatula. Under 
subdued-light, a small amount (mg) of vitamin Ki was transferred to the flask using the 
spatula. The mass was recorded and hexane was added to around two-thirds of the flask 
volume while agitating the spatula to ensure dissolution. The spatula was removed and 
hexane added over the spatula to fill the flask to the correct volume.
2.6.2 GCMS method
All GCMS analysis was performed on an Agilent GCMS system. Sample injection 
was performed with an Agilent 6890 GC with autosampler and equipped with split/splitless 
and on-column injector (Agilent Technologies, Stockport, UK). The GC was interfaced to 
a 5973N inert mass spectrometer equipped with a turbomolecular pump.
2.6.2.1 Injection method
A number of injection methods were investigated, including splitless, pulsed 
splitless and on-column injection. The advantage of splitless injection over split injection 
is that more of the sample is transferred to the column. The liner of the injector can
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contain a small piece of glass wool that can help filter the sample and prevent less volatile 
components entering the column. The major advantage of pulsed splitless mode is that 
greater sample volumes can be injected. With the pulsed splitless method it was possible 
to inject up to 5 pL whereas with split only up to 2 pL of solvent could be injected. The 
use of a liner marketed to convert a split/splitless injector into direct injector (equivalent to 
on-column) was also investigated. This liner tapers to a narrow hole where the analytical 
column fits tightly into the base of the liner. However, this method was not as sensitive as 
on-column injection. Of the injection methods, on-column was selected as it provided the 
greatest sensitivity.
With on-column injection the sample is transferred directly into the column. The 
use of a retention gap or guard column was found to not only improve peak shape but 
also permitted the injection of higher sample volumes. Chromatography was performed 
using a DB5-MS fused-silica capillary column (15 m x 0.25 mm internal diameter (id), 0.25 
pm film thickness). The DB5-MS column was connected to a 0.50 m to 5 m length of 
deactivated fused silica (0.53 mm id) acting as a guard column (retention gap) the other 
end of which was connected to the on-column injector. Helium was used as the carrier 
gas, with a flow rate of 1.2 mL/min operating in constant flow mode. Injection volumes 
were between 1 and 2 pL. Oven conditions were 60 °C for 2 min, ramped at 30 °C/min to 
325 °C, then an isothermal hold of 2 min. The transfer line was held at 325 °C.
2.6.2.2 MS parameters
The mass spectrometer was operated in electron ionisation mode as this method 
minimises the potential for loss of labelled atoms during ionisation processes. The source 
temperature of the mass spectrometer was set at 230 °C and the quadrupole temperature 
at 150 °C. The ionisation energy was 70 eV. The analysis of underivatised vitamin Ki 
was thus performed under the conditions shown in Table 2-6.
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Table 2-6. GC and MS parameters for the analysis of vitamin Ki standards
GC Parameters
Injector On-column, 1 pL injection volume 
5 m x 0.53 mm id deactivated fused
Column silica capillary guard column 
DB5-MS 15 m x 0.25 mm id x 0.25 pm
Column flow 1.5 mL/min
Carrier gas Helium
Initial: 60 °C for 2 min
Oven profile Ramp: 30 °C/min 
Final: 325 °C hold 2 min
Transfer line 325 °C
MS Parameters
Ionisation energy (eV) 70 volts
Source temperature 230 °C
Quad temperature 150 °C
Abbreviations: eV, electron volts; id, internal diameter 
2.6.3 GCMS analysis of standards - results
Electron ionisation of vitamin Ki in the mass spectrometer produced a number of 
characteristic ions (Figure 2-4). The base peak corresponds to the molecular ion (m/z 
450). Other significant ions in this spectrum are m/z 186, 198 and 225.
Figure 2-4. Mass spectrum of unlabelled vitamin K<i
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Figure 2-5 and Figure 2-6 show mass spectra under the same MS conditions for 
the 13C labelled and ring-D4 forms of vitamin K-|.
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Figure 2-5. Mass spectrum of 13C labelled vitamin Ki
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Figure 2-6. Mass spectrum of ring-D4 vitamin K
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Comparison of the three mass spectra of the different isotopomers makes it 
possible to comment on the potential molecular structure of the fragment ions. In the 
spectra of both labelled species, the three major fragment ions all show the same 
increase in molecular weight as the parent ion. This demonstrates the fragment ions all 
contain the same napthoquinone ring structure that includes the labelled atoms. The 
structures of the fragment ions are shown in Table 2-7 and are provided by the detailed 
mass spectrometric study of vitamin Ki by Di Mari et al. (1966) who used a number of 
isotopically labelled vitamin Ki analogues . Further evidence for m/z 186 and 225 comes 
from Fauler et al. (1996), and from a review of the analysis of non-volatile lipids by mass 
spectrometry (Murphy et al., 2001). Other smaller ions (< m/z 180) in the mass spectrum
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of underivatised vitamin Ki are probably representative of various parts of the phytyl side- 
chain and common to each of the three species, characterised by peaks at 14 -  15 mass 
units apart, representing methylene and methyl units (Di Mari etal., 1966).
Table 2-7. Potential structures of fragment ions of vitamin Ki after electron 
ionisation
Molecular structure Mass
450
186
198
CH
225and/or
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2.6.4 Isotopomer distribution
It is possible to calculate the expected isotopic distribution of a molecule from the 
known contribution of the heavier isotopes to each element 1. The theoretical relative 
abundances (i.e. the analytical response for an isotopomer relative to the response of the 
most abundant isotopomer) of masses contributing to total vitamin Ki are shown in Table 
2-8. This information is useful to confirm the identity of a peak, especially when working in 
selected ion monitoring where additional mass spectral information may not be available.
Table 2-8. Theoretical % relative abundance (to M) of isotopomers contributing to 
total vitamin Ki abundance
Mass % relative abundance
450 100.0
451 34.2
452 6.0
453 0.6
2.6.5 Selected ion monitoring
Initial attempts to analyse vitamin Ki in selected ion monitoring (SIM) resulted in 
unexpected isotope ratios, however isotope ratios obtained from SCAN mode were of the 
expected values. There were a number of possible explanations for incorrect isotope 
ratios including inappropriate mass spectrometer settings (high scan speed, short dwell 
time, incorrect mass spectrometer tuning), inappropriate peak width, or a dirty ion source. 
After eliminating these possibilities, the problem was found to be due to the way in which 
the mass spectrometer obtains data and the differences between SIM and SCAN modes. 
In SCAN mode, the mass spectrometer scans at 0.1 amu (atomic mass units) increments. 
Five adjacent data points are smoothed and the centroid mass determined. However, in 
SIM, data are obtained around a specified window (0.9 amu in low resolution and 0.5 amu 
in high resolution). If the mass spectrometer is set to monitor a slightly different mass
1 http://www2.sisweb.com/mstools/isotope.htm (accessed 14th April 2007)
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(e.g. 450.0) than the actual mass (e.g. 450.4) of a molecule, then peak widths may 
overlap. This effect was the cause of the incorrect isotope ratios.
2.6.6 Dynamic mass calibration
The problem of incorrect mass assignment can be overcome by performing a 
dynamic mass calibration (DMC) which allows determination of the centroid mass (the 
mass of greatest abundance within a single peak or compound). To perform a DMC, a 
SIM acquisition was performed around the expected centroid mass at m/z spaced 0.1 
amu apart. The exact mass of vitamin K is 450.35 thus DMC was performed between
450.2 and 450.6 at 0.1 amu increments. The results show (Figure 2-7) that the centroid 
mass for each of the isotopomers of m/z, 450.4, 451.4 and 452.4 is at .4, although for the
454.4 isotopomer the abundance is very similar between .4 and .5 (in high resolution). 
Greater sensitivity was achieved with high resolution.
Figure 2-7. Comparison of low resolution (black bars) and high resolution (white 
bars) and determination of the centroid mass during dynamic mass calibration
m /z 450 m/z 451
452.2  452 .3  452.4  452 .5  452.6  454 .2  454 .3  454 .4  4 5 4 .5  45 4 .6
m/z m/z
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2.6.7 Chromatography of vitamin K-i standards
Figure 2-8 shows the chromatography of vitamin Ki standards as measured in SIM 
mode. The double peak is due to the presence of the c/'s- and trans-isomers in phytol,
used in the synthesis of artificial vitamin Ki (Fauler etal., 1996).
Figure 2-8. Total ion chromatograms of (A) unlabelled, (B) 13C-labelled and (C) ring-
04  vitamin standards analysed in SIM mode
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2.6.8 Contribution of cis- and trans-isomers
Figure 2-9 shows the approximate contribution of the c/s-isomer to total peak area 
for each of the vitamin Ki standards for each isotopomer and total ion count. For 
unlabelled vitamin the cis-isomer contributes around 13% to total vitamin K1( whereas 
for labelled standards the cis-isomer contributes 16 -  17%. These differences in the 
cis:trans ratio are possibly the consequence of variation in the manufacture and synthesis 
between suppliers of the unlabelled and labelled forms. Interestingly, in all three 
standards, the cis-isomer had greater relative abundance at the heavier isotopomers. 
There are a number of possible explanations for this observation. It may be due to the 
peak integration software. The cis and trans peaks are not fully resolved and thus each is 
integrated as far as the valley between to the peaks. The position of the vertical split may 
be affected by the size of the peak that decreases as the isotopomer number increases. 
Related to this is the observation that the heavier isotopomers elute slightly earlier than 
the lighter isotopes. Consequently, the cis-isomer contains an apparently higher 
proportion of the heavier isotopomers overlapping from the trans-isomer.
Figure 2-9. Percent contribu tion of the c is -isom er to each ion and tota l ion count, 
fo r unlabelled, 13C, and ring-D4 labelled standards
30
M M+1 M +2 M +3 M +4 T o ta l
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2.6.9 Selected ion monitoring analysis of vitamin Ki standards
Selected ion monitoring (SIM) of the vitamin standards allowed accurate 
determination of the relative isotopomer distribution for each species. Figure 2-10 shows 
the SIM mass spectra for each standard. The pattern of isotopomer distribution is the 
same for each species but the m/z is shifted by one mass unit for the 13C-labelled species 
and by four mass units for the deuterated species. The relative contributions are shown in 
Table 2-9, and are similar to the theoretical calculated values for unlabelled vitamin Ki 
shown in Table 2-8.
Table 2-9. Relative abundance of M to M+4 ions for unlabelled, 13C-labelled and 
ring-D4 labelled forms of vitamin K-i
% relative abundance
m/z Unlabelled 13c Ring-D4
450.4 100.0
451.4 33.7 100.0
452.4 8.4 32.6
453.4 1.6 8.9
454.4 0.3 2.0 100.0
455.4 0.3 32.7
456.4 8.6
457.4 1.7
458.4 0.3
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Figure 2-10. Selected ion monitoring mass spectra of (A) unlabelled, (B) R e­
labelled and (C) ring-D4 vitamin Ki standards
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2.6.10 Purity of labelled standards
In order to measure the isotopic purity of the labelled standards, the contribution of 
each of the ions from each species was divided by the total ion count from m/z 450 to the 
M+4 of the labelled species. So for the 13C standard:
m/z 451 -  455
  *  100
m/z 450 -  455
Each standard was measured five times. Isotopic purities for 13C- and 2H-labelled 
vitamin Ki were 98.4% and 98.0%, respectively.
2.7 Derivatisation
For separation by GC, compounds must be volatile and thermally stable. In 
derivatisation, functional chemical groups of the analyte molecule are altered by the 
addition of other functional groups to improve chromatographic behaviour and suitability 
for GC analysis. The improvement is the result of any of a number of processes: 
increased volatility, decreased polarity, improved thermal stability, improved separation, 
reduced tailing, improved sensitivity and/or increased molecular weight.
2.7.1 Derivatisation of vitamin ^
Previous work found that derivatisation with /V-perfluoroacyl anhydride preceded 
by reduction with zinc offered improvements in the analysis of vitamin Ki compared to 
underivatised vitamin Ki (Fauler et al., 1996). In this reaction, reduction with zinc is 
spontaneously followed, under acidic conditions, by cyclization of the phytyl side chain 
converting the vitamin K-quinol into a chromanol (Langemann & Isler, 1965). The 
remaining hydroxyl group is converted to the perfluoro ester.
Purity = Z
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2.7.2 Selection of derivative
Initially, derivatisation was frequently unsuccessful or produced very variable 
yields. Changes in experimental procedures to include magnetic stirring in conical shaped 
vials and a change in reagent quality improved reliability of the derivatisation. Previous 
work favoured the heptafluorobutyryl derivative due to the large increase in molecular 
weight that removed the compound away from interfering compounds in plasma (Fauler et 
al., 1996). However, for this work the pentafluoropropionyl derivative was selected 
(Figure 2-11). Although sensitivity was similar between the two derivatives, some 
interference was observed in the M+4 region of the heptafluorobutyryl derivative such that 
it was unsuitable for this work due to use of the ring-D4 labelled form of vitamin Ki.
Figure 2-11. Molecular structure of the pentafluoropropionyl derivative of vitamin 
Ki
2.7.3 Derivatisation method
Pentafluoropropionic anhydride (derivatization grade, 99%), pentafluoropropionic 
acid (Fluka brand, >97.0%) and zinc dust (<10 microns) were purchased from Sigma 
(Sigma-Aldrich Company, Poole, UK) and hexane (Hipersolv) from VWR (VWR 
International Ltd, Poole, UK).
Derivatisation was performed in conical shaped 3 mL reaction vials (Supelco, 
Dorset, UK) in a Pierce Reacti-therm heating/stirring block (Perbio Science, 
Erembodegem, Belgium). 50 pL of pentafluoropropionic anhydride and 25 pL of 
pentafluoropropionic acid were added to a solution of vitamin Ki in 1 mL of hexane. The 
mixture was stirred with a magnetic triangular spin vane and around 100 mg of zinc dust
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was added to each sample. Vials were capped and stirred at room temperature. After 2 
h, 1 mL of deionised water was added and the samples stirred for a further 5 min. The 
samples were transferred to disposable glass tubes (12 x 75 mm, Corning brand) and 
centrifuged for 5 min at room temperature at 1500 g. From the upper layer, 700 pL was 
transferred to amber GC vials. A further 1 mL of hexane was added to the glass tubes 
and, after centrifugation, removed and combined with the first aliquot. The samples were 
dried down under N2 at 40 °C with a Pierce Reacti-therm heating block and Reacti-vap 
evaporator (Perbio Science, Erembodegem, Belgium) and reconstituted in 20 pL hexane 
prior to transfer to glass inserts. The derivatised samples were stored at -18  °C until 
analysis.
2.7.4 Results
Derivatised vitamin Ki eluted slightly before underivatised vitamin Ki as a single 
peak. Isomerisation of the molecule is removed during derivatisation in cyclisation of the 
phytyl side chain.
2.7.4.1 Total Ion spectrum
Mass spectrometry of derivatised vitamin Ki showed the molecular ion of 
unlabelled, 13C- and ring-D4 labelled of vitamin Ki at m/z 598, 599 and 602, respectively 
(Figure 2-12, A-C). A second major ion was observed at m/z 333 (m/z 334 and 337 in 
labelled molecules) corresponding to the fragment ion after loss of the phytyl side chain 
(Figure 2-13).
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Figure 2-12. Mass spectra of derivatised (A) unlabelled, (B) 13C-labelled and (C)
ring-D4 vitamin Ki standards
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Figure 2-13. Molecular structure of the major fragment of the pentafluoropropionyl 
derivative of vitamin Kt
O
2.7.4.2 SIM analysis
For analysis by SIM, it was necessary to perform a dynamic mass calibration as 
for the underivatised samples. SIM analysis was subsequently performed at the decimal 
of 0.4 amu for each mass. The mass spectrum for each species is shown in Figure 2-14. 
The relative contribution of isotopomers to each species is in shown in Table 2-10.
Table 2-10. Relative abundance of M to M+4 ions for derivatised unlabelled, Re­
labelled and ring-D4 labelled forms of vitamin Ki
% relative abundance
m/z Unlabelled 13C Ring-D4
598.4 100.0
599.4 36.8 100.0
600.4 7.1 35.1
601.4 1.0 7.0
602.4 0.1 0.9 100.0
603.4 0.1 36.0
604.4 6.9
605.4 1.0
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Figure 2-14. Selected ion monitoring mass spectra for derivatised (A) unlabelled,
(B) 13C-labelled and (C) ring-D4 vitamin Ki
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2.8 Extraction of vitamin Ki from plasma
The best clean-up procedure is a compromise between minimising the amount of 
time required and providing a clean sample for analysis both in terms of maintaining 
chromatography and ensuring no co-eluting peaks. Saponification is an often-used 
procedure for the extraction of fat-soluble vitamins, however it was not suitable here 
because vitamin Ki is sensitive to strong alkalis. Previous work suggested that 
deproteination, followed by solvent extraction and derivatisation may provide a method for 
analysis of vitamin Ki by GCMS. However, it quickly became clear that this method would 
not be sufficient for this work due to rapidly deteriorating chromatography and lack of 
sensitivity. The chosen final extraction procedure required enzyme hydrolysis, solvent 
extraction and solid phase extraction, prior to derivatisation.
2.8.1 Blood samples
Initial experiments were hindered by the use of pooled plasma from an unknown 
source that proved unsuitable for method development. As a result an ethical application 
was submitted to Cambridge local research ethics committee (LREC) for the collection of 
plasma samples for method development work (Cambridge REC ref: 05/Q0108/30). 
Potential volunteers were provided with an information sheet (Appendix I) and informed 
written consent was obtained from all volunteers (Appendix II).
Blood for method development was collected from volunteers into 9 mL EDTA S- 
monovettes (Sarstedt Ltd, Leicester, UK). Samples were stored on ice and protected from 
light; samples were centrifuged at 4 °C for 20 min at approximately 2000 g. After 
centrifugation, plasma was removed with disposable plastic Pasteur pipettes and pooled 
in a single sterile container. After gentle mixing, pooled plasma was removed into 1 mL 
aliquots and stored at -70  °C until extraction.
Based on data from previous experiments with standards and assuming typical 
vitamin Ki plasma concentrations of 0.29 -  2.64 nmol/L it was established that extraction 
of 1 mL of plasma would be necessary for the measurement of isotope ratios.
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2.8.2 Enzyme hydrolysis
Enzyme hydrolysis has been used previously for the extraction of vitamin K from 
food, in particular milk, oils and infant formulas (Koivu-Tikkanen 2001). However, enzyme 
hydrolysis has not before been applied to the extraction of vitamin Ki from plasma. 
Previous studies measuring carotenoids and vitamin E have used an enzyme hydrolysis 
step prior to analysis (Yeum et al., 1996; Sommerburg et al., 1997). Lipase was used for 
the hydrolysis of TAG, releasing glycerol and free fatty acids, and cholesterol esterase for 
the hydrolysis of plasma cholesterol esters.
2.8.2.1 Method development
A number of factors needed to be considered in the development of an enzyme 
hydrolysis method, including the amount of substrate, additional components for enzyme 
activation, buffer concentration and pH. Since it was preferable to perform hydrolysis of 
TAG and cholesterol esters simultaneously, it was necessary to compromise on the 
optimum conditions. Lipase and cholesterol esterase had the following definitions:
1) Cholesterol esterase -  one unit hydrolyses 1.0 pmol of cholesteryl oleate to 
cholesterol and oleic acid per min at pH 7.0 at 37 °C in the presence of taurocholate.
2) Lipase -  one unit hydrolyses 1.0 micro-equivalent of fatty acid from a TAG in 1 
h at pH 7.7 at 37 °C.
As previously shown in Table 2-1, 1 mL of plasma typically contains approximately
1.5 mg of both TAG and cholesterol esters. Sodium taurocholate was used as an 
activator. The pH of 7.3 was chosen as a compromise between the optimum values for 
each enzyme.
2.8.2.2 Enzyme hydrolysis procedure
Cholesterol esterase (from Pseudomonas sp., EC 3.1.1.13), lipase (from Candida 
rugosa, EC 3.1.1.3) sodium taurocholate, potassium phosphate monobasic (ACS 
reagent), and potassium hydroxide pellets (Aldrich brand) and were all obtained from 
Sigma (Sigma-Aldrich Company, Poole, UK).
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Potassium phosphate buffer (0.1 M) was prepared and the pH adjusted to 7.3 by 
addition of potassium hydroxide pellets. Solutions of cholesterol esterase and sodium 
taurocholate were prepared by adding buffer to weighed quantities to obtain 
concentrations of 60 mg per 10 mL and 5 mg per 10 mL, respectively. Lipase (100 mg) 
was weighed into disposable culture tubes (16 x 100 mm, Corning brand) and to each was 
added 0.5 mL of both the sodium taurocholate and cholesterol esterase solutions. 1 mL 
of plasma was added to each tube. The tubes were covered with laboratory film and 
gently vortexed. They were then incubated in the dark for 2 h in a waterbath set to 37 °C. 
Every 20 min the samples were gently vortexed to disperse the lipase. After cooling, the 
samples underwent solvent extraction as described in section 2.8.3.
2.8.3 Solvent extraction
Vitamin Ki dissolves in a number of solvents, including ethanol, ether, hexane and 
chloroform. Almost all previous sample preparation methods have used ethanol for 
deproteination and hexane to extract non-polar components from plasma (Fauler et al., 
2000).
2.8.3.1 Solvent extraction procedure
Absolute ethanol (Riedel-de Haen brand, £99.8%) was obtained from Sigma 
(Sigma-Aldrich Company, Poole, UK). Hexane (Hipersolv) was obtained from VWR (VWR 
International Ltd, Poole, UK). Following enzyme hydrolysis, and after cooling to room 
temperature, samples were vortexed and divided into two aliquots in disposable culture 
tubes (16 x 100 mm, Corning brand) for solvent extraction. Deproteination was achieved 
by the addition of 2 mL ethanol to each aliquot. The samples were then vortexed for 5 
min at 1200 rpm (IKA Vortex, Esslab, Essex, UK). Extraction of the non-polar lipid fraction 
was performed with the addition of 3 mL of hexane and vortexing for 10 min at 1200 rpm. 
The samples were centrifuged for 10 min at 2000 g. The upper layer (3 x 0.75 mL) was 
removed and transferred to small disposable culture tube (12 x 75 mm, Corning brand). A 
further 1 mL hexane was added and each sample was vortexed and centrifuged as above, 
and 1 mL hexane removed and combined with the first extract. In order to reduce the
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sample volume prior to solid phase extraction, the samples were dried down under N2 at 
40 °C to a volume of around 300 pL using a Pierce Reacti-therm heating block and 
Reacti-vap evaporator (Perbio Science, Erembodegem, Belgium).
2.8.4 Additional extraction procedures
For GCMS analysis both solid phase extraction (SPE) and semi-preparative HPLC 
have been utilised for the purification of vitamin K-i from plasma. Fauler et al. (2000) have 
reviewed extraction methodologies prior to quantitative HPLC analysis of vitamin Ki and 
all have used either SPE with or without semi-preparative HPLC. The use of these 
extraction methods is considered below.
2.8.5 Solid phase extraction (SPE)
Solid phase extraction is a form of chromatography using a solid stationary phase 
and a liquid (solvent) mobile phase. The stationary phase is packed into a polypropylene 
column and held in place by porous frits. The adsorbent is held at the bottom of the 
column to allow sufficient space for a reservoir of solvent. A wide range of adsorbents are 
available depending on the application. The generalised SPE procedure involves four 
steps 1) conditioning of packing material, 2) sample loading, 3) washing and 4) sample 
elution. Conditioning of the column removes any potential interfering chemicals remaining 
from manufacture and wets the packing material. After sample loading, the SPE column 
is washed to remove unwanted compounds from the packing material. The compound of 
interest remains adsorbed to the packing material. During elution, the compound of 
interest is more attracted to the solvent than to the packing material. Other, unwanted 
compounds remain bound to the adsorbent.
The SPE method used here is based on that described by Wang et al., (2004). 
The method utilises 500 mg silica cartridges. An important consideration was the packing 
weight since these cartridges were used previously for the extraction of up to 0.5 mL 
plasma. Advice from manufacturers suggests that compounds to be extracted should not 
be more than 5% of the mass of the packing in the tube. With 500 mg of sorbent up to 25
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mg of compounds can be loaded on the column. Based on the levels of extracted 
compounds shown in Table 2-1, 500 mg provided sufficient loading capacity.
2.8.5.1 Optimisation o f SPE
For quantitative work, it is essential that all vitamin Ki be eluted from the SPE 
column. Since the measurement of isotope ratios by GCMS is independent of vitamin 
concentration (in the absence of fractionation), it was possible to optimise the SPE 
procedure to minimise the elution of potentially interfering compounds, while ensuring the 
majority of vitamin K  ^ was eluted. The method of Wang et al. (2004) requires a solution of 
3.5% diethyl ether in hexane for the elution of vitamin Ki. To optimise elution, steps 1 to 3 
of the procedure were followed as per Wang et al (2004).: (1) the column was washed 
with 6 mL each of diethyl ether in hexane followed by hexane only, (2) the sample was 
added and (3) column was then washed with hexane prior to elution. Solutions of 0.4 mg 
of vitamin K-i per 1 mL of hexane were prepared. High concentrations were used to permit 
measurement using a Unicam 5625 UV spectrophotometer (Unicam, Cambridge, UK). 
Vitamin Ki was measured at wavelengths 243, 247 and 248 nm (Langemann & Isler, 
1965). Solutions of diethyl ether in hexane were prepared as 0.5%, 1%, 1.5%, 2%, 2.5%, 
3% and 3.5%. After sample loading, the vitamin Ki was eluted with each of the solutions 
in turn, from the 0.5% solution upwards. It was found that maximum concentration in the 
eluate was reached with 1.5% solution, and thus this solution was chosen for use during 
the extraction procedure.
2.8.5.2 SPE procedure
Hexane (Hipersolv) and diethyl ether (for chromatography) were obtained from 
VWR (VWR International Ltd, Poole, UK). The SPE cartridges (Waters Sep-Pak-RC™ 
500 mg silica, Hertfordshire, UK) were placed in a 12-port SPE vacuum manifold 
(Supelco, Dorset, UK) and conditioned with 4 mL 1.5% diethyl ether in hexane and then 
with 4 mL hexane. Sample extracts were loaded and the sample tubes rinsed with a 
further 200 pL of hexane. The cartridges were washed with 6 mL of hexane and the 
vitamin Ki was eluted with 7 mL 1.5% diethyl ether in hexane. The sample eluate was
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collected into disposable glass tubes (13 x 100 mm, Fisher brand) and evaporated to 
dryness in a vacuum evaporator (Savant, NY, USA) for 30 min with a medium drying rate. 
The samples were reconstituted in 1 mL hexane, transferred to amber GC vials (Agilent 
Technologies, Stockport, UK) and stored a t -18  °C until derivatisation.
2.8.6 High performance liquid chromatography (HPLC)
High performance liquid chromatography (HPLC) is a powerful and versatile 
method of separating complicated mixtures of compounds. The main components of a 
HPLC system are the solvent reservoir, a high-pressure pump, injector, column, detector 
and, depending on the machine set-up, a sample collector. HPLC columns are typically 
formed from stainless steel and contain a stationary phase that can be polar (for normal 
phase chromatography) or non-polar (for reversed phase chromatography). For 
quantitative or analytical work, columns with a diameter between 1 and 4 mm are used 
whereas for semi-preparative work, columns of diameter up to 25 mm are available. One 
or more solvents are used as mobile phase and pumped at high pressure through the 
column. If a single pump is used the mobile phase is termed isocratic, otherwise a two- 
pump system allows the use of solvent gradient for greater control of chromatography. A 
wide-range of detectors are available for HPLC although most are non-specific. These 
include UVA/IS detectors, fluorescence and electrochemical detectors. The use of mass 
spectrometers and liquid chromatography were considered in section 2.2.2.
2.8.7 Semi-preparative HPLC
The use of semi-preparative HPLC was investigated to assess if this method 
provided any advantages over enzyme hydrolysis and SPE. Previous authors have used 
HPLC to purify plasma samples prior to the analysis by GCMS (Dolnikowski et al., 2002; 
Erkkila et al., 2004) and HPLC is commonly used for the purification of vitamin K  ^ from 
food samples.
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2.8.7.1 Scale-up from analytical methodology
A scaled-up protocol based on the analytical methodology was used (see section 
2.12). Scaling-up was necessary due to the greater volume of plasma to be extracted. 
The critical changes concerned the HPLC column, namely length, width and pore size. 
The analytical column was a Thermo BDS Hypersil C-i8, 15 cm in length, 3 mm wide with 3 
pM pore size. For semi-preparative work it was necessary to use a column with a larger 
pore size due to the greater solvent flow through the column. However, a column identical 
to the analytical column (with the exception of pore size) was unavailable from Thermo. 
Thus, the first step in method development was to source a column with the same 
properties and chromatography as the analytical column, but from a supplier that also 
offered a 5 pM pore size. For column comparison work the scanning fluorescence 
detector was used. An ACE-3 C i8 (10 x 250 mm), 3 pM particle size was sourced 
(HiChrom, Reading, UK) and vitamin K-i chromatography compared between the routine 
analytical system available in our laboratory against a new semi-preparative system. 
Vitamin Ki chromatography was similar between the analytical and semi-preparative 
HPLC systems and with the two different columns. The second step was to scale up from 
the analytical column to semi-preparative column. Equations to calculate of the size of 
column required for semi-preparative HPLC were obtained from Waters (the HPLC 
manufacturer) website.
 , f   _ (diameter semi prep column)2 x length semi prep columnscale up Tactor — —-------------------------------------—------------:-------------------------
(diameter analytical column) x length analytical column 
The scale-up factor was calculated from analytical sample load (up to 125 pL 
plasma) and the potential plasma sample volume (2 mL) necessary to provide sufficient 
vitamin Ki for GCMS analysis. Thus, the scale-up factor was calculated as 16. A column 
length of 250 mm was selected. Column diameter was then calculated by rearranging the 
above equation to:
.. . scale up factor x (diameter analytical column)2 x  length analytical columndiameter semi prep column = J  11-------------------------------   — ---------- - ----------------------------
V length semi prep column
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Thus,
9 3 =  | l6x(3)2 xl50  
V 250
The semi-preparative column dimensions were finalised as diameter 10 mm, 
length of 250 mm and a particle size of 5 pM. A disadvantage of using columns with 
greater particle size is a decrease in column efficiency and resolution. Increasing the 
column length can provide a small increase in resolution but ultimately resolution is 
decreased with the scaled-up procedure. Practically, although resolution was decreased, 
separation of vitamin K-i from other components was still possible.
2.8.7.2 Semi-preparative HPLC procedure
Initial work concentrated on optimising the mobile phase and injection parameters. 
The chosen mobile phase was a 10% isocratic solution since at the required flow rates the 
use of a two-pump gradient approach produced large fluctuations in the baseline. For 
develop work high concentrations of vitamin Ki standards were used with the dual gamma 
absorbance detector.
The final stage was to compare semi-preparative HPLC with enzyme hydrolysis. 
Eight 1 mL pooled plasma samples underwent solvent extraction and SPE. Four of the 
samples were previously subjected to enzyme hydrolysis while the remaining four 
underwent HPLC. Two of each of the samples (non-HPLC and HPLC) were spiked with 
an additional 500 pg of vitamin Ki. On the semi-preparative HPLC, the retention time of 
vitamin K-i was around 22 min and sample was collected with the fraction collector using a 
time window of 1.5 min. The eluate was dried down under N2 at 35 °C. All samples were 
derivatised as described in section 2.7.3 and then analysed by GCMS.
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The HPLC was set up as detailed below:
HPLC: Waters 1525EP Binary HPLC Pump with manual injection
Waters 474 Scanning Fluorescence Detector 
Waters 2487 Dual A Absorbance Detector 
Solvents: 10% dichloromethane in hexane (with in-line degasser)
Column: ACE-5 C18 (10 x 250 mm), 5 pM particle size (p/n ACE-121-2510)
with 3 mL/min flow rate 
Fraction collector: Waters Fraction Collector III
2.8.7.3 Results
Qualitatively, the HPLC extracted samples appeared slightly ‘cleaner’ than the 
enzyme hydrolysis samples. However, all samples had relatively clean chromatograms 
suitable for isotope ratio measurements. Samples that did not undergo HPLC had a 
greater abundance than those that were separated by HPLC.
2.8.7.4 Conclusions
Further extraction by HPLC may provide some benefit in terms of a cleaner 
chromatogram and therefore less gas chromatograph maintenance. However, this 
advantage is outweighed by the apparent greater losses (possibly from fraction collection 
or additional drying down step) and additional time and effort.
2.9 Final extraction methodology
The final protocol for the extraction of vitamin Ki from human plasma utilised 
enzyme hydrolysis with lipase and cholesterol esterase, solvent extraction and solid 
phase extraction, prior to derivatisation and analysis by GCMS. For the analysis of 
plasma samples, the GC parameters were the same as for the standards described above 
(see Table 2-6) but with the addition of a final temperature ramp of 40 °C/min from 325 °C 
to 350 °C and a hold time of 5 min to remove contaminating material. This method 
provided a sufficiently clean sample to measure isotope ratios of extracted vitamin K1 on
125
the GCMS. An example chromatogram from plasma is shown in Figure 2-15. A summary 
of the sample extraction protocol is shown in Figure 2-16.
Figure 2-15. Total ion chromatogram (m/z 598.4 -  602.4) of vitamin Ki extracted 
from pooled plasma
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Figure 2-16. The analytical m ethodology fo r the extraction and derivatisation of 
vitam in Ki from  human plasma samples
E n zy m e
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S o lv e n t
E x trac tio n
S o lid  P hase  
E x tra c tio n
D e riv a tis a tio n
Remove plasmas & 
cholesterol esterase 
(CE) from freezer and 
lipase from fridge 
Set water bath to 37 
°C
Prepare 0.1M 
potassium phosphate 
buffer; adjust pH to 
7.3 using potassium 
hydroxide pellets 
Weigh 100 mg lipase 
large culture tubes 
Weigh 30 mg sodium 
taurocholate (NaTC) 
into scintillation vial; 
add 5 m L  buffer. 
Measure 2 mg CE into 
scintillation vial; add 5 
mL buffer.
Add 0.5 mL NaTC & 
0.5 mL CE to culture 
tubes; add 1 mL 
plasma 
Vortex gently 
Cover with Parafilm 
Incubate for 2 h, 
vortex gently every 30 
min
Remove and allow to 
cool
Divide each sample 
between two large 
culture tubes 
Add 2 mL ethanol 
and shake for 5 min 
at 1200 rpm
Add 3 mL hexane 
and shake for 10 min 
at 1200 rpm 
Centrifuge for 10 min 
at 3000 rpm at room 
temperature 
Remove 3 x 750 pL 
to small disposable 
culture tube 
Add further 1 mL 
hexane to original 
sample and shake 
for 1 0 min at 1200 
rpm
Centrifuge as above 
Remove 1 mL to 
small culture tube
Dry down under N2 at 
40 °C to volume of 
around 300 pL
Use freshly prepared 
1.5% diethyl ether in 
hexane (DEE:HEX) 
Prepare vacuum 
manifold with Waters 
Silica SPE RC- 
cartridges (500 mg)
Wash with 3 mL 
DEE:HEX 
Wash with 4 mL 
hexane, keep wet 
Pour in sample, rinse 
sample tube with 200 
pL hexane and add 
to cartridge; run 
through sample, 
keep wet 
Rinse with 6 mL 
hexane, keep wet 
Change waste 
bottles for 13 x 100 
mm culture tubes 
Elute with 7 mL 
DEE:HEX
Dry in vacuum dryer 
for 30 min, medium 
drying rate, RC = off 
Reconstitute each 
aliquot o f sample in 
400 pL hexane and 
transfer to amber GC 
vial. Rinse culture 
tubes with further 
100 pL hexane and 
add to GC vial.
Transfer sample to 
reaction vial 
Add further 100 pL 
hexane to sample 
and transfer to vial
Add around 100 mg 
of zinc powder 
Add 5 OpL
pentafluoropropionic
anhydride
Add 25 pL
pentafluoropropionic
acid
Cap and stir for 2 h 
Add 1mL water, cap 
and stir for 5 min 
Transfer contents of 
vial to small culture 
tube
Centrifuge for 5 min 
at 2500 rpm at room 
temperature 
Transfer 700 pL to 
amber GC vial 
Add 1 mL hexane to 
tube, centrifuge, add 
to GC vial 
Dry down under N2 
(35 °C)
Reconstitute in 20 pL 
hexane and transfer 
to insert in GC vial
**AII work to be performed under 
reduced light conditions**
Abbreviations: CE, cholesterol esterase; NaTC, sodium taurocholate; DEE, diethyl ether; HEX, hexane; SPE, 
solid phase extraction; GC, gas chromatography
2.10 Method validation and quality
Prior to the analysis of each batch of samples in the subsequent volunteer studies, 
an underivatised vitamin Ki standard was analysed to check chromatographic quality and 
mass spectrometer performance. If chromatographic quality was poor (assessed by the 
degree of separation of the cis- and trans-isomers), an approximate 0.5 m length of guard 
column was trimmed from the injector side. If incorrect isotope ratios or low sensitivity 
were observed then the mass spectrometer was retuned, and, if necessary, the ion source 
cleaned. Samples from a single volunteer visit were analysed as a single batch.
2.10.1 Linearity
The testing of linearity is an important part of method validation for tracer 
methodology and isotope ratio analysis. The linearity of stable isotope measurements 
was assessed by the volumetric preparation of solutions ranging from 0.3125 to 20% 
enrichment at a plasma concentration of 1.1 nmol/L. The resulting linear regressions had 
an R2 value of 0.997 for the 13C labelled and 0.999 for the ring-D4 labelled. Concentration 
dependent linearities were less of a concern in this work because of the narrow range of 
expected and observed concentrations of vitamin Ki in plasma.
2.10.2 Precision
Intra- and inter-assay precisions were calculated from multiple analyses of 
extracted and derivatised pool plasma samples. The coefficient of variation (CV) of 
injections from the same vial for the M+1/M isotope ratio in plasma was less than 3.5%. 
The intra-assay CV of samples extracted together and analysed together was less than 
2%. Finally, the inter-assay precision for analyses performed on different days was less
o
than 3%. At typical physiological concentrations it was not possible to measure the 
M+4/M isotope ratio due to the small contribution of the M+4 isotopomer at natural 
abundance (less than 0.1%).
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2.10.3 Limit of detection
The limit of detection (LOD) for isotope ratio analysis is often higher than for 
quantitative analysis since the total abundance is divided amongst the contributing 
isotopomers. Thus, here the limit of quantitation is more relevant and is estimated to be at 
least 6 pg per injection (1 pL). With the described methodology this is equal to a plasma 
concentration of around 0.3 nmol/L. This value can be improved to around 0.15 nmol/L by 
decreasing the final sample volume to 10 pL.
2.11 Peak integration
Isotope ratios were calculated using the fitting methods of Bluck and Coward 
(1997) of which a detailed description is presented later in section 3.6.1. Typical 
chromatograms obtained after extracting ions 598.4 -  602.4 m/z from the cumulative ion 
counts are shown in Figure 2-17. Note that at physiological concentrations it is not 
possible to measure m/z 602.4.
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Figure 2-17. Extracted ion chromatograms of derivatised vitamin in plasma
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2.12 Quantitative analysis of vitamin K-i by HPLC
Quantitation of plasma vitamin K-i was performed using the method of Wang et al. 
(2004). The principle of the method is based on the reduction of vitamin Ki to its 
fluorescing product, dihydro-vitamin Ki. The use of a post-column zinc reactor is reported 
to have 95% conversion rate (Fauler et al., 2000). The method is summarised here.
Absolute ethanol (Riedel-de Haen brand, £99.8%) was obtained from Sigma 
(Sigma-Aldrich Company, Poole, UK). Dichloromethane, hexane, diethyl ether, methanol, 
acetone, sodium acetate, acetic acid, and zinc chloride were all obtained from VWR (VWR 
International Ltd, Poole, UK). All solvents were HPLC grade.
2.12.1 Sample extraction
Plasma aliquots of 0.25 mL were made up to 0.5 mL with 0.9% (w/v) of saline and 
proteins were precipitated with 1 mL of ethanol in large disposable culture tubes (16 x 100 
mm, Corning brand). Ethanol for deproteination contained 250 pg of internal standard 
(IS), a proprietary vitamin K-derivative obtained from Immundiagnostik AG (Bensheim, 
Germany) and was added to compensate for procedural losses during solvent extraction 
and SPE. Samples were vortexed for 5 min and 3 mL of hexane added. Samples were 
then vortexed for 10 min and the upper layer (3 x 0.75 mL) transferred to a clean tube. 
Solid phase extraction was performed as described in section 2.8.5.2 with the exception 
that 3.5% diethyl ether in hexane was used to elute vitamin Ki. After evaporation, the 
sample was reconstituted in 100 pL of solvent, consisting of 25 pL of dichloromethane and 
75 pL mobile phase solvent A (see below).
2.12.2 Sample analysis
Analysis was performed on a Waters 2790 separation module with an in-line 
degasser and a Waters 474 scanning fluorescence detector (Waters, Milford, MA, USA). 
Separation was performed using a Hypersil BDS-C-is column (3.2 x 150 mm), with a 3 pm 
particle size (Thermo brand, HiChrom, Reading, UK). A guard column was installed in 
front of the analytical column (Hypersil BDS-Ci 8, 3.2 x 7.5 mm, 5 pm particle size). The
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column temperature was kept constant at 22 °C during analysis by a Vydac Model 7956 
column temperature controller (Hichrom, Reading, UK). The post-column zinc reactor (for 
reduction of vitamin Ki) was a stainless steel column (2.1 x 50 mm) packed with zinc dust 
(<10 microns, Sigma-Aldrich, Poole, UK) and installed between the analytical column and 
fluorescence detector. In-line graphite pre-filters were installed, one before the guard 
column and one after the zinc reactor. Fluorescent detection wavelengths were at 244 nm 
excitation and 430 nm emission. Stepwise gradient elution was performed on the HPLC 
to separate vitamin Ki and other plasma components. Solvent A consisted of 99.45% 
methanol and 0.55% aqueous solution of 2 mol/L zinc chloride, 1 mol/L acetic acid and 1 
mol/L sodium acetate. Solvent B was 100% dichloromethane. The solvent gradient was 
i) 95% solvent A and 5% solvent B for 10 min, ii) 65% solvent A and 35% solvent B for 13 
min and iii) 95% solvent A and 5% solvent B for 5 min. The flow rate was 0.6 mL/min and 
the run time was 28 min. A typical chromatogram from the HPLC is shown in Figure 2-18.
Figure 2-18. HPLC chromatogram of vitamin Ki extracted from plasma
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2.12.3 Data analysis and quality control
Peak areas for the IS and sample vitamin Ki peaks were measured using the 
Waters data processing software, Millennium 3.2. For quantitation, a single point 
calibration standard, with IS, containing the equivalent of 1.25 ng/mL of vitamin Ki was 
used. Vitamin Ki concentration was calculated from the ratios of IS to vitamin Ki peaks in 
the samples against the ratio generated from the calibration standard. Quality control was 
performed by the regular (at least weekly) analysis of vitamin Ki extracted from plasma 
samples of known concentration. Intra-assay CVs were around 5% and inter-assay 
around 12%. The laboratory also participates in the vitamin K external quality assurance 
scheme (KEQAS) run by the Human Nutristasis Unit at Guy’s and St Thomas’ Hospital.
2.13 Section 2 conclusions
Until now, only a single method has been published for the extraction and 
measurement of isotope ratios of vitamin K-i from plasma with GCMS. This procedure 
involved laborious sample preparation and required the use of semi-preparative HPLC 
prior to analysis of isotope ratios by GCMS. Even with extensive sample preparation, 
problems with the analysis were still reported (Erkkila et al., 2004). A new method has 
been presented here that uses enzyme hydrolysis, solvent extraction, solid phase 
extraction, and subsequent derivatisation and isotope ratio measurement by GCMS of 
vitamin Ki from plasma, and that removes the need for semi-preparative HPLC. Stable 
isotope tracers provide a powerful tool to investigate questions of vitamin kinetics and 
metabolism. The procedure presented here allows further study of vitamin Ki absorption 
and metabolism using stable isotope labelled vitamin Ki and GCMS.
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3 S t u d y  1: M e a s u r e m e n t  o f  v it a m in  K i k in e t ic s  a n d  b o d y  p o o l  s iz e s
3.1 Background
In the United Kingdom, there is no daily recommended intake for dietary vitamin Ki 
but rather a guideline value of 1 pg/kg body wt/d that was set in 1991, (Department of 
Health 1991) based largely on the requirements to maintain blood coagulation (Frick et al., 
1967). More recent evidence suggests a wider function for vitamin Ki beyond its 
traditional role in blood clotting (Schurgers & Vermeer, 2001; Binkley etal., 2002; Vermeer 
et al., 2004). As a result, an Adequate Intake (Al) in the United States has recently been 
set at 90 and 120 pg/d for women and men, respectively. This value is based primarily on 
the median intakes in healthy individuals from the third National Health and Nutrition 
Examination Survey (NHANES III) (Institute of Medicine 2001). The use of mean intakes 
from large epidemiological surveys is one approach to setting recommended intakes. 
However, it is assumed that the average intake is appropriate because the population is 
apparently healthy and does not suffer from any vitamin Ki deficiency related disease. 
The method is limited by gaps in our knowledge of the role of a specific nutrient. 
Additionally, this approach is heavily reliant on both accurate and representative food 
composition data and the accurate reporting of nutritional intake. Experimental 
approaches offer an alternative, and can provide data on vitamin Ki physiology, 
comprising kinetics and turnover rates, and bioavailability. Kinetic and turnover data 
provide an estimate of the actual use of vitamin K within the body, without the need for 
prior knowledge of the physiological functions of vitamin K.
In Western populations, vitamin Ki is the primary dietary form of vitamin K 
(Schurgers et al., 1999). Although vitamin Ki is found in many foods there is uncertainty 
over the extent of vitamin Ki availability from the diet. There have been several studies to 
measure relative availability from measurements of the area under the plasma response 
curve following oral doses from a variety of sources, including some designated as 
standards such as Konakion®. (Gijsbers et al., 1996; Booth et al., 1999a; Garber et al.,
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1999; Booth et al., 2002). However, the results are difficult to compare because a variety 
of doses have been used, ranging from those typical of a high daily intake but fed in a 
single meal, to quantities at least an order of magnitude higher, and experimental duration 
has varied from hours to days.
More reliable data might be expected to emerge from studies that measure 
absolute amounts of vitamin Ki absorption. In faecal balance studies, absolute absorption 
was estimated as around 80% (Shearer et al., 1970a; Shearer et al., 1974). To 
comprehend fully absorption and to measure absolute vitamin Ki absorption directly, an 
understanding of both uptake and disposal kinetics is required.
A number of approaches are available for the measurement of the kinetics of 
vitamins in humans, including single dose studies with unlabelled compounds, 
depletion/repletion methods and tracer techniques (Bates et al., 2004). A tracer is a 
marked form of a substance that can be used to determine kinetic properties of that 
substance in biological systems. Tracer studies provide a powerful tool since kinetics can 
be measured at physiological levels using a labelled dose of the compound of interest. 
Compounds can either be radiolabelled or labelled using stable isotopes. Radioactive 
tracers have been used to explore the kinetics of vitamin Ki metabolism but early 
investigations (Shearer et al., 1970a; Shearer et al., 1972; Shearer et al., 1974; Shepherd 
et al., 1977) were restricted both by a low specific activity of the tracer dose and the lack 
of a suitable methodology for the analysis of vitamin K concentrations in plasma. More 
recently, Olson et al. (2002) performed experiments that used physiological levels of 
radiolabelled vitamin Ki of much higher specific activity, with high performance liquid 
chromatography (HPLC) for quantitative measurements, and obtained kinetic data 
substantially different from those obtained previously.
The use of radioactive tracers is no longer favoured due to ethical considerations. 
Thus, a major part of this research was to develop the use of a stable isotope 
methodology to measure vitamin Ki kinetics in humans. Stable isotope tracers have a 
number of advantages over radiolabelled compounds. Firstly, they are not a source of 
ionising radiation and are therefore suitable for use in human studies; secondly, with gas
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chromatography mass spectrometry (GCMS), it is possible to positively identify the 
compound of interest by its mass spectrum while at the same time measuring 
tracer/tracee molar ratios, and finally, it is possible to simultaneously use more than one 
tracer (oral and /V) to separate the kinetics of absorption and metabolism (Matthews & 
Bier, 1983; Dainty 2001; Stellaard 2005).
3.2 Study objectives
The three objectives of this study were to:
I. Develop a stable isotope methodology for the measurement of vitamin Ki kinetics
II. Obtain data on vitamin Ki kinetics, turnover and body pool sizes in humans
III. Characterise the absorption of an oral dose of vitamin Ki that can be used in a 
study to measure vitamin K-i bioavailability
3.3 Kinetic analysis
Prior to describing the experimental and data analysis methods used in the study, 
general descriptions of kinetic analysis and compartmental modelling are presented.
3.3.1 Compartments and compartmental modelling
The term compartment does not necessarily relate to a specific physiological 
entity, but rather comprises any number of physiological components that, kinetically at 
least, are homogenous (Dainty 2001), although in some circumstances the sampled 
compartment may be well characterised, e.g. plasma. A compartmental model is a 
theoretical construct linking any number of compartments with exchange between them. 
If linear kinetics are assumed, then the fluxes of transfer between compartments are 
related to the concentration, which leads to a mathematical description of the system 
which is the sum of a number of exponential terms. The number of exponentials needed 
to describe the kinetics of transfer is equal to the number of compartments. Thus, the 
amount of tracer remaining in a system that comprises a single compartment is 
characterised by a single exponential decay. However, if a semi-logarithmic plot of
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remaining tracer against time is non-linear, then the presence of additional compartments 
in the system is suggested.
3.3.2 Curve peeling, intercepts and slopes
The method of curve peeling, or graphically estimating the intercepts and slope of 
an exponential, provides a method of estimating the coefficients of equations that describe 
the kinetic behaviour of a tracer. These terms can then be used to further probe the 
kinetic parameters of a system. The equation describing the disappearance of tracer from 
a model with two compartments is written as:
Qi I Qio = H ]e~9't + H 2e~92t
Where:
q1/q10 is the fraction of tracer remaining in pool 1
Hi  and H2 are the intercepts (coefficients) for each of the exponential terms normalised as a fraction of the 
total
gi and g2 are the slopes for each of the exponential terms 
e = Euler’s number (also called Napier’s constant) 
t = time
3.3.3 Rate constants
In compartmental models, exchange between pools are expressed in terms of k, 
defined as a rate constant of transfer from a pool as a fraction of total content moving per 
unit time. The subscripts refer to the direction of movement with the convention of 
movement from  the second digit to the first digit. For example, k2i is the rate constant for 
transfer from pool 1 to pool 2. The use of 0 in the subscript denotes movement to outside 
the system, e.g. k0i. Two identical subscript digits denote the sum of all output from that 
pool, e.g. kn  describes movement to both pool 2 and the outside from pool 1. The 
fractional rate constant k, can also be expressed as F, the actual rate (flux) by 
incorporating mass in the equation:
k = F / Q
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3.3.4 Two-compartment model for vitamin Ki kinetics
The model used in the present study was a two-compartment model (Figure 3-1) 
with output (k0i) from the sampled (plasma) pool of size (Q,), and exchange between it 
and a remote compartment (Q2) defined in terms of k2i (to 2 from 1) and k12 (to 1 from 2). 
These combine to give two exponential terms for the disappearance of the iv dose.
Figure 3-1. Two compartment model of vitamin Ki kinetics
Qi and Q2 = Body pools 
k = rate constants
Large open arrow shows entry of iv dose 
Dashed line indicates sampling pool
3.3.5 Calculating rate constants from intercepts and slopes
Once values for the intercepts and slopes {H and g) are obtained, any and all of 
the rate constants for a compartmental model can be deduced, including for those pools 
and rates that have not been sampled directly (assuming there is a steady state for 
tracee, i.e. that body pools are constant and input is equal to output). A steady-state for 
tracee is assumed because when using stable isotope tracers, the tracer concentration is 
derived from the tracer to tracee ratio.
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In a two-compartment model with exchange between two pools and input and 
output from a single pool the following equations apply:
ku = H lg l + H 2g 2 
*0 1  +  * 2 1  =  H \ 9 \  + W 2 0 ,2
*11 + *22 = 91 +92 
* 0 1  +  * 2 1  +  * 1 2  = 9 \ + 9 2
* 1 1 * 2 2  ~  * 2 1 * 1 2  ~  9 \ 9 2  
(* 0 1  +  * 2 1 )* 1 2  ~  * 2 1 * 1 2  ~  9 \ 9 2
k - 9x92K \ 2  
* 0 1
'<01+'<2 l + i r 2- = 9 l +92
Ko\
k 21 = 9 1 + 9 2 - ^ 0 1 - - ^ -  
K 01
* o i  + 9 i + 9 2  - * o i  - ^ 2 -  =  H xg x + H 2g 2 
kq\
k -  9 ]92K oi - H{g2+H2gx
k 9 '9212 ~  k K 01
* 2 1  =  9 ]  + 9 2 ~ k o\  ~  k 12
The calculations described here refer specifically to the two-compartment model 
used in the present study, but the same principles apply for any model with two, or more 
compartments.
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3.3.6 Half-times
A common practise when describing the kinetics of a system is to report simply the 
half-time (7>2) of disappearance. Half-times are calculated using the slopes of each of the 
exponentials:
T y2 -  1n / g?o r
T y2 -  0.693 / g-t
3.4 Considerations for study design
Data on kinetics can be obtained with oral doses of a tracer, but assumptions need 
to be made about absorption, thereby decreasing the accuracy of the results. Conversely, 
if we are interested in absorption as the primary outcome then the appearance of tracer in 
plasma generally underestimates true absorption since, although enrichment in plasma 
may provide a measure of absorption, it fails to take account of the flux of tracer between 
body pools. The use of an iv tracer, distinguishable from, but otherwise metabolically 
identical to the oral tracer, provides much additional information that can potentially 
improve estimates of absorption. The dual isotope-type approach was selected for the 
current study in order to produce kinetic information that could be applied to establishing 
the total absorption of oral vitamin Ki in standard form.
In a typical tracer study, a tracer, either radio- or stable isotope-labelled, but 
distinguishable from endogenous tracee, is followed after iv administration. The rapid 
(and assumed instantaneous for kinetic modelling) appearance then gradual 
disappearance of the tracer provides data on kinetic parameters. However, for the 
purpose of the current study it was deemed undesirable to inject a chemically synthesised 
form of vitamin K-j for a number of reasons. Firstly, a sterile, pyrogen-free preparation of 
the labelled vitamin KT could not be guaranteed and secondly, with iv administration the 
risk of an sudden adverse reaction is much greater than with an oral dose. An alternative 
approach was proposed whereby the volunteer would be given oral doses of 13C-labelled 
vitamin Ki over a period of 6 d prior to performing the kinetic study. This intervention had
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the effect of increasing the ratio of the labelled (tracer) to unlabelled (tracee) vitamin Ki 
with the aim of reaching a steady-state (equilibrium) for plasma vitamin Ki enrichment.
On receiving an iv  dose of unlabelled vitamin K-i enrichment rapidly decreased, 
followed by a gradual increase during which the unlabelled vitamin Ki is moving from the 
plasma pool to other body pools and mixing with endogenous vitamin K1. The observed 
changes in enrichment are the reverse of the traditional iv tracer approach where 
enrichment would generally increase after iv  administration, followed by decrease. This 
approach is feasible since, although enrichment is increasing rather decreasing over the 
period of measurement, it is the result of the same metabolic processes. It has the 
additional advantage over the traditional method in that, at the tail end of the experiment 
enrichment levels are higher, whereas if a labelled tracer was given enrichment would 
return to near baseline levels. Any differences in enrichment are more easily measured at 
levels above baseline.
3.4.1 Compartmental model of vitamin Ki uptake
From previous work by Olson et al. (2002), a crude three-compartment model for 
the absorption of vitamin Ki absorption and uptake of vitamin Ki was developed. This 
model, shown in Figure 3-2, was used to predict the approximate effect of different dose 
sizes and bioavailability on levels of vitamin Ki concentration and enrichment, for the oral 
pre-enrichment, iv dose and oral dose for absorption. It is similar to the two-compartment 
model described in section 3.3.4 but with the addition of third compartment that represents 
the gut, and which permitted absorption from the gut to be included in the model. The 
three-compartment model used rate constants derived from the slopes and intercepts 
presented in Olson’s work. Average rate constants from seven subjects in Olson’s study 
were k21 -  0.699, k12-  0.113 and k02 - 0.035. In the three-compartment model k 1gwas set 
at 1. Average pool sizes were calculated as 24 nmol for Q? and 121 nmol for Q2. 
Turnover was estimated as 47 pg/d (104 nmol/d).
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Figure 3-2. Three-compartment model of vitamin Ki absorption and kinetics
g = amount in stomach
Qj = Pool 1 (can be identified as plasma)
Q2 = Pool 2 (vitamin Ki in other tissues)
To determine the approximate duration of oral dosing with 13C-labelled vitamin Ki 
required to reach a steady-state for enrichment the above rate constants and pool sizes 
were used. Assumptions were that intake of vitamin Ki from food was 60 pg/d with a 
bioavailability of 30%. The labelled dose was 9 pg/d with 80% bioavailability. Enrichment 
of vitamin K-i in pool 1 was determined by the relative amounts of unlabelled and Re­
labelled vitamin K-|. Use of this model suggested that a plateau for enrichment would be 
reached after around 6 d (Figure 3-3) based on kinetics determined by Olson et al., 
(2002).
Figure 3-3. Modelled effect of oral dosing with 9 pg/d 13C-labelled vitamin Ki on 
isotopic enrichment of plasma vitamin Ki
30 n
200 2501501000 50
Time, h
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3.5 Study methodology
3.5.1 Choice of tracer
The use of stable isotopes and GCMS allows the simultaneous administration and 
detection of two or more isotopic species of vitamin Ki. For this dual stable isotope-type 
study, two forms of vitamin Ki were custom synthesized by ARC Laboratories, The 
Netherlands. One was labelled with a single 13C atom in the methyl group of the quinone 
ring and has a molecular weight one mass unit greater than unlabelled vitamin Ki (m/z 
451). The second form was labelled with four 2H atoms on the quinone ring and has a 
molecular weight four mass units greater than unlabelled vitamin Ki (m/z 454) (see Figure 
2-3). For this experiment the 13C-labelled species was chosen for oral pre-enrichment and 
the deuterated species for the measurement of absorption. It was expected that the 
relatively small changes in enrichment due to the oral dose would be more readily 
detected, and with the least interference from the unlabelled and labelled forms, by using 
the deuterated species. To measure absorption at the same time as receiving the iv dose, 
the volunteer received an oral deuterated dose of vitamin Ki. The use of these two 
different labelled forms of the vitamin allowed the simultaneous determination of both 
vitamin Ki kinetics and absorption.
3.5.2 Oral doses
Labelled doses for oral administration were provided to volunteers dissolved in 
groundnut oil in capsule form. Manufacture of capsules for use in the current study was 
investigated but since relatively few capsules were required it was not considered 
economical. Gelatine capsules were subsequently sourced from and donated by 
Capsulgel (Colmar, France). Although designed primarily for filling with dry powders, the 
Coni-snap two-piece gelatine capsule was found to be suitable for containing viscous oil 
without leakage. The delivery of oral vitamin K-i in gelatine capsules has been described 
before in a depletion-repletion experiment (Suttie et al., 1988b).
Oral pre-enrichment was achieved using oral doses of 9 pg/d, and from the three- 
compartment model it was estimated that a steady-state for vitamin Ki enrichment would
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be achieved within 5 to 6 d. The daily doses were prepared as three capsules per day, 
each containing 3 pg of 13C-labelled vitamin Ki. For the simultaneous measurement of 
vitamin Ki absorption from an oral dose, a capsule containing 4 pg of deuterated vitamin 
Ki in groundnut oil was prepared. This dose is a considerably lower amount than has 
been used in previous studies measuring vitamin Ki absorption.
3.5.2.1 Preparation o f oral doses
Oral doses in capsule form were prepared by dissolving labelled vitamin K  ^ in 
groundnut oil. Groundnut oil is known to contain very low levels of endogenous vitamin Ki 
(Shearer & Bolton-Smith, 2000). Stock solutions of 40 and 14 mg (13C and ring-D4, 
respectively) per 50 mL ethanol were prepared and stored at -18  °C. For the doses given 
to the volunteers, appropriate volumes of the standard solution were added to groundnut 
oil to supply 3 pg (6.7 nmol) of 13C-labelled and 4 pg (8.9 nmol) ring-D4 vitamin Ki in 0.5 
mL of oil. Ethanol was evaporated from the oil by heating at 40 °C under nitrogen with a 
Pierce Reacti-therm heating block and Reacti-vap evaporator (Perbio Science, 
Erembodegem, Belgium). A 0.5 mL volume of groundnut oil containing labelled vitamin Ki 
was pipetted into the gelatine capsules, which were then sealed. The oil-vitamin Ki mix 
and capsules were freshly prepared for each volunteer. After preparation, capsules were 
stored in amber medicine bottles at 4 °C until use. The vitamin Ki content of the oil was 
confirmed by HPLC.
3.5.3 Intravenous tracer
For the iv  dose, the pharmaceutical preparation of Konakion MM® was chosen. 
This synthesised form of vitamin Ki is in a mixed micelle vehicle of glycholic acid and 
lecithin. Konakion MM® is commonly used as an antidote to anticoagulant drugs of the 
coumarin type and is used in the treatment of haemorrhage or conditions associated with 
low blood levels of prothrombin or factor VII.
Konakion MM® was only available in capsules of 10 mg/mL thus it was necessary 
to dilute an aliquot to the required dosage. Based on previously published kinetics and 
expected absorption of the oral doses, the first four volunteers were given a 30 pg iv  dose.
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The dilution for iv injection was prepared by a research physician as per the instructions 
below immediately prior to injection.
Instructions for preparation of 30 pg iv dose of Konakion MM ®
Amount of vitamin Ki to be injected: 30 pg in 5 mL
Starting solutions: a) 2 x 50 mL bag 5% glucose in saline
b) 1 mL ampoule of 10 mg/mL Konakion MM®
1. Take 300 pL (3 mg) from a 1 mL Konakion® ampoule
2. Add to first bag of 50 mL 5% glucose solution
3. Remove 5 mL from a second bag of glucose
4. Take 5 mL from first bag and add to second bag containing 45 mL of 5% glucose 
Final concentration of 300 pg in 50 mL
5. Remove 5 mL of this solution containing 30 pg of vitamin Ki for injection
As detailed below (section 3.8.1), initial analysis of samples from four subjects showed 
lower than expected isotopic enrichment after the oral pre-enrichment with 13C-labelled 
vitamin Ki. As a result, the remaining six volunteers were given a 6 pg iv dose, prepared 
as detailed below.
Instructions for preparation of 6 pg iv dose of Konakion MM
Amount of vitamin Ki to be injected: 6 pg in 5 mL
Starting solutions: a) 2 x 50 mL bag of 5% glucose in saline
b) 1 mL ampoule of 10 mg/ml Konakion MM®
1. Take 300 pL (3 mg) from a 1 mL Konakion ampoule
2. Add to first bag of 50 mL 5% glucose solution
3. Remove 1 mL from second bag of glucose
4. Take 1 mL from first bag and add to second bag containing 49 mL of 5% glucose 
Final concentration of 60 pg in 50 mL
5. Remove 5 mL of this solution containing 6 pg of vitamin K  ^ for injection
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The concentration of the iv doses was measured by HPLC. After preparation and 
administration of the iv dose, the remaining solution was kept on ice before transfer of 
around 2 mL to tubes for storage at -70 °C prior to analysis. Only two of the four 30 pg 
doses were available for analysis and were measured as 33.4 and 31.0 pg. For the group 
who received the calculated 6 pg dose, the average (± SD) measured dose was 5.8 ± 0.6 
pg. One sample of the 6 pg dose was kept on ice for 6 h after preparation and aliquots 
taken at 1.5, 4.0 and 6.0 h. Measured values were 6.5, 6.0 and 6.4 pg, respectively 
indicating that the preparation was relatively stable over time and that measured values 
reflect the actual dose given.
3.5.4 Ethical permission
Following approval by the MRC Human Nutrition Research Science Coordination 
Committee (SCC), ethical permission for this study was obtained from Cambridge Local 
Research Ethics Committee (REC ref: 04/001). Informed written constant was obtained 
from subjects prior to the start of the study (Appendix III).
3.5.5 Study subjects
Since this was a pilot study no formal sample size calculations were performed. 
Healthy, male or female subjects, aged between 18 and 40 y, were selected. Subjects 
were selected on the basis that the aim of the study was to investigate vitamin Kt  kinetics 
under normal physiological conditions. Exclusion criteria were as detailed below.
General health criteria:
Renal, liver or respiratory disease, malignancy, diabetes, pancreatic or gall bladder 
disease, or any other chronic medical conditions; use of vitamin supplements, smoking, 
recent heavy bleeding or blood donation, history of anaemia, pregnancy or breast feeding. 
Study-specific exclusion criteria:
Bleeding or clotting disorders, gastro-intestinal malabsorption, history of allergies, 
hayfever, eczema or asthma.
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The exclusion of people with a history of allergies was on the basis of a few 
unconfirmed reports of the occurrence of possible anaphylactoid reactions after the iv 
injection of Konakion MM® (Roche Product Information Sheet).
3.5.6 Volunteer recruitment
The information sheet sent to potential volunteers is attached as Appendix IV. 
Volunteer recruitment was slow, partly due to the strict exclusion criteria for allergies and 
a general unease amongst potential volunteers at the prospect of an iv injection. From 60 
letters sent to individuals registered on the HNR Volunteer Database there were no 
replies. Thirty-five people responded after a blanket approach through email and poster 
advertising. Of them, ten agreed to participate, eight were excluded, and the remaining 
17 chose not to take part. Volunteers received an honorarium of £40 for completing the 
study.
3.5.7 Study protocol
At the start of the study volunteers were invited to attend the volunteer suite at 
MRC Human Nutrition Research (HNR) to have the study explained in full and to provide 
them with the opportunity to ask any questions. Their weight was measured to the 
nearest 0.1 kg using Seca 770 digital scales (Seca, Birmingham, UK) and their height was 
measured to the nearest 0.01 m using a Seca 202 wall-mounted stadiometer (Seca, 
Birmingham, UK). The volunteer was given a supply of eighteen capsules containing R e­
labelled vitamin Ki in an amber medicine bottle. The volunteer was asked to take three 
capsules per day, one with each meal, and to avoid foods containing high levels of vitamin 
Ki (green leafy vegetables, broccoli) on day six of study. On days five and six after 
starting the capsules the volunteer was asked to attend MRC HNR to have single 9 mL 
fasting blood samples collected by venepuncture.
On day seven the volunteer attended the volunteer suite at MRC HNR having 
abstained from food and drink (with the exception of water) since the previous evening. 
An indwelling cannula was inserted into each forearm vein. Two baseline 9 mL blood 
samples were collected from one cannula and the volunteer then received, through the
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other cannula, the iv bolus dose of 6 or 30 (jg of Konakion MM® (see section 3.8.1 for 
further explanation). The cannula used to administer the Konakion MM® was removed 
shortly after the dose had been given. At the same time as receiving the iv dose, the 
participant received an oral dose of 4 pg of deuterated vitamin K-|. This was prepared in 
the same way as the 13C-labelled vitamin Ki doses. Subjects were fasted and the capsule 
taken on an empty stomach with water. Blood samples were taken at 2, 5, 10, 20, 30, 40, 
50, 60, 90 min post-dose and then 2, 3, 4, 5 and 6 h post-dose. In order to keep the 
cannula patent, the cannula was flushed after each blood sample and at regular intervals 
with 2 mL of saline. Prior to each blood sample, 2 mL of blood was withdrawn and 
discarded. A total of approximately 170 mL of blood was taken over the course of the 
day.
After 3 h the volunteer was offered a small, low fat meal (toast with jam with tea or 
coffee). On completion of sampling the cannula was removed and the volunteer provided 
with a further meal, after which he/she was free to leave.
3.5.8 Sample collection and analysis
Blood samples were collected into 10 mL syringes and immediately transferred to 
coded tubes containing EDTA (Sarstedt Ltd, Leicester, UK). The tubes were kept on ice, 
and protected from light, until centrifugation at 4 °C for 20 min at 2000 g to separate the 
plasma. The plasma was divided into four 1 mL aliquots in 2 mL microtubes (Sarstedt Ltd, 
Leicester, UK). All samples were stored at -70  °C until analysis.
Extraction of vitamin Ki from plasma was performed with enzyme hydrolysis, 
solvent extraction and solid phase extraction as described in section 2.9. Prior to analysis 
by GCMS, vitamin Ki was derivatised to the pentafluoropropionyl derivative as detailed in 
section 2.7. The GCMS was run in SIM mode and measured ions m/z 598.4 to 602.4 
(Jones et al., 2006). Total plasma vitamin Ki concentrations were measured by high- 
performance liquid chromatography (HPLC) with fluorescence detection after post-column 
reduction (Wang et al., 2004) (section 2.12).
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3.6 Data analysis
3.6.1 Isotopomer ratio analysis
Isotopomer ratios were calculated using the fitting techniques described by Bluck 
and Coward (1997). The method has a number of advantages over alternative peak 
integration techniques mainly by removing subjective decisions of the operator with regard 
to peak truncation and assessment of background. The shape of the peak is determined 
from the species with the greatest intensity, in this case the molecular ion (M), i.e. m/z 
598.4, and the remaining species are fitted to this peak shape, thereby eliminating shifts in 
retention time in the heavier species due to either the sequential nature of mass analysis 
with a quadrupole instrument, or chromatographic reasons. Practically, the use of this 
method involves removing raw data files containing intensity and time/scan number data, 
and copying this information into a template created in Excel. The end-user template is 
described below (Figure 3-4).
An alternative approach to the measurement of each of the isotopomers as 
performed, is to only measure the ions of interest, i.e. M+0, M+1 and M+4. Since fewer 
ions are measured the dwell time can be increased for each ion with an accompanying 
potential increase in precision. However, monitoring of all isotopomers of the molecule of 
interest can provide a greater appreciation of any variation in chromatographic or mass 
spectral quality. This was especially pertinent in this application since the highly 
concentrated sample led to rapid dirtying of the ion source with the consequent shifts in 
mass assignment.
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Figure 3-4. Excel worksheet fo r the calculation o f isotopom er ratios
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1. Measured isotopomers and respective masses
2. Raw mass abundance data and respective scan number exported directly from GCMS software
3. Matrix of intensities for M (molecular ion). The 1st column contains data for M from the first reading. 
The 2nd column is the same data but starting with the 2nd reading, and the 3rd column starts from the 
3rd reading. The final column is the scan number. This data is used for building the envelope around 
which the remaining peak shapes are fitted.
4. Multiple linear regression using least squares method, each array corresponding to each isotopomer 
ratio.
5. The resulting isotopomer ratios (expressed as percentages) obtained from summing the coefficients 
obtained using the LINEST function in Excel. For example, the 599/598 ratio is obtained from 
summing values in cells 114, J14 and K14.
The results of triplicate analyses are summarised with graphical representation of the 
peak shape of the molecular ion (M) and the average and standard deviation for each 
sample, e.g. Figure 3-5.
150
Figure 3-5. Summary Excel worksheet o f isotopom er calculations
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3.6.2 Kinetic methods
Rather than use the above methods directly, a macro in Excel was utilised that 
simplifies the calculations necessary to obtain kinetic information. The data were fitted to 
a two-compartment model, in which, the rate constants combined to give two exponential 
terms that described the disappearance of the iv dose from the plasma (pool 1 or Qy). 
Initial estimates of Qy, k21, k 12 and k01 were used to generate the coefficients of the 
exponentials, and these were compared to the observed values. Using the Solver 
function in Excel, the initial estimates were then adjusted to minimise the differences 
between the modelled and observed data using a non-linear method. The 2_comp macro 
function calculates each of the instantaneous pool sizes of a freely exchanging two-
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compartment system defined by its fractional rate constants and initial conditions 
(personal communication, Dr Les Bluck). It was entered in the form:
_2comp(time, Q1 start, Q2start, rateOI, rate21, rate02, rate12)
The macro returns a two-element single column array containing the amounts of 
material found in each compartment at a specified time. Since this function returns an 
array of values it must be entered as an array formula. In order to generate values for 
each of the rate constants, as well as pool sizes, a template was constructed in Microsoft 
Excel for this purpose. The spreadsheet for determining rate constants and pool sizes, is 
described below and shown in Figure 3-6. Note that bioavailability of the iv dose was 
assumed to be 100%.
152
Figure 3-6. Excel worksheet fo r the calculation o f vitam in K  ^ kinetics
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1. Contains the dose values for the iv dose and the oral deuterated dose
2. Contains the actual sample times, concentration values and isotopomer values (expressed as % to
M). It is necessary to enter the number of pre-dose (baseline) values (cell B20) in order to calculate 
values in [3],
3. Contains the average basal (after 13C pre-loading and before iv dose) isotopomer ratio used in the 
calculation of Xu. The unlabelled isotopomer ratio is equal to that measured immediately after 
administration of the iv dose and is approximately equal to the naturally occurring isotopomer ratio.
4. The first column in this section is equal to the proportion of total vitamin Ki that is from the iv dose
(Xu) and is calculated by:
Xu -  ~ ^ M+1(0
RM+m ~ Rm+\{u)
where the subscripts refer to measurements made before the iv dose (0), after it (t) and in the iv dose 
itself (u).
In the second column are the observed, experimental values for the fraction of the dose remaining in 
Pool 1, calculated by:
X u x  [vit k ]x  (\/l I iv dose)
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The 3rd and 4th columns are part of the _2CO M P array function described above. The 3rd column 
contains the equivalent modelled values for Pool 7, and the final column contains the modelled 
percentage of the iv dose in Pool 2.
5. As described above, the Solver function is used to minimise the difference in the observed and 
modelled data. The Solver function works to minimise the value in cell K20 (equal to the square root 
of the sum of the squares in the differences between the observed and modelled values) by adjusting 
the values for the rate constants koi, k2 i and ki2 , and the volume of Pool 7, V1.
6. The final section shows the pool sizes and turnover for this model. The access pool (Pool 7) is 
calculated by multiplying total vitamin Ki concentration at baseline by the modelled volume of Pool 7. 
The size of remote compartment (Pool 2, that which is not directly sampled) is calculated by:
C?2 = f^ 2\ X  ^^ 12
Total pool size in the measured compartments is the sum of the remote and access pools.
Turnover (F0 1) is calculated by
F0i = ^oi x Qi
and provides an actual measure of the amount of vitamin K losses, as opposed to a rate constant (k) 
that is a fractional loss per unit time.
3.6.3 Calculating absorption
The model for absorption is a simple one-compartment model with total losses as 
rate k0i (Figure 3-7).
Figure 3-7. Model of vitamin Ki absorption kinetics
Qi = Pool 1
Large open arrow shows entry of oral dose
Dashed line indicates sampling pool
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3.6.3.1 Calculation method
The characteristics for the oral dose were obtained from the ring-D4 isotopomer 
data (Rm+4) by deconvolution of appearance of tracer in Q1 and Q2. In this case, 
deconvolution (the mathematical process of separating signals) was used to deduce the 
input (/) (of the oral dose) from the system response (derived from response to iv dose). 
Using * to denote the deuterated material and / the input (nmol/min), the equations are:
= /(f) -  (k2> + koi )Q, * (() + kl2Q2 * (f) (1)
™ llM l  = k2lQ r ( t ) - k l2Q2*(t) (2)
Equation (1) calculates rate of appearance of deuterated material in Q? from the 
rate of input of deuterated material (i(t)) minus exit from Q1 (k2i + k0i) and input from Q2 
(k12). Equation (2) calculates the rate of appearance of deuterated material in Q2 and is 
equal to input from Q1 (k21) and exit from Q2 (k12). Since we cannot sample Q2, Q2 * (t) 
was obtained from equations (1) and (2) iteratively using Euler’s method1. Euler’s method 
is a technique of integration that corrects the slope of the curve at time point intervals to 
better approximate the real shape of the curve and effectively removes the rate constants 
to provide an estimate for /.
The noisy, observed Qi * (t) was smoothed by fitting a normal cubic spline, using a 
roughness penalty approach (see description below) (Green & Silverman, 1994) that also 
provided an estimate of its first derivative with respect to time. Cumulative absorption was 
calculated by integration of / '(t), and this then summarized as a delay followed by a single 
exponential term.
3.6.3.2 Data smoothing
The term ‘spline’ is used to refer to a range of functions for data interpolation 
(estimation of values in a series between two known values) or data smoothing. The
1 http://www.swarthmore.edu/NatSci/echeeve1/Ref/Numericlnt/Euler1.html (accessed 22nd March 2007)
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simplest spline has degree 0 and is also called a step function. The natural cubic spline 
has degree 3. Given a dataset of X and Y, it is therefore possible to estimate the values 
of Y for X’s other than those in the sample. Cubic splines are made to be smooth at the 
known time points (knots) by forcing the first and second derivatives of the function to 
agree at the knots. The first term measures the closeness to the data and the second 
penalizes curvature in the function, with the aim to construct a function that balances the 
twin needs of (1) proximity to the actual sample points, (2) smoothness. So a 'roughness 
penalty' is defined.
As for the calculation of iv  kinetic parameters, the calculation of absorption was 
performed in Excel and is described below and shown in Figure 3-8.
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Figure 3-8. Excel worksheet fo r the calculation o f vitam in K-i absorption parameters
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1. A delay is applied to the model in cell N16. The chosen number of useful values is shown in cell 
Q18, and is user-generated from the entry in cell Q16. The extent of smoothing is determined by the 
value in Q19 and remained constant for all subjects.
2. The column N contains the calculated fraction of the deuterated dose in plasma [Qi * (t)] and is 
calculated by:
R M + m x [ v i t k ] x V \
0 dose
and the next column (O) the values deemed useful. These are subjectively chosen by entering those 
values to be used in the cells highlighted in box 1 (Q16-18).
3. This part of the spreadsheet contains the smoothing coefficients for each of the data points 
calculated in the ‘smoothing’ sheet.
4. The values here contain the cumulative fraction of the dose absorbed at each time point.
5. The Solver function is used to minimise the sum of squares for the corresponding values in columns 
W and Y (observed and modelled fraction of the dose absorbed). The delay represents the delay 
from the start of the experiment to appearance of the tracer in plasma, k is the effective absorption 
rate of the tracer and m is the effective modelled total absorption including extrapolation of the 
observed absorption curve.
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3.7 Results
3.7.1 Subject characteristics
The ten subjects (9 women and 1 man) were aged between 22 and 31 y. They 
had a mean ± SD height of 1.64 ± 0.10 m, body mass of 61.0 ± 10.7 kg and BMI of 22.5 ± 
2.4 kg/m2.
3.7.2 Graphical output
After iv administration, the percent of the dose remaining in plasma drops rapidly 
and slows at around 50 -  60 min, as clearly shown in Figure 3-9 that shows the output 
from just one of the volunteers. The dashed line shows the modelled entry of the iv  dose 
in the remote pool. This chart is plotted directly from the data in columns A, I, J and K of 
the kinetic calculator spreadsheet Figure 3-6.
Figure 3-9. Graphical representation of output from the two-compartment model
100%
80% Accessible Pool j 
Remote pool j
60%
40%
20%
0%
360300180  
Time, min
240120
Data points ( • )  illustrate the observed values, solid line the modelled disappearance of the iv dose from the 
sampled pool (pool 1), and the dashed line the appearance of the /V dose in the remote pool (pool 2).
A similar chart is shown in Figure 3-10, displaying a graphical representation of the 
absorption modelling results. The chart shows observed values, with those in black used 
for the modelling. The solid line shows the smoothed appearance of tracer (left axis)
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while the dashed line is the cumulative absorption (right axis). As with Figure 3-9, this is 
example is from a single volunteer.
Figure 3-10. Typical output from absorption kinetics model
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Solid data points ( • )  up to and including 120 min, are zero values. Subsequent solid points illustrate the 
observed values used for the curve smoothing, while the open data points (o) observed values that were not 
incorporated in the curve smoothing. The solid line shows the modelled appearance of the oral deuterated 
dose in the sampled pool and the dashed line the cumulative absorption of the deuterated oral dose.
3.7.3 Kinetic parameters
A steady-state for plasma vitamin Ki enrichment was established by the dosing 
regime. There were no significant differences between the HPLC data or isotope ratio 
data obtained on days 5, 6 and 7 (calculated by one-way ANOVA). Average ± SD vitamin 
Ki plasma values were 1.40 ± 0.90, 1.21 ± 0.84, 1.09 ± 0.58 nmol/L, on days 5, 6 and 7, 
respectively. Corresponding isotope ratios (for M+1 / M) were 0.434 ± 0.041, 0.439 ± 
0.032 and 0.443 ± 0.031, on days 5,6 and 7, respectively. For the purposes of kinetic 
analysis only those baseline values obtained on day 7 were used in the calculations.
The kinetic parameters obtained are shown in Table 3-1 and the means plotted in 
Figure 3-11.
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Table 3-1. Kinetic parameters obtained from with a two-compartment model after 
an iv dose of vitamin Ki
Subject koi I<21 ki2 Ty2 (fast) 7"y2 (slow) Qi Q2 F0i b
(h-1) (h) (nmol) (pig/kg/d)
Aa 1.19 0.74 0.50 0.33 2.56 1.1 1.7 0.30
Ba 1.46 2.66 3.89 0.10 0.89 1.0 0.7 0.18
Ca 0.89 0.30 0.35 0.53 2.81 2.3 1.9 0.36
F 1.46 1.67 0.22 0.21 6.52 1.6 12.1 0.38
Ga 4.48 10.10 6.28 0.04 0.47 1.2 1.9 0.40
H 1.78 0.86 0.46 0.25 2.26 0.4 0.8 0.12
I 0.77 1.15 1.11 0.26 2.21 3.0 3.2 0.46
J 2.10 2.03 0.52 0.16 2.70 1.3 5.0 0.41
K 1.44 2.82 0.52 0.15 4.13 1.0 5.2 0.29
L 1.55 1.38 0.73 0.21 2.05 2.0 3.8 0.52
Average 1.71 2.37 1.46 0.22 2.66 1.5 3.6 0.34
SD 1.05 2.84 2.00 0.14 1.69 0.8 3.4 0.12
a Subjects who received a 30 pg iv dose. The remaining subjects received a 6 pg iv dose. 
b For (vitamin K loss) was calculated by multiplying koi and Qi and is expressed per kg of body weight. 
Molecular weight of vitamin Ki is 450.
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Figure 3-11. Summary of iv  kinetics and absorption of oral dose from all subjects
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Semi-logarithmic plot showing plasma clearance of the iv vitamin Ki dose and appearance and clearance of a 
ring-D4 oral dose of vitamin Ki (expressed as percentage of the oral dose in plasma) from all subjects 
combined: ■ mean % iv dose in plasma (n=10); solid line is the mean of modelled data from all subjects. □ 
mean % oral dose in plasma (n=10); dashed line is the mean of modelled data from all subjects. Error bars 
are standard errors for observed data points.
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3.7.4 Absorption parameters
Results for absorption of the deuterated vitamin K-i are shown in Table 3-2. 
Average absorption of the oral deuterated dose was 13%.
Table 3-2. Absorption characteristics after an oral dose of ring-D4 vitamin Ki
Dose absorbed Tmax3
Subject (%) (h)
A 10.9 4.0
B 3.4 4.2
C 8.1 5.0
F 25.6 4.7
G 12.1 3.3
H 6.9 5.4
I 2.4 4.7
J 6.4 6.0
K 25.0 5.0
L 26.3 5.1
Average 12.7 4.7
SD 9.4 0.8
a Tmax is the time of peak deuterated vitamin Ki in plasma as determined from the smoothed curve
3.8 Discussion
Data on the kinetics and bioavailability of vitamins are essential as part of the 
assessment of recommended intakes. Bioavailability is commonly assessed on the basis 
of a plasma response to an oral dose. However, relying solely on the appearance of the 
nutrient in the plasma may lead to inaccurate measurements of bioavailability since no 
account is taken of metabolic processes occurring post-absorption. The main purpose of 
the present study was to investigate the kinetics of vitamin Ki metabolism and at the same 
time measure the extent to which oral doses are absorbed using stable isotopes.
3.8.1 Chosen methodology
To simultaneously measure the kinetics and absorption of vitamin Ki the utility of a 
dual-labelled stable isotope-type technique was investigated. The use of stable isotope
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labelled compounds has a number of advantages over radiolabelled tracers. Firstly, they 
remove the potential negative health effects of exposure to ionising radiation and are 
therefore suitable for repeated use in human studies. Secondly, with gas chromatography 
mass spectrometry (GCMS), it is possible to confirm identification of the compound from 
its mass spectrum and measure the tracer/tracee molar ratio. The converse to this is that 
the molecule or molecules of interest need to be identified prior to analysis, whereas with 
radiolabelled compounds, previously unidentified metabolites can be measured. With 
stable isotope tracers it is also possible to measure simultaneously more than one tracer.
The dual-isotope technique requires one labelled form of the vitamin to be given 
orally, and the second intravenously. The advantage of this method is the ability to define 
distribution and disposal of the vitamin after absorption, and hence apply this information 
to the calculation of absorption.
The labelled vitamin Ki used in this study was deemed unsuitable for iv 
administration due to practical and regulatory concerns. Other labelled forms of the 
vitamin suitable for iv administration are not easily available. To solve this problem, 
volunteers in this study were given 13C-labelled vitamin Ki in capsule form for 6 d. Similar 
capsule formulations have been used in studies of vitamin Ki (Suttie et al., 1988b) and 
vitamin E (Acuff et al., 1994). The aim of dosing for 6 d was to reach a steady-state for 
plasma 13C-labelled vitamin K-i enrichment. It was then possible to use tracer doses of 
injectable unlabelled material for kinetic measurements. This approach is the inverse of 
that traditionally applied in tracer experiments where following an iv dose of tracer and the 
rapid increase in enrichment, the gradual decrease is used to calculate disposal kinetics. 
Here, enrichment was increased to a steady-state over a period of 6 d thus allowing the 
use of unlabelled material as the tracer. Following administration of the unlabelled iv 
tracer, the rapid decrease in enrichment followed by the subsequent increase towards 
pre-/V levels was used to model kinetics. An additional advantage is that when analytical 
noise is constant (e.g. from electrical noise and column bleed) this approach has the 
advantage that for later time points (when concentration of vitamin Ki is lower) the
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abundance of the M+1 ion is greater than if enrichment was returning to natural 
abundance, thereby improving the signal to noise ratio.
After the analysis of samples from the first four subjects it was found necessary to 
reduce the level of the iv dose. With the 30 pg dose, it was found that enrichment levels 
were not returning to the baseline level over the duration of the experiment, and hence the 
difference between the maximum and minimum enrichment over the 6 h period was lower 
than expected. This outcome can be attributed to lower than estimated bioavailability of 
the vitamin Ki from the capsule, borne-out in results from absorption of deuterated vitamin 
Ki (see below, section 3.9). Further, the total concentration of vitamin Ki after the iv dose 
was higher than expected due to assumptions of pool volume used in the original 
calculation of the iv dose. As a result, the later subjects received 6 pg of vitamin Ki 
intravenously, rather than 30 pg.
Although efforts were made to recruit equal numbers of men and women there 
was an obvious gender bias in recruitment. It is believed this was due to firstly, a greater 
interest and awareness of women in nutrition and health and secondly, an apparent 
reluctance of some male volunteers to submit to an intravenous dose. There is no data to 
suggest that metabolism of vitamin K  ^ is different between men and women, for example, 
Binkley et al., (2000) showed no significant differences in response to vitamin Ki 
supplementation in 219 men and women.
3.8.2 Rate constants and half-times
Previous work to measure vitamin K1 kinetics has used radiolabelled compounds 
and the characteristics of the system expressed in terms of the half-times of two 
exponentials ( T 1/2(fast) and T 1/2(Siow)) fitted to curves for the disappearance of plasma 
radioactivity. The radioactivity has to varying degrees been identified as associated with 
vitamin K-i. The average values of the corresponding parameters found in the present 
experiments (Table 3-1) most closely resemble the values obtained by Shearer et al., 
(1972), Shearer et al., (1974), Shepherd et al., (1977) and Bjornsson et al., (1979), rather 
than those more recently reported by Olson et al., (2002) (see Table 3-3).
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Table 3-3. Summary of previous attempts to measure vitamin Ki kinetics
Experimental protocol Kinetic parameters
Reference
No. of 
subjects
Dose
(M9)
Period
(h) Measurement
Ty2(fast) (h),
(range or SD)
7y2 (slow) (h)
(range or SD)
Shearer et 
al., (1972) 3 1000 Up to 96a
Lipid soluble 
radioactivity
0.37b
(0.33-0.40)
2.3b
(2.0-2.5)
Shearer et 
al., (1974) 2° 45 7
Pure vitamin Ki 
separated by 
TLC
0.38
(0.35-0.40)
1.8 
(1.7-1.8)
Shepherd et 
al., (1977) Unknown 700d Unknown
Lipid soluble 
radioactivity
0.21e 
(±0.03)
3.4e
(±0.7)
Bjornsson et 
al., (1979) 4 300 10
Pure vitamin Ki 
separated by 
HPLC
0.43
(±0.13)
2.8
(±0.2)
Olson et al., 
(2002) 7 0.3
10, then 
daily
Total plasma 
radioactivity
1.00
(±0.47)
27.6
(±12.4)
Present
study 10 6 / 3 0 6
Vitamin Ki 
enrichment by 
GCMS
0.22
(±0.14)
2.7
(±1.7)
a kinetic parameters are calculated over 6 h
b mean values estimated by division by two of the sum of the minimum and maximum values 
c one subject dosed with warfarin 
d subjects were given an iv dose of 10 pg/kg body weight 
e average of values for young and elderly patients combined. NB: SEM not SD
3.8.3 Identification of vitamin Ki
In the present experiments, because mass spectrometry was used, the kinetic 
data was produced from isotopic enrichment unambiguously associated with vitamin Ki. 
In the case of Olson et al. (2002), genuine tracer quantities were used (0.3 pg) but it is 
unlikely the radioactivity measured represents that only of vitamin Ki. For all samples 
after 2 h post-dose, only total radioactivity in plasma samples was measured. Prior to 2 h, 
selected samples were chromatographed, and it is reported that 90% of the radioactivity 
was associated with the vitamin K-i fraction (Olson et al., 2002). However, it is likely that 
over time, the radioactivity was increasingly representative of metabolites rather than 
vitamin Ki. This conclusion is supported by the earlier work of Shearer et al. (1972). In 
this study, vitamin Ki was administered intravenously and plasma radioactivity measured 
in lipid- and water-soluble fractions. If radioactivity was associated only with intact vitamin
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Ki then it would be expected that all radioactivity should have been present in the lipid- 
soluble fraction. However, at 7 -  8 h post-dose, water-soluble and lipid-soluble 
radioactivity were about equal and at 24 h the water-soluble component was double the 
lipid component (Shearer et al., 1972). This work also suggested that although over 6 h 
radioactivity was identified with two exponentials, over 8 h, the disappearance curve 
appeared to contain more than two exponentials. Subsequent work by Shearer et al., 
(1974) showed that when vitamin Ki was separated from a plasma extract by thin-layer 
chromatography (TLC), 80% of lipid-soluble radioactivity was associated with vitamin Ki 
after 1 h, whereas by 7 h, the proportion had reduced to 40%. These observations show 
the increasing contribution of lipid-soluble polar metabolites to total radioactivity over time, 
and suggest that, even at 8 h the true kinetics of disappearance were obscured by the 
increasing contribution of metabolites, lending further evidence to the questionable results 
from Olson et al. (2002) who measured only total radioactivity. These results stress the 
requirement of a useable, reliable and robust method for the separation of vitamin Kv
3.8.4 Timing of samples
In the present study, and in order to ensure proper characterisation of the kinetics, 
rapid sampling was performed over the expected portion of the fast exponential, and less 
frequent sampling during the second, slower exponential. This protocol is in contrast to 
Olson et al. (2002), where less frequent sampling may be an additional reason for the 
observed disparate half-times. Olson et al. (2002) sampled at 10 min, and then 
subsequently at 30 min, 1, 2, 4 and 10 h, and then daily for 7 d. This sampling regimen 
would make it difficult, if not impossible to detect the initial, fast exponential, and hence 
the reported Ty2(fast) of 1 h (Olson et al., 2002), is likely a combination of the Ty2(fast) and 
Ty!(siow) observed in the current study and previously by other workers (Table 3-3).
3.8.5 Body pools
The estimates of pool sizes (Qi + Q2) of 5.1 nmol are low in comparison to values 
(222 nmol) suggested by direct analysis of tissues (Olson et al., 2002). While Olson’s 
kinetic studies indicated body pool sizes of 1.3 -  2.6 nmol/kg (equivalent to 91 -  182 nmol
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for a 70 kg person), this data should be treated with caution because body pool size was 
determined via the approximation that pool size can be calculated from the intercept of a 
terminal exponential in kinetic studies where the correspondence of tracer radioactivity to 
vitamin Ki abundance was not established.
However, the pool sizes observed in the current study remain low. One 
explanation may be that modelled estimates of initial plasma pool sizes are low (1.5 
nmol). Q? is calculated by multiplying actual baseline vitamin K-! concentration (as 
measured by HPLC) by the modelled plasma volume. This estimate can be increased 
upwards if, rather than using modelled plasma volume, pool volume is calculated directly 
on the basis of body surface area1. In this study, average pool size of Q1 would then be
2.6 nmol. However, total body pool size remains well below previous estimates. In this 
study, baseline plasma values are around 1 nmol/L, similar to values measured in national 
surveys (Thane et al., 2006b).
Q2 is calculated from Q1 and the rates k21 and k12. The value obtained for Qi can 
be considered accurate which suggests the rate constants or model may not represent the 
true physiology. A possible explanation for low pool size is the presence of additional 
vitamin Ki body pools e.g. liver and bone (Shearer et al., 1988; Hodges et al., 1993) 
acting as sinks, or recirculating vitamin Ki to the plasma at rates insufficient to be detected 
in the present experiments.
Direct tissue measurements are the most accurate way to determine body pool 
size. However, the invasive nature of tissue measurements, and the difficulty in using 
post-mortem samples, results in few published values. The liver concentration of vitamin 
Ki is reported to be between 1.1 -  21.3 ng/g (2.4 -  47.3 nmol/kg) liver, based on the 
analysis of livers of 32 adults post-mortem, with total liver stores between 1.7 and 38.3 pg 
(3.8 -  85 nmol). Median values were 12.2 nmol/kg, or 17.3 nmol per liver (Shearer et al., 
1988). A similar average value of 10.6 nmol/kg is reported from six post-mortem samples
1 Plasma volume is assumed proportional to body surface area, with the constant of proportionality 1.41 L/m2 for women
and 1.56 L/m2 for men (from www.medal.org accessed 30th January 2007)
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(Thijssen & Drittij-Reijnders, 1996). Higher values of 28.0 ± 4.3 nmol/kg have been 
reported from seven surgical patients (Usui et al., 1990).
Direct tissue measurements of vitamin Ki in bone have revealed average levels in 
six patients of 10.2 ± 6.4 nmol/kg and 10.7 ± 4.0 nmol/kg (dry weight) in trabecular and 
cortical bone, respectively (Hodges et al., 1993). Based on a value of 10 kg for the dry 
weight of a human skeleton (Mitchell et al., 1945), total skeletal pool size may be in the 
order of 100 nmol. These levels are as much as, if not more than those observed in liver. 
Combining approximate values for bone, liver and plasma gives a potential body pool size 
of 120 nmol. Measurements in tissues other than liver and bone suggest a wide 
distribution of vitamin K1( for example relatively high concentrations were found in heart 
and pancreas (9.3 and 28.4 nmol/kg, respectively) and notable concentrations in lung, 
kidney and brain (1.5, 0.9 and 1.5 nmol/kg, respectively) (Thijssen & Drittij-Reijnders
1996). As a result, total body pool size could be somewhat higher than 120 nmol. To my 
knowledge, there are no available data on the vitamin K content of adipose tissue, a 
known store of other fat-soluble vitamins. It is likely that adipose tissue will contain some 
vitamin Ki by virtue of the transport of vitamin Ki in lipoproteins.
3.8.6 Turnover and deductions regarding daily requirements
Early work by Frick et al. (1967) on vitamin K requirements in humans estimated 
the minimal daily requirement to be 0.03 pg/kg/d. An alternative approach to the 
prediction of daily requirements is to use turnover time. Here, the isotopic data have been 
interpreted on the basis of a simple two-compartment model in an attempt to provide 
values for vitamin Ki turnover (F01) for comparison with current understanding of vitamin 
^  physiology. For a subject in balance, measurement of F0i could provide guidance to 
vitamin Ki requirements, in which case mean values in the present study are equivalent to 
0.34 pg/kg/d. These values are of the same order of magnitude as the current guideline 
daily intakes for vitamin Ki in the UK (> 1 pg/kg body wt) and Al in the United States (90 
and 120 pg for women and men, respectively). Note that the value of 0.34 pg/kg/d takes 
no account of the bioavailability of vitamin Ki, whereas the recommended intakes have a
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‘built-in’ bioavailability factor. A similar calculation to estimate turnover using Olson’s 
figures provides an approximate turnover value of 0.67 pg/kg/d. Despite the differences in 
the kinetics between the model presented here and Olson’s study, the turnover values are 
similar. This is due to the large discrepancy in pool sizes as discussed in section 3.8.5. 
Turnover time from the current study is 3.8 h (see section 1.11.2).
Based on vitamin Ki in liver, Shearer (1988) suggested that, because 
requirements were estimated to be greater than body stores, either menaquinones 
provided a significant contribution to vitamin K needs, or requirements were set too high. 
An alternative explanation may be that there are other significant body stores of vitamin K, 
a notion supported by observations of vitamin K in bone.
Bone may be a potential pool of vitamin Ki because of the requirement of vitamin 
K-i for carboxylation of bone proteins and/or the intrinsic lipid content of bone. Turnover 
may be relatively slow as demonstrated in a recent animal study (Sato et al., 2002). Rats 
were kept on a vitamin Kr deficient diet for 17 d and whereas prothrombin time 
significantly decreased over this time, there was no change in either total osteocalcin or % 
undercarboxylated osteocalcin (%ucOC) suggesting a slower turnover in bone than liver. 
However, depletion experiments in humans have shown that markers of bone turnover are 
a sensitive marker of vitamin Ki status, since over a 15 d cycle, levels of %ucOC 
decreased by 28% (Sokoll et al., 1997).
3.8.7 General considerations
There are four conditions that should be met in order to estimate turnover time: 
specificity of measurement, size of tracer dose, requirement for a steady state, and rapid 
mixing with the exchangeable pool (Shearer & Barkhan, 1979). These are each 
discussed below.
3.8.7.1 Specificity o f measurement
Previous studies have all used radiolabelled vitamin Ki tracers. Specificity, or the 
degree to which the tracer has been positively associated with vitamin K1f varies from not 
at all in the case of Olson et al. (2002), where plasma radioactivity was measured, to this
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study, where vitamin Ki is unequivocally identified using mass spectrometry. In between 
these extremes are attempts to use lipid soluble-radioactivity and separation by either 
thin-layer chromatography (Shearer et al., 1974) or HPLC (Bjornsson et al., 1978). 
Although the latter two provide chromatographic resolution, absolute and positive 
association with pure vitamin Ki cannot be assumed. Disadvantages of TLC are the 
rather cumbersome methods, chromatographic tailing (and lack of resolution), and 
exposure to light. The HPLC method described by Bjornsson et al., (1978) does not rely 
on the direct measurement of radioactivity in vitamin Rather, lipid radioactivity is 
extracted from plasma and subjected to HPLC, and the vitamin K^vitamin K  ^ epoxide ratio 
used to calculate the amount of radioactivity remaining (Bjornsson et al., 1978). With 
mass spectrometry, as in this study, it is possible to simultaneously identify and quantify 
the tracer (in this case, level of enrichment).
Recent work has clearly demonstrated the conversion of oral vitamin K<| to the 
structurally similar menaquinone-4 (Thijssen et al., 2006); whereas vitamin Ki has a single 
double bond in the side chain, menaquinone-4 has four, and consequently a molecular 
weight 6 Da lower (444 Da compared to 450 Da). Such similarly related molecules may 
not have been detected by TLC, although analysis by liquid chromatography has been 
used frequently for analysis of these two forms of vitamin K (e.g. Schurgers & Vermeer, 
2000). Mass spectrometry provides a suitable tool to quantify the extent of this conversion 
by monitoring ions of both vitamin Ki and menaquinone-4. This analysis would be 
possible using the methods described here since the stable isotope label is positioned on 
the napthoquinone ring, whereas it has been suggested that conversion to menaquinone 
occurs through initial conversion to menadione, thus any labelled atoms on the side chain 
many be lost.
An additional consideration is the quantitative measurements. As discussed 
previously, early studies were not able to measure absolute amounts of vitamin Ki. 
Methodological problems are still apparent even in Olson’s study, where it is recognised 
that their chosen method of analysis (Ueno & Suttie, 1983) provides values two-fold 
higher than the method of Sadowski et al,. (1989). Thus, there is a lack of confidence in
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these measurements. However, in this study there is greater confidence in our 
quantitative measurements: analysis was performed using the method of Wang et al., 
(2004), and additionally, all measurements were made under the umbrella of the KEQAS, 
vitamin K external quality assurance scheme run by Human Nutristasis Unit at Guy's and 
St Thomas’ Hospital. Therefore, this study is likely the only one to date that fully meets 
the specificity of measurement criterion, both in terms of quantitative and tracer 
measurements.
3.8.7.2 Size o f tracer dose
The size of tracer dose is a challenging problem with vitamin K due to the small 
pool sizes, especially when compared to other fat-soluble vitamins. A true tracer dose 
should not perturb endogenous kinetics and should be a physiological size dose, i.e. one 
that could realistically be achieved through the diet. Some of the previous studies 
(Shearer et al., 1972; Shepherd et al., 1977; Bjornsson et al., 1979) have used doses 
much higher than obtainable from the diet, and therefore must be considered in the 
pharmacological range. In this study, the 30 and 6 pg doses produced plasma increments 
of 37.6 and 6.8 nmol/L, respectively. The 30 pg dose produced plasma values that are 
not commonly possible to achieve through diet alone, whereas the 6 pg dose produced 
more physiological values although still on the high-side of typical increments. However, 
there was no significant difference in kinetic parameters obtained from either dose.
3.8.7.3 Steady-state
The requirement of a steady-state for vitamin K is the third criterion. In this study, 
measurements of plasma vitamin K status and enrichment showed no significant 
difference between days 5, 6 and 7 of the experiment. However, the more relevant 
question is was there a steady-state over the 6 h duration of the experiment? Based on 
the turnover of vitamin Ki, it may be considered that, even over the relatively short time 
scale of the experiment, that the tracee was decreasing. The result may be an observed 
slope that is shallower than the true curve and hence reported half-times might be slower 
than the true values. However, over the time course of this experiment, vitamin Ki
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concentration was also measured thus any deviation from the steady-state was corrected 
for.
The decision to dose for 6 d in order to reach a steady-state for plasma vitamin K-i 
enrichment was taken with the use kinetic values and pool sizes calculated by Olson et 
al., (2002) as the only suitable and available kinetic data. The actual period required to 
reach a steady state will be influenced by inter-individual variation in vitamin K 
metabolism, habitual vitamin Ki intake and possibly vitamin K status (Olson et al., 2002). 
In the model, intakes of vitamin Ki from food were fixed at 60 pg/d but variation of intake 
both between and within an individual will affect the time taken to reach, and the ‘stability’ 
of the steady-state. With free-living individuals it is not possible to control intake, however 
if an individual’s diet was controlled at the same time as dosing then a true steady-state 
could be established, although the level of enrichment would likely vary between 
individuals. As discussed previously, the observed levels of enrichment were lower than 
expected likely due to assumptions in the bioavailability of both vitamin Ki from food and 
the labelled dose.
To reach a true steady-state, and notwithstanding the challenges above, then it is 
likely that because of the putative body pool (bone and adipose tissue) of vitamin Ki with a 
slower turnover dosing would be required for a longer period than that used here. A study 
in rats demonstrated that after 17 d depletion, although liver stores were largely depleted, 
vitamin K1 in the femur had dropped by only 40% (Sato et al., 2002). It is not possible to 
comment on how representative the kinetics derived from Olson et al. (2002) are of the 
possible slower body pools since vitamin K and metabolites were measured. For the 
purposes of the study described here, i.e. characterisation of the fate of an oral dose over 
the relative-short term to determine absolute absorption, the inability to observe slower 
turnover would have a minimal influence on the results.
3.8.7.4 Rapid mixing
The final condition that must be met is the rapid mixing of the tracer with 
exchangeable pools of endogenous vitamin Ki. A complication of working with highly
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lipophilic compounds such as vitamin Ki is the requirement of a carrier for iv injection. 
There is no detailed data on the metabolism of Konakion after iv injection, (e.g. lipoprotein 
partitioning), so there is some uncertainty as to how Konakion behaves compared to 
absorbed, dietary vitamin Kt in triacylglycerol-rich lipoproteins. Kinetic results from an iv 
dose of Konakion MM® (Soedirman et al., 1996) are similar to those obtained here and 
previously reported with radiolabelled, detergent-solubised vitamin Ki (Shearer et al., 
1972; Shearer et al., 1974). Different metabolism of Konakion and absorbed, oral vitamin 
Ki would have implications for the kinetic parameters obtained from the model. However, 
any differences in metabolism (section 3.9.2) are most likely to occur in the initial stages 
of the model, where the Konakion equilibrates with endogenous Ki in lipoproteins, and 
thus is less likely to have a major affect on turnover values calculated from the second, 
slower exponential.
3.8.8 Potential future studies
Rapid disappearance of vitamin Ki from plasma, relatively rapid turnover, and 
sequestering to body pools with slow turnover has meant that previous studies have been 
unable to measure the kinetics of pure vitamin Ki much beyond 8 h. Olson et al. (2002) 
performed a kinetic study over a number of days but was most likely measuring 
predominantly vitamin Ki metabolites rather than vitamin Ki. In order to further our 
understanding of vitamin K metabolism and additional body pools, studies are required 
that measure kinetics over a longer period than has hitherto been attempted.
One solution to the challenge of measuring kinetics in the longer term, is to give 
higher doses, however one of the difficulties with vitamin Ki is also the low body pool 
sizes, and thus a larger tracer dose would not only be unphysiological but may also 
perturb existing vitamin Ki kinetics. As a result, the most likely way of recording longer- 
term kinetics is to increase sensitivity of the measurements to enable monitoring of 
smaller changes. In future work, a number of approaches may be possible to increase the 
sensitivity, for example increasing enrichment or using more sensitive equipment. 
Remaining with the methodology explored in this study, sensitivity to detect long-term
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kinetics may be enhanced by increasing the levels of pre-enrichment. The oral pre­
enrichment achieved in this study with daily dosing of 9 pg was around 8% above 
baseline. With average intakes of around 70 pg of vitamin Ki per day, it would feasible to 
increase the oral pre-enrichment dose four-fold, while having little affect on total intake. 
With baseline isotopomer enrichments also increased four-fold, it may be possible to 
follow the kinetics of vitamin Ki disposal for longer. Using equipment more sensitive to 
measure isotope ratios could further enhance our ability to track longer-term kinetics. Gas 
chromatography-combustion-isotope ratio mass spectrometry is 200 times more sensitive 
than GCMS in terms of measuring isotope ratios (and has greater precision), but is 1000 
times less sensitive in terms of the amount of material needed to observe a peak (Bier
1997). Therefore, this approach is currently not feasible. An alternative equipment-based 
solution is the use of liquid chromatography mass spectrometry. This approach is 
currently in its infancy for isotope ratio measurements but may provide a solution in the 
future and has the potential additional advantage of reducing the need for some sample 
preparation.
Despite the advantages of using stable isotopes, it may be that the use of 
radiolabelled vitamin K tracers will have to be revisited. The advantage of radiolabelled 
compounds is the ability to detect them at very low levels and thus, in theory at least, it 
should be possible to determine long-term kinetics. However, as demonstrated by the 
short-comings in Olson’s study, there is a requirement for the positive and unequivocal 
association of radioactivity with vitamin Ki. Establishing this correlation is likely to require 
laborious sample extraction as well as the use of semi-preparative HPLC, that in the past 
has either not measured radioactivity in vitamin Ki directly (Bjornsson et al., 1978; 
Bjornsson et al., 1979) or not provided sufficient separation and extraction (Erkkila et al., 
2004).
3.8.9 Kinetics summary
The twin objectives of this part of the experiment were 1) develop a stable isotope 
methodology for the measurement of vitamin Ki kinetics and 2) obtain data on vitamin Ki
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kinetics, turnover and body pool sizes in humans. Both of these objectives have been 
successfully met using a novel approach of oral pre-enrichment and a non-labelled tracer, 
thereby circumventing any ethical concerns with regard to the use of chemically 
synthesised iv tracer.
3.9 Absorption
In this study, post-absorptive kinetics were measured following an iv dose of 
Konakion MM® together with enrichment of plasma vitamin Ki with 13C-labelled vitamin 
Ki. The resulting kinetic parameters were then used to calculate absolute absorption of 
an oral dose of 2H-labelled vitamin Ki. Any reservations about the model in this study to 
fully describe vitamin Ki disposition within the body over the longer-term, do not however 
invalidate the usefulness of the method in providing a description of the response to a 
small, physiologically realistic dose, typical of what might be consumed in a single meal 
(4 pg), or to the measurement of the amount of it that was absorbed. This study is the first 
to measure the absorption of an extrinsically labelled form of vitamin Ki at low levels and, 
as discussed below, the results are considerably different to a previous estimate of 
vitamin Ki absorption (Shearer etal., 1974).
The most commonly used method to measure absorption is relative availability, 
usually by estimation of the area under the plasma vitamin Ki response curve when the 
vitamin is given in either standard or test forms (Gijsbers et al., 1996; Booth et al., 1999a; 
Garber et al., 1999; Schurgers & Vermeer, 2000; Booth et al., 2002). Such studies 
measure study-specific relative absorption and as a result it is very difficult to compare 
between them. Some have measured the relative absorption of vitamin Ki from a food 
source compared to a supplement, either in the form of a tablet, (Garber et al., 1999) or as 
Konakion®, (Gijsbers et al., 1996; Schurgers & Vermeer, 2000), while others have 
compared different food sources only, albeit fortified oil (Booth et al., 1999a; Booth et al.,
2002).
In the present experiments mean absolute absorption was 12.7% with a CV of 
74%. The only other previous study to measure absolute absorption of vitamin Ki in
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healthy subjects estimated absorption at around 80% (Shearer et al., 1974). Absorption 
was assessed by the collection of faecal samples from three volunteers who consumed a 
1 mg oral dose of radiolabelled vitamin Ki. Although Shearer’s initial estimates of 
absorption were between 40 and 50%, this value was later increased on the basis that a 
proportion of radioactivity in faeces was derived from the biliary excretion of metabolites, 
i.e. radioactivity in faeces was from vitamin Ki metabolites that had been absorbed and 
excreted, rather than vitamin Ki that had not been absorbed at all. This study used high 
levels of vitamin Ki to measure absorption; the size of the dose (1 mg) was in the 
pharmacological, not physiological range. In general faecal-balance studies can suffer 
from a number of potential inaccuracies, for example no account is made for losses due to 
bacterial degradation in the gut. However, Shearer et al. (1974) concluded there was no 
significant degradation of vitamin Ki to polar metabolites by gut bacteria.
It is possible that the low levels of absorption found in the present experiments are 
a consequence of the form in which the dose was given. For simplicity, the dose was 
provided in the absence of a test meal. In contrast, Shearer’s estimates of 80% were 
obtained when the standard vitamin Ki dose was provided in milk with a meal of bread 
and cheese (Shearer et al., 1970a). The secretion of bile is essential for absorption of 
vitamin K (Shearer et al., 1974) and it may be in the present study, that a capsule 
containing only 0.5 mL of oil contained insufficient fat to yield much of a gastric response. 
Furthermore, gastric emptying effects and possible lack of gastric motility elicited by the 
capsule may have resulted in the observed low absorption values. Absorption of vitamin 
E from a supplement was significantly greater when taken with a meal, compared to 
consumption on an empty stomach (luliano et al., 2001). Additionally, low vitamin E 
absorption from capsules has also been observed when taken without additional fat 
(Leonard et al., 2004).
There is some evidence to suggest that current estimates of the absorption of 
other fat-soluble vitamins may be exaggerated. For example, a recent study calculated a- 
tocopherol absorption of between 10 and 33% (depending on the level of concomitant fat 
intake). These values are significantly lower than earlier estimates of between 55 and
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79% in humans (Bruno et al., 2006) and may be due to the more physiological size doses 
and method of incorporation of the tracer into the food, p-carotene absorption is reported 
to vary between 3.5% and 90% (Tyssandier et al., 2003). Direct analysis of the micellar 
phase of duodenal contents in humans (using a naso-duodenal tube) showed that a 
maximum of 11% of all-trans [3-carotene and only 2.5% of all-trans lycopene were 
absorbed from vegetable sources (Tyssandier et al., 2003). Work in rats reported only 
10% absorption of vitamin Ki on a standard diet, and 19% from a high vitamin Ki diet 
(supplemented with vitamin Ki in corn oil) over a period of 5 to 9 d (Koivu-Tikkanen et al., 
2000b).
Evidence also exists showing that synthetic forms of vitamin E are less 
bioavailable than natural forms (Lodge 2005) due to the synthetic form containing eight 
steoroisomers (Hoppe et al., 2000). Vitamin Ki exists in two forms due to rotation around 
the double bond in the phytyl side-chain (Figure 2-3). Although both isomers are believed 
to be absorbed, only the trans-isomer is thought to be biologically active (Knauer et al., 
1975; Lowenthal & Vergel Rivera, 1979). The majority of naturally occurring vitamin K 
exists in the trans form (Woollard et al., 2002), whereas our synthetic labelled forms of 
vitamin Ki contained around 15% of the cis-isomer (Section 2.6.8). Although absorption 
may be similar for the two isomers, the kinetic and metabolic behaviour of the two forms 
may be different (Blatt et al., 2004). The contribution of the cis-isomer remains an 
unquantified and potential source of error.
It has been demonstrated in rats that dietary vitamin Ki is converted to MK-4 after 
absorption (Thijssen & Drittij-Reijnders., 1994). A possible pathway was originally 
considered via metabolism of vitamin Kr to menadione by gut bacteria, subsequent 
absorption and conversion to menaquinone-4 in the liver. However, from research in rats, 
gut bacteria have since been shown to be unnecessary in the conversion of vitamin Ki to 
menaquinone-4 (Davidson et al., 1998; Ronden et al., 1998). It has recently been shown 
in a human volunteer study that the conversion to menaquinone-4 occurs via the 
intermediate conversion to mendione (Thijssen et al., 2006). Furthermore, the conversion 
is only observed after oral, not subcutaneous administration of vitamin K  ^ (Sakamoto et
177
al., 1996; Thijssen et al., 2006). The work by Thijssen et al., (2006) has shown that up to 
25% of orally ingested vitamin Ki is not absorbed intact but is metabolised to menadione, 
possibly during transfer across the enteroctye. This metabolism would have the effect of 
decreasing the observed absorption since in the current study only intact vitamin Ki was 
measured. If 25% of the dose had been metabolised to menadione then absorption 
values could be increased to around 17%. Although only a minimal increase, if coupled 
with the other explanations for low absorption, then absorption could be significantly 
greater. For future studies, the measurement of changes in menadione and/or 
menaquinone-4 enrichment may also be worth measuring.
Other sources of potential error in the absorption values derive from the analytical 
and modelling procedures. Firstly, there remains the possibility that potential slower 
reaction rates for enriched samples resulted in less conversion to the derivatised form of 
deuterated vitamin K-i compared to unlabelled vitamin Ki. Theoretically, this is unlikely to 
be important in the derivatisation reaction because the deuterated atoms and their 
chemical bonds to the molecule remain away from the derivatisation reaction sites. 
Furthermore, during the analytical method development work no obvious discrimination 
occurred between the two forms, e.g. in the isotope linearity experiments. The second 
possibility is that assumptions in the model led to an under-estimate of absorption. 
Potential differences in the handling of the iv and oral doses and assumptions of the 
model are considered below (section 3.9.2).
The value for absorption has a CV of 74% and is not unreasonable compared to 
other studies of absorption. The inter-individual CV in AUC values to a tablet form of 
vitamin Ki was 37% (Garber et al., 1999) and for Konakion 41% (Gijsbers et al., 1996). 
For more complex meals, values ranged from 17 -  76% (Gijsbers et al., 1996; Garber et 
al., 1999; Booth et al., 2002). Furthermore, a study measuring a-tocopherol absorption 
has reported a 40-fold difference in AUC and maximal concentrations after an oral dose in 
30 subjects (Roxborough et al., 2000). There are a number of potential physiological and 
genetic reasons for the variation, including factors influencing gastric emptying, absorption 
and uptake. For example, the apolipoprotein E genotype has been demonstrated to alter
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the transport and status of vitamin Ki (Saupe et al., 1993; Yan ef al., 2005) and other fat- 
soluble vitamins (Ortega et al., 2005). Studies of vitamin E absorption from capsules have 
also reported highly variable plasma responses between individuals (Roxborough et al., 
2000; Leonard et al., 2004).
This study is unique in magnitude of the oral dose given. Only high doses of 
between 165 and 1575 pg vitamin Ki have previously been investigated, whereas average 
daily intakes in UK adults have been calculated to be around 70 pg (Thane et al., 2006a). 
Furthermore, plasma response to different levels of vitamin Ki from the same source (e.g. 
spinach) may not be linear (Garber et al., 1999). Evidence from intake estimates and their 
relationship to plasma status suggests the relationship is only linear up to 200 pg 
(McKeown et al., 2002). Although in a depletion/repletion experiment intakes of up to 450 
pg had a linear relationship with vitamin Ki plasma response after 3 and 6 h (Booth et al., 
2003b). Uptake of vitamin Ki from the gut is thought to be a passive process, however 
there is also evidence that there may be an active pathway that can be saturated at higher 
levels (Hollander 1973;1977).
Other attempts to obtain information on vitamin Ki absorption with the stable 
isotopically labelled vitamin are restricted to three studies reporting data from intrinsically 
labelled broccoli (Dolnikowski et al., 2002; Erkkila et al., 2004) and kale (Kurilich et al.,
2003). For the absorption of 70 pg of vitamin Ki from kale, Kurilich et al. (2003) report a 
value of 7% absorption, based on the amount of dose in the plasma at the time of peak 
vitamin Ki concentration. If a similarly crude method is applied to this study, then average 
absorption values are only around 1%. It is unlikely that absorption from vegetables is 
actually greater than that from oil, further suggesting the values obtained from this study 
are low compared to what may have been obtained if the dose had been consumed as a 
food, rather than a capsule. This finding may have implications for supplement forms of 
vitamin Ki, or indeed clinical use of oral vitamin Ki.
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3.9.1 Tmax
The time of peak absorption {Tmax) derived from smoothed values was 4.7 h (SD ± 
0.8). In previous studies measuring absorption from a supplement, Tmax was measured as
2.4 h (Garber et al., 1999) for the tablet form and 4 h for Konakion MM® (Gijsbers et al., 
1996; Schurgers & Vermeer, 2000). Our capsule form of the vitamin appeared to be 
absorbed more slowly than previous supplemental forms, due to either slow transit time 
due to the minimal stimulation of the gut or delay in release from the capsule. The Tmax of 
vitamin K  ^ appearance in plasma from food has been measured as between 2.7 h and 7.7 
h (Gijsbers etal., 1996; Garber etal., 1999; Schurgers & Vermeer, 2000).
3.9.2 Metabolic handling of iv and oral doses
A caveat to this study methodology, and any study investigating the kinetics of 
vitamin K, could be potential differences in the metabolic handling of the oral and Iv doses 
of vitamin Ki. Absorption of vitamin Ki, as with other fat-soluble vitamins, occurs through 
the formation of micelles in the presence of bile salts in the gut lumen. Once internalised 
in the enteroctye, vitamin K is packaged into chylomicrons and enters the circulation via 
the lymph (Shearer et al., 1974; Lamon-Fava et al., 1998; Schurgers & Vermeer, 2002). 
Any differences in the metabolism of the oral and iv forms depends on the fate of vitamin 
Ki from the iv dose. The iv  form, Konakion MM®, is a pharmaceutical preparation of 
vitamin Ki in which the vitamin is solubised in mixed micelles formulated from glycholate 
and lecithin. Upon injection, the vitamin Ki is rapidly released and it is reported that the 
mixed micelles do not influence the behaviour of the vitamin (Soedirman et al., 1996). 
Kinetic results from Konakion alone (Soedirman et al., 1996), detergent-solubised 
radioactive tracers (Shearer et al., 1974) and this study, are all similar. There are no data 
to suggest that Konakion is or is not metabolised differently to absorbed, dietary vitamin 
K-|. However, differences may exist between vitamin K-i uptake from chylomicrons and 
chylomicron remnants compared to the Konakion formulation since the latter lack any of 
the intrinsic proteins that lead to lipoprotein uptake, e.g. apoE.
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From the absorption curves it was possible to obtain an approximate value for the 
Ty2 of disappearance of the deuterated oral dose of vitamin K-i. The terminal slope was 
calculated by regression of the plasma concentration of deuterated vitamin K-i of the final 
two or three data points for each subject. The average Ty2 was calculated from division of
0.693 by the slope. Values were obtained for nine of the ten subjects, and the average 7>2 
was 2.39 h, not significantly different from 2.66 h derived from the iv  kinetics (P=0.78). 
This suggests that there was no difference in the metabolic handling of the oral and iv 
forms of the vitamin. However, the estimate of oral dose Ty2 is very approximate since it 
based only on two or three data points, thus may not represent the true slope. A better 
estimate could be obtained with a greater sampling frequency and longer sampling 
duration.
In the calculations, absorption is calculated on the assumption that the kinetics of 
the iv  dose predict the irreversible disposal of the oral dose. Thus, if irreversible disposal 
occurred at a greater rate than that predicted, then absorption would be under-estimated. 
However, other data supports the kinetic parameters calculated in this study, while other 
work suggests a slower rate of irreversible disposal (Olson et al., 2002).
3.9.3 Absorption summary
The aim of the absorption arm of this experiment was 1) design a methodology to 
measure absorption and 2) obtain values for absorption of an oral dose in a standard 
form, with the possibility of using this as a standard by which to measure absorption in 
future studies.
A method was successfully tested and a value was obtained for absolute absorption 
that included absorbed vitamin Ki that otherwise would not be identified using traditional 
AUC methods, due to transfer to other, non-sampled body pools. In conclusion, the 
absolute absorption of a 4 pg deuterium labelled dose of vitamin Ki has been calculated 
by applying post-absorptive kinetics determined from a simultaneous iv  dose. The percent 
absorption of the vitamin K-i dose was measured as 13%. This method may provide a
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suitable tool to investigate vitamin Ki absorption from food sources at levels commonly 
consumed in a typical Western diet.
3.10 Section 3 conclusions
The kinetics of vitamin K1 uptake and disposal have been fully characterised over a 
6 h period. The results obtained agree with the majority of those published previously 
where radioactive tracers have been utilised, with the exception of work by Olson et al., 
(2002). This work clearly demonstrates the importance of having a reliable method for the 
unambiguous determination of vitamin Ki, such as that described in Section 2. Together 
with previous work, these results point to the possible existence of, as yet, 
uncharacterised body pools of vitamin K1 with slow turnover rates, most likely bone and 
adipose tissue. Further studies are required to determine longer-term kinetics and 
turnover rates.
In the present study, it was possible to apply the kinetic parameters obtained to the 
accurate determination of absorption of vitamin Ki from an oral dose. Absorption was 
measured as 13%, a relatively low estimate, possibly due to the absence of a test meal, 
but also the possibility of conversion to menadione during transition across the enterocyte. 
This possibility requires further investigation, something that could be possible by 
measuring changes in menadione enrichment in the plasma samples obtained during this 
study.
This study has demonstrated the application of a dual stable isotope-type approach 
to the measurement of fat-soluble vitamin absorption and kinetics, specifically vitamin Ki. 
In addition, the use of an oral pre-enrichment method to accurately determine kinetics with 
an unlabelled tracer was demonstrated. Each of these methods provides a basis for the 
further investigation of vitamin Ki kinetics, turnover and absorption.
182
4  S tu d y  2: M e a s u re m e n t o f  v itam in K i  b io a v a ila b il i ty
4.1 Background
In Western populations, vitamin Ki is the primary dietary form of vitamin K 
(Schurgers et al., 1999). Vitamin Ki is found in a wide range of foods but vegetables 
contribute at least 50% to total vitamin Ki intake (section 1.5.1) with the majority from 
green leafy vegetables. Consequently, green leafy vegetables are considered the major 
dietary source of vitamin Ki, however recent evidence shows their contribution may be 
decreasing (Thane et al., 2006a). In the UK, average adult intakes of vitamin Ki are 
reported to be between 60 and 80 pg/d (Fenton et al., 1997; Bolton-Smith et al., 1998; 
Fenton et al., 2000; Thane & Bolton-Smith, 2002b; Thane et al., 2006a). From a recent 
comparison of data between the 1986 -  7 Dietary and Nutritional Survey of British Adults 
and the 2000 -  1 NDNS, those participants who had vitamin Ki intakes below the UK 
guideline, rose from 47% in 1986 -  7 to 59% in 2000 -  1 (Thane et al., 2006a)
Where intakes may be marginal, and in order to set dietary recommendations, it is 
important to understand how representative the measurement of status (typically plasma 
concentration) is of dietary intake. Additionally, defining this relationship is important for 
identifying groups who may be at risk of nutrient deficiency. Furthermore, based on 
evidence showing an influence of fluctuating dietary vitamin Ki intake on anticoagulation 
treatment (Khan et al., 2004; Kurnik et al., 2003; Schurgers et al., 2004; Couris et al., 
2006) data on acute changes in vitamin Ki plasma concentration in response to different 
foods are required.
A number of studies have demonstrated a significant and positive relationship 
between dietary intake and plasma concentration of vitamin Ki, although these 
relationships are not very strong. For example, a recent paper reported correlations of 
r=0.26 for women and r=0.32 for men (P<0.001) (Thane et al., 2006a). This may be partly 
due to plasma status not reflecting chronic intake, although it is probable that 
bioavailability is also an important factor determining the relationship between intake and
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status, particularly in the short term. In common with other fat-soluble vitamins, and as 
discussed in section 1.8/7, bioavailability is a consequence of digestion and absorption. 
As a result, it is theoretically determined by a number of factors; the food matrix, effects of 
cooking or processing, other dietary components such as fat which may affect absorption 
and/or transport of vitamin K-i, and other micronutrients that may enhance or inhibit 
absorption or transport such as vitamin E or dihydro-vitamin Ki. Differences in the 
bioavailability of vitamin Ki between foods could require a reassessment of the relative 
importance of different sources. However, only a limited number of studies have 
attempted to measure vitamin Ki bioavailability. Studies have measured either
bioavailability from different foods and/or the effect of fat on absorption. In summary, 
these studies suggest that absorption is no different between different vegetable sources 
(Garber et al., 1999) and that the presence of fat may enhance vitamin Ki absorption 
(Gijsbers et al., 1996). Studies measuring differences in absorption of vitamin Ki from oil 
or vegetable sources have found conflicting results (Booth et al., 1999a; 2002). The 
varied findings are probably the result of the different methods used and their limitations, 
particularly the use of protocols where comparisons have to be made between foods or 
meals given at different times in different subjects and often using relatively large doses of 
the vitamin. It is also difficult to compare different studies. As described in section 1.12.7, 
a stable isotope labelled version of a nutrient provides a safe method of investigating 
bioavailability to obtain information on the relationship between vitamin Ki dietary intake 
and plasma status, and the relative importance of different sources of vitamin Ki.
4.2 Study objectives
The two primary objectives of this study were to:
I. Develop a stable isotope methodology for the measurement of vitamin Ki 
bioavailability from meals and/or foods
II. Obtain data on the bioavailability of vitamin Ki from meals and measure absorption 
of stable isotope dose
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4.3 Study design
Section 2 described the development of a method for the measurement of plasma 
vitamin enrichment that avoided time-consuming semi-preparative HPLC. This method 
is reliable and precise for the measurement of isotope ratios of vitamin Ki in plasma 
samples. The volunteer study, described in section 3, investigated vitamin K-i kinetics and 
absorption of a labelled oral dose in humans. Estimates of absorption and time profiles 
from this study provided additional data for the development of a further study to measure 
the bioavailability of vitamin Ki from food.
Previously, studies measuring bioavailability have generally focussed on a single 
source of vitamin Ki (e.g. broccoli or vitamin Kr fortified oil) often at much higher 
concentrations than would be present in a typical meal. Although this approach may 
provide mechanistic information and allow comparison between individual foods, it is 
unrepresentative of typical intakes or the way in which people commonly consume foods. 
Furthermore, information is required on which foods or nutrients, when in combination, 
may inhibit or enhance vitamin Ki absorption. Therefore, in the current study, volunteers 
were fed realistic meals containing typical amounts of vitamin Ki.
4.3.1 Meal design
The meals were each designed to reflect a typical dietary intake in the UK. 
Traditional methods of analysing large amounts of dietary data are often based on the 
consumption of separate nutrients, and individuals grouped according to their intake of a 
single nutrient or type of food. Dietary pattern analysis for food consumption provides an 
alternative statistical approach to the study of isolated dietary components and a basis for 
the investigation of the interactive effects of different foods on bioavailability. Fahey et al., 
(2007) have recently described a novel statistical technique for the grouping of individuals 
into clusters based on the consumption of similar foods. This method was applied to data 
from the 2000 -  1 NDNS of Adults. In this survey, 958 women and 766 men provided 
dietary data as 7-d weighed food records. These food data were combined into 25 food 
groups that were used for the modelling. Dietary pattern analysis identified four dietary
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clusters in women and six in men (Fahey et al., 2007). Of these, three showed similar 
patterns between men and women and were chosen for the design of the meals.
Each cluster was defined by the relative consumption of each of the 25 food 
groups (Figure 4-1). Based on each cluster’s defining characteristics and to aid 
identification each cluster was given a single descriptive name (Fahey et al., 2007). A 
danger of the name is that it may lead to assumptions by the reader with regard to the 
types of food that characterise that group however, the same labels, as defined by Fahey 
et al., have also been used in this study for the purposes of recognition.
Cluster 1 was characterised by higher than average consumption of fast and snack 
foods and refined cereals, and lower than average consumption of fruit, vegetables and 
whole grain cereals. This cluster was labelled as a ‘convenience’ diet. Cluster 2, the 
‘cosmopolitan’ diet, was characterised by higher than average consumption of fruits, 
vegetables, whole grains, fish and diary foods. This group had lower consumption of 
refined cereals, and fast and snack foods. Cluster 3 was distinguished by higher than 
average consumption of animal products and refined cereals and average consumption of 
vegetables. This cluster was labelled as ‘animal-oriented’.
4.4 Methods
For the bioavailability study, the test meals were designed based on the 
characteristics of each cluster (Figure 4-1). The clusters represent the intake of each of 
the food groups and not intake of vitamin For example, those individuals in the 
cosmopolitan cluster had a higher intake of vegetables and whole grains compared to 
individuals in the convenience or animal-oriented clusters. Thus, the cosmopolitan meal 
contained more of this food group than either the convenience or animal-oriented meals.
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Figure 4-1. Predicted mean intakes o f food groups in each c luste r as the % 
deviation from the mean food group intake o f all clusters, by c luster and sex (F = 
female; M = male) (adapted from  Fahey eta l., 2007)
Water 
Fruit juice 
Alcohol 
Soft drinks 
Coffee/tea 
Soups 
Fast foods 
Red meat 
White meat 
Fish 
Eggs 
Dairy 
Skimmed milk 
Whole milk 
Fat spreads 
Butter 
Sugars 
Puddings 
Snack foods 
Pasta/rice 
Refined cereals 
Wholegrain cereals 
Potatoes 
Fruit/nuts 
Vegetables
Convenience (F)
□
Cosmopolitan (F) Anim al-oriented (F)
-100  -50 0 50  100  150  200  -100  -50 0 50  100  150  200  -
Convenience (M)
Water 
Fruit juice 
Alcohol 
Soft drinks 
Coffee/tea 
Soups 
Fast foods 
Red meat 
White meat 
Fish 
Eggs 
Dairy 
Skimmed milk 
Whole milk 
Fat spreads 
Butter 
Sugars 
Puddings 
Snack foods 
Pasta/rice 
Refined cereals 
Wholegrain cereals 
Potatoes 
Fruit/nuts 
Vegetables
I
i
r1□j[1n
11
Cosmopolitan (M)°L Anim al-oriented (M)
a
100  -50 0 50  100  150  200-100  -50 0 50  100  150  200  -100  -50 0 50  100  150  200
% deviation from mean intake of all clusters
The food group ‘dairy’ includes cheese, cream, ice cream and yoghurt but excludes those dairy items listed 
separately (milk and butter). Oils were excluded from the analysis because consumption was low.
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The characteristics of each cluster were used to formulate the three different test 
meals. Thus, the convenience meal was designed to contain foods matching the 
convenience cluster’s defining characteristics: higher than average consumption of refined 
cereals and fast foods and below average intake of vegetables. Sources of vitamin K-i in 
this meal were primarily rapeseed oil and other vegetable oils.
The cosmopolitan cluster was characterised by higher than average consumption 
of vegetables, wholegrain cereals, fish and dairy foods and thus the meal was based 
around these characteristics. The main vitamin K  ^ source was vegetables.
Those people defined by the animal-oriented cluster consumed red meat and 
refined cereals in above average amounts, and thus these food groups were prominent in 
the animal-oriented meal. Their consumption of vegetables was average. The main 
vitamin Ki sources in the animal-oriented meal were olive oil and peas.
Actual meal composition is shown in Table 4-1. The convenience meal was a 
chicken pie served with chips, baked beans and white bread. The cosmopolitan meal was 
a fish pie (containing green beans and potatoes), served with wholemeal bread. Finally, 
the animal-oriented meal was a beef lasagne served with white bread. Meals were 
matched for energy (c. 3200 kJ) and percent energy from protein (20%), fat (40%) and 
carbohydrate (40%). Dietary composition was estimated using the MRC Human Nutrition 
Research in-house suite of programs based on McCance and Widdowson’s The 
Composition of Foods, fourth edition (Paul & Southgate, 1978), its supplements (Holland 
etal., 1988; 1989) and the sixth edition (Food Standards Agency 2002).
Each meal was designed to contain around 40 pg of vitamin K-i. This value was 
based on the expected plasma vitamin Ki increment, assuming a relatively low 
bioavailability, and also on analytical limitations. The major food items contributing to total 
vitamin K-i intake are show in Table 4-2. Meals were tested for palatability prior to the 
start of the study. Sixteen of each meal were prepared in single batches and frozen at -18 
°C until use.
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Table 4-1. Ingredients and nutrient composition of each test meal designed for the 
bioavailability study
Convenience Weight Energy Prot Fat CHO Fib VitK
_  g kJ g pg
Chicken, light meat, raw 95 427 22.8 1.1 0.0 0.0 0.0
Flour, self-raising 35 491 3.1 0.4 26.5 1.4 0.3
Margarine, soya based 25 677 0.0 18.3 0.1 0.0 19.5
Milk, whole 65 179 2.1 2.5 3.1 0.0 0.4
Onions 20 20 0.2 0.0 1.0 0.3 0.1
Peas, frozen 16 45 0.9 0.1 1.5 1.1 4.7
Rapeseed oil 9 333 0.0 9.0 0.0 0.0 10.1
Baked beans 70 249 3.6 0.4 10.7 4.8 1.9
Bread, white 40 402 3.3 0.8 19.7 1.5 0.2
Oven chips 60 414 1.9 2.5 18.0 1.7 3.3
Totals 435 3236 38.0 35.1 80.6 10.8 40.5
Cosmopolitan Weight Energy Prot Fat CHO Fib VitKg kJ g pg .
Butter 4 121 0.0 3.3 0.0 0.0 0.3
Cheese, Cheddar 20 342 5.1 6.9 0.0 0.0 0.9
Cream, double 25 462 0.4 12.0 0.7 0.0 1.6
Flour, plain 4 58 0.4 0.1 3.1 0.1 0.0
Green beans 84 78 1.5 0.4 2.4 2.4 32.7
Milk, semi-skimmed 50 99 1.8 0.9 2.4 0.0 0.1
Potatoes, boiled 260 796 4.7 0.3 44.2 3.6 2.4
Salmon, raw 45 337 9.1 5.0 0.0 0.0 0.1
Smoked haddock, raw 50 173 9.5 0.3 0.0 0.0 0.0
Bread, wholemeal 65 601 6.1 1.7 27.1 4.8 1.7
Fat Spread, 70% fat 5 130 0.0 3.5 0.0 0.0 0.7
Totals 612 3197 38.5 34.2 79.8 11.0 40.5
Animal-orientated Weight Energy Prot Fat CHO Fib VitKg kJ g pg _
Beef, lean, raw 95 490 19.2 4.4 0.0 0.0 0.3
Butter 4 121 0.0 3.3 0.0 0.0 0.3
Flour, plain 4 58 0.4 0.1 3.1 0.1 0.0
Lasagna, boiled 70 298 2.1 0.4 15.4 1.0 0.0
Milk, whole 70 192 2.3 2.7 3.3 0.0 0.4
Olive oil 18 666 0.0 18.0 0.0 0.0 10.4
Onions 20 29 0.2 0.0 1.6 0.3 0.1
Peas, frozen 60 175 3.6 0.6 5.8 4.3 17.4
Tomato puree 10 29 0.5 0.0 1.3 0.0 0.8
Tomatoes, canned 160 110 1.6 0.2 4.8 1.3 9.6
Bread, white 95 955 7.9 1.9 46.9 3.5 0.4
Fat spread, 70% fat 5 130 0.0 3.5 0.0 0.0 0.7
Totals 611 3252 37.8 35.0 82.2 10.5 40.4
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Table 4-2. Individual food items contributing more than 3% to total vitamin Ki 
content in each test meal
Meal Meal component Vitamin Ki (pg) % contribution
Convenience Margarine 19.5 48.2
(chicken pie) Rapeseed oil 10.1 25.0
Peas 4.7 11.5
Oven chips 3.3 8.2
Baked beans 1.9 4.7
Cosmopolitan Green beans 32.7 80.7
(fish pie) Potatoes 2.4 6.0
Wholemeal bread 1.7 4.2
Animal- Peas 17.4 43.1
oriented
(lasagne)
Olive oil 10.4 25.6
Tomatoes 9.6 23.8
Soya-based margarine was chosen for its relatively high vitamin Ki content for the 
preparation of pastry in the convenience meal. The fat spread used in all three meals was 
a sunflower-based spreadable fat, lower in vitamin Ki.
4.4.1 Ethical permission
The study protocol was approved by MRC Human Nutrition Research Scientific 
Coordination Committee (SCC) and Research Governance Committees (RGC). Ethical 
permission was obtained from Suffolk Local Research Ethics Committee (Suffolk REC 
05/Q0102/148). Informed written constant was obtained from all subjects prior to the start 
of the study (Appendix V).
4.4.2 Sample size
This randomised three-period study compared the absorption of vitamin Ki from 
three different meals. There was no directly applicable statistical information from which 
to calculate sample size but data from previous dose-response studies provided some 
guidance. These studies indicate an inter-individual coefficient of variation (CV) of 30% 
for area under the curve (AUC) of plasma dose response (Gijsbers et al., 1996). By using 
a sample size formula for a normal distribution, it was calculated that twelve subjects
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would allow the detection of a 25% difference in AUC at the 5% significance level and with 
80% power. The assumption of 30% CV was investigated using sensitivity analysis by 
recalculating the detectable difference for CVs of 20% and 40%. The detectable 
differences were 17% and 33%, respectively. This calculation assumed a two-way cross­
over design and therefore gave a conservative estimate of the detectable difference, both 
because it ignored the additional (third) period and did not take into account the likely 
advantages consequent on providing test and reference materials at the same time and to 
the same subjects.
4.4.3 Study subjects
It was decided to recruit healthy subjects since the aim of the study was to 
investigate absorption under normal physiological conditions. Both men and women were 
recruited, aged between 18 and 65 y, with a BMI between 18 and 25 kg/m2. Exclusion 
criteria were split between two categories:
General health exclusions:
Cancer (within previous 10 y), history of heart disease, diabetes, or other chronic medical 
conditions; anaemia, untreated and elevated blood pressure, recent surgery (minor 
surgery in the last 6 wk or major surgery in the previous 3 mo) or heavy blood losses 
(including blood donation in the last 3 mo); history of food intolerance or food allergies, 
recent rapid weight loss (> 3 kg in previous mo), pregnancy or breast feeding. 
Study-specific exclusions - (those conditions that may affect vitamin absorption or 
metabolism):
Medication that may interfere with vitamin Ki absorption or metabolism (laxatives, 
antibiotics, anti-coagulants, anti-convulsants, bile acid sequestrants, long-term aspirin 
use, Orlistat, cholesterol-lowering drugs); blood coagulation disorders, known high plasma 
cholesterol or high triacylglycerols, liver and gall bladder diseases, malabsorption 
conditions of gastro-intestinal tract, alcohol intake >21 units/wk for women and >28 
units/wk for men.
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4.4.4 Volunteer recruitment
Volunteers were recruited through the HNR Volunteer Database, and through the 
email bulletin of the Cambridge University Graduate Union. The information sheet for 
volunteers is attached as Appendix VI. Volunteers received £90 for full participation in the 
study.
4.4.5 Preparation of labelled vitamin Ki
For this study, 13C-labelled vitamin Ki was chosen from the two available labelled 
forms because, with the expected low concentrations of vitamin Ki, changes in enrichment 
would be detected with a greater signal to noise ratio on top of existing natural 
abundance. In contrast, and as noted in section 2.10, the M+4 isotopomer is not detected 
at natural abundance. A stock solution of 83.8 mg in 100 mL of ethanol was prepared, 
divided into aliquots and stored at -18  °C. To prepare the dose for volunteers, 48 pL of 
the standard solution was added to 1 mL of groundnut oil to supply 20 pg (44.4 nmol) of 
13C-labelled vitamin K1 in 0.5 mL of oil. Ethanol was evaporated from the oil by heating at 
40 °C under N2 with a Pierce Reacti-therm heating block and Reacti-vap evaporator 
(Perbio Science, Erembodegem, Belgium). After vortexing for 1 min, 0.5 mL aliquots of 
groundnut oil containing the labelled vitamin K-i were transferred to gelatine capsules 
(kindly provided by Capsugel, Colmar, France). Capsules were prepared fresh for each 
subject and stored, refrigerated, in amber medicine bottles.
4.4.6 Study protocol
To ensure that vitamin Ki intake prior to each study day was similar between 
subjects, the volunteers were given a meal (pizza) to be consumed the evening prior to 
each study day containing no ingredients known to be high in vitamin Ki. On three 
occasions, at least two weeks apart, volunteers were asked to attend the volunteer suite 
at MRC HNR after an overnight fast. Their weight was measured to the nearest 0.1 kg 
using Seca 770 digital scales (Seca, Birmingham, UK) and their height was measured to 
the nearest 0.01 m using a Seca 202 wall-mounted stadiometer (Seca, Birmingham, UK).
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An indwelling cannula was inserted into a forearm, and two baseline blood samples were 
collected into 7.5 mL EDTA S-monovettes® (Sarstedt Ltd, Leicester, UK). The test meal 
was defrosted overnight and reheated in an electric oven to at least 70 °C for at least 2 
min (as per Food Hygiene and Safety protocols) prior to consumption. Meals were 
weighed after reheating. Immediately before consumption of the test meal the volunteer 
swallowed the vitamin K-i-containing capsule. To minimise sequence effects, subjects 
were randomised for the order they received the meals. With three meals, there are six 
possible combinations, thus two subjects were designated to each sequence. Thirteen,
7.5 mL blood samples were collected at 1.0, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5,
7.0 and 8.0 h after consumption of the meal. A snack (two slices of toast with sunflower 
spread and jam) was provided after 5 h and water was permitted ad libertum throughout 
the study.
4.4.7 Dietary intake
Volunteers were asked to record a 4-d food diary, completed over one weekend 
(Saturday and Sunday) and two weekdays. The primary purpose was to allow the 
determination of the volunteer’s typical dietary intake, which may have been important in 
understanding any large inter-individual observations, or atypical experimental results.
4.4.8 Sample collection and analysis
Blood samples were collected into syringes and immediately transferred to coded 
tubes containing EDTA S-monovettes (Sarstedt Ltd, Leicester, UK). Samples were stored 
on ice, protected from light, and within 1 h centrifuged at 4 °C for 20 min at approximately 
2000 g. The plasma was divided into three 1 mL aliquots and stored in 2 mL microtubes 
(Sarstedt Ltd, Leicester, UK) a t -70  °C until analysis.
Extraction of vitamin Ki from plasma was performed as described in section 2.9. 
Derivatisation was performed as in section 2.7.3. The GCMS was run in SIM mode and 
ions m/z 598.4 to 601.4 were measured. Total plasma vitamin Ki concentrations were 
measured by high-performance liquid chromatography (HPLC) with fluorescence 
detection after post-column reduction (Wang etal., 2004) (section 2.12).
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4.5 Analysis of vitamin Ki in meals
4.5.1 Background
The difficulties encountered in the analysis of vitamin Ki in food are similar to 
those for plasma, with typically low levels and co-extraction of lipids in much greater 
abundance than vitamin Ki. A number of assays have been published for the 
measurement of vitamin Ki in foods. Extraction typically required all, or some of solvent 
lipid extraction, lipid digestion, solid phase extraction and/or semi-preparative HPLC 
(Booth et al., 1994; Koivu-Tikkanen et al., 2000a; Schurgers & Vermeer, 2000; Indyk et 
al., 2003). Quantitation has been always performed by HPLC with either electrochemical 
or fluorescence detection. For quantitative work, internal standards and calibration curves 
should ideally be used. However, the analytical response for an analyte in a complex 
sample may not be the same as in a simple standard and quantitation using a calibration 
curve would require standards that closely match the composition of the sample. For 
routine analyses, it may be feasible to prepare such standards. However for the 
requirements of this study, the procedure was deemed too time consuming. As an 
alternative, the standard addition method was used justified by the accuracy of the results 
required, the small number of samples and time pressures.
Standard addition requires the unknown sample to be divided into two portions and 
a known amount of the analyte (a spike) be added to one portion. The two samples are 
then analysed; the spiked sample shows a larger analytical response than the original 
sample due to the additional amount of analyte. The difference in analytical response 
between the spiked and unspiked samples is due to the amount of analyte in the spike, 
and hence analyte concentration in the original sample can be calculated (see section
4.6.6 for calculations).
4.5.2 Method development
Solvent extraction followed by solid phase extraction, rather than semi-preparative 
HPLC, was the preferred method. The method described here is modified from Booth et 
al. (1994) and quantitation was achieved using the analytical method for vitamin Ki in
194
plasma (Wang et al., 2004). Booth et al. (1994) describe the requirement for both silica 
and C18 SPE. Therefore, early attempts focussed on the use of both SPE columns. 
However, initial experiments revealed significant losses in the extraction. To ascertain 
where the losses were occurring fractions of eluent were collected from each wash of the 
SPE columns. Investigation revealed that almost 80% of the vitamin Ki was lost during 
the washing phase of the Cis column probably due to different brands of SPE columns 
having different retention characteristics. However, it was found that purification of food 
samples using only silica SPE provided a sufficiently clean sample and so the extraction 
was performed with silica SPE only. The full method is detailed below (section 4.5.3).
4.5.3 Extraction and determination of vitamin K-i in meals
Quantitation was performed by the standard addition method. Chemicals were 
purchased from VWR (VWR International Ltd, Poole, UK). A sample meal from each 
batch was defrosted and reheated as for the study subjects, and then liquidised with a 
kitchen blender with an equal weight of purified warm water. A 30 g portion of the meal- 
water mixture was homogenised using an IKA Ultra Turrax T25 basic homogeniser 
(Esslab, Essex, UK). Two grams of the homogenised meal were transferred to a pestle 
and mortar and ground with 18 g of anhydrous sodium sulphate. One gram of the mixture 
was weighed into a 50 mL polypropylene centrifuge tube (Sarstedt Ltd, Leicester, UK) and 
30 mL of 2-propanol: hexane (3:2 v/v) and 10 mL of purified water were added. At this 
stage, the spike of 3 ng of vitamin Ki (Supelco, Poole, Dorset, UK) in 100 pL of hexane 
was added to half the tubes and to the remaining tubes was added 100 pL of hexane only. 
The tubes were vortexed for 3 min and then sonicated for 3 min (Microsonix XL2000 
model with 1/8 inch tapered microtip (Microsonix, USA)). The tubes were vortexed for a 
further 3 min and then centrifuged at 2000 g for 5 min. From the top layer, 9 mL of 
hexane was removed and transferred to a disposable culture tube (16 x 100 mm, Corning 
Ltd., Hemel Hempstead, UK). Excess solvent was evaporated under N2 at 40 °C. The 
contents of the tube were reconstituted in 300 pL of hexane and further purified by solid 
phase extraction using 500 mg silica columns (Sep-Pak-RC™ 500 mg silica, Waters,
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Hertfordshire, UK). The columns were conditioned with 4 mL diethyl ether: hexane 
(96.5:3.5 v/v) and then 4 mL of hexane. The sample was added and washed with 6 mL of 
hexane before elution with 7 mL of diethyl ether: hexane (96.5:3.5 v/v). The sample 
eluent was collected into disposable glass tubes (13 x 100 mm, Fisher brand) and 
evaporated to dryness in a vacuum evaporator (Savant, NY, USA). The samples were 
reconstituted in 200 pL of dichloromethane and 800 pL of methanol and analysed by high 
performance liquid chromatography (HPLC) using the same method as for the plasma 
samples. Extraction and analysis was performed in duplicate.
4.6 Data analysis
4.6.1 Isotopomer ratio analysis
Calculation of enrichments was performed as previously described in Section 
3.6.1, by exporting raw data from the Agilent software into Microsoft Excel templates and 
using the fitting techniques described by Bluck and Coward (1997).
4.6.2 Tracer concentration
Tracer concentration was calculated from the observed isotopomer ratios 
calculated as described in 4.6.1, and total vitamin Ki concentration measured by HPLC, 
using the following equation:
t  x *. (Rm+ho-R m+ho)) n
T ra c e r concentration =  rp  —  ■ ■ \ x Ct
Where R M+l is the ratio of the mass M+1 to M and subscripts refer to baseline (0) and subsequent time 
points (t). Ct is the corresponding total concentration (nmol/L) at each time (min) poin t.
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4.6.3 AUC
Area under the curve (AUC) was used to assess absorption of the labelled vitamin 
Ki tracer. AUC was calculated using the trapezoid rule, a method of numerical 
integration. AUC was calculated using the following equation and units are nmol/L per 
hour:
AUC,., = £ p 2 - ± S i - x ( f l - ( 0)| + { S l ± S i x (( 2 +
Where Ct is the concentration (nmol/L) at each time point and t is each sampling time (min)
These data were used to assess the effect of the meals on the bioavailability of the 
labelled vitamin Ki tracer. This ‘meal effect’ describes meal characteristics e.g. type of fat, 
nutrient composition, energy density, that may have affected absorption of the labelled 
vitamin Ki tracer.
4.6.4 Comparisons of bioavailability
For comparisons of the bioavailability of vitamin Ki from meals (tracee), a different 
approach was taken. In each instance, if the absorption profile with time of vitamin Ki 
from the meal were the same as that of the tracer then the relationship between them 
would be equal to unity, after normalisation for the dose given by adjusting concentrations 
for vitamin Ki provided as tracer or in the meal. By measuring the slope of regressions 
between normalised concentration of tracer and tracee from the meal, it was thus possible 
to measure the relative bioavailability of the vitamin Ki from each meal compared to the 
tracer. This ‘matrix effect’ describes extraction efficiency of vitamin Ki from the meal.
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4.6.5 Statistics
Statistics were performed in Excel (Students f-test) or with STATA 9.1 (Stata 
Corp., Texas, USA). AUC values were checked for normal distribution by observing a 
quintile-quintile plot.
4.6.6 Calculation of vitamin Ki in meals
The standard addition method was used. Peak areas were manually integrated 
using the HPLC software and the amount of vitamin Ki in the sample calculated using the 
equation:
v  _  Xspike *  ^unspiked
*  sample ~
^spiked ^unspiked
Where: X  = amount of vitamin K1
A = peak area
For the measurement of vitamin Ki in each meal, 0.05 g of food was extracted and 
thus the total amount of vitamin Ki within the meal was calculated by:
. Meal weight (g)
Amount in meal = Xsamp/e x  — -------
4.7 Results
4.7.1 Subject characteristics
The twelve subjects (5 women and 7 men) were aged between 22 and 49 y. They 
had a mean ± SD height of 1.73 ± 0.09 m, weight of 69.4 ± 9.3 kg, and BMI of 23.1 ± 2.3 
kg/m2. Average baseline plasma vitamin Ki was 0.35 nmol/L across all 36 visits, with 
individual’s average ranging from 0.12 to 0.74 nmol/L. The average intra-individual 
coefficient of variation (CV) between the three visits was 48%. Average between subject 
CV was 78%.
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4.7.2 Vitamin Ki content of meals
The vitamin Ki content of meals calculated from food composition data was 
estimated at 40 pg. Average meal weights after cooking and reheating were 423 g, 587 g 
and 603 g for the convenience, cosmopolitan and animal-oriented meals, respectively. 
Direct analysis of the meals by HPLC revealed vitamin K-i content as 19.9 pg, 26.3 pg and
33.0 pg for the convenience, cosmopolitan and animal-oriented meals, respectively. 
HPLC chromatograms of the extracted 0.05 g food samples are shown in Figure 4-2.
Figure 4-2. Direct output of HPLC chromatograms of food sample analysis
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4.7.3 Tracer absorption
Absorption of tracer was assessed by calculating area under the curve. Gender 
did not affect AUC of tracer within meals calculated using Students f-test (convenience 
P=0.83, cosmopolitan P=0.88, and animal-oriented P=0.81). The mean ± SD of tracer 
AUC measurements for all subjects were 0.88 ± 0.42, 1.30 ± 0.49 and 1.13 ± 0.60 
nmol/L.h for the convenience, cosmopolitan and animal-oriented meals, respectively 
(Figure 4-3). AUC for tracer measurements were compared using linear regression with 
fixed effects for meal, subject and period. Significantly less vitamin Ki tracer was 
absorbed when consumed with the convenience meal than either the cosmopolitan and 
animal-oriented meals (P=0.001 and P=0.035, respectively). There was no significant 
difference between the cosmopolitan and animal-oriented meals (P=0.120). Table 4-3 
shows individual AUC measurements calculated from the tracer profiles. Tracer profiles 
are shown in Figure 4-4. CVs for tracer AUC measurements within meals were between 
38 and 53%. Calculation of AUC between 0 -  5 h and 5 -  8 h, tested the possible 
influence of the 5 h snack on the results. However, differences between meals in 
absorption of tracer before the snack were similar to differences after the snack.
Figure 4-3. Mean AUC of tracer vitamin Ki consumed with each of the three test 
meals in 12 subjects
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Each bar represents the mean ± SD AUC of absorption of tracer vitamin Ki used to measure meal effect on 
absorption. * indicates significant difference compared to the convenience meal.
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Table 4-3. AUC0.8 of individual tracer measurements for each test meal
Convenience Cosmopolitan Animal-oriented
Subject AUC (nmol/L.h)
A 0.81 1.11 0.85
B 0.64 0.94 0.84
C 1.04 1.71 1.31
D 2.04 1.92 2.44
E 0.94 2.03 1.51
H 0.30 1.11 0.45
I 0.97 0.94 0.96
J 0.51 0.83 0.57
K 0.82 1.02 1.59
L 0.78 1.99 1.49
M 0.69 0.64 0.27
N 1.03 1.40 1.23
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Figure 4-4. Time-concentration profiles of plasma tracer for each subject and each
meal (convenience , cosmopolitan A , and animal-oriented— Q— )
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Figure 4-5. Time-concentration profiles of exogenous plasma tracee for each
subject and each meal (convenience 0 , cosmopolitan A and
animal-oriented — □—  )
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4.7.4 Bioavailability
Bioavailability (matrix effects) from the meals was assessed based on the 
relationship between tracer and exogenous tracee (baseline subtracted tracee). Tracer 
and tracee against time are shown in Figure 4-4 and Figure 4-5. For the regression 
analysis, concentrations were adjusted for vitamin Ki in the meals and capsule. Figure 4- 
6a shows the relationships between tracer and exogenous tracee for subjects A -  H, and 
Figure 4-6b I -  N. The slopes of the regressions are shown in Table 4-4. The means ± 
SD of slopes were 1.88 ± 0.81, 0.59 ± 0.32 and 0.43 ± 0.40 for the convenience, 
cosmopolitan and animal-oriented meals, respectively.
Final values for total bioavailability from the test meals were calculated by 
multiplying values for matrix and meal effects. Final relative bioavailability values were 
then expressed relative to the convenience meal, and were 1.00, 0.46 and 0.29 for the 
convenience, cosmopolitan and animal-oriented, respectively. Relative matrix and meal 
effects, and total relative bioavailability values are shown in Table 4-5.
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Figure 4-6a. Relationship between tracer and exogenous tracer for Subjects A -  H
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Figure 4-6b. Relationship between tracer and exogenous tracer for Subjects I -  N
(convenience 0 , cosmopolitan A and animal-oriented— Q— )
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Table 4-4. Slopes of regressions between tracer and exogenous tracee
Subject Convenience Cosmopolitan Animal-oriented
A 1.61 0.1 -0.56
B 3.34 0.67 1.01
C 1.69 0.58 0.58
D 1.73 0.77 0.19
E 1.54 0.67 0.55
H 3.04 1.07 0.82
I 1.73 0.47 0.43
J 3.09 0.32 0.58
K 1.25 0.23 0.28
L 1.09 0.48 0.67
M 1.59 1.19 0.43
N 0.91 0.56 0.17
Table 4-5. Summary of meal and matrix effects and total relative bioavailability of 
the three test meals
Meal
Meal
effect
Meal effect 
(normalised)
Matrix effect 
Matrix effect (normalised) Total effect
Convenience 0.88 1.00 1.88 1.00 1.00
Cosmopolitan 1.30 1.48 0.59 0.31 0.46
Animal-oriented 1.13 1.28 0.43 0.23 0.29
Meal effect refers to the effect of meal on absorption of tracer vitamin Ki from the capsule from differences in, 
for example, fat and nutrient composition and energy density of the meal. Matrix effect refers to the availability 
of vitamin Ki from within the food matrix. Values are normalised to the convenience meal.
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4.7.5 Dietary intake
The mean daily intakes of macronutrients, vitamin E equivalents and vitamins Ki 
for each of the twelve subjects are shown in Table 4-6. Mean vitamin Ki intakes ranged 
from 32 to 317 pg/d. Five of the subjects had vitamin Ki intakes below the UK guideline 
amount of 1 pg/kg body wt/d and indicated with * in the Table 4-6.
Table 4-6. Average daily nutrient intakes collected from 4-d diet diaries of 12 
subjects
Subject
Energy Protein CHO Fat MUFA PUFA SFA Vitamin E Vitamin Ki
(kcal) (kJ) (9) (g) (mg) (M9)
A 1831 7718 78 269 56 28 10 17 12.0 317
B 2473 10376 83 263 108 43 20 35 13.4 123
C* 2303 9671 73 238 71 26 9 28 6.2 66
D 1830 7688 63 221 63 19 15 22 14.8 139
E* 1361 5726 71 146 57 21 11 18 7.9 32
H 2808 11784 128 280 139 51 18 51 12.1 248
I 2589 10875 65 294 132 54 16 44 10.8 166
J 2789 11702 86 309 113 34 17 44 16.0 161
K* 1863 7849 77 253 67 21 12 24 9.9 55
L* 2397 10095 81 326 71 23 12 19 10.4 57
M* 1764 7425 54 271 59 18 11 20 9.8 62
N 1897 7958 60 204 73 21 16 23 15.1 90
Abbreviations: kcal, kilocalories; kJ, kilo Joules; CHO, carbohydrate; MUFA, monounsaturated fatty acids; 
PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids 
* indicates intake of vitamin Ki less than the UK guideline amount of 1 pg/kg body wt/d
Vitamin Ki intake was not significantly correlated with any of the other dietary 
intake measures. However, subject A appeared as an outlier in a number of the 
regressions. If Subject A was removed then significant correlations were found between 
vitamin K intake and the intake of energy (^=0.53; P=0.011), protein (^=0.43; P=0.029), 
total fat (r*=0.76; P<0.001), MUFA (r^O.60; P=0.005), PUFA (^=0.57; P=0.007) and SFA 
(r^O.80; P<0.001).
Relationships between mean nutrient intakes and average baseline plasma 
vitamin Ki (of the three visits for each subject) were also examined. Significant inverse
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associations were observed between the plasma vitamin Ki against intake of energy 
(r^O.37; P=0.04), protein (r^O.33; P=0.05), total fat (^=0.43; P=0.02), SFA (^=0.41; 
P=0.02) and PUFA (^=0.44; P=0.02). Non-significant associations were observed 
between plasma vitamin Ki levels and intake of CHO (^=0.05; P=0.47), vitamin E 
(^=0.05; P=0.47) and MUFA (^=0.28; P=0.07). Notably, there was no association 
between plasma vitamin Ki concentration and vitamin Ki intake (^=0.00; P=0.99) (Figure 
4-7). Although plasma levels primarily reflect recent intake, the absence of any 
relationship between vitamin K  ^ intake and plasma status is a little surprising. 
Furthermore, if subject A (the point in Figure 4-7) furthest to the right) is removed then 
there is even an inverse association.
Figure 4-7. Relationship between dietary vitamin Ki intake (assessed by 4-d food 
diary) and plasma vitamin Ki status (as the average of three fasted blood samples) 
in 12 subjects
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4.8 Discussion
The aims of this study were to develop a stable isotope-based method to measure 
the relative bioavailability of vitamin Ki, and to obtain data on the bioavailability of vitamin 
Ki from meals.
4.8.1 Methodology
The work described in Section 4 on vitamin Ki kinetics and absorption provided the 
framework on which to design this bioavailability study. Bioavailability was measured over 
a single day due to the relatively fast turnover of vitamin K-t observed in Study 1 and 
previously (Shearer et al., 1970a; Shearer et al., 1974). In contrast, typical studies on 
other fat-soluble vitamins, with slower turnover, need to be performed over several days 
(Brown et al., 1989; Edwards et a i, 2001; van Lieshout et al., 2003; Bruno et al., 2005). 
Additionally, data from the absorption of deuterated vitamin Ki allowed estimates of both 
the size of the dose (from the plasma increment in Study 1), and optimisation of the 
sampling protocol (appearance of the tracer and Tmax).
The meals were designed to contain 40 pg of vitamin Ki. This value was based on 
previous work that measured vitamin Ki absorption from vegetables (Gijsbers et al., 1996; 
Garber et al., 1999; Booth et al., 2002). Consideration was also made for the expected 
plasma vitamin Ki enrichments determined by the relative absorption of the vitamin Ki 
tracer and vitamin Ki within the meal.
The method used 13C-labelled vitamin Ki as a standard, taken at the same time as 
a test meal, which could then be used to measure bioavailability by measuring changes in 
plasma vitamin Ki isotopic enrichment. Similar procedures have previously been used to 
study vitamin E (Jeanes et al., 2004) and vitamin A absorption (Edwards et al., 2001; 
2002). However, results of the plasma response to the labelled tracer showed significant 
differences between meals, with less tracer absorbed when consumed with the 
convenience meal (0.88 nmol/L.h), compared to either the cosmopolitan (1.30 nmol/L.h) 
or animal-oriented (1.13 nmol/L.h) meals. As a result, it was not possible to use the tracer 
as a global standard by which to compare the meal bioavailability data. An alternative
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approach was taken where relative bioavailability was assessed based on the relationship 
between the tracer and tracee absorption profiles with time. Consequently, it is possible 
to consider two separate, but interacting determinants to bioavailability, matrix effects and 
meal effects. The first determinant, matrix effects, relate to the location of the vitamin Ki 
within meal constituents, i.e. whether within vegetable or oil matrix, and the effect of the 
location on bioavailability. Secondly, meal composition affects the bioavailability of free 
vitamin This ‘meal effect’ is the result of the meal modifying conditions within the gut 
that may affect digestion and/or absorption, and the potential effect of enhancers or 
inhibitors of absorption. The absorption of labelled vitamin Ki measured by AUC was 
used to determine meal effects, whereas absorption of vitamin K  ^ from the meal itself was 
used to determine matrix effects. A final relative bioavailability value for each of the meals 
was determined as the product of the matrix and meal effects.
4.8.2 Matrix effects
Using the matrix effects alone, it was observed that absorption of vitamin Ki from 
the convenience meal was at least three times that from the cosmopolitan and animal- 
oriented meals (Table 4-5). Whilst the magnitude of this difference was reduced with 
inclusion of the meal effect, total relative bioavailability remained greater from the 
convenience meal.
Greater absorption of vitamin Ki from the convenience meal may be expected 
given the sources of vitamin Ki. From the percent contribution of different foods to meal 
vitamin K-i content (Table 4-2), more than 80% of the vitamin Ki in the convenience meal 
was in fats and oils, not vegetables. In the cosmopolitan meal, only around 10% was in 
fats, and in the animal-oriented, approximately 20% was in fats. Conversely, the majority 
of vitamin Ki in the cosmopolitan and animal-oriented meals was in vegetables where it is 
tightly bound to the thylakoid membranes, and may be less bioavailable because cell 
walls and membranes must be digested before absorption.
Although it is generally assumed that fat-soluble vitamin absorption is greater from 
oil than from vegetables, there have been few direct comparisons using a crossover study
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design. Vitamins A and E have been studied more extensively than vitamin K yet there is 
still a lack of direct comparisons between oil and vegetables matrices. Parker et al., 
(1999) conclude that carotenoids from oil are probably more bioavailable than those from 
other food matrices but state that only a few foods have been tested.
Previous studies to compare absorption of vitamin K-i from oil and vegetables have 
shown conflicting results. Two papers from a single study are published that compare 
absorption between fortified-oil and broccoli over different time-periods. In one study, 
absorption was reported to be significantly greater from oil than from broccoli (Booth et al., 
2002) but an earlier study found no difference in absorption between these two sources 
(Booth et al., 1999a). The different conclusions clearly demonstrate that outcomes can be 
heavily dependent on the methods used. It is also worth noting that no significant 
differences were observed in post-intervention samples, only in AUC measurements. This 
finding may not be surprising when one considers the relatively fast turnover of vitamin Ki. 
Thus, any differences were evident only a relatively short time after absorption.
No other studies have directly compared absorption of vitamin Ki between oil and 
vegetables matrices. Instead, the focus has been on the comparison of vitamin Ki 
absorption from different vegetables, with or without the addition of fat. However, these 
studies have frequently used relatively large amounts of vitamin K-i (>400 pg) that may not 
be typical of the levels present in meals. In one study, there were no differences in 
absorption (measured by AUC) between vegetable sources of vitamin K  ^ (spinach, 
broccoli, and lettuce) but more vitamin K was absorbed when given in tablet form (Garber 
et a i, 1999). Similar results were found in two other studies, where absorption of vitamin 
Ki in a detergent-solubised form was greater than that from spinach (Gijsbers et a i, 1996; 
Schurgers & Vermeer, 2000).
A number of assumptions with regard to carotenoid absorption/metabolism have 
been identified by Tyssandier et a i (2003) which can be also applied to vitamin Ki. 
Firstly, it is assumed that the carotenoids cannot be absorbed when in the vegetable 
matrix. Secondly, it is assumed that incorporation into mixed micelles is essential for 
absorption and finally that absorption occurs by passive diffusion across the enterocytes.
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These assumptions were tested in human volunteers with the use of naso-gastric and 
naso-duodenal tubes (Tyssandier et at., 2003). Data from ten volunteers intragastrically 
fed liquid test meals (with vegetables as the source of carotenoids) showed that 
carotenoids were present in the fat phase of the stomach contents. This experiment 
shows that lipid-soluble carotenoids dissolve in lipid droplets. The authors describe the 
term ‘bioaccessibility’ defined as ‘the ease with which carotenoids are solubised within the 
mixed micelles from the vegetable matrix’ (Tyssandier et al., 2003). This term is 
comparable to ‘matrix effects’ as described above. A similar experimental approach could 
be used to assess matrix effects on vitamin K  ^ bioavailability from different foods. 
Although direct gastric sampling obviously yields appealing and convincing data, such 
studies are difficult to perform, expensive to run, as well as ethically challenging. 
Furthermore, the results might not fully reflect bioaccessibility from normally consumed 
vegetables since the meals used in this study were homogenised (Tyssandier et al., 2003) 
which breaks up the cells making their contents accessible to digestive enzymes and for 
absorption.
Data from the present study suggests that vitamin Ki bioavailability is greater from 
oil than from a vegetable matrix. This is in agreement with the only other comparable 
study to compare the two sources (Booth et al., 2002). An observation that plasma 
vitamin Ki concentration is highly correlated with a-tocopherol (mainly derived from oils) 
(Sadowski et al., 1989) also hints at greater contribution of vitamin Ki from oils than from 
vegetables. The observed greater bioavailability from oil is likely due to the greater 
extraction efficiency of vitamin K•) from this source compared to vegetable matrix where 
vitamin Ki is tightly bound to cellular structures.
4.8.3 Meal effects
In contrast to the results above, absorption of tracer vitamin Ki taken at the same 
time as the meals was lowest when consumed with the convenience meal. Several 
possible explanations for this apparent paradox relate to meal characteristics that may 
affect digestive processes and/or other components that affect vitamin Ki absorption.
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The processes of digestion and absorption of fats and fat-soluble vitamins follows 
a number of steps. Mechanical grinding and churning of the stomach contents breaks 
down food matrices and reduces the particle size of the food for release into the 
duodenum. Following release from the matrix, vitamin Ki (along with other fat-soluble 
vitamins) is emulsified in the lipid phase within fat globules. Lipid digestion initiated in the 
stomach by gastric lipase continues in the duodenum by pancreatic lipase and bile salts
and leads to the formation of mixed micelles that contain free fatty acids,
monoacylglycerol, phospholipids, cholesterol and fat-soluble vitamins. Micellar 
components are transferred across the intestinal mucosal into the enterocytes. In the 
enterocyte, vitamin K-i is repackaged in chylomicrons that remain the major carrier of post­
prandial vitamin Ki in the circulation (Lamon-Fava et al., 1998; Erkkila et al., 2004). 
Circulating levels of vitamin Ki are largely determined by post-prandial lipaemia. Thus, 
any aspect of the meal that affects gastric emptying or aspects of lipid
absorption/metabolism may influence vitamin Ki bioavailability. This raises the question
was there something about the convenience meal, regardless of the vitamin Ki content of 
that meal, that decreased absorption of the tracer vitamin Ki?
4.8.3.1 Gastric emptying
A number of factors that determine gastric emptying and intestinal transit may 
ultimately affect bioavailability (Schneeman 2004). Meal characteristics that affect gastric 
emptying or intestinal motility include viscosity, osmolarity, particle size, meal volume, the 
lipid, protein, carbohydrate and fibre content, and energy density (Low 1990). Slower 
release of food from the stomach may lead to increased absorption because there is less 
emulsified food for a constant intestinal surface area. Conversely, if gastric emptying is 
faster, then there may be less contact of food with the intestine and lower absorption. To 
minimise differences in gastric emptying between meals, all were balanced for energy, 
percent energy from fat, protein and carbohydrate, and fibre content. However, the 
convenience meal was different to the other meals because it was smaller in weight and
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volume, but had equal energy, and therefore had an energy density almost 50% greater 
than both the cosmopolitan and animal-oriented meals.
The higher energy density of the convenience meal may have affected gastric 
emptying. Evidence suggests that gastric emptying from the stomach is controlled, partly 
through the energy density of the meal, to maintain a constant supply of energy (from 
food) into the duodenum; thus a meal with a greater energy density slows gastric release 
(Hunt 1983) and thereby provides the potential for greater absorption. However, this 
reasoning doesn’t explain the findings of this study, that absorption of the tracer (indicative 
of meal effects) was lowest in the meal with the greatest energy density. Although this 
hypothesis could partly explain the greater absorption of the vitamin Ki from the meal 
itself, it cannot explain lower absorption of the vitamin tracer
That gastric emptying influences bioavailability has also been postulated in a study 
that measured the effect of two different, but isoenergetic meals, on vitamin E absorption 
(Jeanes et al., 2004). The study found that more vitamin E was absorbed from a capsule 
when it was consumed with toast and butter than with cereal and milk. However, the 
authors do not speculate firstly, how the meals would differentially affect gastric emptying 
and secondly, a mechanism for how potential differences in gastric emptying would affect 
absorption.
It is almost certain that gastric emptying is a determinant of the bioavailability of 
vitamin Ki and other nutrients. However, the mechanisms are indirect and are a 
consequence of the meal consumed. It is difficult to state with any confidence that 
differences in gastric emptying resulted in the observations in the present study.
4.8.3.2 Other factors in absorption
The lipid-water mix of the meal may determine the size of emulsified fat globules 
released from the stomach and smaller fat globules provide a greater surface area for the 
action of lipases. Since fat-soluble vitamins are trapped within the fat globule, the rate of 
lipid hydrolysis may affect fat-soluble vitamin availability (Borel et al., 2001). The test 
meals used in this study were matched for fat content, although the greater weight and
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volume of the cosmopolitan and animal-oriented meals are indicative of a higher water 
content and the potential for smaller emulsified fat globules to be released from the 
stomach. However, it has been shown that the size of fat globules did not alter absorption 
of either vitamin A or E (Borel et al., 2001). It is likely that emulsification affects all the fat- 
soluble vitamins equally, thus these findings are equally applicable to vitamin Ki. The 
evidence suggests that emulsification is not an important effect in absorption of vitamin Ki 
and is probably not a factor in the differences observed in this study.
The size of mixed micelles may also be a factor in the absorption of fat-soluble 
vitamins, and is largely dependent on the chain length of fatty acids within the micelle. In 
vitro experiments, using excised sections of rat bowel, showed that longer chain fatty 
acids reduced vitamin Ki absorption. The mechanism is uncertain but may be due to 
increased affinity of the mixed micelle for vitamin or by reduced diffusion through the 
unstirred water layer leading to reduced transfer to enterocytes (Hollander & Rim, 1976).
The unstirred water layer, a thin layer of water surrounding the brush border 
membrane of the microvilli, is important in the absorption of lipids from micellar solutions 
(Wilson et al., 1971) and may play a role in the absorption of vitamin Ki. Mixed micelles 
transport the fat-soluble components, including vitamin Ki, through the unstirred water 
layer to the enterocytes, and the rate of transfer through the layer may affect absorption. 
Hollander et al. (1977), have shown a greater rate of vitamin Ki absorption in rats when 
the thickness of the layer was decreased, and suggested that the layer may be a 
significant barrier to vitamin Ki absorption. However, it is not possible to comment on 
what meal factors may influence the thickness of the unstirred water layer.
Although the above examples (fat globule size, micelle size and unstirred water 
layer thickness) could provide mechanisms for the observed differences in absorption of 
the tracer vitamin Ki between meals, in the absence of supporting evidence the 
hypothesis remains supposition.
216
4.8.3.3 Total fat
Fat is required for vitamin Ki absorption, however the quantity of fat required, and 
whether there is an optimum amount is unknown. Fat may influence absorption either by 
slowing gastric emptying or through the stimulation of bile secretion. In the present study, 
test meals were balanced for fat so, notwithstanding inaccuracies in the food composition 
tables, it is unlikely that total fat provides an explanation for the observed results. In other 
studies, conflicting results have been reported on the effect of total fat. One study found 
the addition of butter to a meal increased absorption (Gijsbers et al., 1996) whereas 
another study found no difference in vitamin Ki absorption from lettuce between a low-fat 
(30%) or high-fat (45%) meal (Garber et al., 1999).
4.8.3.4 Fatty acid composition
There is some evidence to show that the fatty acid composition of a meal can 
influence both uptake and post-prandial transport of vitamin Ki. Differences in fatty acid 
composition may affect absorption by changing the physical characteristics of the mixed 
micelle and/or influencing post-prandial lipid metabolism. In vitro, a monounsaturated 
fatty acid (C18:1), and to a greater extent, a polyunsaturated fatty acid (C18:2), decreased 
vitamin Ki absorption possibly through a greater affinity of the mixed micelle for vitamin Ki 
decreasing transfer across the enterocyte (Hollander & Rim, 1976). In rats, 
polyunsaturated fatty acids significantly decreased the rate of vitamin Ki absorption 
(Hollander et al., 1977).
More recent studies in humans have shown that diets containing PUFA-enriched 
(38%) corn oil resulted in lower plasma vitamin Ki compared with a diet enriched with 
olive / sunflower oil that contained less PUFA (23%) (Schurgers et al., 2002a). There is 
some evidence to suggest that meals containing significant levels of polyunsaturated fatty 
acids can reduce post-prandial lipaemia (Williams 1997). However, other studies have 
shown no effect of varying MUFA or SFA meal content on TAG responses or, by using 
retinyl ester as a marker, on chylomicron metabolism (Jackson et al., 1999). Since the 
presence of vitamin Ki in plasma is largely controlled by lipid digestion and metabolism,
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there is the possibility that fatty acid composition of the meal may affect the transport and 
metabolism of vitamin Ki.
Table 4-7 shows the fatty acid profile, estimated from food composition tables, for 
each test meal. The convenience meal had more than two-fold greater PUFA content 
(37%) than both the cosmopolitan (19%) and animal-oriented meals (14%). Inhibition of 
vitamin Ki uptake or altered post-prandial metabolism by the high PUFA convenience 
meal could explain the lower absorption of vitamin K-i from the capsule. However, these 
concepts are contradictory to the results of total bioavailability and could only be possible 
if considerably more vitamin Ki was available from the convenience meal to counteract 
the negative effect of PUFA.
Table 4-7. Fatty acid compositions of test meals expressed as % of total fat content
Fatty acid
Meal Saturated (%) Monounsaturated (%) Polyunsaturated (%)
Convenience 26 37 37
Cosmopolitan 52 29 19
Animal-oriented 30 56 14
4.8.3.5 Vitamin E
There is some evidence from studies in rats to suggest that vitamin E may affect 
vitamin K plasma status (Alexander et al., 1999; Mitchell et al., 2001). However, other 
studies have shown effects are limited to tissue status, not plasma status both in animal 
(Tovar et al., 2006) and in human studies (Booth et al., 2004). The available evidence 
suggests that vitamin E may interfere with vitamin K metabolism rather than absorption 
(Schurgers et al., 2002a). In the current study, the vitamin E content of each meal was 
calculated using food composition tables, with estimated values as 11.0 mg, 5.3 mg and
5.8 mg for the convenience, cosmopolitan and animal-oriented meals, respectively. 
These values could be used to the explain differences in tracer absorption between 
meals. However, considering the strength of the evidence for vitamin E as an inhibitor of 
vitamin Ki absorption, and the levels of vitamin E in the three test meals, it is unlikely that
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the observed differences in vitamin K-i bioavailability between meals could be attributable
to vitamin E.
4.8.4 Effects of the meal on gelatin capsule
In the present study, volunteers received the 13C-labelled vitamin Kt tracer in a 
gelatin capsule, taken at the same time as the test meal. It is possible that the results 
obtained from absorption of the tracer were less to do with the influence of the meal on 
vitamin Ki per se, and more related to meal effects on digestion of the gelatin capsule. 
Two mechanisms are possible; the meal may have firstly affected the position of the 
capsule in the stomach and secondly the rate of breakdown of the capsule. However, the 
possible mechanisms for these effects are unknown. Similarities within individuals in the 
tracer absorption profiles (see section 4.8.5) suggest the meal did not affect breakdown of 
the capsule.
4.8.5 Comment on absorption profiles
Tracer concentration-time profiles in Figure 4-4 reveal that in the majority of cases, 
an individual’s profiles show a similar pattern between the three test meals (with the 
exception of subjects K, L and N). The inter-individual differences of profiles are not 
related to the meals but rather genetic, metabolic or physiological differences between 
individuals e.g. absorption of vitamin Ki across the enterocytes and/or metabolic handling 
of chylomicrons/vitamin Ki, potentially through apoE genotype.
In a number of individuals tracer vitamin Ki peaked between either 5 and 8 h, or a 
second smaller peak was observed, apparently after the snack. Although there was no 
difference between AUC before and after the snack, the snack may be influencing the 
absorption profile of vitamin f^. It may be that in some individuals, the physiological 
response to the snack releases partially absorbed vitamin Ki into the circulation. A similar 
phenomenon has been observed with fatty acids, where fatty acids consumed during a 
first meal appear in the circulation after ingestion of a second meal a number of hours 
later possibly through retention in the gastric tissue, or stimulation of hydrolysis of lipids in 
chylomicrons (Fielding et al., 1996; Maillot et al., 2005). Similarly, it has been suggested
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that partially absorbed p-carotene can remain in the enterocytes until a later meal when it 
is subsequently packaged into chylomicron and released into the circulation (Dueker et 
al., 2000). An alternative explanation is that vitamin Ki in the liver is being released in 
VLDL causing a small rise in vitamin Ki concentration.
4.8.6 Assessment of methodology
There are a number of techniques available to measure the bioavailability of 
vitamins in humans, including depletion-repletion methods, oral-faecal balance 
techniques, and plasma responses, as either AUC or Cmax. Of the latter two, AUC is the 
most reliable because it is a consequence of the plasma response over the period of 
absorption, rather than a single time-point (Hoppe et al., 2000). The advantages and 
disadvantages of these techniques were considered in section 1.12. The use of stable 
isotopes is believed to provide the most reliable estimates (van Lieshout et al., 2003) 
because of the ability to measure only newly absorbed vitamin. A number of approaches 
are available, particularly if the primary aim is to determine bioavailability from a single 
food, either alone, or within a test meal, or against a reference dose. Test compounds 
can be given either at the same time or on separate occasions. Single dose or multiple 
dosing protocols can be designed. Although there are numerous studies that have 
investigated vitamin A and E bioavailability, both with and without the use of stable 
isotopes, only a small number of studies have investigated vitamin K<\ bioavailability. 
Three of these studies used stable isotopes to measure vitamin K absorption, 
bioavailability and metabolism (Dolnikowski et al., 2002; Kurilich et al., 2003; Erkkila et al., 
2004) but all with intrinsically labelled vegetables. Although the number of foods that can 
be labelled in this way is limited, many are vitamin Kr rich foods e.g. broccoli or kale. 
Given time and resources it could even be possible to produce labelled vitamin in 
rapeseed oil, a relatively good source of vitamin Ki (Shearer et al., 1996), by exposing 
rape to deuterated water or 13C-enriched carbon dioxide (Bluck et al., 2002). A precise 
comparison could then be made between absorption from oil and vegetable as individual 
food items and/or within meals.
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The use of labelled material as a standard to measure absolute bioavailability of 
vitamin A has been investigated (Edwards et al., 2001;2002) but the results are heavily 
based on the value for absolute absorption of the standard. In another study, the effect of 
a meal on absorption of a labelled dose of a-tocopheryl acetate was studied (Jeanes et 
al., 2004). Edwards et al. (2002) used labelled retinyl acetate as an extrinsic reference 
dose and calculated absorption by assuming 80% absorption of the labelled provitamin A. 
Absorption was then calculated by dividing baseline-subtracted unlabelled AUC by 
labelled AUC, and multiplying by the amount of reference dose absorbed (80% of the 
given dose). However, the use of labelled compounds in this way assumed and/or 
required that test foods/meals did not affect absorption of the standard. Whilst this 
assertion was valid for comparison between high and low fat meals, and different food 
sources of p-carotene (Edwards et al., 2001), meal-effected differences were observed on 
bioavailability tracer vitamin E (Jeanes et al., 2004).
In the present study, the original aim was to design a method, using a labelled 
form of vitamin Ki as a standard, to compare absorption from any combination of foods, 
rather than individual food items, by observing tracentracee ratios. An alternative 
approach could be to calculate AUC of the tracee (after subtraction for baseline). If the 
tracer AUC had not been different, it would have been possible to express tracee AUC 
(after correction for the dose) relative to tracer AUC to obtain values for relative 
bioavailability. Using tracee AUC values alone would negate the advantages of having 
the isotope data, hence the described method was chosen. Additionally, with the size of 
the dose given (less than 40 pg) and the consequent small rise in tracee plasma 
concentration and coupled with analytical limitations, this approach was not considered 
the best available.
The advantages of this study compared to previous studies are 1) the crossover 
design in a relatively high number of subjects and 2) low doses of vitamin Ki, particularly 
compared to previous studies. An additional benefit of monitoring both tracer and tracee 
is the separation of meal and matrix effects as discussed above. The tracer data alone
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provides interesting results with regard to the effects of the meal on ‘free’ vitamin K1( at 
least within the limitations of the experiment.
4.8.7 Potential improvements to methodology
Potential improvements to the methodology used in the present study include 
direct injection of the tracer into the meal prior to serving, rather than the use of a capsule 
to deliver the tracer. This protocol would have ensured the tracer was indeed emptied 
from the stomach with the meal, and would remove meal effects on degradation of the 
gelatine capsule and/or absorption of the tracer. The advantage of the capsule however, 
is the certainty that the entire dose has been consumed.
A major limitation of the current protocol is the observed difference in absorption of 
the tracer. This problem could be resolved by staggering consumption of the tracer and 
the tracee, either by a single, bolus dose at sometime prior to consumption of the test 
meal or subjects could be dosed with tracer in much the same way as in the first volunteer 
study with the aim of reaching a steady-state for plasma vitamin Ki enrichment. 
Consumption of an unlabelled test meal would then result in changes to the tracertracee 
ratio, dependent on how much was absorbed. The advantage of including stable isotopes 
over simply giving a meal with vitamin Ki is that low levels of vitamin Ki could be 
administered since small changes in enrichment would be more readily detected than 
changes in absolute concentration.
In the present experiment, samples were collected and AUC calculated over 8 h. 
In all subjects, this time was sufficient for tracer concentration to be close to baseline 
levels. In future studies consideration could be made to increase the sampling time to 9 
or 10 h to ensure tracer concentration has returned to baseline, as is appropriate for true 
AUC measurements. The long period of elevated tracer concentration, and/or late 
appearance of tracer in plasma in this experiment could be a consequence of the large 
meals. Energy content of the meals was around 3200 kJ thus in future studies 
consideration for smaller and lower energy meals may be considered.
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4.8.8 Vitamin Ki content of meals and food composition tables
The approach in this study was to measure bioavailability of vitamin Ki from meals. 
The three meals in this study were designed using the characteristics of dietary clusters 
identified in a national nutrition survey. The meals were formulated to contain equal 
amounts of vitamin K1f with the major difference between the meals being the sources of 
vitamin K-j. However, direct analysis of meals revealed variation in the measured value 
compared to that calculated from food composition tables.
This finding may not be a surprise since the vitamin Ki content within foods of the 
same type is known to be highly variable, especially for margarine which was a major 
source of vitamin Ki in the convenience meal. For example, a study of the vitamin K  ^
content in 70% vegetable oil spread found levels between 0.1 and 60 pg per 100 g 
(Peterson et al., 2002) and another study of six brands reported values that ranged from 
12 to 78 pg per 100 g (Bolton-Smith et al., 2000). Cooking and reheating the meals may 
reduce the vitamin K-i content compared to the calculated values (Ferland & Sadowski, 
1992a). Furthermore, a comparison of the vitamin Ki content of ten meals calculated by 
two nutrient databases compared to direct analysis showed variation of up to 89% 
(McKeown et al., 2000). It is a common difficulty with food composition analysis to get a 
fully representative sample of the different sources or brands etc. of a single food. For 
example, the amount of vitamin Ki in vegetables depends on maturation, geographical 
location and by which part of the vegetable is analysed (Ferland & Sadowski, 1992b).
Although the standard addition method for quantitation is not the most precise 
approach, the results were sufficient for the purposes of this study. Some difficulties were 
apparent with the chromatogram of the convenience meal in that an interfering peak 
eluted close to the peak of interest. The presence of an unidentified peak that elutes just 
before the vitamin Ki peak during the HPLC analysis of canola oil, soybean oil, 
margarines and other processed foods (e.g. baked beans) has been reported (Woollard et 
al., 2002). The convenience meal contained a relatively high proportion of ingredients that 
could exhibit the mystery peak, and it is therefore possible that the same unidentified peak 
was present in the analysis of the convenience meal. The result of the interfering peak
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may be that the estimation of vitamin Ki in the convenience meal was an underestimate. 
However, given the magnitude of the differences in bioavailability, the conclusions are 
unaffected, even when repeating calculations with the 40 pg theoretical value of vitamin 
Ki content in the meal.
4.8.9 Dietary intake data
The difficulties of assessing dietary intake and in particular vitamin K-i intake are 
exemplified in the diets analysed in 12 subjects who participated in this study. One 
particular difficulty is that, although vitamin Ki is found a wide range of foods, there is a 
very wide range of concentrations (Shearer et al., 1996). The result is that dietary intakes 
also have a huge variation, both inter- but also intra-individually, creating a problem when 
trying to estimate intake since a few foods that contain relatively large amounts may not 
be eaten regularly. This is demonstrated in the dietary data between individuals which 
showed that vitamin K1 intakes can differ by a factor of 10 (Table 4-6) and by a factor of 
25 within an individual (data not shown). In terms of assessing typical vitamin Ki intake, a 
food frequency questionnaire may provide a better tool, although consideration needs to 
be made for seasonal variations in intake.
In this study, no significant correlations were observed between the intake of 
vitamin Ki and other nutrients. However, subject A appeared as an outlier in a number of 
the regressions, and the removal of this subject generated significant associations 
between vitamin Ki intake and intake of energy, protein, fat and MUFA, PUFA and SFA. 
This correlation could suggest that oil sources of vitamin K-i make a substantial 
contribution to total vitamin K1 intake.
In these 12 subjects, there was no relationship between vitamin Ki intake and 
status. However, to observe such a relationship may be unexpected for a number of 
reasons. Firstly, the small sample size and secondly, blood samples were not taken at 
the same time as the dietary data were collected. However, multiple blood sampling may 
provide some benefit when trying to find relationships between intake and status. Similar 
conclusions have been drawn by Booth etal. (1997) who measured vitamin Ki intake (with
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a 4-d food diary) and status (plasma sample) on three separate occasions. On the first, 
the regression line between intake and status is almost flat (r=0.13, P=0.30), as in this 
study, whereas a combination of three sets of data reveal a strong relationship (r=0.51, 
P=0.004) (Booth et al., 1997).
A number of significant inverse correlations were observed between vitamin Ki 
status and other nutrients, including fat, SFA and PUFA, i.e. those individuals with the 
highest fat intake, had the lowest plasma levels of vitamin Ki. A possible explanation may 
be that those people who have a high fat diet, perhaps indicative of a less healthy diet, 
consume less of the foods that contain high amounts of vitamin K, and thus have a lower 
status. However, results from the bioavailability study suggest that in terms of status, 
absorption of vitamin Ki from fat is better than that from vegetables. However, the results 
from this food diary analysis should not be over-emphasised. The data was obtained from 
only 12 subjects who completed 4-d  food diaries. In addition, vitamin Ki status was not 
measured at the same time as the dietary data was collected. The observed significant 
relationships may be an artefact of performing multiple statistical tests that result in 
significant findings when in fact there are no significant relationships (type 1 statistical 
error).
4.8.10 Relationship between vitamin Ki intake and plasma status
Bioavailability is an important factor in determination of the relationship between 
intake and status. With good bioavailability data, it may be possible to improve 
relationships between vitamin K intake and status. Although the relationships between 
intake and status are often significant, they are not very strong (Booth et al., 1997; Bolton- 
Smith et al., 1998; Rock et al., 1999; McKeown et al., 2002; Thane et al., 2006b).
The test meals in the present study were formulated based on the characteristic 
foods consumed by individuals identified in dietary clusters from a national survey. Within 
each cluster, the relationship between vitamin Ki intake and status has been investigated. 
Based on the results from the bioavailability study, one might expect there to be 
differences in the relationships of intake and status within the three clusters. However,
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none were found. Furthermore, adjustment of intakes for each cluster based on the 
bioavailability values, decreased rather than improved the relationships1.
There are a number of possible reasons for this observation. Firstly, there is a 
disparity in the time of collection of data for intake and status measurements. The cluster 
analysis on which the meals were based was performed on data from the 2000 -  1 
National Diet and Nutrition Survey (Fahey et al., 2007). It is reported that for 80% of the 
participants in this study, a blood sample was collected within 2 wk following completion of 
the food diary (Thane et al., 2006b). However, since vitamin K-i plasma status is likely to 
reflect only the previous one or two days intake, 2 wk is a considerable period. In fact, 
some blood samples were taken > 100 d after the completion of the diary (Thane et al., 
2006b) and with consideration of potential seasonal variation of vitamin Ki intake 
(Sadowski et al., 1989; McKeown et al., 2002) the plasma measurement is unlikely to 
reflect actual intake. Furthermore, the intra-individual variation in plasma vitamin Ki status 
is greater than other fat-soluble vitamins (Booth et al., 1997; Talwar et al., 2005), probably 
reflecting the large variation in intake because of the distribution of vitamin Ki in foods.
A lack of confidence in sampling provides a second potential confounder for the 
above results. Blood samples were collected both in the fasting and non-fasting state and 
at various times of the day (Thane et al., 2006b) thus limiting their capacity to provide 
uniform comparisons between intake and status.
The third reason could simply be that the test meals do not reflect the clusters of 
which they are supposed to represent. Previous bioavailability studies have primarily 
tested single foods, either individually or in combination with untypical food combinations. 
The meal-based approach more accurately depicts typical consumption of foods in a free- 
living situation where, components of a mixed-meal may work together to negate effects 
that may be observed in experiments with individual foods. The cluster analysis provided 
an objective method by which to design the meals. However, it is obviously not possible 
to fully represent a typical diet within a single meal. This weakness may explain why the
1 Personal communication with Dr Andy Coward, MRC Human Nutrition Research
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conclusions from this bioavailability study do not match with the observation that there is 
little difference in the intake and status relationships between clusters.
Although data from this bioavailability study suggests there may be differences in 
the bioavailability of vitamin Ki between foods and meals, the lack of a significant 
difference between clusters in terms of the relationship between intake and status 
suggests that this difference may be negated in an individuals overall diet.
4.9 Comparison of tracer absorption between Study 1 and Study 2
The results from study 1 that measured vitamin K-i kinetics and absorption showed 
that only around 13% of small oral dose was absorbed. This is much lower than the only 
other previous estimate of absolute absorption of vitamin Ki (Shearer et a/., 1974). A 
possible explanation for low absorption was the absence of a test meal. Together with 
data from Study 2, it was possible to test this hypothesis by comparing the tracer 
absorption parameters of Cmax and AUC, adjusted for size of the dose, in both studies. 
The Cmax of tracer absorption in study 1 was 0.008 nmol/L, compared to an average for all 
meals in study 2 of 0.009 nmol/L. Absorption expressed as AUC over 6 h, also shows 
similar results in both studies (study 1, 0.020 nmol/L.h; study 2, 0.017 nmol/L.h). This 
analysis suggests that the absence of the test meal cannot be the primary reason for 
seemingly low absorption. This evidence, together with no ready metabolic- or model- 
based explanation, suggests that low absorption from the capsule may be due to the 
capsule itself. However, gelatine capsules have been used in previous studies of vitamin 
Ki (Suttie et a l, 1988b) and other fat-soluble vitamins (Dueker et al., 2000) without 
comment.
4.10 Section 4 conclusions
This study has demonstrated a novel approach to measure vitamin Ki bioavailability 
from test meals that may be more relevant to the consumption of foods in a free-living 
population. Results from absorption of the tracer, as measured by AUC, provided data on 
the effect of altering the environment in which the vitamin Ki was absorbed, the ‘meal 
effect’. The results suggested that vitamin Ki tracer was less well absorbed in the
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presence of the convenience meal, than when consumed with the cosmopolitan or animal- 
oriented meals. The reasons for this observation are unclear but may be related to gastric 
emptying effects or fat composition affecting absorption and/or metabolism of vitamin K1f 
however this is largely conjecture.
Bioavailability of vitamin Ki from the meal itself (tracee) was assessed based on 
the relationship between tracer and tracee, and produced the apparently contradictory 
result that absorption from the convenience was better than either the cosmopolitan or 
animal-oriented meals. A possible explanation for this observation is that the over-riding 
factor determining bioavailability is the matrix effect or ‘bioaccessibility’, since in this study, 
although absorption of the tracer was lowest when consumed with the convenience meal, 
overall effects suggest absorption is greatest from the convenience meal.
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5 D is c u s s io n
The research in this thesis was performed on a background of growing evidence 
and interest in the wider role of vitamin K in human health. Vitamin K was originally 
discovered as essential for blood coagulation and current dietary recommendations 
remain largely based on this function alone. A number of vitamin K-dependant (VKD) 
proteins have now been discovered that are distributed in different tissues throughout the 
body, but for some, their precise function remains unknown. Probably the most studied 
extrahepatic VKD protein is osteocalcin; the presence of undercarboxylated osteocalcin is 
often used as a marker of vitamin K status. A number of studies have demonstrated that 
osteocalcin carboxylation is responsive to vitamin K depletion and supplementation. 
There is also a growing body of evidence that links higher vitamin K status (both plasma 
and carboxylated osteocalcin) and higher vitamin Ki intake to clinical markers of bone 
health, such as fracture risk and bone mineral density. Because of the broader functions 
of vitamin K, it may be time to reconsider vitamin Ki dietary recommendations. However, 
there is already concern the majority of people do not meet the current recommendations 
and that intakes are decreasing with time (Thane et ah, 2006a). In the case of vitamin Ki, 
where intakes may be marginal, and for the setting of evidence-based dietary 
recommendations, knowledge of vitamin metabolism and bioavailability are essential. In 
addition, data on vitamin Kbioavailability are also important for the control of coagulation 
status for individuals on anticoagulation treatment (Couris et al., 2006; Custodio das 
Dores et al., 2007). Despite their importance, few studies have investigated the 
metabolism and bioavailability of vitamin K, partly due to the lack of suitable 
methodologies.
Unlike the metabolic analysis of drugs, there are considerable difficulties in the 
study of vitamin metabolism because the compound of interest pre-exists in body pools. 
The use of tracer techniques, in particular stable isotopes, allows the researcher to 
distinguish between the labelled tracer dose and endogenous tracee. Stable isotope 
tracers provide a safe, reproducible and sensitive tool to investigate nutrient bioavailability
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and metabolism but have been used only to a limited extent in vitamin K research, 
particularly in comparison to other vitamins and minerals. The kinetics and bioavailability 
of vitamin A have been the most extensively researched of all the fat-soluble vitamins. 
This interest is probably due to world-wide deficiency and subsequent public health 
importance of vitamin A as well as interest in the many carotenoid precursors of vitamin A. 
Consequently, numerous studies have investigated the bioaccessibility and bioconversion 
of vitamin A using tracer techniques (van Lieshout et al., 2003). Similarly, many studies 
have investigated the relative bioavailability and biopotency of the vitamin E tocopherols 
owing to its antioxidant and putative cardioprotective role (Lodge et al., 2004).
The use of stable isotopes to investigate vitamin Ki has been reported only 
recently (Dolnikowski et al., 2002; Kurilich et al., 2003; Erkkila et al., 2004) due to the lack 
of suitable techniques and a low priority on the research agenda. However, the 
accumulation of evidence for the potentiallly beneficial effects of vitamin Ki, particularly for 
bone health, have stimulated interest and research into vitamin Ki bioavailability. A 
common feature of this thesis is the development and application of stable isotope 
technologies to questions of vitamin K metabolism and bioavailability.
5.1 Analytical methodologies
Prior to studies in human volunteers, it was necessary to develop a method for the 
extraction of vitamin K-i from plasma that provided a sample suitable for gas 
chromatography mass spectrometry and the measurement of isotope ratios. A number of 
purification strategies were combined including enzyme hydrolysis, liquid-liquid extraction 
and solid phase extraction prior to derivatisation. This new method, although somewhat 
labour intensive, provided an alternative to other reported methods in which analyses 
were incomplete due to chromatographic difficulties (Erkkila et al., 2004). Future 
analytical improvements should focus on reducing sample preparation time. A potential 
strategy is to use liquid chromatography mass spectrometry (LCMS) that may require less 
sample clean-up and preparation. Kurilich et al. (2003) reported the use of intrinsic 
labelling and LCMS to measure vitamin Ki bioavailability. Recently, HPLC with tandem
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mass spectrometry has been described for the sensitive measurement of vitamin K1f MK-4 
and MK-7 in human plasma using 180-Iabelled standards (Suhara et a l, 2005).
Although sensitivity was adequate for these studies, if smaller doses, or longer 
term kinetics are investigated then improvements are probably necessary. Remaining 
with GCMS, the use of chemical ionisation may provide some increase in sensitivity but 
there should be concern for the potential exchange of labelled atoms. For vitamins A and 
E, the use of gas chromatography-combustion-isotope ratio mass spectrometry (IRMS), 
with better sensitivity and precision for the measurement of isotopic enrichment, could be 
appropriate for longer-term experiments. At the current time, this method is not possible 
for vitamin Ki due to the limited sensitivity of online IRMS instruments that is typically a 
1000 x less than that afforded by GCMS (Bier 1997). An emerging technique for kinetic 
analysis is accelerator mass spectrometry (AMS) that was originally developed for carbon 
dating with 14C, but more recently has been applied in the bio-analytical field (Vuong et a l, 
2004). AMS provides a very sensitive tool for the investigation of absorption and 
metabolism of vitamins and other phytochemicals (Vuong et a l, 2004). Although based 
on radioactive 14C, very low doses can be used that pose little discernable risk (Vuong et 
al., 2004). An example of this technique is provided by Dueker et a l (2000) who fed 
intrinsically labelled spinach containing 306 pg of 14C-labelled (3-carotene to a single 
volunteer and measured kinetics over more than 200 d. Sensitivity was in the attomole 
range (1 x 10'18 mol). Thus, AMS may provide a suitable tool for further investigations of 
vitamin K kinetics.
A complementary approach to human studies for the measurement of 
bioavailability is in vitro stable isotope methods. Recent in vitro work has compared the 
comparative uptake and metabolism of 180-Iabelled vitamin Ki and MK-4 in human cell 
lines (Suhara et al., 2006).
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5.2 Vitamin Ki kinetics
In comparison to water-soluble vitamins, there are a number of difficulties 
associated with tracer studies of fat-soluble vitamins. Studies in which only an oral dose 
is used to measure kinetics relies heavily on the assumption of the amount of dose 
absorbed, unless stool samples are also collected. Intravenous administration of fat- 
soluble vitamins requires a carrier that may not behave kinetically in the same way as an 
absorbed oral dose. Furthermore, ethical and regulatory difficulties arise if the compound 
to be injected is isotopically labelled. In this study, a novel approach was taken where, 
following pre-enrichment of plasma vitamin Ki with labelled oral vitamin Ki, volunteers 
received an iv dose of a well-established and safe pharmaceutical preparation of vitamin 
Ki, Konakion MM®. With this methodology, it was possible to obtain kinetic data for all 10 
volunteers that were similar to values reported previously from work with radiolabelled 
tracers (Shearer ef a/., 1974; Shepherd et al., 1977; Bjornsson et al., 1979). The kinetics 
of Konakion MM® vitamin Ki disappearance were resolved into two exponentials with Jy2s 
of 0.22 and 2.66 h. Olson et al. (2002) reported kinetic values considerably different to 
those published previously, probably due to the measured radioactivity being associated 
with metabolites rather than vitamin Ki. This discrepancy highlights a major advantage of 
mass spectrometry; that is the unambiguous identification of vitamin Ki from the mass 
spectral information.
The only incongruous value from the kinetic work in this thesis was that calculated 
for the non-sampled body pool size. In the model, the sampled pool (pool 1) represented 
the plasma pool, and the non-sampled pool (pool 2), represented other body stores. The 
calculated size of the pool 2 was much smaller than estimates ascertained from direct 
sampling of body tissues. In the model, all losses from the system were from pool 1 (k0i). 
An alternative model was investigated with losses to the outside exiting only from the pool 
2 (/c02), rather than pool 1. However, this alternative model had little effect on the size of 
pool 2. There is no ready explanation for the observed small size of pool 2, but it may be 
that the model does not represent the actual physiology. Although the present simple
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model was chosen as most likely to represent the known physiology, it is possible, from 
the same slope and intercepts derived from tracer disappearance, to obtain a number of 
different models that have different inputs and outputs (Shipley & Clarke, 1972). 
Additionally, there remains the possibility of other body pools that were not seen in this 
experiment. Direct measurements suggest bone (Hodges et al., 1993) could contain at 
least as much vitamin Ki as liver. This finding is not surprising since vitamin K is 
necessary for the carboxylation of VKD proteins, osteocalcin and MGP, and recent 
experiments have demonstrated chylomicron remnant uptake by osteoblasts and a 
subsequent increase in y-carboxylation of osteocalcin (Niemeier et al., 2005). Additional 
kinetic studies are necessary to further characterise the kinetics and turnover of vitamin K1 
over a longer duration.
As discussed in section 3, a caveat to the study methodology is potential 
differences in the uptake of iv  and oral forms, that is a consequence of the need for a 
carrier for iv administration. Differences may exist between vitamin Ki uptake from 
chylomicrons and chylomicron remnants (CR) compared to the Konakion MM® 
formulation since the latter lack any of the intrinsic proteins that lead to lipoprotein uptake, 
e.g. apoE. However, kinetic results from Konakion MM® alone (Soedirman et al., 1996), 
detergent-solubised radioactive tracers (Shearer et al., 1974) and this study, are all 
similar. It is known that oral vitamin Ki is absorbed in mixed micelles from the gut and 
released into circulation as components of chylomicrons. The Ty2 of initial vitamin Ki 
clearance obtained in this thesis is similar to that reported for hepatic chylomicron 
clearance (0.28 h) (Cortner et al., 1987). These values suggest that uptake of Konakion 
MM® is representative of uptake of an oral dose absorbed from the gut, at least during the 
initial period of uptake represented by the fast exponential. Further evidence to suggest 
no difference between the kinetics of the iv and oral doses comes from comparison of the 
disappearance of the oral dose compared to the iv dose (section 3.9.2). The TVi for 
disappearance of the oral dose was not significantly different from the Ty of the second, 
slower exponential of the iv dose. Although this calculation is approximate, it suggests 
that there were no gross differences. A possible future approach for the generation of
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vitamin Ki suitable for iv  administration could be similar to that used by Niemeier et al. 
(2005) for the generation of vitamin Kr enriched CR for in vitro work. In this method, a 
single, fasted volunteer was given a fat-rich breakfast with 10 mg of vitamin Ki. After 4 h, 
a blood sample was taken and the chylomicron fraction separated by ultra-centrifugation. 
The collected CR were then utilised for in vitro experiments (Niemeier et al., 2005). A 
comparable protocol could be applied for further in vivo measurements whereby an 
individual is given a vitamin Ki-enriched breakfast, a blood sample is taken and 
chylomicrons separated for analysis and subsequent re-administration to the same 
volunteer.
5.3 Vitamin Ki absorption
In the first volunteer study, the absolute absorption of a 4 pg oral dose of 
deuterated vitamin Ki was measured as only 13%, considerably lower than the only other 
previous estimate of around 80% (Shearer et al., 1974). Absolute absorption was 
calculated by application of the rate constants obtained from iv  dose to appearance of the 
deuterated oral dose in plasma. As discussed above, there is no evidence that the 
kinetics of disappearance of the iv dose do not reflect those of the oral dose. If the 
calculated kinetics were incorrect and if irreversible disposal occurred at a greater rate 
than that predicted, then absorption would be under-estimated. However, other data 
supports the kinetic parameters calculated in this study (Shearer et al., 1974; Shepherd et 
al., 1977; Bjornsson et al., 1978a), while other work suggests a slower rate of irreversible 
disposal (Olson et al., 2002). An alternative explanation for the low absorption was the 
absence of a test meal, but it was not supported by data from the second volunteer study. 
It is possible that the gelatine capsule was the cause of the low absorption, although 
similar gelatine capsules have been used in previous studies with no reports of lower than 
expected absorption (Suttie et al., 1988b; Dueker et al., 2000; Jeanes et al., 2004). Thus, 
there is no obvious explanation for the low bioavailability observed in this study. Further 
work is necessary to investigate the absolute absorption of vitamin Ki to provide an
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accurate reference for the assessment of bioavailability, and ultimately lead to a better 
understanding of the relationship between intake and status.
5.4 Bioavailability of vitamin Ki
The second volunteer study presented in this thesis aimed to measure the 
bioavailability of vitamin Ki from different meals. The protocol was developed based on 
data obtained in the first volunteer study that showed a short (<8 h) protocol would be 
sufficient to measure vitamin Ki bioavailability. A novel approach was taken for the design 
of the test meals. A typical method for the measurement of vitamin bioavailability is to use 
a single test meal that might consist of a simple homogenous food plus a significant 
source of the vitamin of interest; often less attention is paid to the composition of the 
whole meal. Whilst this approach may provide mechanistic data, it does not provide a 
true representation of the normal consumption of foods that may negate the impact of 
individual foods on bioavailability. Test meals in this study were formulated to reflect 
typical UK dietary patterns that were recently identified in dietary pattern analysis of data 
from the 2000 -  1 National Diet and Nutrition Survey of Adults (Fahey et al., 2007). The 
test meal was consumed with 20 pg 13C-labelled vitamin Ki as a standard by which to 
compare bioavailability.
Due to the influence of the meal, absorption of labelled vitamin Ki from the capsule 
was different between the meals, with tracer absorption with the conveneince meal 
significantly lower than tracer absorption with the other meals. The possible reasons 
include factors related to gastric emptying and fat content and fatty acid profile, which 
were considered in section 4. The differences in tracer absorption are probably due to a 
multitude of interactive effects and it is difficult to comment with any certainty on likely 
explanations for the observation. A similar study that measured the absorption of 2H- 
labelled a-tocopheryl acetate also reported that the type of meal and the fat content 
significantly influenced absorption (Jeanes et al., 2004).
Justification for the absence of a test meal in the first experiment is provided by the 
variable and occasionally complicated nature of the tracer absorption curves from the
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second volunteer study. In the bioavailability study, in some instances, appearance of the 
tracer dose was maximal after 2 h, whereas in others, the peak tracer concentration did 
not occur until 6 or 7 h. Furthermore, in some individuals two peaks were observed during 
the 8 h duration of the experiment. Interestingly, the pattern within an individual was 
usually similar for the three test-meals suggesting that the differences were subject- 
dependent differences, for example apoE genotype. These differences highlight the 
potential inaccuracies of using single time point measurements to assess absorption and 
dose-response relationships, such as used by Schurgers et al. (2004). The variation in 
the absorption profile may be in part due to the relatively large size and energy content of 
the test-meals.
Relative bioavailability of vitamin Ki from the meal was assessed based on the 
relationship between tracer and tracee over the 8 h experiment. The results suggest that 
absorption of vitamin Ki from the convenience meal was greater than from the other 
meals. This finding is in line with the general view that absorption from oil is greater than 
that from a vegetable source due to greater bioaccessibility (Vermeer et al., 2004).
Further research is necessary to confirm that vitamin Ki is more bioavailable from 
fats than from vegetables. The use of labelled vitamin Ki as a standard to compare 
unlabelled vitamin Ki absorption would be possible with adjustments to the methodology 
used here. Alternative approaches were discussed in section 4 but could include either a 
stable isotope labelled dose taken a number of hours prior to the test meal to remove 
meal effects, or oral pre-enrichment as performed in the kinetics study. In each case, 
bioavailability could be assessed by the change in the isotope ratio before and after 
consumption of the meal. The advantage of the isotope dose is the ability to detect 
smaller changes than with plasma concentration alone that would permit lower doses of 
vitamin Ki within test meals or foods. The advantages of using an extrinsically labelled 
dose include control of the extent and positioning of labelling and, with a suitable 
methodology, the ability to measure bioavailability from a wide range of foods. The 
alternative method of intrinsic labelling has the advantage of producing labelled vitamin Ki 
within the plant matrix. However, there is no control of the positioning of labelling, and
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furthermore the requirement to measure multiple ions by mass spectrometry can import 
additional error. Intrinsic labelling has only been applied to vegetable matrices. An 
alternative is to produce intrinsically labelled vitamin K-i in vegetable oil by growing, for 
example, rapeseed oil in an atmosphere in which carbon dioxide is 13C-enriched or 
hydroponically with deuterated water. This approach may provide the best available 
option to determine the relative bioavailability of vitamin Ki from oils and vegetables.
The use of plasma response provides information on the amount of vitamin Ki 
absorbed but longer-term studies are necessary to ascertain the effect of different sources 
of vitamin Ki on other tissue markers of vitamin K status. Such studies are difficult and 
expensive to perform because of requirement to control diets over the longer term.
5.5 Further work
There are potential improvements common to both volunteer studies. Firstly, a 
better understanding of the contribution of the cis-isomer to the outcomes should be 
investigated. Evidence suggests that although the cis-isomer is absorbed it is not 
biologically active (Knauer et al., 1975). Further work could investigate the absorption of 
the c/s-isomer that contributed around 16% to total vitamin Ki in the administered oral 
doses. Separation, and thus fraction collection, of the isomers is possible by HPLC 
(Woollard et al., 2002). From analysis by GCMS of the derivatised forms any difference in 
the kinetics of uptake could be identified.
The tissue specific accumulation of menaquinone-4 (MK-4) has been 
demonstrated in rats (Davidson et al., 1998) and humans (Thijssen eta!., 1996a). In rats, 
it has been established that tissue MK-4 is primarily synthesised from dietary vitamin Ki 
(Thijssen et al., 1994; Thijssen et al., 1996b) and in humans that MK-4 in breast milk 
originates from dietary vitamin Ki (Thijssen et al., 2002). More recently, it has reported 
that oral, but not subcutaneous, vitamin Ki supplementation in humans led to an increase 
in the urinary excretion of menadione (Thijssen et al., 2006). The authors hypothesise 
that menadione is an intermediate in the conversion of dietary vitamin K  ^ to MK-4, and 
that the conversion to menadione may take place in the enterocytes. MK-4 is then
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synthesised from menadione in the tissues, since menadione is able to cross barriers 
such as the blood-brain barrier (Thijssen et al., 2006). The first study in this thesis that 
measured absolute absorption only measured vitamin Kt, thus the estimate of 13% 
absorption could be increased if a proportion of the absorbed dose was converted to 
menadione.
Further analysis of plasma samples collected in either of the studies described in 
this thesis could provide additional data on the apparent conversion of vitamin Ki to 
menadione. The labelled atoms were positioned on the 1’,4,-naphthoquinone structure 
and thus would be unaffected by side chain removal, and subsequent synthesis to MK-4. 
The low dose (4 pg) in the first study may preclude analysis of these samples. However, 
it would be interesting to track the appearance of labelled menadione in the plasma of 
individuals from the bioavailability study. New methods may have to be devised for 
menadione analysis by GCMS since, like vitamin K1f current methods utilise HPLC, 
although it is likely that MK-4 analysis would be possible using the GCMS method 
described here with monitoring of the appropriate ions. The development of HPLC-mass 
spectrometric methods may provide a suitable tool. The use of HPLC-tandem mass 
spectrometry has recently been described for the sensitive measurement of MK-4 (Suhara 
et al., 2005).
5.6 Implications of increased dietary recommendations
If dietary recommendations for vitamin Ki were increased, the question that follows 
is how to increase the actual intake of individuals? Already, using the current UK 
recommendations over 50% of individuals fail to met the guideline value and if the higher 
US values are used then almost 80% of individuals would not reach the cut-off values 
(Thane et al., 2006a).
A number of strategies could be implemented to improve vitamin K intake. Green 
leafy vegetables contain the highest amounts of vitamin Ki and evidence suggests that a 
decrease in green leafy vegetable consumption is a primary reason for the decrease in 
overall intakes observed in the UK between 1986 -  7 and 2000 -  1 (Thane et al., 2006a).
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Promotion of native, seasonal, green ieafy vegetables may contribute to an increase in 
vitamin Ki intakes with additional benefits of simultaneously increasing population intakes 
of vitamin A and folate. The promotion of green leafy vegetables, although relatively 
simple to implement, may not be the most effective method of increasing vitamin K-i 
intakes. Efforts to increase fruit and vegetable consumption through the ‘five a day’ 
campaign have had only limited success, with the NDNS 2000 -  1 survey reporting 
average daily consumption of only 2.8 portions (Swan 2004). In the UK and elsewhere in 
Europe, a deficit in the consumption of vegetables compared to fruit has been highlighted 
despite the ‘five a day’ campaigns (Naska et al., 2000). It has been suggested that fruit 
and vegetable intake recommendations should be promoted separately (Naska et al., 
2000). Furthermore, evidence presented in this thesis and previous data (Booth et al., 
2002) show that the bioavailability of vitamin Ki from green leafy vegetables may be less 
than that from vegetable oils. Although green leafy vegetables may be high in vitamin Ki, 
a better strategy for increasing intakes may be to focus on vegetable oils and fats.
If, after consideration for bioavailability, vegetable fats and oils are proven a better 
source of vitamin K1s then methods to improve their vitamin K-i content could be 
investigated. Further research is required to determine the relative importance of the 
main sources of vitamin Ki. Vitamin Ki is rapidly degraded by sun- and fluorescent light 
(Ferland & Sadowski, 1992a) thus, the vitamin Ki content of oils could be diminished by 
inappropriate storage conditions. The majority of vitamin Kr rich vegetable oils are 
marketed in clear bottles thus using amber bottles or canned packaging may improve the 
vitamin Ki content.
An alternative approach is food fortification. Flour fortification with folic acid has 
recently been recommended by the UK Scientific Advisory Committee on Nutrition 
(SACN) to improve the folate intake of young women in order to prevent neural tube 
defects during early pregnancy (Scientific Advisory Committee on Nutrition 2006). In 
addition, by law in the UK, margarines are fortified with vitamins A and D to contain similar 
levels to those naturally contained in butter. The fortification of margarines and oils with
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vitamin Ki would be a feasible strategy to increase vitamin Ki intake, particularly if further 
evidence shows that bioavailability from oils is better than that from vegetables.
The third strategy to increase vitamin Ki intake is supplementation. Any 
programme of supplementation would target a specific population group. Based on 
current evidence the best choice might be older woman at risk of osteoporosis. Evidence 
suggests that older women have a greater level of ucOC and may have a greater 
requirement for vitamin K compared to younger women (Tsugawa et al., 2006). The 
strategies outlined above assume that vitamin Ki alone can have a beneficial effect. 
However, it has been suggested that the greatest benefit of vitamin Ki supplementation 
may only be obtained in combination with vitamin D and calcium (Vermeer et al., 2004) as 
observed in two long-term (>2 y) supplementation studies (Braam et al., 2003; Bolton- 
Smith et al., 2007). In the latter study, vitamin Ki supplementation was performed with 
200 pg/d that the authors claim is achievable through dietary modification. However, 
evidence that relative vitamin Ki bioavailability from supplements is at least four times that 
from vegetables (Gijsbers et al., 1996; Garber et al., 1999; Schurgers & Vermeer, 2000) 
suggests that this assertion is unlikely. Based on current evidence, the relative difficulty of 
implementing a nationwide scheme may preclude supplementation as an appropriate 
population strategy.
5.7 Concluding remarks
Stable isotope tracer methods provide a safe and accurate method with which to 
investigate vitamin kinetics and bioavailability. Within this thesis is described the first 
method for the analysis of stable isotope labelled vitamin Ki from plasma by gas 
chromatography mass spectrometry. The development of this method permitted further 
study of vitamin Ki kinetics and bioavailability.
This study was also the first to measure vitamin Ki kinetics using stable isotopes. 
The results obtained were similar to those presented in comparable studies of vitamin Ki 
kinetics that have used radiolabelled isotopes. Vitamin Ki disappearance was resolved 
into two exponentials with a rapid disappearance suggestive of uptake by the liver.
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Further studies are required to determine vitamin Ki kinetics over a longer duration, and 
using stable isotope methods, the potential impact of vitamin Ki conversion to menadione 
and MK-4. The value for absolute absorption of an oral dose of vitamin Ki calculated 
using the disposal kinetics of vitamin Ki was much lower than the only other previous 
estimate.
In a novel approach, dietary pattern analysis was used to design test-meals for the 
measurement of vitamin Ki bioavailability. Consistent with previous studies on vitamin Ki 
bioavailability and other fat-soluble vitamins, it was concluded that bioavailability was 
highest from oil rather than vegetable sources. Greater consideration should be given to 
the contribution of foods lower in vitamin Ki but eaten more often and with potential 
greater bioavailability. Further work is necessary to refine bioavailability methodologies 
and in particular, for vitamin Ki, a greater knowledge of absolute and relative 
bioavailability is required.
Prior to any increase in current vitamin Ki dietary recommendations, further 
research is necessary. Although the ability of vitamin Ki to decrease the 
undercarboxylation of VKD is well established, there is a need for a better understanding 
of the relationships between undercarboxylated VKD proteins and health, in particular the 
role of osteocalcin in bone metabolism and the significance of undercarboxylated 
osteocalcin. If greater vitamin Ki intake is confirmed as having a beneficial effect on 
health, then strategies for improving vitamin Ki intakes and tissue status should be based 
on a thorough understanding of vitamin Ki bioavailability.
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APPENDIX II
RC
Human
N utrition
Research
C O N S E N T  BY V O L U N T E E R  T O P A R T I C I P A T E  I N
N U T R I T I O N A L  S T U D Y
C o l le c t io n  o f  b lo o d ,  u r in e  a n d  s a l iv a  s a m p le s  f r o m  
v o lu n t e e r s  f o r  u s e  i n  l a b o r a t o r y  m e t h o d  d e v e lo p m e n t
LREC Reference Number: 0 5 /Q 0 1 0 8 /3 0
Name of Lead Investigator: M r Kerry Jones
Please initial box
1. I  confirm  th a t I  have read and understand th e  inform ation sheet -------------
(version 1, D e c04) fo r th e  above study and have had the opportunity to
ask questions. -------------
2. I  understand th a t sam ples taken  as part of the protocol of this study
m ay be stored and used in subsequent nutritional studies. ________
3. I  understand th a t m y participation is vo luntary  and th a t I  am  free to  
w ithdraw  a t any tim e , w ithout giving any reason, w ithout m y medical 
care or legal rights being affected.
4 . I  understand th a t fu ture  research using the sam ple I  give m ay include 
genetic research aim ed a t understanding the genetic influences on 
nutrition. Since the sam ples are anonym ised this will not have any 
im plications fo r m e personally.
5. I  understand th a t m y donated sam ple is provided as a g ift and as 
such I have no access to the results of any analysis of the sam ple.
6. I  agree to take  p art in the above study.
N a m e  o f v o lu n te e r  
(Please print)
D a te S ig n a tu re
N a m e  o f W itness D ate S ig n a tu re
(M u s t n ot be m e m b e r  o f research  te a m )
(Please print)
N a m e  o f R esearch D a te  S ig n a tu re
T e a m  m e m b e r  
(Please print)
Version 1, Dec04
APPENDIX III
RC
Human
N utrition
Research
C O N S E N T  BY V O L U N T E E R  TO P A R T I C I P A T E  I N
N U T R I T I O N A L  S T U D Y
Investigation  into the availab ility  and m etabolism  of
vitam in  K
LREC Reference Number: 0 4 /0 0 1  
Name of Lead Investigator: Mr Kerry Jones
Please initial 
box_______
1. I  confirm  th a t I  have read and understood the inform ation sheet 
dated Nov 2 0 0 4 , Version 2 for the above study and have had the  
opportunity to  ask questions.
2. I  understand th a t m y participation is vo luntary and th a t I  am  free to  
w ithdraw  a t any tim e , w ithout giving any reason, w ithout m y medical 
care or legal rights being affected.
3. I  am  willing th a t m y general practitioner is notified of m y participation  
in this research.
4 . I  agree to  tak e  p art in the above study.
Name of Research Subject Date Signature
(Please print)
Name of Witness to Signature Date Signature
(Must not be m ember of research team )
(Please print)
Name of Research Team member Date Signature
(Please print)
3 copies required: top copy for researcher; one copy for volunteer; one copy to be kept with research subject's 
notes.
Version 01, December 2003
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APPENDIX V
RC
Human
N utrition
Research
CONSENT FORM
Bioavailability of vitamin K from meals
LREC Reference Number: 05/Q 0102/148 
Name of Chief Investigator: Mr Kerry Jones
Please initial box
1. I  confirm  th a t I  have read and understand the inform ation sheet
dated O ctober 2 0 0 5  (version 0 1 ) for the above study and have had____________ ________
the opportunity to ask questions.
2. I  understand th a t m y participation is vo luntary and th a t I  am  free to -------------
w ithdraw  a t any tim e , w ithout giving any reason, and w ithout m y
m edical care or legal rights being affected.
3. I  consent to  m y general practitioner (GP) being notified of m y  
participation in this research.
4 . I  agree to tak e  p art in the above study.
5. I  understand th a t sam ples taken  as p art o f the protocol o f this study  
m ay be stored and used in fu rth er nutrition research studies. 
Sam ples will only be used in studies th a t have been approved by the  
appropria te Ethics C om m ittee.
Name of Volunteer Signature Date
(Please print)
Name of Research Team member Signature Date
(Please print)
Version 01 11/10/2005
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